<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Chondroitin for osteoarthritis - Singh, JA - 2015 | Cochrane Library</title> <meta content="Chondroitin for osteoarthritis - Singh, JA - 2015 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005614.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Chondroitin for osteoarthritis - Singh, JA - 2015 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005614.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD005614.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Chondroitin for osteoarthritis" name="citation_title"/> <meta content="Jasvinder A Singh" name="citation_author"/> <meta content="Birmingham VA Medical Center" name="citation_author_institution"/> <meta content="jasvinder.md@gmail.com" name="citation_author_email"/> <meta content="Shahrzad Noorbaloochi" name="citation_author"/> <meta content="Minneapolis VA Medical Center and University of Minnesota" name="citation_author_institution"/> <meta content="Roderick MacDonald" name="citation_author"/> <meta content="Minneapolis VA Medical Center" name="citation_author_institution"/> <meta content="Lara J Maxwell" name="citation_author"/> <meta content="Ottawa Hospital Research Institute (OHRI), The Ottawa Hospital ‐ General Campus" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="1" name="citation_issue"/> <meta content="10.1002/14651858.CD005614.pub2" name="citation_doi"/> <meta content="2015" name="citation_date"/> <meta content="2015/01/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005614.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005614.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD005614.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anti‐Inflammatory Agents, Non‐Steroidal [therapeutic use]; Chondroitin Sulfates [*therapeutic use]; Glucosamine [therapeutic use]; Hand; Osteoarthritis [*drug therapy]; Osteoarthritis, Hip [drug therapy]; Osteoarthritis, Knee [drug therapy]; Pain Measurement; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005614.pub2&amp;doi=10.1002/14651858.CD005614.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005614.pub2&amp;doi=10.1002/14651858.CD005614.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005614.pub2&amp;doi=10.1002/14651858.CD005614.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005614.pub2&amp;doi=10.1002/14651858.CD005614.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005614.pub2&amp;doi=10.1002/14651858.CD005614.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005614.pub2&amp;doi=10.1002/14651858.CD005614.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005614.pub2&amp;doi=10.1002/14651858.CD005614.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005614.pub2&amp;doi=10.1002/14651858.CD005614.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005614.pub2&amp;doi=10.1002/14651858.CD005614.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005614.pub2&amp;doi=10.1002/14651858.CD005614.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005614.pub2&amp;doi=10.1002/14651858.CD005614.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005614.pub2&amp;doi=10.1002/14651858.CD005614.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005614.pub2&amp;doi=10.1002/14651858.CD005614.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005614.pub2&amp;doi=10.1002/14651858.CD005614.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005614.pub2&amp;doi=10.1002/14651858.CD005614.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005614.pub2&amp;doi=10.1002/14651858.CD005614.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005614.pub2&amp;doi=10.1002/14651858.CD005614.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005614.pub2&amp;doi=10.1002/14651858.CD005614.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005614.pub2&amp;doi=10.1002/14651858.CD005614.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005614.pub2&amp;doi=10.1002/14651858.CD005614.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005614.pub2&amp;doi=10.1002/14651858.CD005614.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005614.pub2&amp;doi=10.1002/14651858.CD005614.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD005614.pub2&amp;doi=10.1002/14651858.CD005614.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="eLIOL3Be";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD005614\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD005614\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005614\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005614\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","de","zh_HANT","ko","ms","ja","hr","fr","ta","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD005614.pub2",title:"Chondroitin for osteoarthritis",firstPublishedDate:"Jan 28, 2015 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Musculoskeletal Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005614.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005614.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD005614.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD005614.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005614.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD005614.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;アブストラクト&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;de&quot;,&quot;title&quot;:&quot;Laienverständliche Zusammenfassung&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ta&quot;,&quot;title&quot;:&quot;எளியமொழிச் சுருக்கம்&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]},{&quot;param&quot;: &quot;comments&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Comments&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD005614.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD005614.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD005614.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD005614.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>20724 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD005614.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005614.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005614.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005614.pub2/full#CD005614-abs-0006"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005614.pub2/full#CD005614-sec-0098"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005614.pub2/full#CD005614-sec-0043"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005614.pub2/full#CD005614-sec-0044"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005614.pub2/full#CD005614-sec-0049"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005614.pub2/full#CD005614-sec-0050"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005614.pub2/full#CD005614-sec-0073"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005614.pub2/full#CD005614-sec-0092"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005614.pub2/appendices#CD005614-sec-0103"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/table_n/CD005614StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/table_n/CD005614StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005614.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005614.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD005614.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005614.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD005614.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD005614.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Chondroitin for osteoarthritis</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005614.pub2/information#CD005614-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Jasvinder A Singh</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005614.pub2/information#CD005614-cr-0003">Shahrzad Noorbaloochi</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005614.pub2/information#CD005614-cr-0004">Roderick MacDonald</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD005614.pub2/information#CD005614-cr-0005">Lara J Maxwell</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/information/en#CD005614-sec-0119">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 January 2015 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD005614.pub2">https://doi.org/10.1002/14651858.CD005614.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD005614-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005614-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD005614-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005614-abs-0017">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005614-abs-0005">Français</a> </li> <li class="section-language"> <a class="" href="full/ja#CD005614-abs-0004">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD005614-abs-0003">한국어</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD005614-abs-0002">繁體中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD005614-abs-0001" lang="en"> <section id="CD005614-sec-0001"> <h3 class="title" id="CD005614-sec-0001">Background</h3> <p>Osteoarthritis, a common joint disorder, is one of the leading causes of disability. Chondroitin has emerged as a new treatment. Previous meta‐analyses have shown contradictory results on the efficacy of chondroitin. This, in addition to the publication of more trials, necessitates a systematic review. </p> </section> <section id="CD005614-sec-0002"> <h3 class="title" id="CD005614-sec-0002">Objectives</h3> <p>To evaluate the benefit and harm of oral chondroitin for treating osteoarthritis compared with placebo or a comparator oral medication including, but not limited to, nonsteroidal anti‐inflammatory drugs (NSAIDs), analgesics, opioids, and glucosamine or other "herbal" medications. </p> </section> <section id="CD005614-sec-0003"> <h3 class="title" id="CD005614-sec-0003">Search methods</h3> <p>We searched seven databases up to November 2013, including the Cochrane Central Register of Controlled Trials (CENTRAL), Ovid MEDLINE, CINAHL, EMBASE, Science Citation Index (Web of Science) and Current Controlled Trials. We searched the US Food and Drug Administration (FDA) and European Medicines Agency (EMEA) websites for adverse effects. Trial registers were not searched. </p> </section> <section id="CD005614-sec-0004"> <h3 class="title" id="CD005614-sec-0004">Selection criteria</h3> <p>All randomized or quasi‐randomized clinical trials lasting longer than two weeks, studying adults with osteoarthritis in any joint, and comparing chondroitin with placebo, an active control such as NSAIDs, or other "herbal" supplements such as glucosamine. </p> </section> <section id="CD005614-sec-0005"> <h3 class="title" id="CD005614-sec-0005">Data collection and analysis</h3> <p>Two review authors independently performed all title assessments, data extractions, and risk of bias assessments. </p> </section> <section id="CD005614-sec-0006"> <h3 class="title" id="CD005614-sec-0006">Main results</h3> <p>Forty‐three randomized controlled trials including 4,962 participants treated with chondroitin and 4,148 participants given placebo or another control were included. The majority of trials were in knee OA, with few in hip and hand OA. Trial duration varied from 1 month to 3 years. Participants treated with chondroitin achieved statistically significantly and clinically meaningful better pain scores (0‐100) in studies less than 6 months than those given placebo with an absolute risk difference of 10% lower (95% confidence interval (CI), 15% to 6% lower; number needed to treat (NNT) = 5 (95% CI, 3 to 8; n = 8 trials) (level of evidence, low; risk of bias, high); but there was high heterogeneity between the trials (T<sup>2</sup> = 0.07; I<sup>2</sup> = 70%, which was not easily explained by differences in risk of bias or study sample size). In studies longer than 6 months, the absolute risk difference for pain was 9% lower (95% CI 18% lower to 0%); n = 6 trials; T<sup>2</sup> = 0.18; I<sup>2</sup> = 83% ), again with low level of evidence. </p> <p>For the Western Ontario and McMaster Universities Osteoarthritis Index Minimal Clinically Important Improvement (WOMAC MCII Pain subscale) outcome, a reduction in knee pain by 20% was achieved by 53/100 in the chondroitin group versus 47/100 in the placebo group, an absolute risk difference of 6% (95% CI 1% to 11%), (RR 1.12, 95% CI 1.01 to 1.24; T<sup>2</sup> = 0.00; I<sup>2</sup> = 0%) (n = 2 trials, 1253 participants; level of evidence, high; risk of bias, low). </p> <p>Differences in Lequesne's index (composite of pain,function and disability) statistically significantly favoured chondroitin as compared with placebo in studies under six months, with an absolute risk difference of 8% lower (95% CI 12% to 5% lower; T<sup>2</sup>= 0.78; n = 7 trials) (level of evidence, moderate; risk of bias, unclear), also clinically meaningful. Loss of minimum joint space width in the chondroitin group was statistically significantly less than in the placebo group, with a relative risk difference of 4.7% less (95% CI 1.6% to 7.8% less; n = 2 trials) (level of evidence, high; risk of bias, low). Chondroitin was associated with statistically significantly lower odds of serious adverse events compared with placebo with Peto odds ratio of 0.40 (95% CI 0.19 to 0.82; n = 6 trials) (level of evidence, moderate). Chondroitin did not result in statistically significant numbers of adverse events or withdrawals due to adverse events compared with placebo or another drug. Adverse events were reported in a limited fashion, with some studies providing data and others not. </p> <p>Comparisons of chondroitin taken alone or in combination with glucosamine or another supplement showed a statistically significant reduction in pain (0‐100) when compared with placebo or an active control, with an absolute risk difference of 10% lower (95% CI 14% to 5% lower); NNT = 4 (95% CI 3 to 6); T<sup>2</sup> = 0.33; I<sup>2</sup> = 91%; n = 17 trials) (level of evidence, low). For physical function, chondroitin in combination with glucosamine or another supplement showed no statistically significant difference from placebo or an active control, with an absolute risk difference of 1% lower (95% CI 6% lower to 3% higher with T<sup>2</sup> = 0.04; n = 5 trials) (level of evidence, moderate). Differences in Lequesne's index statistically significantly favoured chondroitin as compared with placebo, with an absolute risk difference of 8% lower (95% CI, 12% to 4% lower; T<sup>2</sup> = 0.12; n = 10 trials) (level of evidence, moderate). Chondroitin in combination with glucosamine did not result in statistically significant differences in the numbers of adverse events, withdrawals due to adverse events, or in the numbers of serious adverse events compared with placebo or with an active control. </p> <p>The beneficial effects of chondroitin in pain and Lequesne's index persisted when evidence was limited to studies with adequate blinding or studies that used appropriate intention to treat (ITT) analyses. These beneficial effects were uncertain when we limited data to studies with appropriate allocation concealment or a large study sample (&gt; 200) or to studies without pharmaceutical funding. </p> </section> <section id="CD005614-sec-0007"> <h3 class="title" id="CD005614-sec-0007">Authors' conclusions</h3> <p>A review of randomized trials of mostly low quality reveals that chondroitin (alone or in combination with glucosamine) was better than placebo in improving pain in participants with osteoarthritis in short‐term studies. The benefit was small to moderate with an 8 point greater improvement in pain (range 0 to 100) and a 2 point greater improvement in Lequesne's index (range 0 to 24), both likely clinically meaningful. These differences persisted in some sensitivity analyses and not others. Chondroitin had a lower risk of serious adverse events compared with control. More high‐quality studies are needed to explore the role of chondroitin in the treatment of osteoarthritis. The combination of some efficacy and low risk associated with chondroitin may explain its popularity among patients as an over‐the‐counter supplement. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD005614-abs-0006" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD005614-abs-0006">English</a> </li> <li class="section-language"> <a class="" href="full/de#CD005614-abs-0007">Deutsch</a> </li> <li class="section-language"> <a class="" href="full/es#CD005614-abs-0016">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD005614-abs-0018">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD005614-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD005614-abs-0012">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD005614-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD005614-abs-0009">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD005614-abs-0010">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ta#CD005614-abs-0014">தமிழ்</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD005614-abs-0008">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD005614-abs-0006" lang="en"> <h3>Chondroitin for osteoarthritis</h3> <p>We conducted a review of the effects of chondroitin sulfate for people with osteoarthritis. We found 43 studies with 9,110 people after searching for studies up to November 2013. Majority were studies of knee osteoarthritis (few hand, one hip) ranging from 1 month to 3 years. Several studies were funded by makers of chondroitin. </p> <p><b>This review shows that in people with osteoarthritis:</b> </p> <p>‐ Chondroitin may improve pain slightly in the short‐term (less than 6 months);</p> <p>‐ Chondroitin improves knee pain by 20% in slightly more people;</p> <p>‐ Chondroitin probably improves quality of life slightly as measured by Lequesne's index (combined measure of pain, function, and disability); </p> <p>‐ Chondroitin has little or no difference in adverse and serious adverse events versus other agents; and </p> <p>‐ Chondroitin slightly slows down the narrowing of joint space on X‐rays of the affected joint. </p> <p>We identified a lot of studies in which unsound methods were used to assess the effects of chondroitin. For some outcomes, there was not enough data. In some studies, whose methodological quality was better, chondroitin showed no improvement in pain and in physical function. Other analyses based on different methodological quality criteria reported improvement in pain and physical functionality when chondroitin was given. </p> <p><b>What is osteoarthritis and what is chondroitin?</b> </p> <p>Osteoarthritis is a disease of the joints, such as the knee or hip. When the joint loses cartilage, the bone grows to try to repair the damage, but this bone growth may make the situation worse. This can make the joint painful and unstable, which can affect physical function or ability to use the joint. </p> <p>Chondroitin is an over‐the‐counter nutritional supplement made primarily of chondroitin sulfate. It is said to work by stopping the degradation of cartilage and restoring lost cartilage. It also contains sulfur‐containing amino acids, which are essential building blocks for cartilage molecules in the human body. </p> <p><b>What happens to people with osteoarthritis who take chondroitin?</b> </p> <p><b>Pain level after 6 months (lower score is better)</b> </p> <p>‐ People who took chondroitin scored 10 points lower on 0 to 100 pain scale than those who took a placebo (10% absolute difference). </p> <p>‐ People who took chondroitin rated their pain at 18 on a 0 to 100 scale.</p> <p>‐ People who took placebo rated their pain at 28 on a 0 to 100 scale.</p> <p>In studies longer than 6 months, we are uncertain whether pain is reduced more by chondroitin than placebo. </p> <p><b>Reduction in knee pain by 20% (as measured by the WOMAC<sup>1</sup> Pain subscale)</b> </p> <p>‐ 6 more people out of 100 experienced improvement of 20% in their knee pain (6% absolute difference). </p> <p>‐ 53 people out of 100 who took chondroitin experienced improvement in their knee pain compared to 47 people out of 100 who took placebo. </p> <p><b>Lequesne’s index (a combination index of pain and physical function, indicating quality of life) after 6 months</b> </p> <p>‐ People who took chondroitin scored 2 points lower (better) on Lequesne's index (score range 0 to 24). </p> <p>‐ People who took chondroitin scored 5 on a scale of 0 to 24 on Lequesne's index.</p> <p>‐ People who took placebo scored 7 on a scale of 0 to 24 on Lequesne's index.</p> <p><b>Radiographic outcome: reduction in minimum joint space width (mm) (smaller decrease in reduction in minimum joint space width is better) after 2 years</b> </p> <p>‐ People who took chondroitin had 0.18 mm less reduction in minimum joint space width than those who took placebo. </p> <p>‐ People who took chondroitin had a reduction in minimum joint space width of 0.12 mm. </p> <p>‐ People who took placebo had a reduction in minimum joint space width of 0.30 mm.</p> <p><b>Serious adverse events</b> </p> <p>‐ 3 fewer of 100 people who took chondroitin experienced serious adverse events (such as a serious lung infection or tuberculosis). </p> <p>‐ 3 of 100 people experienced a serious adverse event with chondroitin compared to 6 of 100 people who took placebo.  </p> <p> <b>People who dropped out of the studies for adverse events</b> </p> <p>‐ People who took chondroitin had no difference in the risk of dropping out of the studies for adverse events than those who took a placebo.This may have happened by chance. </p> <p><b><sup>1</sup>Western Ontario and McMaster Universities Osteoarthritis Index</b> </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD005614-sec-0098" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD005614-sec-0098"></div> <h3 class="title" id="CD005614-sec-0099">Implications for practice</h3> <section id="CD005614-sec-0099"> <p>The improvement in joint pain with chondroitin (alone or in combination with glucosamine) in participants with osteoarthritis was clinically meaningful and statistically significantly better than placebo, based on trials of mostly low quality. Participants reported statistically significantly more favorable ratings on patient and physician global assessment scales, Lequesne's index (a combination of pain, physical function and disability), which seemed clinically meaningful as well, based on evidence of low to moderate quality. There was statistically significantly less reduction in minimal joint space width with chondroitin compared to placebo groups, based on evidence of moderate to high quality, but the significance of this radiographic benefit is unclear to us. </p> <p>Differences in physical function (by WOMAC) and most other clinical and radiographic outcomes were not statistically significant. WOMAC scores were reported in few trials, but Lequesne's index (a pain, physical function and disability composite) was reported by several studies, and was statistically significantly different between chondroitin and control/placebo, and the difference is considered clinically meaningful. It is important to note that the risk of serious side effects was lower in the chondroitin group than in comparator groups. Chondroitin was also tested alone and in combination with glucosamine against placebo or control treatments (NSAIDs), and similar observations were made. These differences in pain with chondroitin (alone or in combination with glucosamine) compared with placebo were attenuated or were no longer significant in some sensitivity analyses, but they persisted in other sensitivity analyses (blinding, ITT). Results were sensitive to trial quality, trial sponsorship, and trial sample size, such that trials with unclear or no allocation concealment, with pharmaceutical sponsorship, and with smaller sample size were more likely to show significant differences between groups, and those not in these categories showed a smaller and/or insignificant difference between chondroitin and comparator. On the other hand, when we limited analysis to studies with adequate blinding and studies using intention‐to‐treat (ITT) analyses, the differences in pain between chondroitin (alone or in combination with glucosamine) and placebo persisted. </p> <p>Osteoarthritis is a challenging disease, and at present, very few effective and safe treatment options are available. Frequently used treatments such as NSAIDs are associated with significant adverse events, especially in the elderly. In addition, these medications are not universally effective, and a large proportion of patients fail with these over time. Analgesics such as acetaminophen are not very effective in severe osteoarthritis, and also have potential liver toxicity. The elderly may experience adverse events to narcotics, such as constipation, falls, confusion, etc. which sometimes are used for the treatment of severe osteoarthritis. Thus, a clear need exists for several more effective and safe treatment options. </p> <p>Chondroitin is available over the counter as a supplement. Chondroitin seems to be well tolerated with no major safety issues, and its efficacy seems to range from small to medium treatment effect. However, most data have come from several small trials of short duration, with most sample sizes &lt; 100. Given the widespread use of this supplement, it is important that we understand its efficacy and role in the treatment of osteoarthritis. At this time, we suggest that patients and physicians discuss the pros and cons of using chondroitin for osteoarthritis and use it in conjunction with other modalities for osteoarthritis treatment, including weight loss and quadriceps strengthening and appropriate pharmacological treatment. We believe that larger high‐quality studies of chondroitin in various subgroups of osteoarthritis (early vs late vs end‐stage osteoarthritis, mild vs severe osteoarthritis, erosive vs. non‐erosive osteoarthritis) are needed. </p> </section> <h3 class="title" id="CD005614-sec-0100">Implications for research</h3> <section id="CD005614-sec-0100"> <p>Most evidence for chondroitin comes from small trials. The National Institutes of Health (NIH) has already sponsored and conducted the GAIT trial (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>), which showed no statistically significant difference from placebo. Well‐designed high‐quality RCTs of chondroitin in participants with early and late osteoarthritis are desirable because they can add valuable information to knowledge gaps in this area. Larger samples and appropriate controls (placebo or NSAIDs) are needed, and trials need to provide longer follow‐up and closer monitoring so investigators can see long‐term effects and detect any safety concerns. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD005614-sec-0043" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD005614-sec-0043"></div> <div class="table" id="CD005614-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Chondroitin versus placebo for osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chondroitin versus placebo for osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with osteoarthritis<br/> <b>Settings:</b> international inpatient and outpatient clinics, hospitals, and research centers<br/> <b>Intervention:</b> Chondroitin versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Chondroitin versus Placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain on a 0 to 100 mm scale ‐ Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain on a 0 to 100 scale in the control groups was</p> <p><b>28 points</b><sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain on a 0 to 100 scale in the intervention groups was</p> <p><b>10.1 mm lower</b> </p> <p>(14.6 to 5.7 lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1077<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean Difference ‐10.14 (95% CI ‐14.58 to ‐5.71)</p> <p>Absolute risk difference</p> <p>‐10% (95% CI ‐15% to ‐6%)</p> <p>Relative risk difference</p> <p>‐36% (95% CI ‐52% to ‐20%)</p> <p>NNTB = 5 (95% CI 3 to 8)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain on a 0 to 100 scale ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain on a 0 to 100 scale in the control groups was</p> <p><b>30 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain on a 0 to 100 scale in the intervention groups was</p> <p><b>9 points lower</b> </p> <p>(18 to 0 lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>989<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean Difference ‐9.01 (95% CI ‐17.68 to ‐0.34)</p> <p>Absolute risk difference</p> <p>‐9% (95% CI ‐18% to 0%)</p> <p>Relative risk difference</p> <p>‐30% (95% CI ‐60% to 0%)</p> <p>NNTB = n/a</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>WOMAC MCII Pain subscale (reduction in knee pain by 20%) ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>471 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>528 per 1000</b> <br/> (476 to 584) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> <br/> (1.01 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1253<br/> (2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference 6% (1% to 11%)</p> <p>Relative risk difference 12% (1% to 24%)</p> <p>NNTB = 16 (9 to 136)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Composite Measure of Pain, Function and Disability as assessed with Lequesne's Index on 0 to 24 scale (lower indicates less pain and disability) ‐ Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean Lequesne's index on 0 to 24 scale in the control groups was <b>7.4 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean Lequesne's index on 0 to 24 scale in the intervention groups was<br/> <b>1.98 lower</b> <br/> (2.79 to 1.17 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>903<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.57 (95% CI ‐0.84 to ‐0.30)<br/> Absolute risk difference ‐8% (95% CI ‐12% to ‐5%) </p> <p>Relative risk difference ‐18% (95% CI ‐25% to ‐10%)</p> <p>NNTB=2 (95% CI 2, 3)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Radiographic Outcome: Reduction in Minimum Joint Space Width (JSW) in mm ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</b> </p> <p>Scale: millimeters (smaller decrease in reduction in minimum joint space width is better)<br/> Follow‐up: 3 to 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction in JSW in the control group was <b>0.3 mm</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction in JSW in the intervention groups was<br/> <b>0.18 mm lower</b> <br/> (0.06 to 0.30 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>922<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference not calculable because no range is provided for this measure</p> <p>Relative risk difference: 4.7% (95% CI, 1.6% to 7.8%)</p> <p>NNTB = 7 (95% CI 5 to 13)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> Follow up: 3 to 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b> <br/> (32 to 69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> <br/> (0.74 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2406</p> <p>(10 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 0% change (‐1% to 2%)</p> <p>Relative percentage change: 8% (‐26% to 57%)</p> <p>NNTH = not applicable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of serious adverse events</b> Follow‐up: 3 to 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>27 per 1000</b> <br/> (13 to 53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.40</b> <br/> (0.19 to 0.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>954<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: ‐3% (95% CI ‐6% to ‐1%)</p> <p>Relative percentage change: ‐58% (95% CI ‐17% to ‐79%)</p> <p>NNTH was significantly in favor of chondroitin and was 29 (95% CI 22 to 93)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Concerns of risk of bias due to lack of reporting of methods of randomization or allocation concealment or methods were unclear and the majority were sponsored by a manufacturer of chondroitin sulfate.<br/> <sup>2</sup>Significant heterogeneity between study results is evident, with I<sup>2</sup> over 70%, and the studies are split between significant and non significant results from chondroitin. Two studies reporting significant benefit from chondroitin have confidence intervals that do not overlap with those of two studies that report no significant benefit from chondroitin.<br/> <sup>3</sup> This baseline came from Clegg as Sawitzke referenced Clegg and provided both shorter and longer term outcomes </p> <p><sup>4</sup> Four of the seven studies reporting on this outcome did not report their methods of randomization, five did not report allocation concealment and seven are sponsored by a manufacturer of chondroitin sulfate or do not report their source of sponsorship. I<sup>2</sup>=67%<br/> <sup>5</sup> Downgraded for imprecision; total number of events less than 300 and relative risk increase is larger than 25%<br/> <sup>6</sup> Two of six studies did not report their methods of randomization, five of the six studies did not report their methods of allocation concealment, and all six studies were sponsored by a manufacturer of chondroitin sulfate or did not report their source of funding. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005614-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Chondroitin with or without glucosamine versus placebo/control for osteoarthritis (studies with estimated SDs not analyzed)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chondroitin sulfate/CSGH versus placebo/control for osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with osteoarthritis<br/> <b>Settings:</b> international inpatient and outpatient clinics, hospitals, and research centers<br/> <b>Intervention:</b> chondroitin sulfate or chondroitin sulfate with glucosamine versus placebo/control </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Chondroitin sulfate/chondroitin sulfate with glucosamineversus placebo/control</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain (short‐ and long‐term)</b> <br/> Scale from 0 to 100 mm </p> <p>(lower is better)<br/> Follow‐up: 3 to 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain (short‐ and long‐term) in the control groups was<br/> <b>30.2 mm</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain on 0 to 100 scale (short‐ and long‐term studies) in the intervention groups was </p> <p><b>9.6 mm lower</b> <br/> (14 mm to 5.2 mm lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2262<br/> (17 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.65 (95% CI ‐0.95 to ‐0.35)</p> <p>Absolute risk difference</p> <p>‐10% lower (95% CI ‐14% to ‐5%)</p> <p>Relative risk difference</p> <p>‐20% lower (95% CI ‐30% to ‐11%)</p> <p>NNTB = 4 (95% CI 3 to 6)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>WOMAC MCII Pain subscale (reduction in knee pain by 20%) Long‐term studies (≥ 6 months) dose ≥ 800 mg/d</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>471 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>528 per 1000</b> <br/> (476 to 584) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> <br/> (1.01 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1253<br/> (2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference 6% (1% to 11%)</p> <p>Relative risk difference 12% (1% to 24%)</p> <p>NNTB = 16 (9 to 136)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Composite Measure of Pain, Function and Disability as assessed through Lequesne's index</b> <br/> Scale from 0 to 24 </p> <p>(lower indicates less pain and disability)<br/> Follow‐up: 3 to 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean Lequesne's index in the control groups was <b>9.7 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean Lequesne's index on 0 to 24 scale in the intervention groups was<br/> <b>2 points lower</b> <br/> (3 lower to 1 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1756<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>3,4</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.48 (95% CI ‐0.72 to ‐0.24)</p> <p>Absolute risk difference</p> <p>‐8% (95% CI ‐12% to ‐4%)</p> <p>Relative risk difference</p> <p>‐18% lower (95% CI ‐26% to ‐9%)</p> <p>NNTB = 5 (95% CI 3 to 9)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; NNTB: Number needed to treat for an additional beneficial outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>11 of the 17 studies reporting on this outcome did not report their methods of randomization, 13 of the 17 did not report the method of allocation concealment. 16 of the 17 studies were sponsored by a manufacturer of chondroitin sulfate or did not report their source of funding.<br/> <sup>2</sup>Significant heterogeneity among the results is evident, with I<sup>2</sup> of 90%. The confidence intervals did not overlap one another, indicating a high degree of inconsistency in the effects observed in each study.<br/> <sup>3</sup> Significant inconsistency was noted in the results of these studies, with five studies reporting significant benefit from chondroitin and three reporting no significant difference between chondroitin. This inconsistency is made serious by the lack of overlap in the confidence intervals of studies with contradictory results. </p> <p><sup>4</sup>Six of the 10 studies did not report their methods of randomization or allocation concealment. All ten studies did not report their source of funding or were sponsored by a manufacturer of chondroitin sulfate. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD005614-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Chondroitin with or without glucosamine versus placebo/control for osteoarthritis (sensitivity analysis including studies with estimated SDs)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chondroitin sulfate/CSGH versus placebo/control for osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with osteoarthritis<br/> <b>Settings:</b> international inpatient and outpatient clinics, hospitals, and research centers <br/> <b>Intervention:</b> Chondroitin sulfate or Chondroitin sulfate with glucosamine versus placebo/control </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Chondroitin sulfate/Chondroitin sulfate with glucosamineversus placebo/control</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain (short‐ and long‐term)</b> <br/> Scale from 0 to 100 </p> <p>(lower is better)<br/> Follow‐up: 3 to 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain (short‐ and long‐term) in the control groups was<br/> <b>30.2 mm</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain on 0 to 100 scale (short‐ and long‐term studies) in the intervention groups was<br/> <b>9.5 mm lower</b> <br/> (13mm lower to 6.1 mm lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3038<br/> (22 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.64 (95% CI ‐0.88 to ‐0.41)</p> <p>Absolute risk difference</p> <p>‐10% (95% CI ‐13% to ‐6%)</p> <p>Relative risk difference</p> <p>‐20% (95% CI ‐27% to ‐13%)</p> <p>NNTB = 4 (95% CI 3 to 6)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physical function (short‐ and long‐term)</b> <br/> Scale from 0 to 100 </p> <p>(lower is better)<br/> Follow‐up: 3‐24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physical function (short‐ and long‐term) in the control groups was<br/> <b>31.8 mm</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physical function (short‐ and long‐term) on a 0 to 100 scale (higher is worse) in the intervention groups was </p> <p><b>1.3 mm lower</b> <br/> (5.7 mm lower to 3.1 mm higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1163<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.07 (95% CI ‐0.31 to 0.17)</p> <p>Absolute risk difference</p> <p>‐1% (95% CI ‐6% to 3%)</p> <p>Relative risk difference</p> <p>‐3% (95% CI ‐13% to 7%)</p> <p>NNTB = not applicable</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Composite Measure of Pain, Function and Disability as assessed through Lequesne's index (short‐ and long‐term)</b> <br/> Scale from 0 to 24 (lower indicates less pain and disability)<br/> Follow‐up: 3 to 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean Lequesne's index (short‐ and long‐term) in the control groups was<br/> <b>9.7 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean Lequesne's index on 0 to 24 scale (higher is worse; short‐ and long‐term results combined) in the intervention groups was<br/> <b>2.5 points lower</b> <br/> (3.5 to 1.5 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2334<br/> (16 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.57 (95% CI ‐0.79 to ‐0.35)</p> <p>Absolute risk difference</p> <p>‐10% (95% CI ‐14% to ‐6%)</p> <p>Relative risk difference</p> <p>‐22% (95% CI ‐30% to ‐13%)</p> <p>NNTB = 4 (95% CI 3 to 6)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g., the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; NNTB: Number needed to treat for an additional beneficial outcome. NNTB is not applicable when the result is not statistically significant. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>17 of the 23 studies reporting on this outcome did not report their methods of randomization, 19 of the 23 did not report the method of allocation concealment. 22 of the 23 studies were sponsored by a manufacturer of chondroitin sulfate or did not report their source of funding.<br/> <sup>2</sup>Significant heterogeneity among the results is evident, with I<sup>2</sup> of 88%. The confidence intervals did not overlap one another, indicating a high degree of inconsistency in the effects observed in each study.<br/> <sup>3</sup>Two of the five studies reporting on this outcome did not report their methods of randomization. Three of the five studies did not report their methods of allocation concealment. All five studies were funded by a manufacturer of chondroitin sulfate or did not report their source of funding.<br/> <sup>4</sup>13 of the 16 studies did not report their methods of randomization, 14 of the 16 did not describe the method of allocation concealment. All 16 studies did not report their source of funding or were sponsored by a manufacturer of chondroitin sulfate. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD005614-sec-0044" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD005614-sec-0044"></div> <section id="CD005614-sec-0045"> <h3 class="title" id="CD005614-sec-0045">Description of the condition</h3> <p>Osteoarthritis, the most common of all joint disorders, is one of the leading causes of disability in the United States (<a href="./references#CD005614-bbs2-0124" title="GabrielSE , CrowsonCS , O'FallonWM . Costs of osteoarthritis: estimates from a geographically defined population. Journal of Rheumatology1995;22(Suppl 43):23‐5. ">Gabriel 1995</a>; <a href="./references#CD005614-bbs2-0144" title="PeyronJG , AltmanRD . Osteoarthritis: diagnosis and management. In: MoskowitzRW , HowellDS , GoldbergVM , MankinHJ editor(s). The Epidemiology of Osteoarthritis. Philadelphia: WB Saunders, 1992:15‐38. ">Peyron 1992</a>). Pathologically, osteoarthritis is characterized by softening and degeneration of articular cartilage, formation of new bone at joint margins, and capsular fibrosis. Clinically, osteoarthritis manifests as joint pain, stiffness, deformity, and loss of function. Clinical and radiographic surveys have found that the prevalence of osteoarthritis increases with age, from 1% in people &lt; 30 years to 10% in those &lt; 40 years to more than 50% in individuals &gt; 60 years of age (<a href="./references#CD005614-bbs2-0121" title="FelsonDT . The epidemiology of knee osteoarthritis: results from the Framingham Osteoarthritis Study. Seminars in Arthritis and Rheumatism1990;20(3(Suppl 1)):42‐50. ">Felson 1990</a>; <a href="./references#CD005614-bbs2-0154" title="vanSasseJL , vanRomundeLK , CatsA , VanderbrouckeJP . Epidemiology of osteoarthritis: Zoetermeer survey. Comparison of radiological osteoarthritis in a Dutch population with that in 10 other populations. Annals of the Rheumatic Diseases1989;48(4):271‐80. ">van Saase 1989</a>). Autopsy studies show cartilage changes in almost all people above 65 years of age (<a href="./references#CD005614-bbs2-0120" title="FelsonDT . Epidemiology of knee and hip osteoarthritis. Epidemiologic Reviews1988;10:1‐28. ">Felson 1988</a>). Osteoarthritis is equally common in men and women between 45 and 55 years but is more common in women after 55 years of age (<a href="./references#CD005614-bbs2-0102" title="AltmanR , AlarconG , AppelrouthD , BlochD , BorensteinD , BrandtK , et al. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the hand. Arthritis and Rheumatism1990;33(11):1601‐10. ">Altman 1990</a>). Risk factors for osteoarthritis include obesity, joint dysplasia (abnormal anatomy of the joint due to abnormal growth), trauma, occupational activity, and family history, among others (<a href="./references#CD005614-bbs2-0148" title="SolomonL . Clinical features of osteoarthritis. In: RuddyS , HarrisED , SledgeCB editor(s). Kelly's Textbook of Rheumatology. 6th Edition. Vol. 2, Philadelphia: WB Saunders Company, 2001:1409‐18. ">Solomon 2001</a>). Osteoarthritis is classified as primary or secondary based on the absence or presence of anteceding joint abnormality or injury. Primary osteoarthritis is further classified as generalized or localized to a joint area such as hand, knee, hip, spinal apophyseal joints (between spinal bones/vertebrae), and foot, or to other joints (shoulder, elbow, wrist, and ankle) (<a href="./references#CD005614-bbs2-0148" title="SolomonL . Clinical features of osteoarthritis. In: RuddyS , HarrisED , SledgeCB editor(s). Kelly's Textbook of Rheumatology. 6th Edition. Vol. 2, Philadelphia: WB Saunders Company, 2001:1409‐18. ">Solomon 2001</a>). </p> </section> <section id="CD005614-sec-0046"> <h3 class="title" id="CD005614-sec-0046">Description of the intervention</h3> <p>Treatment of osteoarthritis is primarily directed at relieving pain and improving functional status. Various treatment options are available for patients with osteoarthritis, including the following: (1) oral medications: analgesics such as acetaminophen, aspirin, nonsteroidal anti‐inflammatory drugs (NSAIDs), and opioids (<a href="./references#CD005614-bbs2-0107" title="CepedaMS , CamargoF , ZeaC , ValenciaL . Tramadol for osteoarthritis. Cochrane Database of Systematic Reviews2006, Issue 3. [DOI: 10.1002/14651858.CD005522.pub2] ">Cepeda 2006</a>; <a href="./references#CD005614-bbs2-0152" title="TowheedT , MaxwellL , JuddM , CattonM , HochbergMC , WellsGA . Acetaminophen for osteoarthritis. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD004257.pub2] ">Towheed 2006</a>); (2) local therapies (applied as gels or creams): topical NSAIDs and capsaicin; (3) intra‐articular therapies: corticosteroid and hyaluronic acid injections (<a href="./references#CD005614-bbs2-0105" title="BellamyN , CampbellJ , WelchV , GeeTL , BourneR , WellsGA . Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database of Systematic Reviews2006, Issue 2. [DOI: 10.1002/14651858.CD005321.pub2] ">Bellamy 2006</a>); (4) nonpharmacologic methods: physical therapy, aerobic therapy, strengthening exercises, transcutaneous electric nerve stimulation, and wedged insoles (<a href="./references#CD005614-bbs2-0123" title="FransenM , McConnellS . Exercise for osteoarthritis of the knee. Cochrane Database of Systematic Reviews2008, Issue 4. [DOI: 10.1002/14651858.CD004376.pub2] ">Fransen 2008</a>); and (5) surgical treatments: joint replacement and arthroscopic debridement of the affected joint (<a href="./references#CD005614-bbs2-0134" title="LaupattarakasemW , LaopaiboonM , LaupattarakasemP , SumananontC . Arthroscopic debridement for knee osteoarthritis. Cochrane Database of Systematic Reviews2008, Issue 1. [DOI: 10.1002/14651858.CD005118.pub2] ">Laupattarakasem 2008</a>). However, frequent side effects, limited efficacy, and variable rates of success limit the use of many non‐surgical treatments. </p> <p>Over the past few years, various nutritional supplements, including chondroitin, glucosamine, avocado/soybean unsaponifiables, and diacerein, have emerged as new treatment options for osteoarthritis (<a href="./references#CD005614-bbs2-0110" title="DealCL , MoskowitzRW . Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondroitin sulfate and collagen hydrolysate. Rheumatic Disease Clinics of North America1999;25:379‐95. ">Deal 1999</a>). These supplements are characterized by both slow onset of action over six to eight weeks and a carryover of effect for up to two months after withdrawal (<a href="./references#CD005614-bbs2-0115" title="FajardoM , DiCesarePE . Disease‐modifying therapies for osteoarthritis. Drugs Aging2005;22(2):141‐61. ">Fajardo 2005</a>). According to recent recommendations from the American College of Rheumatology and the European League Against Rheumatism, drugs for treatment of osteoarthritis are classified as symptom‐modifying or structure‐modifying drugs, depending on their capacity to interfere with disease progression (<a href="./references#CD005614-bbs2-0103" title="AltmanRD , HochbergM , MoskowitzRW , SchnitzerJ . on behalf of the American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the medical management of osteoarthritis on the hip and the knee. Arthritis and Rheumatism2000;43:1905‐15. ">Altman 2000</a>; <a href="./references#CD005614-bbs2-0143" title="PendeltonA , ArdenN , DougadosM , DohertyM , BannwarthB , BijlsmaJW , et al. EULAR recommendations for the management of knee osteoarthritis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Annals of the Rheumatic Diseases2000;59:936‐44. ">Pendelton 2000</a>). The current body of evidence suggests that chondroitin falls into the symptom‐modifying category (i.e., chondroitin has a primary effect on improvement of pain and function), and glucosamine and diacerein into the structure‐modifying category (<a href="./references#CD005614-bbs2-0112" title="DougadosM , LeClaireP , van derHeijdeD , BlochDA , BellamyN , AltmanRD . Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for clinical trials response criteria initiative. Osteoarthritis and Cartilage2000;8:395‐403. ">Dougados 2000</a>; <a href="./references#CD005614-bbs2-0084" title="RichyF , BruyereO , EthgenO , CucheratM , HenrotinY , ReginsterJY . Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta‐analysis. Archives of Internal Medicine2003;163(13):1514‐22. ">Richy 2003</a>) (i.e., they have an effect on progression of arthritis, such as an effect on joint space narrowing as assessed by radiography of the involved joint). One of the main proposed advantages of these medications over traditional medical therapies is their safety profile. </p> </section> <section id="CD005614-sec-0047"> <h3 class="title" id="CD005614-sec-0047">How the intervention might work</h3> <p>Chondroitin sulfate belongs to a family of heteropolysaccharides called <i>glycosaminoglycans,</i> or GAGs. Chondroitin sulfate is found in human cartilage, bone, cornea, skin, and arterial wall. Sources of chondroitin used in nutritional supplements include bovine trachea, pork byproducts, shark cartilage, and whale septum (<a href="./references#CD005614-bbs2-0126" title="HendlerSS , RorvikD (editors) . PDR for Nutritional Supplements. 1st Edition. Montvale: Thomson Healthcare, 2001:93‐96. ">Hendler 2001</a>). Proposed mechanisms of action include restoring the extracellular matrix of cartilage, preventing further cartilage degradation (<a href="./references#CD005614-bbs2-0131" title="JohnsonKA , HulseDA , HartRC , KochevarD , ChuQ . Effects of an orally administered mixture of chondroitin sulfate, glucosamine hydrochloride and manganese ascorbate on synovial fluid chondroitin sulfate 3B3 and 7D4 epitope in a canine cruciate ligament transection model of osteoarthritis. Osteoarthritis and Cartilage2001;9(1):14‐21. ">Johnson 2001</a>), and overcoming a dietary deficiency of sulfur‐containing amino acids, which are essential building blocks for cartilage extracellular matrix molecules (<a href="./references#CD005614-bbs2-0109" title="CordobaF , NimniME . Chondroitin sulfate and other sulfate containing chondroprotective agents may exhibit their effects by overcoming a deficiency of sulfur amino acids. Osteoarthritis and Cartilage2003;11(3):228‐30. ">Cordoba 2003</a>). A large number of patients with osteoarthritis in the United States and around the world are already using chondroitin alone or in combination with glucosamine for relief of osteoarthritis‐related joint pain. Both glucosamine and chondroitin are available over the counter as nutritional supplements, and combination therapy of glucosamine and chondroitin has been used, but it is unclear whether these two supplements produce an additive or a synergistic effect. </p> </section> <section id="CD005614-sec-0048"> <h3 class="title" id="CD005614-sec-0048">Why it is important to do this review</h3> <p>A meta‐analysis of glucosamine and chondroitin for treatment of osteoarthritis published in 2000 (<a href="./references#CD005614-bbs2-0139" title="McAlindonTE , LaValleyMP , GulinJP , FelsonDT . Glucosamine and chondroitin for treatment of osteoarthritis: a systematic review and meta‐analysis. JAMA2000;283(11):1469‐75. ">McAlindon 2000a</a>) concluded that both supplements were effective for pain relief and functional outcomes with moderate to large effects, but quality issues and publication bias seemed to inflate the effect sizes. The Cochrane review of glucosamine for treating osteoarthritis concluded that studies using a non‐Rotta preparation or adequate allocation concealment failed to show benefit in pain and function, while studies evaluating the Rotta preparation showed that glucosamine was superior to placebo in the treatment of pain and functional impairment resulting from symptomatic osteoarthritis (<a href="./references#CD005614-bbs2-0151" title="TowheedTE , MaxwellL , AnastassiadesTP , SheaB , HouptJ , WelchV , et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database of Systematic Reviews2005, Issue 2. [DOI: 10.1002/14651858.CD002946.pub2] ">Towheed 2005</a>). Meta‐analyses of chondroitin for osteoarthritis (<a href="./references#CD005614-bbs2-0067" title="LeebBF , SchweitzerH , MontagK , SmolenJS . A metaanalysis of chondroitin sulfate in the treatment of osteoarthritis. Journal of Rheumatology2000;27(1):205‐11. ">Leeb 2000</a>) and glucosamine and chondroitin for knee osteoarthritis (<a href="./references#CD005614-bbs2-0084" title="RichyF , BruyereO , EthgenO , CucheratM , HenrotinY , ReginsterJY . Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta‐analysis. Archives of Internal Medicine2003;163(13):1514‐22. ">Richy 2003</a>) that included studies up to March 2002 concluded that chondroitin was effective for pain and function compared with placebo. A limitation noted in both of these meta‐analyses is that trials included in the analyses allowed coadministration of analgesics or NSAIDs during the study, leading to possible confounding of the results. Publication of additional studies of chondroitin over the past few years since these meta‐analyses were published necessitates a new systematic review. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD005614-sec-0049" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD005614-sec-0049"></div> <p>To evaluate the benefit and harm of oral chondroitin for the treatment of osteoarthritis compared with placebo or a comparator oral medication including, but not limited to, nonsteroidal anti‐inflammatory drugs (NSAIDs), analgesics, opioids, and glucosamine or other "herbal" medications. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD005614-sec-0050" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD005614-sec-0050"></div> <section id="CD005614-sec-0051"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD005614-sec-0052"> <h4 class="title">Types of studies</h4> <p>Randomized controlled trials (RCTs) of two weeks' duration or longer were included if they reported clinical outcomes data and were published in full. Randomized controlled trials of shorter than two weeks' duration were excluded because this time frame may be too short to allow assessment of harms and benefits based on biological plausibility. </p> </section> <section id="CD005614-sec-0053"> <h4 class="title">Types of participants</h4> <p>Adults (age &gt; 18 years) with osteoarthritis of any joint.</p> </section> <section id="CD005614-sec-0054"> <h4 class="title">Types of interventions</h4> <p>Chondroitin arm:<br/> Use of oral chondroitin alone or in combination with other oral drugs such as glucosamine. </p> <p>Comparator arm:<br/> Placebo or active medications including NSAIDs, analgesics (e.g., acetaminophen), opioid pain‐relieving medications, glucosamine or other "herbal" medications, or other comparator oral medications. </p> </section> <section id="CD005614-sec-0055"> <h4 class="title">Types of outcome measures</h4> <section id="CD005614-sec-0056"> <h5 class="title">Major outcomes</h5> <p> <ol id="CD005614-list-0001"> <li> <p>Pain: pain subscale of the Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) (<a href="./references#CD005614-bbs2-0104" title="BellamyN , BuchananWW , GoldsmithCH , CampbellJ , StittLW . Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. Journal of Rheumatology1988;15:1833‐40. ">Bellamy 1988</a>) or Numeric rating scale or Visual Analog Scale; rest pain; pain on motion; pain on walking for index joint; pain in index joint during activities other than walking; or other similar pain scale. A higher score indicates worse pain state in general. Clinically clinically meaningful threshold in pain intensity has been defined as an improvement of 0.9‐1.3 cm on a 0‐10 cm pain scale (<a href="./references#CD005614-bbs2-0132" title="KellyAM . Does the clinically significant diVerence in VAS pain score diVer with age, gender or cause of pain?. Acad Emerg Med1998;5:1086‐90. ">Kelly 1998</a>; <a href="./references#CD005614-bbs2-0133" title="KellyAM . The minimum clinically significant difference in visual analogue scale pain score does not differ with severity of pain. Emerg Med J2001;18(3):205‐7. ">Kelly 2001</a>; <a href="./references#CD005614-bbs2-0150" title="ToddKH . Clinical versus statistical significance in the assessment of pain relief. Ann Emerg Med1996;27(4):439‐41. ">Todd 1996</a>). This threshold was also endorsed by the The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) (<a href="./references#CD005614-bbs2-0113" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain2008;9:105–21. ">Dworkin 2008</a>). Percent pain responders, defined as the proportion with minimal clinically important improvement [MCII] on WOMAC (<a href="./references#CD005614-bbs2-0114" title="EscobarA , QuintanaJM , BilbaoA , ArosteguiI , LafuenteI , VidaurretaI . Responsiveness and clinically important differences for the WOMAC and SF‐36 after total knee replacement. Osteoarthritis Cartilage2007;15(3):273‐80. ">Escobar 2007</a>), was another major outcome of interest. </p> </li> <li> <p>Physical function: both performance‐based (e.g., 50‐foot walk) and patient‐based (WOMAC minimal clinically important improvement, MCII (<a href="./references#CD005614-bbs2-0114" title="EscobarA , QuintanaJM , BilbaoA , ArosteguiI , LafuenteI , VidaurretaI . Responsiveness and clinically important differences for the WOMAC and SF‐36 after total knee replacement. Osteoarthritis Cartilage2007;15(3):273‐80. ">Escobar 2007</a>); WOMAC total and subscale scores). WOMAC subscale scores are transformed on a scale of 0 to 100, with higher scores indicating worse pain, function, and overall status. </p> </li> <li> <p>Lequesne's index (<a href="./references#CD005614-bbs2-0136" title="LequesneMG . The Algofunctional Indices for Hip and Knee Osteoarthritis. Journal of Rheumatology1997;24(4):779‐81. ">Lequesne 1997</a>): combines pain, walking ability, and activities of daily living into a composite, with scores ranging from 0 to 24 and higher score indicating worse status of osteoarthritis and disability/quality of life (composite pain, function and disability scale). Clinically meaningful thresholds have not been defined in publications, therefore we used the moderate effect size of 0.5 as meaningful. Personal communications with developer of the scale (Dr. Lequesne) indicated that a change of approximately 2‐units for a baseline score of 9‐11.5 may be clinically meaningful. </p> </li> <li> <p>Radiographic outcomes: radiologic changes in joint space width or narrowing in millimeters, or other radiographic criteria. </p> </li> <li> <p>Total number of adverse effects or events (AEs).</p> </li> <li> <p>Total number of withdrawals and withdrawals judged to be due to adverse effects in each group. </p> </li> <li> <p>Serious adverse effects (SAEs).</p> </li> </ol> </p> </section> <section id="CD005614-sec-0057"> <h5 class="title">Minor outcomes</h5> <p>Clinical efficacy outcomes:</p> <p> <ul class="plain" id="CD005614-list-0002"> <li> <ol id="CD005614-list-0003"> <li> <p>Patient and Physician global assessment, typically on an ordinal scale or a 0 to 100 visual analogue scale (VAS) or a numeric rating scale. </p> </li> <li> <p>Responders: defined as percentage of participants achieving OMERACT‐OARSI response criteria (<a href="./references#CD005614-bbs2-0112" title="DougadosM , LeClaireP , van derHeijdeD , BlochDA , BellamyN , AltmanRD . Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for clinical trials response criteria initiative. Osteoarthritis and Cartilage2000;8:395‐403. ">Dougados 2000</a>; <a href="./references#CD005614-bbs2-0145" title="PhamT , van derHeijdeD , AltmanRD , AndersonJJ , BellamyN , HochbergM , et al. OMERACT‐OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis and Cartilage2004;12:389‐99. ">Pham 2004</a>), percentage achieving minimal clinically important improvement (MCII) on WOMAC (<a href="./references#CD005614-bbs2-0153" title="TubachF , RavaudP , BaronG , FalissardB , LogeartI , BellamyN , et al. Evaluation of clinically relevant changes in patient reported outcomes in knee or hip osteoarthritis: the minimal clinically important improvement. Annals of the Rheumatic Diseases2005;64(1):29‐33. ">Tubach 2005</a>), or percentage achieving responder status based on other validated scales/criteria. </p> </li> <li> <p>Quality of life as assessed by specific (Health Assessment Questionnaire (HAQ)) and generic questionnaires (Short‐Form‐36 (SF‐36)) and others. Score on HAQ‐Disability Index (HAQ‐DI) usually ranges from 0 to 3, with a score of 3 indicating worse functional status. SF‐36 domain scores range from 0 to 100, with 100 indicating the best health status on each domain score. Summary scores (physical and mental component summary scores) are calculated by combining the eight domains and are norm‐based, with mean score of 50 and standard deviation of 10. </p> </li> <li> <p>Need for joint surgery or arthroscopy.</p> </li> <li> <p>Need for use of concomitant medications for pain relief.</p> </li> <li> <p>Number of deaths.</p> </li> <li> <p>Specific adverse effects (gastrointestinal, cardiac, renal, hematologic, and other adverse events). </p> </li> </ol> </li> </ul> </p> <p>We searched the US Food and Drug Administration (FDA) website to obtain the adverse effect data. </p> <p>Pharmacoeconomics: whenever applicable, we attempted to perform analyses by comparing chondroitin with a comparator regarding the cost of drugs per month and the number needed to treat for an additional beneficial outcome (NNTB) to prevent one participant from having an adverse event and the NNTB to have one participant achieve MCII on WOMAC. We analyzed direct medical and non‐medical costs as well as indirect medical costs in the analysis and reported indirect costs (productivity losses) separately (<a href="./references#CD005614-bbs2-0125" title="GabrielS , DrummondM , MaetzelA , BoersM , CoyleD , WelchV , et al. OMERACT 6 Economics Working Group report. A proposal for a reference case for economic evaluation in rheumatoid arthritis. The Journal of Rheumatology2003;30:886‐90. ">Gabriel 2003</a>). </p> <p><b>For the 'Summary of findings' (SoF) table, we prespecified seven outcomes as recommended by the Cochrane Musculoskeletal Group (CMSG)</b>: pain, WOMAC MCII, Lequesne's index as a measure of overall pain/function/disability/quality of life, radiographic change, total adverse events, withdrawals due to adverse events, and serious adverse events. We decided to present both short‐ and long‐term measures of pain (short‐ and long‐term pain severity); long‐term WOMAC MCII for pain, and short‐term Lequesne's index. </p> </section> </section> </section> <section id="CD005614-sec-0058"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD005614-sec-0059"> <h4 class="title">Electronic searches</h4> <p>The trials search coordinator (TSC) carried out the searches of the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, LILACS, CINAHL, AMED, and Current Controlled Trials updated to November 2013<b>.</b> No language or date restrictions were applied in the search for trials.Please see <a href="./appendices#CD005614-sec-0104">Appendix 1</a>; <a href="./appendices#CD005614-sec-0105">Appendix 2</a>; <a href="./appendices#CD005614-sec-0106">Appendix 3</a>; <a href="./appendices#CD005614-sec-0107">Appendix 4</a>; <a href="./appendices#CD005614-sec-0108">Appendix 5</a>; <a href="./appendices#CD005614-sec-0109">Appendix 6</a>; and <a href="./appendices#CD005614-sec-0110">Appendix 7</a> for full search strategies. No trial registers were searched. We searched the US Food and Drug Administration (FDA) and European Medicines Agency (EMEA) websites using terms “chondroitin” to obtain the adverse effect data and/or warnings. </p> </section> <section id="CD005614-sec-0060"> <h4 class="title">Searching other resources</h4> <p>The reference lists of the studies included in the review were searched for additional trials. Because numerous international nutraceutical companies market chondroitin, we anticipated that it would not be feasible to contact each of them for unpublished data. We did not search conference proceedings or journals specifically for the review, as prespecified. </p> <p>We planned to summarize in our discussion non‐randomized, post‐marketing surveillance studies if they included 500 or more participants, reported adverse events or safety data, and were of one year's duration or longer because they may be more accurate in detecting rare adverse events. </p> </section> </section> <section id="CD005614-sec-0061"> <h3 class="title" id="CD005614-sec-0061">Data collection and analysis</h3> <section id="CD005614-sec-0062"> <h4 class="title">Selection of studies</h4> <p>We used our predetermined criteria to identify potential trials for inclusion. Two review authors (JAS, SN/KM) independently assessed the methods sections of all identified trials according to the predetermined assessment criteria (<i>see</i> "Selection criteria"). Disagreements were resolved by consensus. For disagreements not resolved by consensus, the third review author (RM) would have served as the referee. </p> </section> <section id="CD005614-sec-0063"> <h4 class="title">Data extraction and management</h4> <p>Two review authors with the help of research associates (JAS/PF, SN/KM) independently extracted data from the included trials. Extracted data included information such as the population of the study, interventions provided, the number of study centers, funding sources, and outcomes and analyses derived from standardized data extraction forms. When we needed more information, we contacted the authors of the studies. We extracted raw data from the published reports for outcomes of interest such as the standard deviation, the mean for continuous data, and the number of events for dichotomous data to evaluate efficacy. When this was impossible, for example, if data were reported as median scores only, we presented and described them in the "<a href="./references#CD005614-sec-0126" title="">Characteristics of included studies</a> table." When possible, we extracted data on the basis of the intention‐to‐treat analysis. </p> </section> <section id="CD005614-sec-0064"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (JAS, SN) independently assessed the risk of bias for each included trial using The Cochrane Collaboration recommendations for assessment. The main criteria that were applied to measure the risk of bias included the presence of blinding (participants, personnel, and outcome assessors), allocation concealment, random sequence generation, incomplete outcome data, and selective outcome reporting (<a href="./references#CD005614-bbs2-0128" title="HigginsJP , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). The risk of bias in each study was explicitly judged for each criterion using the following standard: low risk of bias, high risk of bias, or unclear risk of bias (either lack of information or uncertainty over the potential for bias). Disagreements were resolved by discussion between the two review authors. </p> </section> <section id="CD005614-sec-0065"> <h4 class="title">Measures of treatment effect</h4> <p>We extracted all possibly extractable results from the included trials. For each randomized controlled trial, we calculated point estimates, such as risk ratios (RRs) with 95% confidence intervals (CIs) for dichotomous outcomes. For continuous measures, we calculated mean differences when possible because results presented in this form are more readily interpreted by clinicians. Standardized mean differences were used as measures of treatment effect when outcomes assessed the same construct but used different outcome measures, such as data that used different and inconvertible scales to measure the same construct of interest. In our extraction of pain data, we applied a hierarchy when extracting data on various scales, extracting data on a 0 to 100 scale first, a 0 to 10 cm VAS scale second, a WOMAC pain subscale third, and all other pain outcomes thereafter. Whenever possible, we standardized the data presented to a 0 to 100‐mm scale. In our extraction of physical function data, we extracted physical function on a WOMAC scale first and all other physical function measures thereafter. Data on this outcome were standardized to a 0 to 100‐mm scale whenever possible. </p> </section> <section id="CD005614-sec-0066"> <h4 class="title">Unit of analysis issues</h4> <p>For studies with more than two arms being included in the same meta‐analysis, the placebo group would be handled so as to not double‐count participants. </p> </section> <section id="CD005614-sec-0067"> <h4 class="title">Dealing with missing data</h4> <p>We decided a priori not to impute any data for missing data. When we reviewed studies with missing data, such as loss of follow‐up, or when authors of the study provided mean values on various outcomes but did not provide a standard deviation, we sent email queries to the authors to request the missing data. When data for variability statistics (as standard deviation) could not be obtained, we used the formula in <a href="#CD005614-fig-0001">Figure 1</a> to estimate the standard deviation; however, this was not done for the main analysis but only as part of a sensitivity analysis to facilitate comparisons of our review with reviews that had imputed such missing data. </p> <div class="figure" id="CD005614-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Formula used to estimate standard deviations for studies that did not provide them." data-id="CD005614-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Formula used to estimate standard deviations for studies that did not provide them.</p> </div> </div> </div> </section> <section id="CD005614-sec-0068"> <h4 class="title">Assessment of heterogeneity</h4> <p>Factors assessed for clinical homogeneity included duration of osteoarthritis, population demographics, outcomes, and control groups. We performed a Chi<sup>2</sup> test (P &lt; 0.10) and used I<sup>2</sup> and T<sup>2</sup> statistics to quantify heterogeneity. As we chose to use the random‐effects model, we used T<sup>2</sup> as a measure of heterogeneity between trials. In interpreting the T<sup>2</sup> statistic, a T<sup>2</sup> of 0.04 was prespecified to represent low heterogeneity, 0.09 to represent moderate heterogeneity, and 0.16 to represent high heterogeneity between trials (<a href="./references#CD005614-bbs2-0149" title="SpiegelhalterDJ , AbramsKR , MylesJP . Bayesian Approaches to Clinical Trials and Health‐Care Evaluation. New York: J Wiley, 2004. ">Spiegelhalter 2004</a>). In interpreting the I<sup>2</sup> statistic, we complied with the recommendations put forth in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, which determined that 0% to 40% might not be important; 30% to 60% may represent moderate heterogeneity; 50% to 90% may represent substantial heterogeneity; and 75% to 100% may indicate considerable heterogeneity (<a href="./references#CD005614-bbs2-0111" title="DeeksJ , HigginsJ , AltmanD . Chapter 9: Analysing data and undertaking meta‐analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Deeks 2011</a>). </p> </section> <section id="CD005614-sec-0069"> <h4 class="title">Assessment of reporting biases</h4> <p>To assess reporting biases, we made a funnel plot when performing analyses on 10 or more studies. The funnel plot is a scatter plot that incorporates the sample size on the y‐axis and the treatment effect along the x‐axis. A good indication of reporting bias or other biases related to small study size is observation of asymmetry in the funnel plot. </p> </section> <section id="CD005614-sec-0070"> <h4 class="title">Data synthesis</h4> <p>The random‐effects model was the default model for pooling outcomes in the meta‐analysis. The number needed to treat for an additional beneficial outcome (NNTB) was calculated as the inverse of the absolute risk difference. We used the Wells Calculator, available at the CMSG editorial office, to calculate NNTs for continuous outcomes. The following minimally important clinical differences (MCIDs) were used for the calculator:<br/> Pain: 15 on a 0‐100 scale (<a href="./references#CD005614-bbs2-0117" title="FarrarJT , YoungJP , Jr , LaMoreauxL , WerthJL , PooleRM . Clinical importance of changes in chronic pain intensity measured on an 11‐point numerical pain rating scale. Pain2001;94(2):149‐58. ">Farrar 2001</a>)<br/> Lesquene Index: 0.5 SD<br/> Reduction in minimum JSW: 0.4mm (<a href="./references#CD005614-bbs2-0137" title="Maillefert JF Rheumatology2002 . Relevant change in radiological progression in patients with hip osteoarthritis II Determination using an expert opinion approach. Rheumatology2002;41:148‐52. ">Maillefert 2002</a>) </p> <p>Standardized mean difference (SMD) was used to calculate the benefit of chondroitin over the comparator group for continuous outcomes such as pain measured on a VAS or other similar scales. Standardized mean difference is very similar to the term "effect size," which is commonly used in presenting comparisons of active treatment with control. When calculating the SMD, we divided the difference in mean outcome between groups by the standard deviation of the outcome among participants. We obtained the relative difference in the change from baseline (benefit) by dividing the absolute benefit by the baseline mean of the control group. </p> <p>The "Summary of findings" tables included in RevMan 5 was completed to communicate the key outcomes of the review. We used GRADE Profiler software to develop the tables and the GRADE system which assesses study limitations, indirectness, inconsistency, imprecision and publication bias to provide an overall grading of the quality of the evidence. </p> </section> <section id="CD005614-sec-0071"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>In this review, we performed subgroup analysis, based on the trials' duration, by the type of treatment arm and the type of control arm. For the main analysis, we divided the studies into short‐term trials—those lasting less than six months—and long‐term trials—those lasting six months or longer. This was done on the a priori clinical impression that short‐term benefits and harms of chondroitin sulfate may differ from long‐term benefits and harms. We made a decision that where both long‐ and short‐term effects of chondroitin could be calculated for an outcome (such as pain, physical function etc.), we will present them separately. </p> <p>We analyzed in one analysis trials that had the same composition in their treatment and control arms. For example, we analyzed in one analysis trials that compared treatment with chondroitin alone versus treatment with placebo alone and in another analysis studies that compared treatment with chondroitin alone versus treatment with an active control. </p> </section> <section id="CD005614-sec-0072"> <h4 class="title">Sensitivity analysis</h4> <p>Sensitivity analyses were performed to check for the effects of various factors. The sensitivity analyses performed stratified data by allocation concealment, blinding, study size, study sponsorship by a pharmaceutical manufacturer of chondroitin sulfate, publication year, and analyses according to the intention‐to‐treat principle. Sensitivity analysis was performed on only the top four outcomes of the "Summary of findings tables" (pain, physical function, responders as defined by WOMAC minimal clinically important difference (MCID) or Outcome Measures in Rheuamtology Clinical Trials‐Osteoarthritis Research Society International (OMERACT‐OARSI) responder, and radiographic progression), under which data from two or more studies were included. If a study provided both short‐ and long‐term data for an outcome (e.g., 3‐ and 12‐month data on pain outcome), we considered only the 12‐month outcome for these sensitivity analyses. This was done to allow inclusion of a meaningful number of studies in various subgroups. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD005614-sec-0073" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD005614-sec-0073"></div> <section id="CD005614-sec-0074"> <h3 class="title">Description of studies</h3> <section id="CD005614-sec-0075"> <h4 class="title">Results of the search</h4> <p>Review authors found a total of 187 potential studies in the first search for this systematic review. Of these 187, 57 studies were obtained on 1 January 2006 for further investigation (<a href="#CD005614-fig-0002">Figure 2</a>). Of these, 19 studies met the inclusion criteria. The remaining studies were excluded (refer to "<a href="./references#CD005614-sec-0127" title="">Characteristics of excluded studies</a>"). We performed a second search via MEDLINE on 12 September 2006 and identified 26 additional potential studies. Of these 26, two studies qualified for inclusion. We performed another search on 4 June 2007. This search yielded 12 results, of which three qualified for inclusion in our review. We performed another search on 21 May 2008. This time, we identified 15 additional references, of which one study qualified. On 30 June 2009, we performed another search that identified 32 studies. Of the 32 references pulled in the MEDLINE search, 15 were duplicates that had been pulled in the 21 May 2008 search. Of the remaining 17 new references, six qualified as potential studies for inclusion in the meta‐analysis. Of these six studies, two qualified. One of our Russian translators identified two additional studies for inclusion in our review. Later, on 20 July 2011, we performed another search, which yielded 29 results. Of these 29 potential studies, six fit the inclusion criteria. One study (<a href="./references#CD005614-bbs2-0016" title="KahanA , UebelhartD , DeVathaireF , DelmasPD , ReginsterJY . Long‐term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2009;60(2):524‐33. ">Kahan 2009</a>) was a duplicate from our previous search; therefore, five studies were picked for inclusion. On 12 June 2012, another search was performed to make sure that we included all studies that had been published up to the completion of our meta‐analysis. This search yielded 764 results. Of these, sixteen were pulled for further review. Upon examination, five of these studies were deemed to fit the inclusion criteria and were added to our meta‐analysis. A review of other meta‐analyses performed on chondroitin revealed seven new possible studies for inclusion, of which two fit our inclusion criteria. A final search update was done in November, 2013 that yielded 794 titles/abstracts. An additional 4 studies were included from this search, of which one was a long‐term follow‐up of a previously included study by <a href="./references#CD005614-bbs2-0101" title="WildiL , RaynauldJP , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee OA patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind placebo controlled pilot study using MRI. Osteoporosis InternationalMarch 2011;22:S137. ">Wildi 2011A</a>, but with a different outcome. Overall, therefore, 45 studies were included in our review. One study, <a href="./references#CD005614-bbs2-0053" title="BrandaoGDC , KorukianM , BrandaoDDC , MainineS , DeSouza JrAP . Association of glucosamine sulphate and chondroitin sulphate for patients with osteoarthritis of the knee. [Portuguese]. Revista Brasileira de Medicina2009;66(11):405‐8. MonfortJ , OrellanaC , MontanesF , GarciaN , TioL , BenitoP . Chondroitin sulfate and not acetaminophen effectively reduces synovitis in patients with knee osteoarthritis: results from a pilot study. Osteoarthritis and CartilageApr 2012;20:S283‐4. ">Brandao 2009</a>, could not be obtained, and another study, <a href="./references#CD005614-bbs2-0096" title="VertkinAL , NaumovAV . Deforming osteoarthrosis: strategy of treatment in patients with co‐morbidities. Russkiy Meditsinskiy Journal2007;15(4):319. ">Vertkin 2007</a>, was found to have an obvious mismatch in its data, as reported by the translating abstractor. Both studies were therefore excluded, yielding a total of 43 studies to be included in this systematic review and meta‐analysis. </p> <div class="figure" id="CD005614-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Figure 2. Study Flow chart" data-id="CD005614-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Figure 2. Study Flow chart</p> </div> </div> </div> </section> <section id="CD005614-sec-0076"> <h4 class="title">Included studies</h4> <p>See Figure 2 for a flow diagram of the search results. The "<a href="./references#CD005614-sec-0126" title="">Characteristics of included studies</a> table" provides further information about the included studies. </p> <p>A total of 43 studies with 9,110 participants were included in this review. In all, 4,962 participants were treated with chondroitin (with/without glucosamine, NSAIDs) and 4,148 participants were included in the control group. Trial duration varied 1 month to 3 years. Data were usable from 30 studies in the meta‐analysis. Examples of some studies with non‐usable data were as follows: the treatment regimens were too different from the cohort of included studies (<a href="./references#CD005614-bbs2-0004" title="AlekseevaLI . Results of an open comparative randomized clinical trial to assess efficacy and safety of two regimens of treatment with Theraflex preparation in knee osteoarthritis patients. Russkiy Meditsinskiy Journal2008;16(5):316. ">Alekseeva 2008</a>; <a href="./references#CD005614-bbs2-0009" title="CohenM , WolfeR , MaiT , LewisD . A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. Journal of Rheumatology2003;30(3):523‐8. ">Cohen 2003</a>; <a href="./references#CD005614-bbs2-0020" title="Magrans‐CourtneyT , WilbornC , RasmussenC , FerreiraM , GreenwoodL , CampbellB , et al. Effects of diet type and supplementation of glucosamine, chondroitin, and MSM on body composition, functional status, and markers of health in women with knee osteoarthritis initiating a resistance‐based exercise and weight loss program. Journal of International Society of Sports Medicine2011;8:8. ">Magrans‐Courtney 2011</a>; <a href="./references#CD005614-bbs2-0029" title="NguyenP , MohamedSE , GardinerD , SalinasT . A randomized double‐blind clinical trial of the effect of chondroitin sulfate and glucosamine hydrochloride on temporomandibular joint disorders: a pilot study. Cranio2001;19(2):130‐9. ">Nguyen 2001</a>), or they did not report clinical data (<a href="./references#CD005614-bbs2-0035" title="RovettaG , MonteforteP , MolfettaG , BalestraV . Chondroitin sulfate in erosive osteoarthritis of the hands. International Journal of Tissue Reactions2002;24(1):29‐32. ">Rovetta 2002</a>; <a href="./references#CD005614-bbs2-0036" title="RovettaG , MontefortP , MolfettaG , BalestraV . A two‐year study of chondroitin sulfate in erosive osteoarthritis of the hands: behavior of erosions, osteophytes, pain and hand dysfunction. Drugs Under Experimental and Clinical Research2004;XXX(1):11‐6. ">Rovetta 2004</a>). </p> <p><b>1. Design</b> </p> <p>All included studies were randomized trials. Most were also blinded, with very few exceptions (<a href="./references#CD005614-bbs2-0002" title="AlekseevaLI , CichasovaNV , BenevolenskaiaLI , NasonovEL , MendelOI . Combined medication ARTRA in the treatment of osteoarthrosis. Ter Arkh2005;77(11):69‐75. ">Alekseeva 2005a</a>; <a href="./references#CD005614-bbs2-0004" title="AlekseevaLI . Results of an open comparative randomized clinical trial to assess efficacy and safety of two regimens of treatment with Theraflex preparation in knee osteoarthritis patients. Russkiy Meditsinskiy Journal2008;16(5):316. ">Alekseeva 2008</a>; <a href="./references#CD005614-bbs2-0019" title="LilaAM , MazurovVI , ShidlovskayaOV , ShostakMS . THERAFLEX in comprehensive therapy of knee osteoarthrosis and spinal osteochondrosis (results of a clinical trial). Russkiy Meditsinskiy Journal2005;13(24):1618. ">Lila 2005</a>). Most studies were parallel‐arm trials. </p> <p><b>2. Sample sizes</b> </p> <p>Sample sizes ranged from ≤ 30 participants in a few trials (e.g., <a href="./references#CD005614-bbs2-0020" title="Magrans‐CourtneyT , WilbornC , RasmussenC , FerreiraM , GreenwoodL , CampbellB , et al. Effects of diet type and supplementation of glucosamine, chondroitin, and MSM on body composition, functional status, and markers of health in women with knee osteoarthritis initiating a resistance‐based exercise and weight loss program. Journal of International Society of Sports Medicine2011;8:8. ">Magrans‐Courtney 2011</a>; <a href="./references#CD005614-bbs2-0035" title="RovettaG , MonteforteP , MolfettaG , BalestraV . Chondroitin sulfate in erosive osteoarthritis of the hands. International Journal of Tissue Reactions2002;24(1):29‐32. ">Rovetta 2002</a>) to 1,583 in the GAIT trial (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>). Most studies had a sample size larger than 50 participants; in particular, several studies had sample sizes of 100 or more (<a href="./references#CD005614-bbs2-0001" title="AlekseevaLI , BenevolenskaiaLI , NasonovEL , ChichasovaNV , KariakinAN . Structum (chondroitin sulfate)—a new agent for the treatment of osteoarthrosis. Ter Arkh1999;71(5):51‐3. ">Alekseeva 1999</a>; <a href="./references#CD005614-bbs2-0002" title="AlekseevaLI , CichasovaNV , BenevolenskaiaLI , NasonovEL , MendelOI . Combined medication ARTRA in the treatment of osteoarthrosis. Ter Arkh2005;77(11):69‐75. ">Alekseeva 2005a</a>; <a href="./references#CD005614-bbs2-0004" title="AlekseevaLI . Results of an open comparative randomized clinical trial to assess efficacy and safety of two regimens of treatment with Theraflex preparation in knee osteoarthritis patients. Russkiy Meditsinskiy Journal2008;16(5):316. ">Alekseeva 2008</a>; <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0015" title="GabayC , Medinger‐SadowskiC , GasconD , KoloF , FinckhA . Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis. Arthritis and Rheumatism2011;63(11):3383‐91. ">Gabay 2011</a>; <a href="./references#CD005614-bbs2-0016" title="KahanA , UebelhartD , DeVathaireF , DelmasPD , ReginsterJY . Long‐term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2009;60(2):524‐33. ">Kahan 2009</a>; <a href="./references#CD005614-bbs2-0018" title="L’HirondelJL . Clinical double‐blinded study with orally administered chondroitin sulfate versus placebo in patients with tibiofemoral gonarthrosis (125 patients) [Klinische Doppelblind‐Studie mit oral verabreichtem Chondroitinsulfatgegen Placebo bei der tibiofemoralen Gonarthrose (125 patients)]. Litera Rheumatologica1992;14:77‐84. ">L'Hirondel 1992</a>; <a href="./references#CD005614-bbs2-0022" title="MazieresB , CombeB , Phan VanA , TondutJ , GrynfelttM . Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. Journal of Rheumatology2001;28(1):173‐81. SawitzkeAD , ShiH , FincoMF , DunlopDD , Bingham IIICO , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis and Rheumatism2008;58:3183‐91. ">Mazieres 2001</a>; <a href="./references#CD005614-bbs2-0024" title="MichelBA , StuckiG , FreyD , DeVathaireF , VignonE , BruehlmannP , et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis and Rheumatism2005;52(3):779‐86. ">Michel 2005</a>; <a href="./references#CD005614-bbs2-0025" title="MöllerI , PérezM , MonfortJ , BenitoP , CuevasJ , PernaC , et al. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double‐blind, placebo‐controlled study. Osteoarthritis and Cartilage2010;18:S32‐40. ">Moller 2010</a>; <a href="./references#CD005614-bbs2-0026" title="MorrealeP , ManopuloR , GalatiM , BoccaneraL , SaponatiG , BocchiL . Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. Journal of Rheumatology1996;23(8):1385‐91. ">Morreale 1996</a>; <a href="./references#CD005614-bbs2-0028" title="NasonovaVA , AlekseevaLI , Arkhangel'skaiaGS , DavydovaAF , Karmil'tsevaEA , KoganKM , et al. Results of the multicenter clinical trial of structum preparation in Russia. Ter Arkh2001;73(11):84‐7. ">Nasonova 2001</a>; <a href="./references#CD005614-bbs2-0030" title="PavelkaK , ManopuloR , BusciL . Double‐blind, dose‐effect study of oral chondroitin 4 &amp; 6 sulfate 1200 mg, 800 mg, 200 mg, and placebo in the treatment of knee osteoarthritis. Litera Rhumatologica1999;24:21‐30. ">Pavelka 1999</a>; <a href="./references#CD005614-bbs2-0031" title="PavelkaK , CosteP , GéherP . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659–70. ">Pavelka 2010</a>; <a href="./references#CD005614-bbs2-0032" title="RaiJ , PalSK , GulA , SenthilR , SinghH . Efficacy of chondroitin sulfate and glucosamine sulfate in the progression of symptomatic knee osteoarthritis: a randomized, placebo‐controlled, double‐blind study. Bulletin PGI2004;38:18‐22. ">Rai 2004</a>; <a href="./references#CD005614-bbs2-0037" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , BinghamCOIII , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis Rheum2008;58:3183‐91. ">Sawitzke 2008</a>; <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a>; <a href="./references#CD005614-bbs2-0040" title="UebelhartD , MalaiseM , MarcolongoR , deVathaireF , PipernoM , MailleuxE , et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one‐year, randomized, double‐blind, multicenter study versus placebo. Osteoarthritis Cartilage2004;12(4):269‐76. ">Uebelhart 2004</a>; <a href="./references#CD005614-bbs2-0014" title="FardelloneP , ZaimM , SaurelAS , MaheuE . Comparative efficacy and safety study of two chondroitin sulfate preparations from different origin (avian and bovine) in symptomatic osteoarthritis of the knee. The open rheumatology journal2013;7(1):1‐12. ">Fardellone 2013</a>). </p> <p><b>3. Setting</b> </p> <p>Many studies were single‐center studies (e.g., <a href="./references#CD005614-bbs2-0020" title="Magrans‐CourtneyT , WilbornC , RasmussenC , FerreiraM , GreenwoodL , CampbellB , et al. Effects of diet type and supplementation of glucosamine, chondroitin, and MSM on body composition, functional status, and markers of health in women with knee osteoarthritis initiating a resistance‐based exercise and weight loss program. Journal of International Society of Sports Medicine2011;8:8. ">Magrans‐Courtney 2011</a>; <a href="./references#CD005614-bbs2-0027" title="NakasoneY , WatabeK , WatanabeK , TomonagaA , NagaokaI , YamamotoT , et al. Effect of a glucosamine‐based combination supplement containing chondroitin sulfate and antioxidant micronutrients in subjects with symptomatic knee osteoarthritis: a pilot study. Experimental and Therapeutic Medicine2011;2(5):893. ">Nakasone 2011</a>; <a href="./references#CD005614-bbs2-0035" title="RovettaG , MonteforteP , MolfettaG , BalestraV . Chondroitin sulfate in erosive osteoarthritis of the hands. International Journal of Tissue Reactions2002;24(1):29‐32. ">Rovetta 2002</a>; <a href="./references#CD005614-bbs2-0040" title="UebelhartD , MalaiseM , MarcolongoR , deVathaireF , PipernoM , MailleuxE , et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one‐year, randomized, double‐blind, multicenter study versus placebo. Osteoarthritis Cartilage2004;12(4):269‐76. ">Uebelhart 2004</a>). Other studies were multicenter studies (e.g., <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0040" title="UebelhartD , MalaiseM , MarcolongoR , deVathaireF , PipernoM , MailleuxE , et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one‐year, randomized, double‐blind, multicenter study versus placebo. Osteoarthritis Cartilage2004;12(4):269‐76. ">Uebelhart 2004</a>; <a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). </p> <p><b>4. Participants</b> </p> <p>Most studies included participants with knee osteoarthritis, with a few exceptions; a few studies included participants with hand osteoarthritis (<a href="./references#CD005614-bbs2-0015" title="GabayC , Medinger‐SadowskiC , GasconD , KoloF , FinckhA . Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis. Arthritis and Rheumatism2011;63(11):3383‐91. ">Gabay 2011</a>; <a href="./references#CD005614-bbs2-0035" title="RovettaG , MonteforteP , MolfettaG , BalestraV . Chondroitin sulfate in erosive osteoarthritis of the hands. International Journal of Tissue Reactions2002;24(1):29‐32. ">Rovetta 2002</a>; <a href="./references#CD005614-bbs2-0036" title="RovettaG , MontefortP , MolfettaG , BalestraV . A two‐year study of chondroitin sulfate in erosive osteoarthritis of the hands: behavior of erosions, osteophytes, pain and hand dysfunction. Drugs Under Experimental and Clinical Research2004;XXX(1):11‐6. ">Rovetta 2004</a>; <a href="./references#CD005614-bbs2-0041" title="VerbruggenG , GoemaereS , VeysEM . Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clinical Rheumatology2002;21:231‐43. ">Verbruggen 2002</a>); one study included participants with hip osteoarthritis (<a href="./references#CD005614-bbs2-0011" title="ConrozierT . Anti‐arthrosis treatments: efficacy and tolerance of chondroitin sulfates (CS 4&amp;6). Presse Med1998;27:1862‐5. ">Conrozier 1998</a>). </p> <p><b>5. Interventions</b> </p> <p>One study used a cream that included chondroitin (<a href="./references#CD005614-bbs2-0009" title="CohenM , WolfeR , MaiT , LewisD . A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. Journal of Rheumatology2003;30(3):523‐8. ">Cohen 2003</a>); this study was not included in the analyses. Other studies administered oral chondroitin. Most studies gave chondroitin at 800 mg daily dose or higher, with notable exceptions such as <a href="./references#CD005614-bbs2-0017" title="KanzakiN , SaitoK , MaedaA , KitagawaY , KisoY , WatanabeK , et al. Effect of a dietary supplement containing glucosamine hydrochloride, chondroitin sulfate and quercetin glycosides on symptomatic knee osteoarthritis: a randomized, double‐blind, placebo‐controlled study. Journal of Science and Food Agriculture2012;92:862‐9. ">Kanzaki 2011</a>, <a href="./references#CD005614-bbs2-0027" title="NakasoneY , WatabeK , WatanabeK , TomonagaA , NagaokaI , YamamotoT , et al. Effect of a glucosamine‐based combination supplement containing chondroitin sulfate and antioxidant micronutrients in subjects with symptomatic knee osteoarthritis: a pilot study. Experimental and Therapeutic Medicine2011;2(5):893. ">Nakasone 2011</a>; <a href="./references#CD005614-bbs2-0029" title="NguyenP , MohamedSE , GardinerD , SalinasT . A randomized double‐blind clinical trial of the effect of chondroitin sulfate and glucosamine hydrochloride on temporomandibular joint disorders: a pilot study. Cranio2001;19(2):130‐9. ">Nguyen 2001</a>; <a href="./references#CD005614-bbs2-0030" title="PavelkaK , ManopuloR , BusciL . Double‐blind, dose‐effect study of oral chondroitin 4 &amp; 6 sulfate 1200 mg, 800 mg, 200 mg, and placebo in the treatment of knee osteoarthritis. Litera Rhumatologica1999;24:21‐30. ">Pavelka 1999</a>; <a href="./references#CD005614-bbs2-0032" title="RaiJ , PalSK , GulA , SenthilR , SinghH . Efficacy of chondroitin sulfate and glucosamine sulfate in the progression of symptomatic knee osteoarthritis: a randomized, placebo‐controlled, double‐blind study. Bulletin PGI2004;38:18‐22. ">Rai 2004</a>, in which a dose of chondroitin &lt; 800 mg/d was used. </p> <p><b>6. Outcomes</b> </p> <p>All studies had pain and function or quality of life as primary or secondary outcome. Two studies examined only radiographic outcomes (<a href="./references#CD005614-bbs2-0035" title="RovettaG , MonteforteP , MolfettaG , BalestraV . Chondroitin sulfate in erosive osteoarthritis of the hands. International Journal of Tissue Reactions2002;24(1):29‐32. ">Rovetta 2002</a>; <a href="./references#CD005614-bbs2-0037" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , BinghamCOIII , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis Rheum2008;58:3183‐91. ">Sawitzke 2008</a>). </p> <p>A summary of studies is provided below.</p> <p><a href="./references#CD005614-bbs2-0001" title="AlekseevaLI , BenevolenskaiaLI , NasonovEL , ChichasovaNV , KariakinAN . Structum (chondroitin sulfate)—a new agent for the treatment of osteoarthrosis. Ter Arkh1999;71(5):51‐3. ">Alekseeva 1999</a> was a parallel arm RCT that included 100 patients, 50 each randomzied to chondroitin sulfate and control group in patients aged 45 and older, with knee osteoarthritis diagnosed according to ACR (1986) criteria and with Kellgren‐Lawrence X‐ray grade II or III. They had moderate to severe pain (&gt; 30 mm on 100‐mm VAS), Lequese’s index 4 to 11 points, and had taken NSAIDs for at least 30 days over previous three months. Patients received either chondroitin sulfate 1000 mg/d (two capsules of 250 mg twice a day) with meals or ibuprofen up to 1200 mg/d (no rules for dose selection given). Paracetamol was allowed as rescue analgesia. The outcomes included VAS Pain (walking/rest), Lequesne's index, Patient global assessment (% improved), Patient global assessment on VAS and concomitant medication use. The study was sponsored by a manufacturer of chondroitin sulfate. </p> <p><a href="./references#CD005614-bbs2-0002" title="AlekseevaLI , CichasovaNV , BenevolenskaiaLI , NasonovEL , MendelOI . Combined medication ARTRA in the treatment of osteoarthrosis. Ter Arkh2005;77(11):69‐75. ">Alekseeva 2005a</a> was a randomized, parallel, independent group study involving 90 participants (45 in the control group, 45 in the active chondroitin sulfate group) that compared 1000 mg and 500 mg of chondroitin sulfate with 100 mg diclofenac daily for six months. Participants were included if they were diagnosed with knee osteoarthritis according to American College of Rheumatology (ACR) 1991 criteria, had a Kellgren‐Lawrence X‐ray grade II or III, moderate to severe pain on motion assessed on a 0 to 100‐mm VAS scale (&gt; 40 mm), and had been taking nonsteroidal anti‐inflammatory drugs for at least 30 days in the previous three months. The active group consisted of 45 participants who were treated with 1000 mg of chondroitin sulfate daily for the first month, then with 500 mg of chondroitin sulfate daily for the next five months. The control group was treated with 100 mg diclofenac daily. Outcomes assessed included (1) Total WOMAC score, (2) Patient global assessment, (3) Physician global assessment, and (4) Adverse events. </p> <p><a href="./references#CD005614-bbs2-0003" title="AlekseevaLI , ArtemenkoNA , ZotkinEG , KudryavtcevaNV , LesnyakOM , MendelOI , et al. Rational selection of basal therapy in osteoarthritis. Results of the open randomized multicenter clinical trial of ARTRA preparation in Russia. Russkiy Meditsinskiy Journal2005;13(24):1637. ">Alekseeva 2005b</a> was an open‐label, randomized, multicenter clinical trial involving 375 participants for six months. Participants were included if they were diagnosed with knee osteoarthritis according to ACR criteria, were in the Kellgren‐Lawrence X‐ray grade of II or III, had pain on walking of greater than 40 mm on the 0 to 100‐mm VAS, and had taken nonsteroidal anti‐inflammatory drugs for at least 30 days in the past three months. A total of 203 participants were randomly assigned to the chondroitin sulfate in combination with glucosamine group, and 172 participants to the control group. Participants assigned to the chondroitin sulfate in combination with glucosamine treatment group received 1000 mg of chondroitin sulfate daily plus 1000 mg of glucosamine daily for the first month, then 500 mg chondroitin sulfate and 500 mg glucosamine daily for the next five months. Participants in the active group were also allowed up to 100 mg diclofenac daily with dose reductions and cessation permitted with restrictions. The control group was treated with 100 mg of diclofenac daily for six months. This group was also allowed dose reduction and cessation of the use of diclofenac without restrictions. Outcomes reported were WOMAC Total, pain, physical function, and stiffness. </p> <p><a href="./references#CD005614-bbs2-0004" title="AlekseevaLI . Results of an open comparative randomized clinical trial to assess efficacy and safety of two regimens of treatment with Theraflex preparation in knee osteoarthritis patients. Russkiy Meditsinskiy Journal2008;16(5):316. ">Alekseeva 2008</a> was an open‐label, comparative, randomized, independent, parallel‐group experimental design clinical trial that compared the effects of intermittent versus constant therapy with chondroitin sulfate and glucosamine. Participants were included in the study if they were diagnosed with RA according to the ACR (1991) criteria, were in the Kellgren‐Lawrence X‐ray grade II or III, had pain on walking of greater than 40 mm on the 0 to 100‐mm VAS, and had taken NSAIDs for at least 30 days over the previous three months. A total of 50 participants were randomly assigned to the active group, which was treated with chondroitin sulfate combined with glucosamine for nine months daily. In the comparator group, chondroitin sulfate and glucosamine were taken for two three‐month cycles with a three‐month treatment‐free interval between cycles. Participants were also allowed 1200 mg of Ibuprofen taken in 400‐mg capsules three times daily, with dose reductions permitted at the physician's discretion in both groups. The study reported on the following outcomes: WOMAC pain, performance‐based physical function, Patient and Physician global assessments, knee ultrasound, and adverse events. </p> <p><a href="./references#CD005614-bbs2-0005" title="ArtemenkoNA , ChvamaniyaNA . Characteristics of progression and treatment of osteoarthritis. Russkiy Meditsinksiy Journal2005;13(7):403. ">Artemenko 2005</a> was a nine‐month, open‐label, comparative, parallel‐design trial that assessed the efficacy of 1000 mg of chondroitin sulfate in combination with 1000 mg of glucosamine for one month, followed by five months of treatment with 500 mg of chondroitin sulfate and 500 mg of glucosamine chloride in comparison with treatment with 50 to 100 mg of diclofenac. A total of 31 participants were randomly assigned to the active arm, and 16 participants were randomly assigned to the control arm. Participants diagnosed with knee osteoarthritis according to ACR criteria, with Kellgren‐Lawrence X‐ray grade II or III, and with pain on walking greater than 40 mm on the 100‐mm VAS were included in the study. Participants with pain on walking less than 40 mm on the 100‐mm VAS, with secondary osteoarthritis, or receiving treatment with other “chondroprotective drugs” (not specified) during the six months before commencement of the trial were excluded from the study. Outcomes of interest in this study were pain, stiffness, Total WOMAC scores, rest and motion pain on VAS, Lequesne's index score, and Patient and Physician global assessments. </p> <p><a href="./references#CD005614-bbs2-0006" title="BourgeoisP , ChalesG , DehaisJ , DelcambreB , KuntzJL , RozenbergS . Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage1998;6(Suppl A):25‐30. ">Bourgeois 1998</a> was a three‐month, phase III, randomized, participant‐ and investigator‐blind, double‐dummy, parallel‐group clinical trial that assessed the effects of chondroitin sulfate 4&amp;6 in participants with internal or external, femoral‐tibial knee osteoarthritis. Participants of either sex, aged 45 or older, with femoral tibial, unilateral or bilateral knee osteoarthritis grade I to III diagnosed according to ACR criteria. Participants must have also required stable daily administration of one of the authorized NSAIDs for at least one month before the trial. All participants meeting the inclusion criteria were randomly assigned to one of three groups: chondroitin sulfate 4&amp;6 1200 mg daily (N = 40), CS 4&amp;6 400 mg three times daily (N = 43), or placebo (N = 44). The primary outcome of interest in the study was Lequesne's index. Secondary outcomes included spontaneous pain on 0 to 100‐mm VAS, Patient and Physician global assessments, consumption of NSAIDs, adverse effects, withdrawals, and deaths. </p> <p><a href="./references#CD005614-bbs2-0007" title="BucsiL , PoorG . Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow‐acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage1998;6(Suppl A):31‐6. ">Bucsi 1998</a> was a randomized, participant‐ and investigator‐blind, placebo‐controlled studying involving two centers and lasting six months. A total of 39 and 46 participants were randomly assigned to the active and control groups, respectively. Participants in the chondroitin sulfate group were treated with 400 mg of chondroitin sulfate twice daily for six months. Participants in the control group were given an identical administration of placebo. Participants were included in the study if they were hospitalized patients or outpatients with idiopathic or secondary clinically symptomatic knee osteoarthritis for longer than six months who showed upon entry a Kellgren‐Lawrence radiologic score of I to III. The primary end point was spontaneous joint pain on a 0 to 100‐mm VAS when pain during daily physical activity was considered. Secondary outcomes were paracetamol consumption, time taken for a 20‐m walk on a flat surface, pain, maximal walking distance, discomfort in daily life movements, Lequesne's index, and Patient and Physician global assessment. </p> <p><a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a> was a multicenter, participant‐ and investigator‐blind, placebo‐ and celecoxib‐controlled Glucosamine/chondroitin Arthritis Intervention Trial (GAIT). Participants were included in the trial if they were at least 40 years old, showed clinical and radiographic evidence of osteoarthritis, had a summed pain score of 125 to 400 on the index knee according to WOMAC, and belonged to ARA functional class I, II, or III. Participants were randomly assigned to one of five treatment groups: 1500 mg of glucosamine daily, 1200 mg of chondroitin sulfate daily, both glucosamine and chondroitin sulfate daily, 200 mg of celecoxib daily, or placebo. A total of 313 participants were assigned to the placebo group, 317 to the glucosamine alone group, 318 to the chondroitin group, 317 to the glucosamine and chondroitin sulfate combination group, and 318 to the celecoxib group. The primary outcome for this study was a 20% decrease in the summed score for the WOMAC pain subscale from baseline to week 24. Secondary outcomes for this study were WOMAC stiffness and physical function subscale scores; Patient and Physician global assessment of response to therapy and pain; presence or absence of soft tissue swelling, effusion, or both in the index knee; SF‐36 scores; and analgesic use. Data used for global assessments were Patient and Physician global assessments of "response to therapy scores." </p> <p><a href="./references#CD005614-bbs2-0009" title="CohenM , WolfeR , MaiT , LewisD . A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. Journal of Rheumatology2003;30(3):523‐8. ">Cohen 2003</a> was a single‐center, randomized, participant‐ and investigator‐blind, placebo‐controlled trial lasting eight weeks. The study assessed the effects of chondroitin sulfate preparation cream. Participants diagnosed with osteoarthritis of the knee according to ACR criteria had knee pain due to osteoarthritis greater than 4 cm on a 0 to 10‐cm VAS in one or both knees for longer than four weeks. A total of 30 participants were randomly assigned to the active cream group, and 29 were randomly assigned to the inactive cream group. The treatment cream consisted of 30 mg/g of glucosamine sulfate, 50 mg/g of chondroitin sulfate, and 140 mg/g of shark cartilage, of which 10% to 30% is chondroitin sulfate, 32 mg/g is camphor, and 9 mg/g is peppermint oil scent. The inactive cream was a simple conventional cosmetic cream of identical scent and appearance. The primary outcome of this study was pain on a 0 to 100‐mm VAS. Secondary outcomes were pain, stiffness, and physical function on WOMAC and the SF‐36 questionnaire. </p> <p><a href="./references#CD005614-bbs2-0010" title="ConrozierT , VignonE . The efficacy of chondroitin sulfate in the treatment of the arthrosis of the hip joint. A double‐blind study versus placebo [Die Wirkung von Chondroitinsulfat bei der Behandlungder Hu¨ftgelenksarthrose: eine Doppelblindstudie gegen Placebo]. Litera Rheumatoiogica1992;14:69‐75. ">Conrozier 1992</a> was a participant‐ and investigator‐blind, placebo‐controlled study that took place in France for six months. Participants were included in the study if they were diagnosed with hip joint arthrosis with narrowing but intra‐articular space (degree I, II, III) and pain of the hip joint requiring regular analgesics or NSAIDs. A total of 56 participants were randomly assigned to each of the active and treatment groups Participants in the treatment group received three capsules of 400 mg of chondroitin sulfate, and those in the placebo group received an identical administration of placebo capsules. The primary outcomes of the study were Lequesne's index, pain relief on Huskisson's VAS, consumption of analgesics or nonsteroidal antirheumatics (NSARs), and participant evaluation. Secondary outcomes included morning stiffness, maximum walking distance, frequency of waking at night, and intermalleolar distance. </p> <p><a href="./references#CD005614-bbs2-0012" title="DasA , Jr , HammadTA . Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage2000;8(5):343‐50. ">Das 2000</a> was a randomized, placebo‐controlled, participant‐ and investigator‐blind study. Participants were included if they were in grade II, III, or IV of the Kellgren‐Lawrence scale, were between the ages of 45 and 75, were able to walk, were symptomatic for longer than six months, and had unilateral or bilateral osteoarthritis. Included participants must have been willing to comply with the protocol. A total of 46 participants were assigned to the chondroitin sulfate and glucosamine group and received two capsules of 500 mg of glucosamine and 400 mg of chondroitin sulfate plus 76 mg of manganese. Those in the placebo group received placebo tablets. The primary outcomes in this study were Lequesne's index, WOMAC score, and Patient global assessment. Secondary outcomes were consumed amounts of rescue pain medications and adverse events. </p> <p><a href="./references#CD005614-bbs2-0013" title="DebiR . Glucosamine sulfate and chondroitin sulfate for degenerative joint disease. Harefuah2000;138:451. ">Debi 2000</a> was a randomized, participant‐ and investigator‐blind study that compared glucosamine sulfate and chondroitin sulfate versus placebo and lasted one month. The original language of this study was Hebrew; thus we acquired a translator and translated the article. All study participants had osteoarthritis; 36 participants were randomly assigned to the active chondroitin sulfate group and 20 to the inactive group. All patients "suffering from osteoarthritis" were included in the study. Outcomes of the study were Patient global assessment, performance‐based physical function, and radiographic changes on X‐ray. </p> <p><a href="./references#CD005614-bbs2-0014" title="FardelloneP , ZaimM , SaurelAS , MaheuE . Comparative efficacy and safety study of two chondroitin sulfate preparations from different origin (avian and bovine) in symptomatic osteoarthritis of the knee. The open rheumatology journal2013;7(1):1‐12. ">Fardellone 2013</a> was a multicenter, prospective, randomized, double‐blind, double‐placebo, active‐controlled, parallel group study performed in patients with symptomatic knee OA that compared two chondroitin preparations, Structum® 500 mg twice daily or Chondrosulf® 400 mg three times daily over a 24‐week duration. Inclusion criteria were as follows: age 50 to 80 years, medial and/or lateral femoro‐tibial OA of the knee according to American College of Rheumatology (ACR) criteria, symptomatic for more than 6 months, with a baseline level of symptoms as follows, global pain score on a Visual Analog Scale (VAS 0 to 100) of at least 40 millimeters (mm), a Lequesne’s algofunctional index (LFI 0 to 24) score greater than or equal to 7, radiographic OA as defined by a Kellgren‐Lawrence grade II or III on an antero‐posterior weight‐bearing view of both knees taken. Primary outcome was global pain on 0 to 100 mm VAS. Secondary outcomes included patient’s and investigator’s global assessment scores (VAS), Osteoarthritis of the knee or hip Quality of Life dimension score (OAKHQOL), Short‐form 12 (SF‐12) scores and the use of analgesic medications (paracetamol and/or NSAIDs). </p> <p><a href="./references#CD005614-bbs2-0015" title="GabayC , Medinger‐SadowskiC , GasconD , KoloF , FinckhA . Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis. Arthritis and Rheumatism2011;63(11):3383‐91. ">Gabay 2011</a> was an investigator‐initiated, single‐center, randomized, participant‐ and investigator‐blind, placebo‐controlled clinical trial that examined the efficacy of chondroitin in participants with hand osteoarthritis. Participants were included in the trial if they were at least 40 years old and fulfilled the ACR criteria for the classification of hand osteoarthritis. In addition, radiographic features of hand osteoarthritis affecting at least two joints of the target hand on standard plain films obtained within six months of enrolment and at least two painful flares of osteoarthritis in the finger joints during the previous 12 months were required. The target hand was defined as the participant's most symptomatic hand or, when both hands were equally painful, the participant's dominant hand. To be eligible for the study, participants had to have presented with symptomatic osteoarthritis. Minimum symptoms included joint pain of at least 40 mm on a 0 to 100‐mm VAS and a Functional Index for Hand Osteoarthritis (FIHOA) score of at least 6 in the target hand (0 to 30 scale). The study lasted for six months. A total of 80 participants were randomly assigned to receive 800 mg of chondroitin sulfate daily. In all, 82 participants were randomly assigned to receive placebo sachets. The primary outcomes of the study were change in the Patient’s assessment of global spontaneous hand pain on VAS and change in Patient’s assessment of global spontaneous hand function on the FIHOA score from baseline to month six. Secondary outcomes were grip strength and duration of morning stiffness. </p> <p><a href="./references#CD005614-bbs2-0016" title="KahanA , UebelhartD , DeVathaireF , DelmasPD , ReginsterJY . Long‐term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2009;60(2):524‐33. ">Kahan 2009</a> is an international, randomized, participant‐ and investigator‐blind, placebo‐controlled trial that lasted two years. Participants were included in the trial if they were outpatients between 40 and 80 years old who had been diagnosed with primary knee osteoarthritis of the medial tibiofemoral compartment according to ACR criteria. A total of 309 participants were randomly assigned to the active chondroitin group, which received 800 mg of chondroitin sulfate daily for two years. In all, 313 participants were randomly assigned to the placebo group and received placebo sachets of identical appearance and regimen. The primary outcome of the study was pain modification in the minimum joint space width of the medial compartment of the target tibiofemoral joint. Secondary outcomes included assessment of pain using a 0 to 100‐mm VAS, WOMAC Total and subscale scores, Patient and Physician global assessments, cumulative consumption of acetaminophen, and cumulative consumption of NSAIDs. Results and data for joint space width are taken from Kahan's supplementary report, published in 2006, in which results for joint space narrowing were presented for the placebo and chondroitin sulfate groups. </p> <p><a href="./references#CD005614-bbs2-0017" title="KanzakiN , SaitoK , MaedaA , KitagawaY , KisoY , WatanabeK , et al. Effect of a dietary supplement containing glucosamine hydrochloride, chondroitin sulfate and quercetin glycosides on symptomatic knee osteoarthritis: a randomized, double‐blind, placebo‐controlled study. Journal of Science and Food Agriculture2012;92:862‐9. ">Kanzaki 2011</a> was a prospective, randomized, placebo‐controlled, parallel‐group comparative study that was designed to assess the efficacy and safety of a GCQ supplement (that contained chondroitin) for a duration of six months. The study involved two clinical service organization centers that were under the control of two medical investigators in Japan. Male and female Japanese participants between 40 and 85 years of age were diagnosed with knee osteoarthritis, and the presence of knee pain was confirmed by assessment of scores on the "walking" subscale of the Japanese Orthopedic Association (JOA). A total of 20 participants were randomly assigned to receive 1200 mg glucosamine hydrochloride, 300 mg shark cartilage extract (60 mg as chondroitin sulfate), and 45 mg quercetin glycosides in a daily dose of six tablets in the active group. In all, 20 participants were randomly assigned to the placebo group and received indistinguishable placebo tablets, which were administered identically with six tablets a day. The primary outcomes of the study were Japan Orthopaedic Association subscale scores. Subscales documented walking ability, ascending and descending ability and pain on stairs, range of motion, and degree of joint swelling. The study’s secondary outcomes were pain at rest on VAS, pain on walking on VAS, and pain on ascending and descending of stairs on VAS. </p> <p><a href="./references#CD005614-bbs2-0018" title="L’HirondelJL . Clinical double‐blinded study with orally administered chondroitin sulfate versus placebo in patients with tibiofemoral gonarthrosis (125 patients) [Klinische Doppelblind‐Studie mit oral verabreichtem Chondroitinsulfatgegen Placebo bei der tibiofemoralen Gonarthrose (125 patients)]. Litera Rheumatologica1992;14:77‐84. ">L'Hirondel 1992</a> was a participant‐ and investigator‐blind, parallel‐design, randomized study in which orally administered chondroitin sulfate was compared with placebo in participants with tibiofemoral gonarthrosis for six months; the study was conducted in France. Participants were included if they had painful tibiofemoral gonarthrosis with an intra‐articular space but without dislocation of the main axis and with or without meniscus calcification. A total of 63 participants were randomly assigned to the active chondroitin sulfate group, and 62 participants were randomly assigned to the placebo group. The chondroitin sulfate group received three sachets of 400 mg chondroitin sulfate daily, and the placebo group received three identical sachets of placebo. Participants were allowed to continue their ongoing treatments through the first two months of the study and were then allowed 500 mg of paracetamol from months 2 to 6, according to their pain intensity. The primary outcomes of this study were Lequesne's index, adverse effects, pain relief on Huskisson's VAS, consumption of analgesics and nonsteroidal antirheumatics, and total efficacy as evaluated by the investigator. Secondary outcomes included extent of flexion and extension of the joint, extent of joint circumference, and verification of a static incident, an abnormal movement, or an intra‐articular effusion. </p> <p><a href="./references#CD005614-bbs2-0019" title="LilaAM , MazurovVI , ShidlovskayaOV , ShostakMS . THERAFLEX in comprehensive therapy of knee osteoarthrosis and spinal osteochondrosis (results of a clinical trial). Russkiy Meditsinskiy Journal2005;13(24):1618. ">Lila 2005</a> was a randomized, open efficacy trial that included participants 45 to 75 years of age who were diagnosed with osteoarthritis according to ACR 1987 criteria and were in Kellgren‐Lawrence X‐ray grade I to III. They had a pain score greater than 40 mm on a VAS (0 to 100 mm) for pain on walking and had daily morning stiffness for at least 30 minutes. A total of 30 participants who fulfilled these criteria were randomly assigned to the active chondroitin sulfate in combination with glucosamine and placebo groups. Those assigned to the active group received 800 mg of chondroitin sulfate in combination with 1000 mg of glucosamine daily for the first month, then 400 mg of chondroitin sulfate plus 500 mg of glucosamine daily for the next two months. The control group received diclofenac 75 mg daily. Outcomes of in the study included WOMAC subscales, rest or motion pain on a 0 to 100‐mm VAS, morning stiffness, Patient and Physician global assessments, and adverse events. </p> <p><a href="./references#CD005614-bbs2-0020" title="Magrans‐CourtneyT , WilbornC , RasmussenC , FerreiraM , GreenwoodL , CampbellB , et al. Effects of diet type and supplementation of glucosamine, chondroitin, and MSM on body composition, functional status, and markers of health in women with knee osteoarthritis initiating a resistance‐based exercise and weight loss program. Journal of International Society of Sports Medicine2011;8:8. ">Magrans‐Courtney 2011</a> was a randomized, participant‐ and investigator‐blind, placebo‐controlled, parallel clinical trial that lasted 14 weeks. Women with physician‐diagnosed osteoarthritis between the ages of 18 and 70 years who had a body mass index (BMI) greater than 27 kg/m<sup>2</sup> and no recent participation in a diet or exercise program were included in the study. A total of 16 participants were assigned to the active treatment arm, in which participants received a total of 1500 mg of glucosamine (from d‐glucosamine HCL), 1200 mg/d of chondroitin sulfate (from chondroitin sulfate sodium), 120 mg/d of niacin, 120 mg/d of sodium, 45 mg/d of zinc, 900 mg/d of MSM, 300 mg/d of Boswellia serrata extract, 180 mg/d of white willow bark extract, and 15 mg/d of rutin powder. A total of 14 participants were randomly assigned to receive placebo of identical appearance and dosage. All randomly assigned participants also participated in a 14‐week circuit‐style workout consisting of 14 exercises (e.g., elbow flexion/extension, knee flexion/extension, shoulder press/lat pull, hip abductor/adductor, chest press/seated row, horizontal leg press, squat, abdominal crunch/back extension, pec deck, oblique, shoulder shrug/dip, hip extension, side bends, stepping three times a week). Participants in each treatment group were then randomly assigned to begin a high‐protein or high‐carbohydrate diet program. Both programs were composed of three phases. During the first phase, which lasted one week, participants were allowed to consume a total of 1200 kcal daily. For the next nine weeks, participants were given 1600 kcal/d. The final four weeks of the diet (Phase III) served as a weight maintenance period. The high‐protein (HP) diet regimen was composed of 7% carbohydrate, 63% protein, and 30% fat during Phase I, and 15% carbohydrate, 55% protein, and 30% fat during Phase II. Upon completion of the high‐carbohydrate diet program, participants were instructed to consume a diet consisting of 55% carbohydrate, 15% protein, and 30% fat. In the final phase of the diet program, all participants were allowed 55% carbohydrate, 15% protein, and 30% fat. The primary outcomes were measures of pain, including pain on VAS, stiffness, physical function, and Total score on the WOMAC scale. Secondary outcomes included weight loss, body composition, measures of quality of life, changes in energy intake, anthropometrics, body composition, resting energy expenditures, cardiovascular and muscular fitness, balance and functional capacity, serum and whole blood clinical markers, hormonal profiles, pain indices, psychosocial parameters, and knee range of motion and circumference. </p> <p><a href="./references#CD005614-bbs2-0021" title="MazieresB , LoyauG , MenkesCJ , ValatJP , DreiserRL , CharlotJ , et al. Chondroitin sulfate in the treatment of gonarthrosis and coxarthrosis. 5‐months result of a multicenter double‐blind controlled prospective study using placebo. Rev Rhum Mal Osteoartic1992;59(7‐8):466‐72. ">Mazieres 1992</a> was a multicenter, randomized, controlled, parallel, independent, participant‐ and investigator‐blind study that lasted three months; participants were 50 years of age or older; had a pain score of at least 40 mm on a 0 to 100‐mm VAS and a score greater than 4 on Lequesne's Index; and were diagnosed with gonarthroses of the femorotibial and internal or external compartment or coxarthrosis. A total of 58 participants were randomly assigned to the active group and received 2000 mg of chondroitin sulfate daily for three months. In all, 56 participants were randomly assigned to the placebo group. Outcomes of interest in the study were rest or motion pain on VAS, Lequesne's index, Patient and Physician global assessments, and NSAID use. </p> <p><a href="./references#CD005614-bbs2-0022" title="MazieresB , CombeB , Phan VanA , TondutJ , GrynfelttM . Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. Journal of Rheumatology2001;28(1):173‐81. SawitzkeAD , ShiH , FincoMF , DunlopDD , Bingham IIICO , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis and Rheumatism2008;58:3183‐91. ">Mazieres 2001</a> was a participant‐ and investigator‐blind, randomized, parallel‐group study that lasted six months. The study included outpatients older than 50 years of age who met the following criteria: (1) clinically and radiographically confirmed osteoarthritis of one or both knees according to the criteria of the ACR; (2) an algofunctional index of Lequesne (AFI) ≥ 4; (3) pain with activity ≥ 30 mm on a 100‐mm VAS; (4) regular consumption of NSAIDs for three months; and (5) radiographic grade II to III on the Kellgren‐Lawrence scale. In participants with osteoarthritis of both knees, the most painful side was assessed. A total of 67 participants were randomly assigned to the active chondroitin sulfate group and received 500 mg of chondroitin sulfate twice daily for three months. In all, 63 participants were randomly assigned to the placebo treatment group and received placebo sachets. The primary outcome of the study was Lequesne's AFI. Secondary outcomes were pain on physical activity as measured on a 0 to 100‐mm VAS, pain on rest as measured on a 0 to 100‐mm VAS, self‐assessed effect of osteoarthritis on daily activities as measured on a 0 to 100‐mm VAS, participant's overall assessment of change as measured on a five‐point categorical scale (much better, better, unchanged, somewhat worse, much worse), and daily NSAID and analgesics consumption. </p> <p><a href="./references#CD005614-bbs2-0023" title="MessierSP , MihalkoS , LoeserRF , LegaultC , JollaJ , PfruenderJ , et al. Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study. Osteoarthritis Cartilage2007;15(11):1256‐66. ">Messier 2007</a> was a participant‐ and investigator‐blind, placebo‐controlled, randomized clinical trial that lasted 12 months, of which six months was applicable to the current review. For the remaining six months, investigators assessed the effect of exercise combined with chondroitin sulfate and glucosamine, and thus the data could not be used. Participants were included if they were 50 years of age or older, had mild to moderate knee osteoarthritis on a Kellgren‐Lawrence scale (II or III) according to ACR criteria, and were not currently participating in another study. A total of 45 participants were randomly assigned to the chondroitin sulfate and glucosamine hydrochloride group and received 1200 mg of chondroitin sulfate plus 1500 mg of glucosamine hydrochloride once or three times daily. In all, 44 participants were randomly assigned to the placebo group and received placebo sachets of identical appearance and odor in a blinded fashion. The primary outcome of the study was physical function as measured on the WOMAC. Secondary outcomes were pain on WOMAC, distance walked in six minutes, mental status as measured on the Mini Mental State Examination (MMSE), balance, and strength of concentric extension and flexion in the most affected knee. </p> <p><a href="./references#CD005614-bbs2-0024" title="MichelBA , StuckiG , FreyD , DeVathaireF , VignonE , BruehlmannP , et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis and Rheumatism2005;52(3):779‐86. ">Michel 2005</a> was a randomized, participant‐ and investigator‐blind, placebo‐controlled trial that lasted two years and was conducted in Zurich, Switzerland. Participants were included in the study if they were between the ages of 40 and 85 years and had clinically symptomatic knee osteoarthritis (knee pain while standing, walking, and/or on motion for at least 25 or 30 days before study entry, with no required minimum level of pain on the day of entry). Partcipants had to be diagnosed with knee osteoarthritis according to ACR clinical and radiographic criteria for osteoarthritis of the knee. Participants with osteoarthritis of grade I, II or III according to Kellgren‐Lawrence (KL) were eligible for study entry. Participants with osteoarthritis of KL grade 4, indicating a greatly narrowed joint space with sclerosis of subchondral bone, were excluded. The target knee was defined as the most symptomatic knee at study entry. A total of 150 participants were randomly assigned to the active chondroitin sulfate group and received 800 mg of chondroitin sulfate once daily for two years. In all, 150 participants were randomly assigned to the placebo group and received placebo sachets. The primary outcome of interest was the minimum and mean joint space width of the more severely affected compartment of the target knee. Secondary outcomes were stiffness and physical function on WOMAC, total consumption of rescue drugs during the trial, average number of tablets of study drug taken per day, and adverse events. </p> <p><a href="./references#CD005614-bbs2-0025" title="MöllerI , PérezM , MonfortJ , BenitoP , CuevasJ , PernaC , et al. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double‐blind, placebo‐controlled study. Osteoarthritis and Cartilage2010;18:S32‐40. ">Moller 2010</a> was a randomized, participant‐ and investigator‐blind, placebo‐controlled multicenter study that lasted three months. Participants eligible for the study were men and women 40 years of age or older who had osteoarthritis of the knee as defined by the criteria of the ACR, pain in the affected knee scored as 30 on a continuous 0 to 100‐mm Huskisson’s VAS, and a confirmatory knee X‐ray diagnosis (Kellgren‐Lawrence grade I to III) associated with cutaneous plaque‐type psoriasis with a Psoriasis Area and Severity Index (PASI) score of 5. A total of 60 participants were randomly assigned to receive 800 mg of chondroitin sulfate daily. In all, 56 participants were randomly assigned to receive matched placebo capsules. Primary outcomes were a decrease in pain intensity as assessed by VAS and clinical improvement of psoriasis as determined by PASI score at the end of treatment as compared with baseline. Secondary outcomes were pain relief and function improvement in the knee according to the Lequesne AFI, acetaminophen consumption, histopathologic data, changes in psoriatic lesions according to physician global assessment (PGA), assessment of efficacy by participants and investigators, and quality of life as measured by SF‐36. </p> <p><a href="./references#CD005614-bbs2-0026" title="MorrealeP , ManopuloR , GalatiM , BoccaneraL , SaponatiG , BocchiL . Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. Journal of Rheumatology1996;23(8):1385‐91. ">Morreale 1996</a> was a six‐month, randomized, participant‐ and investigator‐blind, parallel‐group study that was conducted at two centers. Participants were between 40 and 75 years of age and had grade I or II monolateral or bilateral knee osteoarthritis; they were not taking NSAIDs or chondroprotective treatment for 15 to 30 days before study initiation. A total of 74 participants were randomly assigned to the chondroitin sulfate group and received 400 mg of chondroitin sulfate three times daily plus three tablets of placebo for the first month, only 400 mg of chondroitin sulfate for the second month, and only placebo tablets from months 3 to 6. A total of 72 participants were randomly assigned to the control group; they received 50 mg of diclofenac sodium three times daily plus three tablets of placebo in the first month of the trial; only three placebo sachets in the second month of the trial, and placebo from months 3 to 6. Only the first month's results were applicable to the study because the treatment setup created dependence over the months of the study and did not allow for stratification of the data into three separate calculable data sets. The primary outcomes of the study were Lequesne's AFI score, spontaneous pain on a 0 to 100‐mm VAS, and pain on load on a 4‐point scale of absent, light, moderate, and intense. The secondary outcome of interest in the study was paracetamol consumption. </p> <p><a href="./references#CD005614-bbs2-0027" title="NakasoneY , WatabeK , WatanabeK , TomonagaA , NagaokaI , YamamotoT , et al. Effect of a glucosamine‐based combination supplement containing chondroitin sulfate and antioxidant micronutrients in subjects with symptomatic knee osteoarthritis: a pilot study. Experimental and Therapeutic Medicine2011;2(5):893. ">Nakasone 2011</a> was a randomized, participant‐ and investigator‐blind, placebo‐controlled study designed to assess the efficacy and safety of the test supplement in adult participants with symptomatic knee osteoarthritis; the study lasted 16 weeks and was conducted at two clinical service organizations in Yokohama, Japan. All male and female Japanese participants were 40 to 83 years of age and presented with clinical and radiographic evidence of mild knee osteoarthritis, defined by a score of 30 to 75 on a 100‐mm VAS and by radiologic severity of affected knee joints mainly graded 1 to 2 on the Kellgren‐Lawrence (KL) scale. Participants with diagnosed bilateral knee osteoarthritis were asked to specify the worse affected knee at baseline, and this knee was evaluated throughout the study period. A total of 16 participants were randomly assigned to the treatment group, which received 1200 mg of orally administered glucosamine hydrochloride, 200 mg of shark cartilage (60 mg of chondroitin sulfate), 300 mg of MSM, 105 mg of guava leaf extract, 5.6 μg of vitamin D, and 7.35 mg of vitamin B1 seven times daily; 16 participants were assigned to the inactive placebo group. The primary efficacy outcomes of this study were scores on the Japanese Knee Osteoarthritis Measure subscales of pain/stiffness, conditions of daily life, general conditions, and health conditions. Other reported outcomes were pain on VAS, pain on rest on VAS, pain on walking on VAS, pain on ascending or descending stairs on VAS, synovial inflammation, and cartilage metabolism. </p> <p><a href="./references#CD005614-bbs2-0029" title="NguyenP , MohamedSE , GardinerD , SalinasT . A randomized double‐blind clinical trial of the effect of chondroitin sulfate and glucosamine hydrochloride on temporomandibular joint disorders: a pilot study. Cranio2001;19(2):130‐9. ">Nguyen 2001</a> is a three‐month, randomized, participant‐ and investigator‐blind pilot study that included participants with pain in one or both temporomandibular joints (TMJs) and moderate or severe pain on lateral or dorsal palpation of the TMJ. A total of 24 participants were randomly assigned to the chondroitin sulfate group and received two tablets of 250 mg of glucosamine hydrochloride and 200 mg of chondroitin daily. Outcomes of the study were pain on VAS (0 to 100 mm), on the McGill Pain Questionnaire's pain rating scales, and on the mood and functioning questionnaire; tenderness on TMJ palpation; jaw range of motion; daily pain rating on the VAS; analgesic use; and daily change in pain intensity. </p> <p><a href="./references#CD005614-bbs2-0030" title="PavelkaK , ManopuloR , BusciL . Double‐blind, dose‐effect study of oral chondroitin 4 &amp; 6 sulfate 1200 mg, 800 mg, 200 mg, and placebo in the treatment of knee osteoarthritis. Litera Rhumatologica1999;24:21‐30. ">Pavelka 1999</a> was a phase II, randomized, participant‐ and investigator‐blind, dose‐effect study. Participants were older than 30 years of age and had femorotibial osteoarthritis of the knee, according to ACR criteria, with clinical symptoms that persisted for at least three months; Lequesne's Index greater than or equal to 8 points; pain on Huskisson's VAS greater than or equal to 40 mm during physical activity; and persistence of some articular joint space as documented on radiography. Participants were randomly assigned to one of four groups. In all, 35 participants were randomly assigned to the 200‐mg chondroitin sulfate group and received one sachet of 200 mg chondroitin sulfate; 35 participants to 800 mg of chondroitin sulfate and given one sachet of 800 mg chondroitin sulfate; 35 participants to the 1200‐mg chondroitin sulfate group and given one sachet of 1200 mg chondroitin sulfate; and 35 participants to the placebo group and given one placebo sachet. The primary outcome of the study was Lequesne's Index and Spontaneous Pain on Huskisson's VAS on a 0 to 100‐mm scale, Patient and Physician Global Efficacy Evaluations, and Paracetamol Consumption from Day 15 to Day 90. </p> <p><a href="./references#CD005614-bbs2-0031" title="PavelkaK , CosteP , GéherP . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659–70. ">Pavelka 2010</a> was a six‐month, controlled, randomized, multinational, multicenter, participant‐ and investigator‐blind, double‐dummy, parallel‐group study that was carried out at five centers in the Czech Republic, three in the Slovak Republic, five in Hungary, seven in Poland, and six in Romania. Participants had to be “aged 45 years or above and [to have] femoro‐tibial osteoarthritis of the knees longer than six months with pain and functional discomfort over one month during the past three months, were complying with the clinical and radiologic criteria of the American College of Rheumatology of knee osteoarthritis, had a Lequesne's index between 5 and 13 and a radiologic score of grade I, II or III of the modified Kellgren‐Lawrence scale on a frontal image of extended knee, on both knees, the image being not older than six months, had pain on movement and/or pain at rest in the last 48 hours [of] at least 40 mm evaluated on a VAS, and/or at least 40 mm evaluated on at least two items among the five items n the A‐section of the WOMAC Index, with no intake of analgesics for 48 hours and NSAID for 5 days.” A total of 142 participants were randomly assigned to receive 300 mg of avocado soybean unsaponifiable daily. In all, 121 participants in the comparator group were randomly assigned to receive 400 mg three times daily. The primary outcome of the study was the change in the WOMAC index from the beginning of the study to the end of treatment. Secondary outcomes were the Lequesne index, pain on active movement and at rest, and global assessment of efficacy. </p> <p><a href="./references#CD005614-bbs2-0032" title="RaiJ , PalSK , GulA , SenthilR , SinghH . Efficacy of chondroitin sulfate and glucosamine sulfate in the progression of symptomatic knee osteoarthritis: a randomized, placebo‐controlled, double‐blind study. Bulletin PGI2004;38:18‐22. ">Rai 2004</a> was a randomized, participant‐ and investigator‐blind, placebo‐controlled trial with participants older than 50 years of age who had primary knee osteoarthritis, mainly on the medial femorotibial compartment, according to the clinical and radiographic criteria of ACR and a Lequesne's index score of 4 or greater. The treatment group (n = 50) received a drug called <i>kondro</i> and was compared with a placebo group (n = 50). Kondro is a combination of chondroitin and glucosamine, although the exact amounts of either were not specified on the pharmaceutical company's website. Outcomes of interest in the study were Lequesne's index scores and joint space narrowing as shown on X‐rays. </p> <p><a href="./references#CD005614-bbs2-0033" title="RailhacJJ , ZaimM , SaurelAS , VialJ , FournieB . Effect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: A randomized, double‐blind, placebo‐controlled pilot study using MRI. Clinical Rheumatology2012;31(9):1347‐57. ">Railhac 2012</a> was a randomized, double‐blind, placebo‐controlled, parallel group, multicenter study conducted in 20 French rheumatology practice centers comparing Structum® 500 mg (chondroitin) or matching placebo, twice daily by oral route as from baseline to week 48. Primary outcomes were pain on VAS (0 to 100) and Lequesne index scores. Secondary outcomes were clinical improvement according to the patient and the investigator and the use of rescue medication (paracetamol and/or NSAIDs). The first author was an employee of the maker of chondroitin product discussed. </p> <p><a href="./references#CD005614-bbs2-0034" title="RaynauldJP , Martel‐PelletierJ , DoraisM , HaraouiB , ChoquetteD , AbramF , et al. Total Knee Replacement as a Knee Osteoarthritis Outcome: Predictors Derived from a 4‐Year Long‐Term Observation following a Randomized Clinical Trial Using Chondroitin Sulfate. Cartilage2013;4(3):219‐26. ">Raynauld 2013</a> was a long‐term follow‐up study of <a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>, as described above. Four‐year outcome of total knee replacement was presented along with its predictors, where one group was treated with chondroitin or placebo once daily for the first 6 months (double‐blind phase) followed by 6 months of treatment with 800 mg chondroitin sulfate once daily for both groups (open‐label phase). Thirty‐five patients were randomized each to chondroitin and placebo, of whom 57 patients were followed for this study. Thirteen patients underwent total knee replacement at 4‐years, 9/34 in the placebo and 4/35 in the chondroitin group. Details of inclusion/exclusion criteria are provided in <a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>. </p> <p><a href="./references#CD005614-bbs2-0035" title="RovettaG , MonteforteP , MolfettaG , BalestraV . Chondroitin sulfate in erosive osteoarthritis of the hands. International Journal of Tissue Reactions2002;24(1):29‐32. ">Rovetta 2002</a> was a 24‐month, randomized trial involving 24 "consecutive" participants of both sexes (2 men and 22 women) with a mean age of 53 years who were suffering from osteoarthritis and were showing central erosions of the distal interphalangeal (DIP) and/or proximal interphalangeal (PIP) joints. Participants were randomly assigned to one of two groups: naproxen 500 mg/daily only (Group A) or chondroitin sulfate 800 mg daily plus naproxen 500 mg daily (Group B). The only outcome of interest in the study was the joint count for erosions; results were taken at baseline and at 12 and 24 months. </p> <p><a href="./references#CD005614-bbs2-0036" title="RovettaG , MontefortP , MolfettaG , BalestraV . A two‐year study of chondroitin sulfate in erosive osteoarthritis of the hands: behavior of erosions, osteophytes, pain and hand dysfunction. Drugs Under Experimental and Clinical Research2004;XXX(1):11‐6. ">Rovetta 2004</a> is the same trial as <a href="./references#CD005614-bbs2-0035" title="RovettaG , MonteforteP , MolfettaG , BalestraV . Chondroitin sulfate in erosive osteoarthritis of the hands. International Journal of Tissue Reactions2002;24(1):29‐32. ">Rovetta 2002</a>; however, the authors present results on several different outcomes. The outcomes of this study are radiographic joint counts for Heberden and Bouchard nodes; the Dreiser index was used to assess pain and function and Patient and Physician global assessments on a 0 to 10‐cm VAS. </p> <p><a href="./references#CD005614-bbs2-0037" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , BinghamCOIII , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis Rheum2008;58:3183‐91. ">Sawitzke 2008</a> was the follow‐up of <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a> study and presented the mean change in JSW in the medial compartment of the knee over 2 years. </p> <p><a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a> was a 24‐month, participant‐ and investigator‐blind, placebo‐controlled study that was conducted at nine sites in the United States ancillary to the Glucosamine/chondroitin Arthritis Intervention Trial (GAIT), a follow‐up report of <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; investigators enrolled 662 participants with knee osteoarthritis who satisfied radiographic criteria (Kellgren‐Lawrence (KL) grade II or III changes and baseline joint space width of at least 2 mm). Participants were included in the study if they were at least 40 years old, had been diagnosed with osteoarthritis for at least six months, and showed radiographic evidence of osteoarthritis by KL grade II or III. A total of 134 participants were assigned to receive 500 mg of glucosamine three times daily. In all, 126 participants were assigned to receive 400 mg of chondroitin sulfate three times daily; 129 to receive a combination of the glucosamine and chondroitin sulfate dosages; 142 to receive 200 mg of celecoxib daily; and 131 to receive a placebo. The study’s primary outcome was a 20% reduction in WOMAC pain over 24 months. Secondary outcomes were pain reduction attributable to each treatment WOMAC function subscale and the likelihood of achieving an OMERACT/OARSI response over 24 months. </p> <p><a href="./references#CD005614-bbs2-0039" title="UebelhartD , ThonarEJ , DelmasPD , ChantraineA , VignonE . Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage1998;6(Suppl A):39‐46. ">Uebelhart 1998</a> was a one‐year, randomized, participant‐ and investigator‐blind, controlled pilot study with 46 participants of both sexes between the ages of 35 and 79 who had symptomatic osteoarthritis. The chondroitin active group received 400 mg of chondroitin sulfate twice daily, while the placebo group received placebo sachets. A total of 23 participants were randomly assigned to chondroitin sulfate, and 23 participants were randomly assigned to the placebo group. Primary outcomes of the study were the degree of spontaneous joint pain as measured on VAS (0 to 100 mm) and overall mobility capacity on VAS. Secondary outcomes included the actual joint space measurement taken by X‐ray and the levels of biochemical markers of bone and joint metabolism. In our meta‐analysis, we subtracted the rating for overall mobility capacity from 100 because the scale for this outcome took 0 as the worst score and 100 as the best score. Because all of the other studies that presented data on this outcome did so on an opposite scale, which took 0 as the best and 100 as the worst, we inverted the scale for this study's outcome of physical function to standardize and incorporate its data. </p> <p><a href="./references#CD005614-bbs2-0040" title="UebelhartD , MalaiseM , MarcolongoR , deVathaireF , PipernoM , MailleuxE , et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one‐year, randomized, double‐blind, multicenter study versus placebo. Osteoarthritis Cartilage2004;12(4):269‐76. ">Uebelhart 2004</a> was a multicenter, participant‐ and investigator‐blind, placebo‐controlled, one‐year trial that compared chondroitin sulfate with placebo. Participants 40 years of age or older had stiffness of less than 30, bilateral or monolateral idiopathic knee osteoarthritis according to the ACR, and a Kellgren‐Lawrence score of I to III, with a minimum of 25% remaining medial femorotibial joint space. A total of 54 participants were randomly assigned to the chondroitin sulfate group and received 800 mg daily of chondroitin sulfate for two periods of three months (1 to 90 days and 181 to 270 days) over a two‐year period. The primary outcome of the study was the score on Lequesne's index. Secondary outcomes were spontaneous pain on a 100‐mm VAS, time to walk 20 meters, Patient global assessment of efficacy on a 0 to 4 Scale, consumption of analgesics, joint space narrowing on X‐ray, and adverse events. </p> <p><a href="./references#CD005614-bbs2-0041" title="VerbruggenG , GoemaereS , VeysEM . Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clinical Rheumatology2002;21:231‐43. ">Verbruggen 2002</a> was a randomized, participant‐ and investigator‐blind, placebo‐controlled trial that assessed the effects of chondroitin sulfate as a disease modifying osteoarthritis drug (DMOAD) at Ghent University Hospital. Participants were included if they were between 40 and 70 years of age and had symptoms producing osteoarthritis of the finger joint that were confirmed according to the presence of osteophytes and/or joint space narrowing, with or without subchondral sclerosis on hand X‐rays. The study reported that all participants were Caucasian. A total of 44 participants were randomly assigned to the active chondroitin sulfate group and received 400 mg of chondroitin sulfate three times daily for three years. In all, 48 participants were randomly assigned to the placebo group and received placebo sachets three times daily for three years. </p> <p><a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a> was a multicenter, randomized, participant‐ and investigator‐blind, controlled trial that compared chondroitin sulfate with placebo in participants with primary knee osteoarthritis lasting six months. Participants were included if they were diagnosed with primary osteoarthritis of the knee in accordance with the clinical and radiologic criteria of the ACR and if they had clinical signs of synovitis (warmth, swelling, or effusion), a disease severity grade 2 or 3 based on the Kellgren–Lawrence radiographic system, a minimal medial joint space width (JSW) of 2 mm on standing knee X‐ray, and a VAS pain index of at least 40 mm while walking. Participants were required to have no significant laboratory abnormalities. In all, 35 participants were randomly assigned to receive 800 mg of chondroitin sulfate as two capsules of 400 mg once daily. A total of 34 participants were randomly assigned to receive placebo once daily. The primary outcome of the study was synovial membrane thickness. Secondary outcomes were cartilage volume; bone marrow lesions; WOMAC pain, function, stiffness, and total score; pain on VAS; and quality of life as assessed by SF‐36. </p> <p><a href="./references#CD005614-bbs2-0043" title="ZegelsB , CrozesP , UebelhartD , BruyereO , ReginsterJY . Equivalence of a single dose (1200 mg) compared to a three‐time a day dose (400 mg) of chondroitin 4&amp;6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthritis &amp; Cartilage2013;21(1):22‐7. ">Zegels 2012</a> was a multicenter, randomized, double blind, double‐dummy study with an allocation ratio of 1:1:1, in 10 centres in Belgium, three in France and two in Switzerland that compared oral sachet of chondroitin sulfate 1200 mg/day, one oral capsule of chondroitin sulfate 400 mg three times a day and placebo.  Primary outcome was Lequesne's index and secondary outcomes were Pain VAS, treatment compliance and adverse effects.   </p> </section> <section id="CD005614-sec-0077"> <h4 class="title">Excluded studies</h4> <p>After review of the full texts, 58 studies were excluded, all of which are included in the reference list (<a href="#CD005614-sec-0077">Excluded studies</a>). Of these studies, 11 were excluded because they were reviews and 13 because they were not randomized. Six studies were excluded because they did not provide data on any clinical outcomes specified. Two studies were excluded because they were duplicates, 16 because they were abstracts, one because it could not be obtained and the author did not respond to requests to provide the study for review, four because they were commentaries, another four because investigators did not study the efficacy of chondroitin or did not study osteoarthritis, and one because an obvious mismatch was noted in the data provided. Details are given in the excluded studies section (<a href="./references#CD005614-sec-0127" title="">Characteristics of excluded studies</a>). </p> </section> </section> <section id="CD005614-sec-0078"> <h3 class="title">Risk of bias in included studies</h3> <p><a href="#CD005614-fig-0003">Figure 3</a> and <a href="#CD005614-fig-0004">Figure 4</a> provide information about the risk of bias assessment performed for each individual study. </p> <div class="figure" id="CD005614-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD005614-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> </div> <div class="figure" id="CD005614-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD005614-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> </div> <section id="CD005614-sec-0079"> <h4 class="title">Allocation</h4> <p>Risk of bias assessment was performed by two assessors independently (SN, PF/JAS). All disagreements were settled by consensus. </p> <p>Of the 43 studies included in this meta‐analysis, 30 did not report methods of randomization adequately (<a href="./references#CD005614-bbs2-0001" title="AlekseevaLI , BenevolenskaiaLI , NasonovEL , ChichasovaNV , KariakinAN . Structum (chondroitin sulfate)—a new agent for the treatment of osteoarthrosis. Ter Arkh1999;71(5):51‐3. ">Alekseeva 1999</a>; <a href="./references#CD005614-bbs2-0002" title="AlekseevaLI , CichasovaNV , BenevolenskaiaLI , NasonovEL , MendelOI . Combined medication ARTRA in the treatment of osteoarthrosis. Ter Arkh2005;77(11):69‐75. ">Alekseeva 2005a</a>; <a href="./references#CD005614-bbs2-0003" title="AlekseevaLI , ArtemenkoNA , ZotkinEG , KudryavtcevaNV , LesnyakOM , MendelOI , et al. Rational selection of basal therapy in osteoarthritis. Results of the open randomized multicenter clinical trial of ARTRA preparation in Russia. Russkiy Meditsinskiy Journal2005;13(24):1637. ">Alekseeva 2005b</a>; <a href="./references#CD005614-bbs2-0004" title="AlekseevaLI . Results of an open comparative randomized clinical trial to assess efficacy and safety of two regimens of treatment with Theraflex preparation in knee osteoarthritis patients. Russkiy Meditsinskiy Journal2008;16(5):316. ">Alekseeva 2008</a>; <a href="./references#CD005614-bbs2-0005" title="ArtemenkoNA , ChvamaniyaNA . Characteristics of progression and treatment of osteoarthritis. Russkiy Meditsinksiy Journal2005;13(7):403. ">Artemenko 2005</a>; <a href="./references#CD005614-bbs2-0006" title="BourgeoisP , ChalesG , DehaisJ , DelcambreB , KuntzJL , RozenbergS . Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage1998;6(Suppl A):25‐30. ">Bourgeois 1998</a>; <a href="./references#CD005614-bbs2-0007" title="BucsiL , PoorG . Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow‐acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage1998;6(Suppl A):31‐6. ">Bucsi 1998</a>; <a href="./references#CD005614-bbs2-0009" title="CohenM , WolfeR , MaiT , LewisD . A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. Journal of Rheumatology2003;30(3):523‐8. ">Cohen 2003</a>; <a href="./references#CD005614-bbs2-0010" title="ConrozierT , VignonE . The efficacy of chondroitin sulfate in the treatment of the arthrosis of the hip joint. A double‐blind study versus placebo [Die Wirkung von Chondroitinsulfat bei der Behandlungder Hu¨ftgelenksarthrose: eine Doppelblindstudie gegen Placebo]. Litera Rheumatoiogica1992;14:69‐75. ">Conrozier 1992</a>; <a href="./references#CD005614-bbs2-0011" title="ConrozierT . Anti‐arthrosis treatments: efficacy and tolerance of chondroitin sulfates (CS 4&amp;6). Presse Med1998;27:1862‐5. ">Conrozier 1998</a>; <a href="./references#CD005614-bbs2-0012" title="DasA , Jr , HammadTA . Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage2000;8(5):343‐50. ">Das 2000</a>; <a href="./references#CD005614-bbs2-0013" title="DebiR . Glucosamine sulfate and chondroitin sulfate for degenerative joint disease. Harefuah2000;138:451. ">Debi 2000</a>; <a href="./references#CD005614-bbs2-0017" title="KanzakiN , SaitoK , MaedaA , KitagawaY , KisoY , WatanabeK , et al. Effect of a dietary supplement containing glucosamine hydrochloride, chondroitin sulfate and quercetin glycosides on symptomatic knee osteoarthritis: a randomized, double‐blind, placebo‐controlled study. Journal of Science and Food Agriculture2012;92:862‐9. ">Kanzaki 2011</a>; <a href="./references#CD005614-bbs2-0018" title="L’HirondelJL . Clinical double‐blinded study with orally administered chondroitin sulfate versus placebo in patients with tibiofemoral gonarthrosis (125 patients) [Klinische Doppelblind‐Studie mit oral verabreichtem Chondroitinsulfatgegen Placebo bei der tibiofemoralen Gonarthrose (125 patients)]. Litera Rheumatologica1992;14:77‐84. ">L'Hirondel 1992</a>; <a href="./references#CD005614-bbs2-0019" title="LilaAM , MazurovVI , ShidlovskayaOV , ShostakMS . THERAFLEX in comprehensive therapy of knee osteoarthrosis and spinal osteochondrosis (results of a clinical trial). Russkiy Meditsinskiy Journal2005;13(24):1618. ">Lila 2005</a>; <a href="./references#CD005614-bbs2-0020" title="Magrans‐CourtneyT , WilbornC , RasmussenC , FerreiraM , GreenwoodL , CampbellB , et al. Effects of diet type and supplementation of glucosamine, chondroitin, and MSM on body composition, functional status, and markers of health in women with knee osteoarthritis initiating a resistance‐based exercise and weight loss program. Journal of International Society of Sports Medicine2011;8:8. ">Magrans‐Courtney 2011</a>; <a href="./references#CD005614-bbs2-0021" title="MazieresB , LoyauG , MenkesCJ , ValatJP , DreiserRL , CharlotJ , et al. Chondroitin sulfate in the treatment of gonarthrosis and coxarthrosis. 5‐months result of a multicenter double‐blind controlled prospective study using placebo. Rev Rhum Mal Osteoartic1992;59(7‐8):466‐72. ">Mazieres 1992</a>; <a href="./references#CD005614-bbs2-0022" title="MazieresB , CombeB , Phan VanA , TondutJ , GrynfelttM . Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. Journal of Rheumatology2001;28(1):173‐81. SawitzkeAD , ShiH , FincoMF , DunlopDD , Bingham IIICO , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis and Rheumatism2008;58:3183‐91. ">Mazieres 2001</a>; <a href="./references#CD005614-bbs2-0026" title="MorrealeP , ManopuloR , GalatiM , BoccaneraL , SaponatiG , BocchiL . Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. Journal of Rheumatology1996;23(8):1385‐91. ">Morreale 1996</a>; <a href="./references#CD005614-bbs2-0027" title="NakasoneY , WatabeK , WatanabeK , TomonagaA , NagaokaI , YamamotoT , et al. Effect of a glucosamine‐based combination supplement containing chondroitin sulfate and antioxidant micronutrients in subjects with symptomatic knee osteoarthritis: a pilot study. Experimental and Therapeutic Medicine2011;2(5):893. ">Nakasone 2011</a>; <a href="./references#CD005614-bbs2-0028" title="NasonovaVA , AlekseevaLI , Arkhangel'skaiaGS , DavydovaAF , Karmil'tsevaEA , KoganKM , et al. Results of the multicenter clinical trial of structum preparation in Russia. Ter Arkh2001;73(11):84‐7. ">Nasonova 2001</a>; <a href="./references#CD005614-bbs2-0030" title="PavelkaK , ManopuloR , BusciL . Double‐blind, dose‐effect study of oral chondroitin 4 &amp; 6 sulfate 1200 mg, 800 mg, 200 mg, and placebo in the treatment of knee osteoarthritis. Litera Rhumatologica1999;24:21‐30. ">Pavelka 1999</a>; <a href="./references#CD005614-bbs2-0032" title="RaiJ , PalSK , GulA , SenthilR , SinghH . Efficacy of chondroitin sulfate and glucosamine sulfate in the progression of symptomatic knee osteoarthritis: a randomized, placebo‐controlled, double‐blind study. Bulletin PGI2004;38:18‐22. ">Rai 2004</a>; <a href="./references#CD005614-bbs2-0035" title="RovettaG , MonteforteP , MolfettaG , BalestraV . Chondroitin sulfate in erosive osteoarthritis of the hands. International Journal of Tissue Reactions2002;24(1):29‐32. ">Rovetta 2002</a>; <a href="./references#CD005614-bbs2-0036" title="RovettaG , MontefortP , MolfettaG , BalestraV . A two‐year study of chondroitin sulfate in erosive osteoarthritis of the hands: behavior of erosions, osteophytes, pain and hand dysfunction. Drugs Under Experimental and Clinical Research2004;XXX(1):11‐6. ">Rovetta 2004</a>; <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a>; <a href="./references#CD005614-bbs2-0039" title="UebelhartD , ThonarEJ , DelmasPD , ChantraineA , VignonE . Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage1998;6(Suppl A):39‐46. ">Uebelhart 1998</a>; <a href="./references#CD005614-bbs2-0041" title="VerbruggenG , GoemaereS , VeysEM . Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clinical Rheumatology2002;21:231‐43. ">Verbruggen 2002</a>; <a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>; <a href="./references#CD005614-bbs2-0034" title="RaynauldJP , Martel‐PelletierJ , DoraisM , HaraouiB , ChoquetteD , AbramF , et al. Total Knee Replacement as a Knee Osteoarthritis Outcome: Predictors Derived from a 4‐Year Long‐Term Observation following a Randomized Clinical Trial Using Chondroitin Sulfate. Cartilage2013;4(3):219‐26. ">Raynauld 2013</a>). There were 13 studies that reported adequate methods of randomization ( <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0015" title="GabayC , Medinger‐SadowskiC , GasconD , KoloF , FinckhA . Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis. Arthritis and Rheumatism2011;63(11):3383‐91. ">Gabay 2011</a>; <a href="./references#CD005614-bbs2-0016" title="KahanA , UebelhartD , DeVathaireF , DelmasPD , ReginsterJY . Long‐term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2009;60(2):524‐33. ">Kahan 2009</a>; <a href="./references#CD005614-bbs2-0023" title="MessierSP , MihalkoS , LoeserRF , LegaultC , JollaJ , PfruenderJ , et al. Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study. Osteoarthritis Cartilage2007;15(11):1256‐66. ">Messier 2007</a>; <a href="./references#CD005614-bbs2-0024" title="MichelBA , StuckiG , FreyD , DeVathaireF , VignonE , BruehlmannP , et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis and Rheumatism2005;52(3):779‐86. ">Michel 2005</a>; <a href="./references#CD005614-bbs2-0025" title="MöllerI , PérezM , MonfortJ , BenitoP , CuevasJ , PernaC , et al. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double‐blind, placebo‐controlled study. Osteoarthritis and Cartilage2010;18:S32‐40. ">Moller 2010</a>; <a href="./references#CD005614-bbs2-0029" title="NguyenP , MohamedSE , GardinerD , SalinasT . A randomized double‐blind clinical trial of the effect of chondroitin sulfate and glucosamine hydrochloride on temporomandibular joint disorders: a pilot study. Cranio2001;19(2):130‐9. ">Nguyen 2001</a>; <a href="./references#CD005614-bbs2-0031" title="PavelkaK , CosteP , GéherP . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659–70. ">Pavelka 2010</a>; <a href="./references#CD005614-bbs2-0037" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , BinghamCOIII , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis Rheum2008;58:3183‐91. ">Sawitzke 2008</a>; <a href="./references#CD005614-bbs2-0040" title="UebelhartD , MalaiseM , MarcolongoR , deVathaireF , PipernoM , MailleuxE , et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one‐year, randomized, double‐blind, multicenter study versus placebo. Osteoarthritis Cartilage2004;12(4):269‐76. ">Uebelhart 2004</a>; <a href="./references#CD005614-bbs2-0014" title="FardelloneP , ZaimM , SaurelAS , MaheuE . Comparative efficacy and safety study of two chondroitin sulfate preparations from different origin (avian and bovine) in symptomatic osteoarthritis of the knee. The open rheumatology journal2013;7(1):1‐12. ">Fardellone 2013</a>; <a href="./references#CD005614-bbs2-0033" title="RailhacJJ , ZaimM , SaurelAS , VialJ , FournieB . Effect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: A randomized, double‐blind, placebo‐controlled pilot study using MRI. Clinical Rheumatology2012;31(9):1347‐57. ">Railhac 2012</a>; <a href="./references#CD005614-bbs2-0043" title="ZegelsB , CrozesP , UebelhartD , BruyereO , ReginsterJY . Equivalence of a single dose (1200 mg) compared to a three‐time a day dose (400 mg) of chondroitin 4&amp;6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthritis &amp; Cartilage2013;21(1):22‐7. ">Zegels 2012</a>). </p> <p>In all, 34 studies did not report the methods of allocation concealment used or had unclear methods of allocation concealment (<a href="./references#CD005614-bbs2-0001" title="AlekseevaLI , BenevolenskaiaLI , NasonovEL , ChichasovaNV , KariakinAN . Structum (chondroitin sulfate)—a new agent for the treatment of osteoarthrosis. Ter Arkh1999;71(5):51‐3. ">Alekseeva 1999</a>; <a href="./references#CD005614-bbs2-0002" title="AlekseevaLI , CichasovaNV , BenevolenskaiaLI , NasonovEL , MendelOI . Combined medication ARTRA in the treatment of osteoarthrosis. Ter Arkh2005;77(11):69‐75. ">Alekseeva 2005a</a>; <a href="./references#CD005614-bbs2-0003" title="AlekseevaLI , ArtemenkoNA , ZotkinEG , KudryavtcevaNV , LesnyakOM , MendelOI , et al. Rational selection of basal therapy in osteoarthritis. Results of the open randomized multicenter clinical trial of ARTRA preparation in Russia. Russkiy Meditsinskiy Journal2005;13(24):1637. ">Alekseeva 2005b</a>; <a href="./references#CD005614-bbs2-0004" title="AlekseevaLI . Results of an open comparative randomized clinical trial to assess efficacy and safety of two regimens of treatment with Theraflex preparation in knee osteoarthritis patients. Russkiy Meditsinskiy Journal2008;16(5):316. ">Alekseeva 2008</a>; <a href="./references#CD005614-bbs2-0005" title="ArtemenkoNA , ChvamaniyaNA . Characteristics of progression and treatment of osteoarthritis. Russkiy Meditsinksiy Journal2005;13(7):403. ">Artemenko 2005</a>; <a href="./references#CD005614-bbs2-0006" title="BourgeoisP , ChalesG , DehaisJ , DelcambreB , KuntzJL , RozenbergS . Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage1998;6(Suppl A):25‐30. ">Bourgeois 1998</a>; <a href="./references#CD005614-bbs2-0007" title="BucsiL , PoorG . Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow‐acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage1998;6(Suppl A):31‐6. ">Bucsi 1998</a>; <a href="./references#CD005614-bbs2-0009" title="CohenM , WolfeR , MaiT , LewisD . A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. Journal of Rheumatology2003;30(3):523‐8. ">Cohen 2003</a>; <a href="./references#CD005614-bbs2-0010" title="ConrozierT , VignonE . The efficacy of chondroitin sulfate in the treatment of the arthrosis of the hip joint. A double‐blind study versus placebo [Die Wirkung von Chondroitinsulfat bei der Behandlungder Hu¨ftgelenksarthrose: eine Doppelblindstudie gegen Placebo]. Litera Rheumatoiogica1992;14:69‐75. ">Conrozier 1992</a>; <a href="./references#CD005614-bbs2-0011" title="ConrozierT . Anti‐arthrosis treatments: efficacy and tolerance of chondroitin sulfates (CS 4&amp;6). Presse Med1998;27:1862‐5. ">Conrozier 1998</a>; <a href="./references#CD005614-bbs2-0013" title="DebiR . Glucosamine sulfate and chondroitin sulfate for degenerative joint disease. Harefuah2000;138:451. ">Debi 2000</a>; <a href="./references#CD005614-bbs2-0015" title="GabayC , Medinger‐SadowskiC , GasconD , KoloF , FinckhA . Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis. Arthritis and Rheumatism2011;63(11):3383‐91. ">Gabay 2011</a>; <a href="./references#CD005614-bbs2-0017" title="KanzakiN , SaitoK , MaedaA , KitagawaY , KisoY , WatanabeK , et al. Effect of a dietary supplement containing glucosamine hydrochloride, chondroitin sulfate and quercetin glycosides on symptomatic knee osteoarthritis: a randomized, double‐blind, placebo‐controlled study. Journal of Science and Food Agriculture2012;92:862‐9. ">Kanzaki 2011</a>; <a href="./references#CD005614-bbs2-0018" title="L’HirondelJL . Clinical double‐blinded study with orally administered chondroitin sulfate versus placebo in patients with tibiofemoral gonarthrosis (125 patients) [Klinische Doppelblind‐Studie mit oral verabreichtem Chondroitinsulfatgegen Placebo bei der tibiofemoralen Gonarthrose (125 patients)]. Litera Rheumatologica1992;14:77‐84. ">L'Hirondel 1992</a>; <a href="./references#CD005614-bbs2-0019" title="LilaAM , MazurovVI , ShidlovskayaOV , ShostakMS . THERAFLEX in comprehensive therapy of knee osteoarthrosis and spinal osteochondrosis (results of a clinical trial). Russkiy Meditsinskiy Journal2005;13(24):1618. ">Lila 2005</a>; <a href="./references#CD005614-bbs2-0020" title="Magrans‐CourtneyT , WilbornC , RasmussenC , FerreiraM , GreenwoodL , CampbellB , et al. Effects of diet type and supplementation of glucosamine, chondroitin, and MSM on body composition, functional status, and markers of health in women with knee osteoarthritis initiating a resistance‐based exercise and weight loss program. Journal of International Society of Sports Medicine2011;8:8. ">Magrans‐Courtney 2011</a>; <a href="./references#CD005614-bbs2-0021" title="MazieresB , LoyauG , MenkesCJ , ValatJP , DreiserRL , CharlotJ , et al. Chondroitin sulfate in the treatment of gonarthrosis and coxarthrosis. 5‐months result of a multicenter double‐blind controlled prospective study using placebo. Rev Rhum Mal Osteoartic1992;59(7‐8):466‐72. ">Mazieres 1992</a>; <a href="./references#CD005614-bbs2-0022" title="MazieresB , CombeB , Phan VanA , TondutJ , GrynfelttM . Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. Journal of Rheumatology2001;28(1):173‐81. SawitzkeAD , ShiH , FincoMF , DunlopDD , Bingham IIICO , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis and Rheumatism2008;58:3183‐91. ">Mazieres 2001</a>; <a href="./references#CD005614-bbs2-0024" title="MichelBA , StuckiG , FreyD , DeVathaireF , VignonE , BruehlmannP , et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis and Rheumatism2005;52(3):779‐86. ">Michel 2005</a>; <a href="./references#CD005614-bbs2-0026" title="MorrealeP , ManopuloR , GalatiM , BoccaneraL , SaponatiG , BocchiL . Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. Journal of Rheumatology1996;23(8):1385‐91. ">Morreale 1996</a>; <a href="./references#CD005614-bbs2-0027" title="NakasoneY , WatabeK , WatanabeK , TomonagaA , NagaokaI , YamamotoT , et al. Effect of a glucosamine‐based combination supplement containing chondroitin sulfate and antioxidant micronutrients in subjects with symptomatic knee osteoarthritis: a pilot study. Experimental and Therapeutic Medicine2011;2(5):893. ">Nakasone 2011</a>; <a href="./references#CD005614-bbs2-0028" title="NasonovaVA , AlekseevaLI , Arkhangel'skaiaGS , DavydovaAF , Karmil'tsevaEA , KoganKM , et al. Results of the multicenter clinical trial of structum preparation in Russia. Ter Arkh2001;73(11):84‐7. ">Nasonova 2001</a>; <a href="./references#CD005614-bbs2-0030" title="PavelkaK , ManopuloR , BusciL . Double‐blind, dose‐effect study of oral chondroitin 4 &amp; 6 sulfate 1200 mg, 800 mg, 200 mg, and placebo in the treatment of knee osteoarthritis. Litera Rhumatologica1999;24:21‐30. ">Pavelka 1999</a>; <a href="./references#CD005614-bbs2-0031" title="PavelkaK , CosteP , GéherP . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659–70. ">Pavelka 2010</a>; <a href="./references#CD005614-bbs2-0032" title="RaiJ , PalSK , GulA , SenthilR , SinghH . Efficacy of chondroitin sulfate and glucosamine sulfate in the progression of symptomatic knee osteoarthritis: a randomized, placebo‐controlled, double‐blind study. Bulletin PGI2004;38:18‐22. ">Rai 2004</a>; <a href="./references#CD005614-bbs2-0035" title="RovettaG , MonteforteP , MolfettaG , BalestraV . Chondroitin sulfate in erosive osteoarthritis of the hands. International Journal of Tissue Reactions2002;24(1):29‐32. ">Rovetta 2002</a>; <a href="./references#CD005614-bbs2-0036" title="RovettaG , MontefortP , MolfettaG , BalestraV . A two‐year study of chondroitin sulfate in erosive osteoarthritis of the hands: behavior of erosions, osteophytes, pain and hand dysfunction. Drugs Under Experimental and Clinical Research2004;XXX(1):11‐6. ">Rovetta 2004</a>; <a href="./references#CD005614-bbs2-0037" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , BinghamCOIII , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis Rheum2008;58:3183‐91. ">Sawitzke 2008</a>; <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a>; <a href="./references#CD005614-bbs2-0039" title="UebelhartD , ThonarEJ , DelmasPD , ChantraineA , VignonE . Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage1998;6(Suppl A):39‐46. ">Uebelhart 1998</a>; <a href="./references#CD005614-bbs2-0041" title="VerbruggenG , GoemaereS , VeysEM . Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clinical Rheumatology2002;21:231‐43. ">Verbruggen 2002</a>; <a href="./references#CD005614-bbs2-0014" title="FardelloneP , ZaimM , SaurelAS , MaheuE . Comparative efficacy and safety study of two chondroitin sulfate preparations from different origin (avian and bovine) in symptomatic osteoarthritis of the knee. The open rheumatology journal2013;7(1):1‐12. ">Fardellone 2013</a>; <a href="./references#CD005614-bbs2-0033" title="RailhacJJ , ZaimM , SaurelAS , VialJ , FournieB . Effect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: A randomized, double‐blind, placebo‐controlled pilot study using MRI. Clinical Rheumatology2012;31(9):1347‐57. ">Railhac 2012</a>; <a href="./references#CD005614-bbs2-0043" title="ZegelsB , CrozesP , UebelhartD , BruyereO , ReginsterJY . Equivalence of a single dose (1200 mg) compared to a three‐time a day dose (400 mg) of chondroitin 4&amp;6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthritis &amp; Cartilage2013;21(1):22‐7. ">Zegels 2012</a>). Nine studies reported adequate methods of allocation concealment (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0012" title="DasA , Jr , HammadTA . Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage2000;8(5):343‐50. ">Das 2000</a>; <a href="./references#CD005614-bbs2-0016" title="KahanA , UebelhartD , DeVathaireF , DelmasPD , ReginsterJY . Long‐term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2009;60(2):524‐33. ">Kahan 2009</a>; <a href="./references#CD005614-bbs2-0023" title="MessierSP , MihalkoS , LoeserRF , LegaultC , JollaJ , PfruenderJ , et al. Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study. Osteoarthritis Cartilage2007;15(11):1256‐66. ">Messier 2007</a>; <a href="./references#CD005614-bbs2-0025" title="MöllerI , PérezM , MonfortJ , BenitoP , CuevasJ , PernaC , et al. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double‐blind, placebo‐controlled study. Osteoarthritis and Cartilage2010;18:S32‐40. ">Moller 2010</a>; <a href="./references#CD005614-bbs2-0029" title="NguyenP , MohamedSE , GardinerD , SalinasT . A randomized double‐blind clinical trial of the effect of chondroitin sulfate and glucosamine hydrochloride on temporomandibular joint disorders: a pilot study. Cranio2001;19(2):130‐9. ">Nguyen 2001</a>; <a href="./references#CD005614-bbs2-0040" title="UebelhartD , MalaiseM , MarcolongoR , deVathaireF , PipernoM , MailleuxE , et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one‐year, randomized, double‐blind, multicenter study versus placebo. Osteoarthritis Cartilage2004;12(4):269‐76. ">Uebelhart 2004</a>; <a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>; <a href="./references#CD005614-bbs2-0034" title="RaynauldJP , Martel‐PelletierJ , DoraisM , HaraouiB , ChoquetteD , AbramF , et al. Total Knee Replacement as a Knee Osteoarthritis Outcome: Predictors Derived from a 4‐Year Long‐Term Observation following a Randomized Clinical Trial Using Chondroitin Sulfate. Cartilage2013;4(3):219‐26. ">Raynauld 2013</a>). For a more detailed description of allocation concealment in the individual studies, refer to the risk of bias tables included under the characteristics of included studies and to <a href="#CD005614-fig-0001">Figure 1</a> and Figure 2. </p> </section> <section id="CD005614-sec-0080"> <h4 class="title">Blinding</h4> <p>Of the 43 studies included in this meta‐analysis, 14 used unclear methods of blinding (<a href="./references#CD005614-bbs2-0007" title="BucsiL , PoorG . Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow‐acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage1998;6(Suppl A):31‐6. ">Bucsi 1998</a>; <a href="./references#CD005614-bbs2-0009" title="CohenM , WolfeR , MaiT , LewisD . A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. Journal of Rheumatology2003;30(3):523‐8. ">Cohen 2003</a>; <a href="./references#CD005614-bbs2-0011" title="ConrozierT . Anti‐arthrosis treatments: efficacy and tolerance of chondroitin sulfates (CS 4&amp;6). Presse Med1998;27:1862‐5. ">Conrozier 1998</a>; <a href="./references#CD005614-bbs2-0013" title="DebiR . Glucosamine sulfate and chondroitin sulfate for degenerative joint disease. Harefuah2000;138:451. ">Debi 2000;</a><a href="./references#CD005614-bbs2-0015" title="GabayC , Medinger‐SadowskiC , GasconD , KoloF , FinckhA . Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis. Arthritis and Rheumatism2011;63(11):3383‐91. ">Gabay 2011;</a><a href="./references#CD005614-bbs2-0018" title="L’HirondelJL . Clinical double‐blinded study with orally administered chondroitin sulfate versus placebo in patients with tibiofemoral gonarthrosis (125 patients) [Klinische Doppelblind‐Studie mit oral verabreichtem Chondroitinsulfatgegen Placebo bei der tibiofemoralen Gonarthrose (125 patients)]. Litera Rheumatologica1992;14:77‐84. ">L'Hirondel 1992</a>; <a href="./references#CD005614-bbs2-0021" title="MazieresB , LoyauG , MenkesCJ , ValatJP , DreiserRL , CharlotJ , et al. Chondroitin sulfate in the treatment of gonarthrosis and coxarthrosis. 5‐months result of a multicenter double‐blind controlled prospective study using placebo. Rev Rhum Mal Osteoartic1992;59(7‐8):466‐72. ">Mazieres 1992;</a><a href="./references#CD005614-bbs2-0027" title="NakasoneY , WatabeK , WatanabeK , TomonagaA , NagaokaI , YamamotoT , et al. Effect of a glucosamine‐based combination supplement containing chondroitin sulfate and antioxidant micronutrients in subjects with symptomatic knee osteoarthritis: a pilot study. Experimental and Therapeutic Medicine2011;2(5):893. ">Nakasone 2011;</a><a href="./references#CD005614-bbs2-0032" title="RaiJ , PalSK , GulA , SenthilR , SinghH . Efficacy of chondroitin sulfate and glucosamine sulfate in the progression of symptomatic knee osteoarthritis: a randomized, placebo‐controlled, double‐blind study. Bulletin PGI2004;38:18‐22. ">Rai 2004;</a><a href="./references#CD005614-bbs2-0037" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , BinghamCOIII , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis Rheum2008;58:3183‐91. ">Sawitzke 2008;</a><a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010;</a><a href="./references#CD005614-bbs2-0041" title="VerbruggenG , GoemaereS , VeysEM . Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clinical Rheumatology2002;21:231‐43. ">Verbruggen 2002</a>; <a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>;<a href="./references#CD005614-bbs2-0034" title="RaynauldJP , Martel‐PelletierJ , DoraisM , HaraouiB , ChoquetteD , AbramF , et al. Total Knee Replacement as a Knee Osteoarthritis Outcome: Predictors Derived from a 4‐Year Long‐Term Observation following a Randomized Clinical Trial Using Chondroitin Sulfate. Cartilage2013;4(3):219‐26. ">Raynauld 2013</a>). Nine studies did not have participant and investigator blinding (<a href="./references#CD005614-bbs2-0001" title="AlekseevaLI , BenevolenskaiaLI , NasonovEL , ChichasovaNV , KariakinAN . Structum (chondroitin sulfate)—a new agent for the treatment of osteoarthrosis. Ter Arkh1999;71(5):51‐3. ">Alekseeva 1999</a>, <a href="./references#CD005614-bbs2-0002" title="AlekseevaLI , CichasovaNV , BenevolenskaiaLI , NasonovEL , MendelOI . Combined medication ARTRA in the treatment of osteoarthrosis. Ter Arkh2005;77(11):69‐75. ">Alekseeva 2005a</a>, <a href="./references#CD005614-bbs2-0003" title="AlekseevaLI , ArtemenkoNA , ZotkinEG , KudryavtcevaNV , LesnyakOM , MendelOI , et al. Rational selection of basal therapy in osteoarthritis. Results of the open randomized multicenter clinical trial of ARTRA preparation in Russia. Russkiy Meditsinskiy Journal2005;13(24):1637. ">Alekseeva 2005b</a>, <a href="./references#CD005614-bbs2-0004" title="AlekseevaLI . Results of an open comparative randomized clinical trial to assess efficacy and safety of two regimens of treatment with Theraflex preparation in knee osteoarthritis patients. Russkiy Meditsinskiy Journal2008;16(5):316. ">Alekseeva 2008</a>, <a href="./references#CD005614-bbs2-0005" title="ArtemenkoNA , ChvamaniyaNA . Characteristics of progression and treatment of osteoarthritis. Russkiy Meditsinksiy Journal2005;13(7):403. ">Artemenko 2005</a>, <a href="./references#CD005614-bbs2-0019" title="LilaAM , MazurovVI , ShidlovskayaOV , ShostakMS . THERAFLEX in comprehensive therapy of knee osteoarthrosis and spinal osteochondrosis (results of a clinical trial). Russkiy Meditsinskiy Journal2005;13(24):1618. ">Lila 2005</a>, <a href="./references#CD005614-bbs2-0028" title="NasonovaVA , AlekseevaLI , Arkhangel'skaiaGS , DavydovaAF , Karmil'tsevaEA , KoganKM , et al. Results of the multicenter clinical trial of structum preparation in Russia. Ter Arkh2001;73(11):84‐7. ">Nasonova 2001</a>, <a href="./references#CD005614-bbs2-0036" title="RovettaG , MontefortP , MolfettaG , BalestraV . A two‐year study of chondroitin sulfate in erosive osteoarthritis of the hands: behavior of erosions, osteophytes, pain and hand dysfunction. Drugs Under Experimental and Clinical Research2004;XXX(1):11‐6. ">Rovetta 2004</a>, <a href="./references#CD005614-bbs2-0035" title="RovettaG , MonteforteP , MolfettaG , BalestraV . Chondroitin sulfate in erosive osteoarthritis of the hands. International Journal of Tissue Reactions2002;24(1):29‐32. ">Rovetta 2002</a>); 20 studies (<a href="./references#CD005614-bbs2-0006" title="BourgeoisP , ChalesG , DehaisJ , DelcambreB , KuntzJL , RozenbergS . Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage1998;6(Suppl A):25‐30. ">Bourgeois 1998</a>, <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>, <a href="./references#CD005614-bbs2-0010" title="ConrozierT , VignonE . The efficacy of chondroitin sulfate in the treatment of the arthrosis of the hip joint. A double‐blind study versus placebo [Die Wirkung von Chondroitinsulfat bei der Behandlungder Hu¨ftgelenksarthrose: eine Doppelblindstudie gegen Placebo]. Litera Rheumatoiogica1992;14:69‐75. ">Conrozier 1992</a>, <a href="./references#CD005614-bbs2-0012" title="DasA , Jr , HammadTA . Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage2000;8(5):343‐50. ">Das 2000</a>, <a href="./references#CD005614-bbs2-0016" title="KahanA , UebelhartD , DeVathaireF , DelmasPD , ReginsterJY . Long‐term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2009;60(2):524‐33. ">Kahan 2009</a>, <a href="./references#CD005614-bbs2-0017" title="KanzakiN , SaitoK , MaedaA , KitagawaY , KisoY , WatanabeK , et al. Effect of a dietary supplement containing glucosamine hydrochloride, chondroitin sulfate and quercetin glycosides on symptomatic knee osteoarthritis: a randomized, double‐blind, placebo‐controlled study. Journal of Science and Food Agriculture2012;92:862‐9. ">Kanzaki 2011</a>, <a href="./references#CD005614-bbs2-0020" title="Magrans‐CourtneyT , WilbornC , RasmussenC , FerreiraM , GreenwoodL , CampbellB , et al. Effects of diet type and supplementation of glucosamine, chondroitin, and MSM on body composition, functional status, and markers of health in women with knee osteoarthritis initiating a resistance‐based exercise and weight loss program. Journal of International Society of Sports Medicine2011;8:8. ">Magrans‐Courtney 2011</a>, <a href="./references#CD005614-bbs2-0022" title="MazieresB , CombeB , Phan VanA , TondutJ , GrynfelttM . Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. Journal of Rheumatology2001;28(1):173‐81. SawitzkeAD , ShiH , FincoMF , DunlopDD , Bingham IIICO , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis and Rheumatism2008;58:3183‐91. ">Mazieres 2001</a>, <a href="./references#CD005614-bbs2-0023" title="MessierSP , MihalkoS , LoeserRF , LegaultC , JollaJ , PfruenderJ , et al. Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study. Osteoarthritis Cartilage2007;15(11):1256‐66. ">Messier 2007</a>, <a href="./references#CD005614-bbs2-0024" title="MichelBA , StuckiG , FreyD , DeVathaireF , VignonE , BruehlmannP , et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis and Rheumatism2005;52(3):779‐86. ">Michel 2005</a>, <a href="./references#CD005614-bbs2-0025" title="MöllerI , PérezM , MonfortJ , BenitoP , CuevasJ , PernaC , et al. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double‐blind, placebo‐controlled study. Osteoarthritis and Cartilage2010;18:S32‐40. ">Moller 2010</a>, <a href="./references#CD005614-bbs2-0026" title="MorrealeP , ManopuloR , GalatiM , BoccaneraL , SaponatiG , BocchiL . Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. Journal of Rheumatology1996;23(8):1385‐91. ">Morreale 1996</a>, <a href="./references#CD005614-bbs2-0029" title="NguyenP , MohamedSE , GardinerD , SalinasT . A randomized double‐blind clinical trial of the effect of chondroitin sulfate and glucosamine hydrochloride on temporomandibular joint disorders: a pilot study. Cranio2001;19(2):130‐9. ">Nguyen 2001</a>, <a href="./references#CD005614-bbs2-0030" title="PavelkaK , ManopuloR , BusciL . Double‐blind, dose‐effect study of oral chondroitin 4 &amp; 6 sulfate 1200 mg, 800 mg, 200 mg, and placebo in the treatment of knee osteoarthritis. Litera Rhumatologica1999;24:21‐30. ">Pavelka 1999</a>, <a href="./references#CD005614-bbs2-0031" title="PavelkaK , CosteP , GéherP . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659–70. ">Pavelka 2010</a>, <a href="./references#CD005614-bbs2-0039" title="UebelhartD , ThonarEJ , DelmasPD , ChantraineA , VignonE . Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage1998;6(Suppl A):39‐46. ">Uebelhart 1998</a>, <a href="./references#CD005614-bbs2-0040" title="UebelhartD , MalaiseM , MarcolongoR , deVathaireF , PipernoM , MailleuxE , et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one‐year, randomized, double‐blind, multicenter study versus placebo. Osteoarthritis Cartilage2004;12(4):269‐76. ">Uebelhart 2004</a>; <a href="./references#CD005614-bbs2-0014" title="FardelloneP , ZaimM , SaurelAS , MaheuE . Comparative efficacy and safety study of two chondroitin sulfate preparations from different origin (avian and bovine) in symptomatic osteoarthritis of the knee. The open rheumatology journal2013;7(1):1‐12. ">Fardellone 2013</a>; <a href="./references#CD005614-bbs2-0033" title="RailhacJJ , ZaimM , SaurelAS , VialJ , FournieB . Effect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: A randomized, double‐blind, placebo‐controlled pilot study using MRI. Clinical Rheumatology2012;31(9):1347‐57. ">Railhac 2012</a>; <a href="./references#CD005614-bbs2-0043" title="ZegelsB , CrozesP , UebelhartD , BruyereO , ReginsterJY . Equivalence of a single dose (1200 mg) compared to a three‐time a day dose (400 mg) of chondroitin 4&amp;6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthritis &amp; Cartilage2013;21(1):22‐7. ">Zegels 2012</a>) used investigator and participant blinding and described adequately the methods used. </p> </section> <section id="CD005614-sec-0081"> <h4 class="title">Incomplete outcome data</h4> <p>Of the 43 studies included in this meta‐analysis, 10 used unclear methods in handling missing outcomes (<a href="./references#CD005614-bbs2-0002" title="AlekseevaLI , CichasovaNV , BenevolenskaiaLI , NasonovEL , MendelOI . Combined medication ARTRA in the treatment of osteoarthrosis. Ter Arkh2005;77(11):69‐75. ">Alekseeva 2005a</a>; <a href="./references#CD005614-bbs2-0003" title="AlekseevaLI , ArtemenkoNA , ZotkinEG , KudryavtcevaNV , LesnyakOM , MendelOI , et al. Rational selection of basal therapy in osteoarthritis. Results of the open randomized multicenter clinical trial of ARTRA preparation in Russia. Russkiy Meditsinskiy Journal2005;13(24):1637. ">Alekseeva 2005b</a>; <a href="./references#CD005614-bbs2-0004" title="AlekseevaLI . Results of an open comparative randomized clinical trial to assess efficacy and safety of two regimens of treatment with Theraflex preparation in knee osteoarthritis patients. Russkiy Meditsinskiy Journal2008;16(5):316. ">Alekseeva 2008</a>; <a href="./references#CD005614-bbs2-0007" title="BucsiL , PoorG . Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow‐acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage1998;6(Suppl A):31‐6. ">Bucsi 1998</a>; <a href="./references#CD005614-bbs2-0013" title="DebiR . Glucosamine sulfate and chondroitin sulfate for degenerative joint disease. Harefuah2000;138:451. ">Debi 2000</a>; <a href="./references#CD005614-bbs2-0017" title="KanzakiN , SaitoK , MaedaA , KitagawaY , KisoY , WatanabeK , et al. Effect of a dietary supplement containing glucosamine hydrochloride, chondroitin sulfate and quercetin glycosides on symptomatic knee osteoarthritis: a randomized, double‐blind, placebo‐controlled study. Journal of Science and Food Agriculture2012;92:862‐9. ">Kanzaki 2011</a>; <a href="./references#CD005614-bbs2-0018" title="L’HirondelJL . Clinical double‐blinded study with orally administered chondroitin sulfate versus placebo in patients with tibiofemoral gonarthrosis (125 patients) [Klinische Doppelblind‐Studie mit oral verabreichtem Chondroitinsulfatgegen Placebo bei der tibiofemoralen Gonarthrose (125 patients)]. Litera Rheumatologica1992;14:77‐84. ">L'Hirondel 1992</a>; <a href="./references#CD005614-bbs2-0027" title="NakasoneY , WatabeK , WatanabeK , TomonagaA , NagaokaI , YamamotoT , et al. Effect of a glucosamine‐based combination supplement containing chondroitin sulfate and antioxidant micronutrients in subjects with symptomatic knee osteoarthritis: a pilot study. Experimental and Therapeutic Medicine2011;2(5):893. ">Nakasone 2011</a>; <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a>; <a href="./references#CD005614-bbs2-0039" title="UebelhartD , ThonarEJ , DelmasPD , ChantraineA , VignonE . Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage1998;6(Suppl A):39‐46. ">Uebelhart 1998</a>). Of the remaining 33 studies, 25 were assessed to have adequately handled missing outcome data by accounting for and providing a clear explanation of all dropouts or performing the appropriate statistical methods for handling missing data (<a href="./references#CD005614-bbs2-0006" title="BourgeoisP , ChalesG , DehaisJ , DelcambreB , KuntzJL , RozenbergS . Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage1998;6(Suppl A):25‐30. ">Bourgeois 1998</a>; <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0009" title="CohenM , WolfeR , MaiT , LewisD . A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. Journal of Rheumatology2003;30(3):523‐8. ">Cohen 2003</a>; <a href="./references#CD005614-bbs2-0010" title="ConrozierT , VignonE . The efficacy of chondroitin sulfate in the treatment of the arthrosis of the hip joint. A double‐blind study versus placebo [Die Wirkung von Chondroitinsulfat bei der Behandlungder Hu¨ftgelenksarthrose: eine Doppelblindstudie gegen Placebo]. Litera Rheumatoiogica1992;14:69‐75. ">Conrozier 1992</a>; <a href="./references#CD005614-bbs2-0011" title="ConrozierT . Anti‐arthrosis treatments: efficacy and tolerance of chondroitin sulfates (CS 4&amp;6). Presse Med1998;27:1862‐5. ">Conrozier 1998</a>; <a href="./references#CD005614-bbs2-0012" title="DasA , Jr , HammadTA . Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage2000;8(5):343‐50. ">Das 2000</a>; <a href="./references#CD005614-bbs2-0015" title="GabayC , Medinger‐SadowskiC , GasconD , KoloF , FinckhA . Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis. Arthritis and Rheumatism2011;63(11):3383‐91. ">Gabay 2011</a>; <a href="./references#CD005614-bbs2-0016" title="KahanA , UebelhartD , DeVathaireF , DelmasPD , ReginsterJY . Long‐term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2009;60(2):524‐33. ">Kahan 2009</a>; <a href="./references#CD005614-bbs2-0020" title="Magrans‐CourtneyT , WilbornC , RasmussenC , FerreiraM , GreenwoodL , CampbellB , et al. Effects of diet type and supplementation of glucosamine, chondroitin, and MSM on body composition, functional status, and markers of health in women with knee osteoarthritis initiating a resistance‐based exercise and weight loss program. Journal of International Society of Sports Medicine2011;8:8. ">Magrans‐Courtney 2011</a>; <a href="./references#CD005614-bbs2-0021" title="MazieresB , LoyauG , MenkesCJ , ValatJP , DreiserRL , CharlotJ , et al. Chondroitin sulfate in the treatment of gonarthrosis and coxarthrosis. 5‐months result of a multicenter double‐blind controlled prospective study using placebo. Rev Rhum Mal Osteoartic1992;59(7‐8):466‐72. ">Mazieres 1992</a>; <a href="./references#CD005614-bbs2-0022" title="MazieresB , CombeB , Phan VanA , TondutJ , GrynfelttM . Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. Journal of Rheumatology2001;28(1):173‐81. SawitzkeAD , ShiH , FincoMF , DunlopDD , Bingham IIICO , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis and Rheumatism2008;58:3183‐91. ">Mazieres 2001</a>; <a href="./references#CD005614-bbs2-0023" title="MessierSP , MihalkoS , LoeserRF , LegaultC , JollaJ , PfruenderJ , et al. Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study. Osteoarthritis Cartilage2007;15(11):1256‐66. ">Messier 2007</a>; <a href="./references#CD005614-bbs2-0024" title="MichelBA , StuckiG , FreyD , DeVathaireF , VignonE , BruehlmannP , et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis and Rheumatism2005;52(3):779‐86. ">Michel 2005</a>; <a href="./references#CD005614-bbs2-0026" title="MorrealeP , ManopuloR , GalatiM , BoccaneraL , SaponatiG , BocchiL . Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. Journal of Rheumatology1996;23(8):1385‐91. ">Morreale 1996</a>; <a href="./references#CD005614-bbs2-0030" title="PavelkaK , ManopuloR , BusciL . Double‐blind, dose‐effect study of oral chondroitin 4 &amp; 6 sulfate 1200 mg, 800 mg, 200 mg, and placebo in the treatment of knee osteoarthritis. Litera Rhumatologica1999;24:21‐30. ">Pavelka 1999</a>; <a href="./references#CD005614-bbs2-0031" title="PavelkaK , CosteP , GéherP . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659–70. ">Pavelka 2010</a>; <a href="./references#CD005614-bbs2-0035" title="RovettaG , MonteforteP , MolfettaG , BalestraV . Chondroitin sulfate in erosive osteoarthritis of the hands. International Journal of Tissue Reactions2002;24(1):29‐32. ">Rovetta 2002</a>; <a href="./references#CD005614-bbs2-0036" title="RovettaG , MontefortP , MolfettaG , BalestraV . A two‐year study of chondroitin sulfate in erosive osteoarthritis of the hands: behavior of erosions, osteophytes, pain and hand dysfunction. Drugs Under Experimental and Clinical Research2004;XXX(1):11‐6. ">Rovetta 2004</a>; <a href="./references#CD005614-bbs2-0037" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , BinghamCOIII , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis Rheum2008;58:3183‐91. ">Sawitzke 2008</a>; <a href="./references#CD005614-bbs2-0040" title="UebelhartD , MalaiseM , MarcolongoR , deVathaireF , PipernoM , MailleuxE , et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one‐year, randomized, double‐blind, multicenter study versus placebo. Osteoarthritis Cartilage2004;12(4):269‐76. ">Uebelhart 2004</a>; <a href="./references#CD005614-bbs2-0041" title="VerbruggenG , GoemaereS , VeysEM . Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clinical Rheumatology2002;21:231‐43. ">Verbruggen 2002</a>; <a href="./references#CD005614-bbs2-0014" title="FardelloneP , ZaimM , SaurelAS , MaheuE . Comparative efficacy and safety study of two chondroitin sulfate preparations from different origin (avian and bovine) in symptomatic osteoarthritis of the knee. The open rheumatology journal2013;7(1):1‐12. ">Fardellone 2013</a>; <a href="./references#CD005614-bbs2-0033" title="RailhacJJ , ZaimM , SaurelAS , VialJ , FournieB . Effect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: A randomized, double‐blind, placebo‐controlled pilot study using MRI. Clinical Rheumatology2012;31(9):1347‐57. ">Railhac 2012</a>; <a href="./references#CD005614-bbs2-0034" title="RaynauldJP , Martel‐PelletierJ , DoraisM , HaraouiB , ChoquetteD , AbramF , et al. Total Knee Replacement as a Knee Osteoarthritis Outcome: Predictors Derived from a 4‐Year Long‐Term Observation following a Randomized Clinical Trial Using Chondroitin Sulfate. Cartilage2013;4(3):219‐26. ">Raynauld 2013</a>; <a href="./references#CD005614-bbs2-0043" title="ZegelsB , CrozesP , UebelhartD , BruyereO , ReginsterJY . Equivalence of a single dose (1200 mg) compared to a three‐time a day dose (400 mg) of chondroitin 4&amp;6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthritis &amp; Cartilage2013;21(1):22‐7. ">Zegels 2012</a>). The remaining eight studies failed to provide an adequate account of their withdrawals and missing outcome data or to perform the appropriate statistical methods. </p> </section> <section id="CD005614-sec-0082"> <h4 class="title">Selective reporting</h4> <p>Only one study (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>) reported on outcome measures as recommended by the Outcome Measures in Rheumatology (OMERACT) group. Therefore, it was difficult to find commonly reported outcomes across the studies. Furthermore, because review authors could not gain access to the study protocols, it was difficult to decipher whether the studies reported on all outcomes specified in the study protocol. </p> </section> <section id="CD005614-sec-0083"> <h4 class="title">Other potential sources of bias</h4> <p>Although no other sources of bias were detected, most of the included studies were funded by a manufacturer of chondroitin, which may qualify as a confounding source. This issue is discussed further in the <a href="#CD005614-sec-0092">Discussion</a> section of this review, as the source of funding for trials is not a factor that directly influences the methods used in the analysis. For more information on the source of funding for each study, please refer to the "<a href="./references#CD005614-sec-0126" title="">Characteristics of included studies</a> tables." </p> </section> </section> <section id="CD005614-sec-0084"> <h3 class="title" id="CD005614-sec-0084">Effects of interventions</h3> <p>See: <a href="./full#CD005614-tbl-0001"><b>Summary of findings for the main comparison</b> Chondroitin versus placebo for osteoarthritis</a>; <a href="./full#CD005614-tbl-0002"><b>Summary of findings 2</b> Chondroitin with or without glucosamine versus placebo/control for osteoarthritis (studies with estimated SDs not analyzed)</a>; <a href="./full#CD005614-tbl-0003"><b>Summary of findings 3</b> Chondroitin with or without glucosamine versus placebo/control for osteoarthritis (sensitivity analysis including studies with estimated SDs)</a> </p> <p>Five comparison groups were used for this analysis. We performed the meta‐analysis by stratifying the compiled data into the following comparable groups. </p> <p>1. Chondroitin sulfate versus placebo</p> <p>2. Chondroitin sulfate versus control</p> <p>3. Chondroitin sulfate plus glucosamine versus placebo</p> <p>4. Chondroitin sulfate plus glucosamine versus NSAIDs control</p> <p>5. Chondroitin sulfate/chondroitin sulfate plus glucosamine/chondroitin sulfate plus other supplement versus placebo or control </p> <p>Overall, 43 studies were included in this review. Of the 43 studies, 30 provided usable data, since outcomes reported matched with those specified for our systematic review. Several studies provided data for more than one of our comparison arms, such as <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>, <a href="./references#CD005614-bbs2-0037" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , BinghamCOIII , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis Rheum2008;58:3183‐91. ">Sawitzke 2008</a> and <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a>, which tested the efficacy of chondroitin alone, in combination with glucosamine, and in comparison with both placebo and an NSAID control. We came across additional studies that were not classifiable into these comparison arms or did not provide usable data. Data from <a href="./references#CD005614-bbs2-0004" title="AlekseevaLI . Results of an open comparative randomized clinical trial to assess efficacy and safety of two regimens of treatment with Theraflex preparation in knee osteoarthritis patients. Russkiy Meditsinskiy Journal2008;16(5):316. ">Alekseeva 2008</a> were not used in the meta‐analysis because this study compared intermittent versus constant therapy with chondroitin and glucosamine. This treatment regimen did not fit into any of the comparison arms of the meta‐analysis. Data from <a href="./references#CD005614-bbs2-0029" title="NguyenP , MohamedSE , GardinerD , SalinasT . A randomized double‐blind clinical trial of the effect of chondroitin sulfate and glucosamine hydrochloride on temporomandibular joint disorders: a pilot study. Cranio2001;19(2):130‐9. ">Nguyen 2001</a> were not used, except for data on safety, because the study was designed in a before and after design by which all participants received treatment with chondroitin sulfate, which was not compatible with the setup of any other study included in this review. We summarized the results of this study in the discussion section. Data from <a href="./references#CD005614-bbs2-0020" title="Magrans‐CourtneyT , WilbornC , RasmussenC , FerreiraM , GreenwoodL , CampbellB , et al. Effects of diet type and supplementation of glucosamine, chondroitin, and MSM on body composition, functional status, and markers of health in women with knee osteoarthritis initiating a resistance‐based exercise and weight loss program. Journal of International Society of Sports Medicine2011;8:8. ">Magrans‐Courtney 2011</a> were not usable in the meta‐analysis because the chondroitin arm was confounded by additional co‐treatments, including a diet and exercise program. Findings of this study were also summarized in the discussion section. Moreover, data from <a href="./references#CD005614-bbs2-0035" title="RovettaG , MonteforteP , MolfettaG , BalestraV . Chondroitin sulfate in erosive osteoarthritis of the hands. International Journal of Tissue Reactions2002;24(1):29‐32. ">Rovetta 2002</a> and <a href="./references#CD005614-bbs2-0036" title="RovettaG , MontefortP , MolfettaG , BalestraV . A two‐year study of chondroitin sulfate in erosive osteoarthritis of the hands: behavior of erosions, osteophytes, pain and hand dysfunction. Drugs Under Experimental and Clinical Research2004;XXX(1):11‐6. ">Rovetta 2004</a> were not included in the data meta‐analysis because the authors did not provide the data gathered during their study—only their conclusions. Data from <a href="./references#CD005614-bbs2-0009" title="CohenM , WolfeR , MaiT , LewisD . A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. Journal of Rheumatology2003;30(3):523‐8. ">Cohen 2003</a> were not used in this meta‐analysis because this study compared topical treatment with chondroitin sulfate, not oral treatment with placebo. Data from <a href="./references#CD005614-bbs2-0014" title="FardelloneP , ZaimM , SaurelAS , MaheuE . Comparative efficacy and safety study of two chondroitin sulfate preparations from different origin (avian and bovine) in symptomatic osteoarthritis of the knee. The open rheumatology journal2013;7(1):1‐12. ">Fardellone 2013</a> were summarized but not used in meta‐analyses, since the trial compared two different preparations of chondroitin, namely the bovine and the avian chondroitin preparations—these results were summarized in the systematic review. <a href="./references#CD005614-bbs2-0011" title="ConrozierT . Anti‐arthrosis treatments: efficacy and tolerance of chondroitin sulfates (CS 4&amp;6). Presse Med1998;27:1862‐5. ">Conrozier 1998</a>, <a href="./references#CD005614-bbs2-0018" title="L’HirondelJL . Clinical double‐blinded study with orally administered chondroitin sulfate versus placebo in patients with tibiofemoral gonarthrosis (125 patients) [Klinische Doppelblind‐Studie mit oral verabreichtem Chondroitinsulfatgegen Placebo bei der tibiofemoralen Gonarthrose (125 patients)]. Litera Rheumatologica1992;14:77‐84. ">L'Hirondel 1992</a> and <a href="./references#CD005614-bbs2-0032" title="RaiJ , PalSK , GulA , SenthilR , SinghH . Efficacy of chondroitin sulfate and glucosamine sulfate in the progression of symptomatic knee osteoarthritis: a randomized, placebo‐controlled, double‐blind study. Bulletin PGI2004;38:18‐22. ">Rai 2004</a> were not included in the main analysis because they did not provide standard deviations. We included these studies in the sensitivity analysis only when all studies without standard deviations were included after an estimate had been calculated for them. Therefore, results of the studies are summarized in the discussion section. Moreover, although we came to a consensus that data from three‐month and 12‐month time points from <a href="./references#CD005614-bbs2-0040" title="UebelhartD , MalaiseM , MarcolongoR , deVathaireF , PipernoM , MailleuxE , et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one‐year, randomized, double‐blind, multicenter study versus placebo. Osteoarthritis Cartilage2004;12(4):269‐76. ">Uebelhart 2004</a> should be used, the study was based on an intermittent design, by which participants in the chondroitin sulfate group were treated with chondroitin sulfate for the first three months, were not treated for the next three months, were treated again for another three months, and then were no longer treated. </p> <section id="CD005614-sec-0085"> <h4 class="title">CHONDROITIN SULFATE VERSUS PLACEBO</h4> <p>(<i>See Table 1 under Data and analyses.</i>) </p> <p><b>1. Pain:</b> Twelve studies provided data (<a href="./references#CD005614-bbs2-0006" title="BourgeoisP , ChalesG , DehaisJ , DelcambreB , KuntzJL , RozenbergS . Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage1998;6(Suppl A):25‐30. ">Bourgeois 1998</a>; <a href="./references#CD005614-bbs2-0007" title="BucsiL , PoorG . Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow‐acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage1998;6(Suppl A):31‐6. ">Bucsi 1998</a>; <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0022" title="MazieresB , CombeB , Phan VanA , TondutJ , GrynfelttM . Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. Journal of Rheumatology2001;28(1):173‐81. SawitzkeAD , ShiH , FincoMF , DunlopDD , Bingham IIICO , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis and Rheumatism2008;58:3183‐91. ">Mazieres 2001</a>; <a href="./references#CD005614-bbs2-0026" title="MorrealeP , ManopuloR , GalatiM , BoccaneraL , SaponatiG , BocchiL . Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. Journal of Rheumatology1996;23(8):1385‐91. ">Morreale 1996</a>; <a href="./references#CD005614-bbs2-0030" title="PavelkaK , ManopuloR , BusciL . Double‐blind, dose‐effect study of oral chondroitin 4 &amp; 6 sulfate 1200 mg, 800 mg, 200 mg, and placebo in the treatment of knee osteoarthritis. Litera Rhumatologica1999;24:21‐30. ">Pavelka 1999</a>; <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a>; <a href="./references#CD005614-bbs2-0039" title="UebelhartD , ThonarEJ , DelmasPD , ChantraineA , VignonE . Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage1998;6(Suppl A):39‐46. ">Uebelhart 1998</a>; <a href="./references#CD005614-bbs2-0040" title="UebelhartD , MalaiseM , MarcolongoR , deVathaireF , PipernoM , MailleuxE , et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one‐year, randomized, double‐blind, multicenter study versus placebo. Osteoarthritis Cartilage2004;12(4):269‐76. ">Uebelhart 2004</a>; <a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>; <a href="./references#CD005614-bbs2-0033" title="RailhacJJ , ZaimM , SaurelAS , VialJ , FournieB . Effect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: A randomized, double‐blind, placebo‐controlled pilot study using MRI. Clinical Rheumatology2012;31(9):1347‐57. ">Railhac 2012</a>; <a href="./references#CD005614-bbs2-0043" title="ZegelsB , CrozesP , UebelhartD , BruyereO , ReginsterJY . Equivalence of a single dose (1200 mg) compared to a three‐time a day dose (400 mg) of chondroitin 4&amp;6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthritis &amp; Cartilage2013;21(1):22‐7. ">Zegels 2012</a>) for short‐term and/or long‐term pain. The difference was statistically significant in the eight short‐term studies (<a href="./references#CD005614-bbs2-0006" title="BourgeoisP , ChalesG , DehaisJ , DelcambreB , KuntzJL , RozenbergS . Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage1998;6(Suppl A):25‐30. ">Bourgeois 1998</a>; <a href="./references#CD005614-bbs2-0021" title="MazieresB , LoyauG , MenkesCJ , ValatJP , DreiserRL , CharlotJ , et al. Chondroitin sulfate in the treatment of gonarthrosis and coxarthrosis. 5‐months result of a multicenter double‐blind controlled prospective study using placebo. Rev Rhum Mal Osteoartic1992;59(7‐8):466‐72. ">Mazieres 1992</a>; <a href="./references#CD005614-bbs2-0026" title="MorrealeP , ManopuloR , GalatiM , BoccaneraL , SaponatiG , BocchiL . Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. Journal of Rheumatology1996;23(8):1385‐91. ">Morreale 1996</a>; <a href="./references#CD005614-bbs2-0030" title="PavelkaK , ManopuloR , BusciL . Double‐blind, dose‐effect study of oral chondroitin 4 &amp; 6 sulfate 1200 mg, 800 mg, 200 mg, and placebo in the treatment of knee osteoarthritis. Litera Rhumatologica1999;24:21‐30. ">Pavelka 1999</a>; <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a>; <a href="./references#CD005614-bbs2-0039" title="UebelhartD , ThonarEJ , DelmasPD , ChantraineA , VignonE . Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage1998;6(Suppl A):39‐46. ">Uebelhart 1998</a>; <a href="./references#CD005614-bbs2-0040" title="UebelhartD , MalaiseM , MarcolongoR , deVathaireF , PipernoM , MailleuxE , et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one‐year, randomized, double‐blind, multicenter study versus placebo. Osteoarthritis Cartilage2004;12(4):269‐76. ">Uebelhart 2004</a>; <a href="./references#CD005614-bbs2-0033" title="RailhacJJ , ZaimM , SaurelAS , VialJ , FournieB . Effect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: A randomized, double‐blind, placebo‐controlled pilot study using MRI. Clinical Rheumatology2012;31(9):1347‐57. ">Railhac 2012</a>), with a mean difference of ‐10.14 units (95% CI, ‐14.58 to ‐5.71) between chondroitin and placebo arms on a 0 to 100 pain scale. This translated into an absolute risk difference of 10% lower (95% CI, 15% to 6% lower) and a NNT=5 (95% CI 3 to 8) (n=8 trials; level of evidence, low). In six long‐term studies (<a href="./references#CD005614-bbs2-0007" title="BucsiL , PoorG . Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow‐acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage1998;6(Suppl A):31‐6. ">Bucsi 1998</a>; <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0039" title="UebelhartD , ThonarEJ , DelmasPD , ChantraineA , VignonE . Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage1998;6(Suppl A):39‐46. ">Uebelhart 1998</a>; <a href="./references#CD005614-bbs2-0040" title="UebelhartD , MalaiseM , MarcolongoR , deVathaireF , PipernoM , MailleuxE , et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one‐year, randomized, double‐blind, multicenter study versus placebo. Osteoarthritis Cartilage2004;12(4):269‐76. ">Uebelhart 2004</a>; <a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>; <a href="./references#CD005614-bbs2-0043" title="ZegelsB , CrozesP , UebelhartD , BruyereO , ReginsterJY . Equivalence of a single dose (1200 mg) compared to a three‐time a day dose (400 mg) of chondroitin 4&amp;6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthritis &amp; Cartilage2013;21(1):22‐7. ">Zegels 2012</a>), chondroitin was associated with a mean difference of ‐9.00 (95% CI ‐17.7 to ‐0.34) on a 0‐100 scale, which corresponds to absolute risk difference of 9% lower (95% CI, 18% to 0% lower; p=0.05). Heterogeneity was moderate in both long‐term and short‐term studies, with T<sup>2</sup> of 0.07 and I<sup>2</sup> of 69% in the short‐term and T<sup>2</sup> of 0.12 and I<sup>2</sup> of 83% in the long‐term pain studies. Because 12 studies were included for short‐ or long‐term pain outcomes, we created a funnel plot to detect bias. <a href="#CD005614-fig-0005">Figure 5</a> shows the presence of bias, as the plot does not take the shape of a funnel. </p> <div class="figure" id="CD005614-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 1 Chondroitin versus placebo, outcome: 1.1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Chondroitin versus placebo, outcome: 1.1 Pain on a 0 to 100 scale. </p> </div> </div> </div> <p>Sensitivity analysis showed that the results were robust with respect to blinding and ITT, but not robust with respect to allocation concealment, study size, study sponsorship, or publication year (<a href="./references#CD005614-fig-0113" title="">Analysis 6.1</a>; <a href="./references#CD005614-fig-0122" title="">Analysis 10.1</a>; <a href="./references#CD005614-fig-0131" title="">Analysis 14.1</a>; <a href="./references#CD005614-fig-0140" title="">Analysis 18.1</a>; <a href="./references#CD005614-fig-0149" title="">Analysis 22.1</a>; <a href="./references#CD005614-fig-0175" title="">Analysis 31.1</a>). Studies that were adequately blinded had a similar result to the original estimate, and most studies included in the analyses had adequate blinding. Studies using appropriate ITT analyses had an effect size of ‐0.46 for pain which was significant , similar to the overall effect, while those with unclear ITT had a larger effect size of ‐1.00, while 1 study with high risk of bias for ITT analyses had an effect size 0.24, which was insignificant. Most included studies used appropriate ITT analyses. </p> <p>Among studies that used adequate methods of allocation concealment, no significant difference was reported between placebo and chondroitin while studies that used unclear methods of allocation concealment, participants treated with chondroitin had statistically significantly better scores than those in the placebo group.A difference was seen between the results of studies with large and small sample sizes. Studies with large sample sizes reported no statistically significant difference in pain scores between chondroitin and placebo while studies with small sample sizes reported that pain scores for participants in the chondroitin group were significantly better than those in the placebo group. </p> <p>Studies funded by chondroitin sulfate manufacturers showed that participants in the chondroitin group had statistically significantly better pain scores than those in the placebo group, and the effect size was ‐0.52. Studies that did not specify their source of funding or with no pharmaceutical sponsorship did not report a statistically significant difference between participants in the chondroitin group and those in the placebo group, but the effect size was greater at ‐0.73. Thus, the effect of study sponsorship on findings was mixed. </p> <p>Studies published before 2000 showed that participants treated with chondroitin had significantly better pain scores than those in the placebo group while studies published after 2000 reported no statistically significant difference between chondroitin and placebo. </p> <p><b>2. MCII WOMAC:</b> Two studies provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0016" title="KahanA , UebelhartD , DeVathaireF , DelmasPD , ReginsterJY . Long‐term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2009;60(2):524‐33. ">Kahan 2009</a>). A significantly greater number of participants in the chondroitin sulfate group experienced an MCII in pain on WOMAC (Risk ratio of 1.12, 95% CI 1.01 to 1.24; P = 0.04) with an absolute difference of 6% (95% CI 1% to 11%) and an NNT=16 (95% CI 9 to 136). Sensitivity analyses showed the results were robust to study sponsorship. </p> <p><b>3. Physical function:</b> Three studies provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a>; <a href="./references#CD005614-bbs2-0039" title="UebelhartD , ThonarEJ , DelmasPD , ChantraineA , VignonE . Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage1998;6(Suppl A):39‐46. ">Uebelhart 1998</a>) in the long‐term analysis, and two studies provided data in the short‐term analysis (<a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a>; <a href="./references#CD005614-bbs2-0039" title="UebelhartD , ThonarEJ , DelmasPD , ChantraineA , VignonE . Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage1998;6(Suppl A):39‐46. ">Uebelhart 1998</a>). <a href="./references#CD005614-bbs2-0039" title="UebelhartD , ThonarEJ , DelmasPD , ChantraineA , VignonE . Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage1998;6(Suppl A):39‐46. ">Uebelhart 1998</a> presented data on 0 = best and 100 = worst scale, and the mean score was transformed by subtracting the scores from 100 to make the data compatible with those of the other studies, which presented data on a 0 = best and 100 = worst scale. No statistically significant difference was noted between chondroitin and placebo in the short‐term studies (SMD 0.11, 95% CI ‐0.47 to 0.68; P = 0.72; T<sup>2</sup> = 0.13; moderate level of heterogeneity with an I<sup>2</sup>of 70%) or long‐term studies (SMD ‐0.20, 95% CI ‐0.53 to 0.14; P = 0.25; T<sup>2</sup> = 0.06; moderate level of heterogeneity, with an I<sup>2</sup>of 77%). This equated a mean difference of 2.39 (95% CI, ‐9.81 to 14.58) in short‐term and ‐4.31 (95% CI, ‐11.33 to 2.70) in long‐term studies, on a 0‐100 scale. This equated to an absolute risk difference of 8% lower with chondroitin versus placebo (24% lower to 7% higher; n = 3 trials; level of evidence, moderate) for long‐term physical function studies. </p> <p>Sensitivity analyses demonstrated the results were robust to blinding but not to allocation concealment, sample size, pharmaceutical sponsorship, publication year or ITT analyses (<a href="./references#CD005614-fig-0115" title="">Analysis 6.3</a>; <a href="./references#CD005614-fig-0124" title="">Analysis 10.3</a>; <a href="./references#CD005614-fig-0133" title="">Analysis 14.3</a>; <a href="./references#CD005614-fig-0142" title="">Analysis 18.3</a>; <a href="./references#CD005614-fig-0142" title="">Analysis 18.3</a>; <a href="./references#CD005614-fig-0151" title="">Analysis 22.3</a>; <a href="./references#CD005614-fig-0177" title="">Analysis 31.3</a>). Studies with an unclear allocation, small sample size, with pharmaceutical sponsorship, with publication prior to 1999, and with unclear impact of missing data showed that participants in the chondroitin sulfate group performed statistically significantly better on physical function scales than those in the placebo arm. </p> <p><b>4. WOMAC stiffness:</b> One study provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>). No significant difference between chondroitin and placebo was noted (P = 0.21). </p> <p><b>5. Patient global assessment of good to very good:</b> Three studies provided data (<a href="./references#CD005614-bbs2-0006" title="BourgeoisP , ChalesG , DehaisJ , DelcambreB , KuntzJL , RozenbergS . Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage1998;6(Suppl A):25‐30. ">Bourgeois 1998</a>; <a href="./references#CD005614-bbs2-0007" title="BucsiL , PoorG . Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow‐acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage1998;6(Suppl A):31‐6. ">Bucsi 1998</a>; <a href="./references#CD005614-bbs2-0030" title="PavelkaK , ManopuloR , BusciL . Double‐blind, dose‐effect study of oral chondroitin 4 &amp; 6 sulfate 1200 mg, 800 mg, 200 mg, and placebo in the treatment of knee osteoarthritis. Litera Rhumatologica1999;24:21‐30. ">Pavelka 1999</a>). A total of 68% of participants in the chondroitin sulfate group and 33% of participants in the placebo group reported a good to very good assessment of their status. Participants in the chondroitin sulfate group were twice as likely as those in the placebo group to report good to very good overall assessment with a significant risk ratio (RR) of 2.11 (95% CI 1.49 to 2.99; P &lt; 0.0001) in short‐term and RR of 2.04 (95% CI 1.28 to 3.27; P = 0.003) in long‐term studies. </p> <p><b>6. Patient global assessment on VAS:</b> Three studies provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0015" title="GabayC , Medinger‐SadowskiC , GasconD , KoloF , FinckhA . Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis. Arthritis and Rheumatism2011;63(11):3383‐91. ">Gabay 2011</a>; <a href="./references#CD005614-bbs2-0016" title="KahanA , UebelhartD , DeVathaireF , DelmasPD , ReginsterJY . Long‐term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2009;60(2):524‐33. ">Kahan 2009</a>). No significant difference was reported between chondroitin and placebo in short‐ or long‐term studies, with SMD of ‐0.03 (95% CI ‐0.48 to 0.21; P = 0.45) and 0.01 (95% CI ‐0.21 to 0.23; P = 0.92), respectively. </p> <p><b>7. Physician global assessment of good to very good:</b> Three studies provided data (<a href="./references#CD005614-bbs2-0006" title="BourgeoisP , ChalesG , DehaisJ , DelcambreB , KuntzJL , RozenbergS . Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage1998;6(Suppl A):25‐30. ">Bourgeois 1998</a>; <a href="./references#CD005614-bbs2-0007" title="BucsiL , PoorG . Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow‐acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage1998;6(Suppl A):31‐6. ">Bucsi 1998</a>; <a href="./references#CD005614-bbs2-0030" title="PavelkaK , ManopuloR , BusciL . Double‐blind, dose‐effect study of oral chondroitin 4 &amp; 6 sulfate 1200 mg, 800 mg, 200 mg, and placebo in the treatment of knee osteoarthritis. Litera Rhumatologica1999;24:21‐30. ">Pavelka 1999</a>). A total of 71% of physician global assessments in the chondroitin sulfate group and 36% of those in the placebo group were good to very good assessments, leading to a significant risk in short‐ or long‐term studies, with RR of 1.95 (95% CI 1.42 to 2.69; P &lt; 0.00001) and 2.12 (95% CI 1.33 to 3.38; P = 0.002), respectively. </p> <p><b>8. Physician global assessment on VAS:</b> Two studies provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0016" title="KahanA , UebelhartD , DeVathaireF , DelmasPD , ReginsterJY . Long‐term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2009;60(2):524‐33. ">Kahan 2009</a>). No significant difference was noted between chondroitin and placebo (SMD 0.09, 95% CI ‐0.05 to 0.23, P = 0.19). </p> <p><b>9. Total Knee arthroplasty during follow‐up:</b> One study provided data (<a href="./references#CD005614-bbs2-0034" title="RaynauldJP , Martel‐PelletierJ , DoraisM , HaraouiB , ChoquetteD , AbramF , et al. Total Knee Replacement as a Knee Osteoarthritis Outcome: Predictors Derived from a 4‐Year Long‐Term Observation following a Randomized Clinical Trial Using Chondroitin Sulfate. Cartilage2013;4(3):219‐26. ">Raynauld 2013</a>), which was a follow‐up of <a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>. No significant difference was noted between chondroitin and placebo, RR was 0.43 (95% CI 0.15 to 1.27; P =0.13). </p> <p><b>10. Grip strength (kg/cm<sup>2</sup>):</b> One study provided data (<a href="./references#CD005614-bbs2-0015" title="GabayC , Medinger‐SadowskiC , GasconD , KoloF , FinckhA . Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis. Arthritis and Rheumatism2011;63(11):3383‐91. ">Gabay 2011</a>). No significant difference was noted between chondroitin and placebo, mean difference was 0.90 (95% CI ‐2.29 to 4.09; see Table 1). </p> <p><b>11. Morning stiffness (minutes):</b> One study provided data (<a href="./references#CD005614-bbs2-0015" title="GabayC , Medinger‐SadowskiC , GasconD , KoloF , FinckhA . Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis. Arthritis and Rheumatism2011;63(11):3383‐91. ">Gabay 2011</a>). No significant difference was reported between chondroitin and placebo ‐0.60 (95% CI ‐5.16 to 3.96; P = 0.80; see Table 1). </p> <p><b>12. Cartilage volume loss (global):</b> One study provided data (<a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). Participants in the chondroitin group had significantly less global cartilage volume loss than those in the placebo group, mean difference was 1.80 (95% CI 0.23 to 3.37; P = 0.02; see Table 1). </p> <p><b>13. Cartilage volume loss (lateral compartment):</b> One study provided data (<a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). Participants in the chondroitin group had significantly less lateral compartment cartilage volume loss than those in the placebo group, mean difference was 2.19 (95% CI 0.31 to 4.07; P = 0.02; see Table 1). </p> <p><b>14. Cartilage volume loss (medial compartment):</b> One study provided data (<a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). No significant difference in cartilage volume loss was noted between chondroitin and placebo, mean difference was 1.47 (95% CI ‐0.88, 3.82; P = 0.22). </p> <p><b>15. Cartilage volume loss (condyles):</b> One study provided data (<a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). No significant difference in cartilage volume loss was reported between chondroitin and placebo, mean difference was 0.64 (95% CI ‐1.59, 2.87;P = 0.57; see Table 1). </p> <p><b>16. Cartilage volume loss (lateral condyles):</b> One study provided data (<a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). No significant difference in cartilage volume loss was noted between chondroitin and placebo, mean difference was 1.84 (95% CI ‐0.44 to 4.12; P = 0.11; see Table 1). </p> <p><b>17. Cartilage volume loss (medial condyles):</b> One study provided data (<a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). No significant difference in cartilage volume loss was reported between chondroitin and placebo, mean difference was ‐0.65 (95% CI ‐4.14 to 2.84; P = 0.71; see Table 1). </p> <p><b>18. Cartilage volume loss (tibial plateaus):</b> One study provided data (<a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). Participants in the chondroitin group had significantly less tibial plateau cartilage volume loss than those in the placebo group, mean difference was 2.98 (95% CI 1.15 to 4.81; P = 0.001; see Table 1). </p> <p><b>19. Cartilage volume loss (lateral tibial plateaus):</b> One study provided data (<a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). No significant difference in cartilage volume loss was reported between chondroitin and placebo, mean difference was 2.31 (95% CI ‐0.09 to 4.71; P = 0.06; see Table 1). </p> <p><b>20. Cartilage volume loss (medial tibial plateaus):</b> One study provided data (<a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). Participants in the chondroitin group had significantly less cartilage volume loss in their medial tibial plateaus than those in the placebo group, mean difference was 4.47 (95% CI 1.57 to 7.37; P = 0.003; see Table 1). </p> <p><b>21. Cartilage volume loss (trochlea):</b> One study provided data (<a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). No significant difference in cartilage volume loss was reported between chondroitin and placebo, mean difference was 0.65 (95% CI ‐1.79 to 3.09; P = 0.60; see Table 1). </p> <p><b>22. Change in bone marrow lesion scores (global):</b> One study provided data (<a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). No significant difference between chondroitin and placebo was noted across all bone marrow lesion regions, mean difference was ‐0.07 (95% CI ‐0.65 to 0.51; Table 1). </p> <p><b>23. Change in bone marrow lesion scores (lateral compartment):</b> One study provided data (<a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). No significant difference between chondroitin and placebo was noted across all bone marrow lesion regions, mean difference was ‐0.10 (95% CI ‐0.30 to 0.10; P = 0.32; see Table 1). </p> <p><b>24. Change in bone marrow lesion scores (medial compartment):</b> One study provided data (<a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). No significant difference between chondroitin and placebo was noted across all bone marrow lesion regions, mean difference was 0.02 (95% CI ‐0.52 to 0.56; P = 0.94; see Table 1). </p> <p><b>25. Change in bone marrow lesion scores (condyles):</b> One study provided data (<a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). No significant difference between chondroitin and placebo was noted across all bone marrow lesion regions, mean difference was 0.02 (95% CI ‐0.35 to 0.39; P = 0.92; see Table 1). </p> <p><b>26. Change in bone marrow lesion scores (lateral condyles):</b> One study provided data (<a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). No significant difference between chondroitin and placebo was noted across all bone marrow lesion regions, mean difference was ‐0.04 (95% CI ‐0.14 to 0.06; P = 0.45; see Table 1). </p> <p><b>27. Change in bone marrow lesion scores (medial condyles):</b> One study provided data (<a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). No significant difference between chondroitin and placebo was noted across all bone marrow lesion regions, mean difference was 0.13 (95% CI ‐0.22 to 0.48; P = 0.47; see Table 1). </p> <p><b>28. Change in bone marrow lesion scores (tibial plateaus):</b> One study provided data (<a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). No significant difference between chondroitin and placebo was noted across all bone marrow lesion regions, mean difference was ‐0.10 (95% CI ‐0.46 to 0.26; P = 0.58; see Table 1). </p> <p><b>29. Change in bone marrow lesion scores (lateral tibial plateaus):</b> One study provided data (<a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). No significant difference between chondroitin and placebo was noted across all bone marrow lesion regions, mean difference was ‐0.01 (95% CI ‐0.18 to 0.16; P = 0.91; see Table 1). </p> <p><b>30. Change in bone marrow lesion scores (medial tibial plateaus):</b> One study provided data (<a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). No significant difference between chondroitin and placebo was noted across all bone marrow lesion regions, mean difference was ‐0.10 (95% CI ‐0.40 to 0.20; P = 0.22; see Table 1). </p> <p><b>31. Change in bone marrow lesion scores (trochlea):</b> One study provided data (<a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). No significant difference between chondroitin and placebo was noted across all bone marrow lesion regions, mean difference was ‐0.16 (95% CI ‐0.10 to 0.42; P = 0.52; see Table 1). </p> <p><b>32. OMERACT‐OARSI responder:</b> One study provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>). The proportion of participants achieving responder status in the chondroitin sulfate group was not significantly different from that in the placebo group, mean difference was (95% CI ; P = 0.09; see Table 1). </p> <p><b>33. Lequesne's index score:</b> Nine studies provided data (<a href="./references#CD005614-bbs2-0006" title="BourgeoisP , ChalesG , DehaisJ , DelcambreB , KuntzJL , RozenbergS . Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage1998;6(Suppl A):25‐30. ">Bourgeois 1998</a>; <a href="./references#CD005614-bbs2-0007" title="BucsiL , PoorG . Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow‐acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage1998;6(Suppl A):31‐6. ">Bucsi 1998</a>; <a href="./references#CD005614-bbs2-0022" title="MazieresB , CombeB , Phan VanA , TondutJ , GrynfelttM . Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. Journal of Rheumatology2001;28(1):173‐81. SawitzkeAD , ShiH , FincoMF , DunlopDD , Bingham IIICO , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis and Rheumatism2008;58:3183‐91. ">Mazieres 2001</a>; <a href="./references#CD005614-bbs2-0026" title="MorrealeP , ManopuloR , GalatiM , BoccaneraL , SaponatiG , BocchiL . Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. Journal of Rheumatology1996;23(8):1385‐91. ">Morreale 1996</a>; <a href="./references#CD005614-bbs2-0025" title="MöllerI , PérezM , MonfortJ , BenitoP , CuevasJ , PernaC , et al. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double‐blind, placebo‐controlled study. Osteoarthritis and Cartilage2010;18:S32‐40. ">Moller 2010</a>; <a href="./references#CD005614-bbs2-0030" title="PavelkaK , ManopuloR , BusciL . Double‐blind, dose‐effect study of oral chondroitin 4 &amp; 6 sulfate 1200 mg, 800 mg, 200 mg, and placebo in the treatment of knee osteoarthritis. Litera Rhumatologica1999;24:21‐30. ">Pavelka 1999;</a><a href="./references#CD005614-bbs2-0040" title="UebelhartD , MalaiseM , MarcolongoR , deVathaireF , PipernoM , MailleuxE , et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one‐year, randomized, double‐blind, multicenter study versus placebo. Osteoarthritis Cartilage2004;12(4):269‐76. ">Uebelhart 2004</a>; <a href="./references#CD005614-bbs2-0033" title="RailhacJJ , ZaimM , SaurelAS , VialJ , FournieB . Effect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: A randomized, double‐blind, placebo‐controlled pilot study using MRI. Clinical Rheumatology2012;31(9):1347‐57. ">Railhac 2012</a>; <a href="./references#CD005614-bbs2-0043" title="ZegelsB , CrozesP , UebelhartD , BruyereO , ReginsterJY . Equivalence of a single dose (1200 mg) compared to a three‐time a day dose (400 mg) of chondroitin 4&amp;6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthritis &amp; Cartilage2013;21(1):22‐7. ">Zegels 2012</a>). Lequesne's Index score was significantly lower (better) in chondroitin‐treated participants than in placebo‐treated participants with (mean difference (MD) ‐1.98, 95% CI ‐2.79 to ‐1.17; P &lt; 0.00001) in short‐term studies. This translates into an absolute risk difference of 8.3% lower in chondroitin versus placebo (11.6% lower to 4.9% lower; T<sup>2</sup> = 0.78; I<sup>2</sup> = 67%; n = 7 trials; level of evidence, moderate). For long‐term studies, SMD was ‐1.60, (95% CI ‐3.49 to 0.29; P =0.10; T<sup>2</sup> = 1.88; I<sup>2</sup> = 68%;), not statistically significant. </p> <p><b>34. HAQ Disability score:</b> One study provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>). No significant difference was reported between chondroitin and placebo, mean difference was (P = 0.26). </p> <p><b>35. Radiographic</b> —<b>minimum joint space width (mm):</b> Two studies provided data (<a href="./references#CD005614-bbs2-0039" title="UebelhartD , ThonarEJ , DelmasPD , ChantraineA , VignonE . Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage1998;6(Suppl A):39‐46. ">Uebelhart 1998</a>; <a href="./references#CD005614-bbs2-0040" title="UebelhartD , MalaiseM , MarcolongoR , deVathaireF , PipernoM , MailleuxE , et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one‐year, randomized, double‐blind, multicenter study versus placebo. Osteoarthritis Cartilage2004;12(4):269‐76. ">Uebelhart 2004</a>). No significant difference was noted between chondroitin and placebo (MD 0.16, 95% CI ‐0.16 to 0.48; P = 0.32). </p> <p><b>36. Radiographic</b> —<b>reduction in minimum joint space width (mm):</b> Two studies provided data (<a href="./references#CD005614-bbs2-0016" title="KahanA , UebelhartD , DeVathaireF , DelmasPD , ReginsterJY . Long‐term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2009;60(2):524‐33. ">Kahan 2009</a>; <a href="./references#CD005614-bbs2-0024" title="MichelBA , StuckiG , FreyD , DeVathaireF , VignonE , BruehlmannP , et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis and Rheumatism2005;52(3):779‐86. ">Michel 2005</a>). Participants in the chondroitin group experienced significantly less reduction in minimum joint space width as compared with those in the placebo group (MD 0.18, 95% CI 0.06 to 0.30; P &lt; 0.0001). This translated into significantly less loss of minimum joint space width in the chondroitin group than in the placebo group, with a relative risk difference of 4.72% less (95% CI 1.58% to 7.87% less; n = 2 trials; level of evidence, high). </p> <p><b>37. Radiographic</b> —<b>mean joint space width (mm):</b> One study provided data (<a href="./references#CD005614-bbs2-0039" title="UebelhartD , ThonarEJ , DelmasPD , ChantraineA , VignonE . Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage1998;6(Suppl A):39‐46. ">Uebelhart 1998</a>). No significant difference was reported between chondroitin and placebo (MD 0.17, 95% CI ‐0.47 to 0.81; P = 0.60). </p> <p><b>38. Radiographic</b> —<b>change in mean joint space width (mm):</b> Three studies provided data (<a href="./references#CD005614-bbs2-0016" title="KahanA , UebelhartD , DeVathaireF , DelmasPD , ReginsterJY . Long‐term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2009;60(2):524‐33. ">Kahan 2009</a>; <a href="./references#CD005614-bbs2-0024" title="MichelBA , StuckiG , FreyD , DeVathaireF , VignonE , BruehlmannP , et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis and Rheumatism2005;52(3):779‐86. ">Michel 2005</a>; <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a>). Participants in the chondroitin group experienced significantly less change in their mean joint space width as compared with those in the placebo group (MD 0.13, 95% CI 0.07 to 0.20; P &lt;0.0001). </p> <p><b>39. SF‐36 (Physical component score):</b> One study provided data (<a href="./references#CD005614-bbs2-0025" title="MöllerI , PérezM , MonfortJ , BenitoP , CuevasJ , PernaC , et al. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double‐blind, placebo‐controlled study. Osteoarthritis and Cartilage2010;18:S32‐40. ">Moller 2010</a>). No significant difference was reported between chondroitin and placebo (P = 0.81). </p> <p><b>40. SF‐36 (Mental component score):</b> One study provided data (<a href="./references#CD005614-bbs2-0025" title="MöllerI , PérezM , MonfortJ , BenitoP , CuevasJ , PernaC , et al. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double‐blind, placebo‐controlled study. Osteoarthritis and Cartilage2010;18:S32‐40. ">Moller 2010</a>). No significant difference was noted between chondroitin and placebo (P = 0.96). </p> <p><b>41. All withdrawals:</b> Fifteen studies provided data (<a href="./references#CD005614-bbs2-0006" title="BourgeoisP , ChalesG , DehaisJ , DelcambreB , KuntzJL , RozenbergS . Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage1998;6(Suppl A):25‐30. ">Bourgeois 1998</a>; <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0010" title="ConrozierT , VignonE . The efficacy of chondroitin sulfate in the treatment of the arthrosis of the hip joint. A double‐blind study versus placebo [Die Wirkung von Chondroitinsulfat bei der Behandlungder Hu¨ftgelenksarthrose: eine Doppelblindstudie gegen Placebo]. Litera Rheumatoiogica1992;14:69‐75. ">Conrozier 1992</a>; <a href="./references#CD005614-bbs2-0015" title="GabayC , Medinger‐SadowskiC , GasconD , KoloF , FinckhA . Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis. Arthritis and Rheumatism2011;63(11):3383‐91. ">Gabay 2011</a>; <a href="./references#CD005614-bbs2-0016" title="KahanA , UebelhartD , DeVathaireF , DelmasPD , ReginsterJY . Long‐term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2009;60(2):524‐33. ">Kahan 2009</a>; <a href="./references#CD005614-bbs2-0021" title="MazieresB , LoyauG , MenkesCJ , ValatJP , DreiserRL , CharlotJ , et al. Chondroitin sulfate in the treatment of gonarthrosis and coxarthrosis. 5‐months result of a multicenter double‐blind controlled prospective study using placebo. Rev Rhum Mal Osteoartic1992;59(7‐8):466‐72. ">Mazieres 1992</a>; <a href="./references#CD005614-bbs2-0022" title="MazieresB , CombeB , Phan VanA , TondutJ , GrynfelttM . Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. Journal of Rheumatology2001;28(1):173‐81. SawitzkeAD , ShiH , FincoMF , DunlopDD , Bingham IIICO , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis and Rheumatism2008;58:3183‐91. ">Mazieres 2001</a>; <a href="./references#CD005614-bbs2-0024" title="MichelBA , StuckiG , FreyD , DeVathaireF , VignonE , BruehlmannP , et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis and Rheumatism2005;52(3):779‐86. ">Michel 2005</a>; <a href="./references#CD005614-bbs2-0025" title="MöllerI , PérezM , MonfortJ , BenitoP , CuevasJ , PernaC , et al. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double‐blind, placebo‐controlled study. Osteoarthritis and Cartilage2010;18:S32‐40. ">Moller 2010</a>; <a href="./references#CD005614-bbs2-0026" title="MorrealeP , ManopuloR , GalatiM , BoccaneraL , SaponatiG , BocchiL . Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. Journal of Rheumatology1996;23(8):1385‐91. ">Morreale 1996</a>; <a href="./references#CD005614-bbs2-0030" title="PavelkaK , ManopuloR , BusciL . Double‐blind, dose‐effect study of oral chondroitin 4 &amp; 6 sulfate 1200 mg, 800 mg, 200 mg, and placebo in the treatment of knee osteoarthritis. Litera Rhumatologica1999;24:21‐30. ">Pavelka 1999</a>; <a href="./references#CD005614-bbs2-0039" title="UebelhartD , ThonarEJ , DelmasPD , ChantraineA , VignonE . Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage1998;6(Suppl A):39‐46. ">Uebelhart 1998</a>; <a href="./references#CD005614-bbs2-0040" title="UebelhartD , MalaiseM , MarcolongoR , deVathaireF , PipernoM , MailleuxE , et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one‐year, randomized, double‐blind, multicenter study versus placebo. Osteoarthritis Cartilage2004;12(4):269‐76. ">Uebelhart 2004</a>; <a href="./references#CD005614-bbs2-0041" title="VerbruggenG , GoemaereS , VeysEM . Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clinical Rheumatology2002;21:231‐43. ">Verbruggen 2002</a>; <a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). The number of participants who withdrew from the study for any reason did not differ significantly between chondroitin and placebo groups (RR 0.80, 95% CI 0.63 to 1.02; P = 0.07). </p> <p><b>42. Withdrawals due to adverse events:</b> Ten studies provided data (<a href="./references#CD005614-bbs2-0006" title="BourgeoisP , ChalesG , DehaisJ , DelcambreB , KuntzJL , RozenbergS . Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage1998;6(Suppl A):25‐30. ">Bourgeois 1998</a>; <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0015" title="GabayC , Medinger‐SadowskiC , GasconD , KoloF , FinckhA . Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis. Arthritis and Rheumatism2011;63(11):3383‐91. ">Gabay 2011</a>; <a href="./references#CD005614-bbs2-0016" title="KahanA , UebelhartD , DeVathaireF , DelmasPD , ReginsterJY . Long‐term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2009;60(2):524‐33. ">Kahan 2009</a>; <a href="./references#CD005614-bbs2-0022" title="MazieresB , CombeB , Phan VanA , TondutJ , GrynfelttM . Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. Journal of Rheumatology2001;28(1):173‐81. SawitzkeAD , ShiH , FincoMF , DunlopDD , Bingham IIICO , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis and Rheumatism2008;58:3183‐91. ">Mazieres 2001</a>; <a href="./references#CD005614-bbs2-0024" title="MichelBA , StuckiG , FreyD , DeVathaireF , VignonE , BruehlmannP , et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis and Rheumatism2005;52(3):779‐86. ">Michel 2005</a>; <a href="./references#CD005614-bbs2-0025" title="MöllerI , PérezM , MonfortJ , BenitoP , CuevasJ , PernaC , et al. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double‐blind, placebo‐controlled study. Osteoarthritis and Cartilage2010;18:S32‐40. ">Moller 2010</a>; <a href="./references#CD005614-bbs2-0026" title="MorrealeP , ManopuloR , GalatiM , BoccaneraL , SaponatiG , BocchiL . Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. Journal of Rheumatology1996;23(8):1385‐91. ">Morreale 1996</a>; <a href="./references#CD005614-bbs2-0040" title="UebelhartD , MalaiseM , MarcolongoR , deVathaireF , PipernoM , MailleuxE , et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one‐year, randomized, double‐blind, multicenter study versus placebo. Osteoarthritis Cartilage2004;12(4):269‐76. ">Uebelhart 2004</a>; <a href="./references#CD005614-bbs2-0041" title="VerbruggenG , GoemaereS , VeysEM . Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clinical Rheumatology2002;21:231‐43. ">Verbruggen 2002</a>), four short‐term and 6 long‐term studies. No statistically significant difference was reported between placebo and chondroitin sulfate (RR 0.95, 95% CI 0.31 to 2.89; P = 0.70) for short‐term or long‐term studies, RR of 1.09 [95% CI, 0.73 to 1.63]. The overall RR combining short‐ and long‐term studies was 1.08 (95% CI, 0.74 to 1.57). </p> <p><b>43. Withdrawals due to inefficacy:</b> Ten studies provided data (<a href="./references#CD005614-bbs2-0006" title="BourgeoisP , ChalesG , DehaisJ , DelcambreB , KuntzJL , RozenbergS . Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage1998;6(Suppl A):25‐30. ">Bourgeois 1998</a>; <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0016" title="KahanA , UebelhartD , DeVathaireF , DelmasPD , ReginsterJY . Long‐term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2009;60(2):524‐33. ">Kahan 2009</a>; <a href="./references#CD005614-bbs2-0022" title="MazieresB , CombeB , Phan VanA , TondutJ , GrynfelttM . Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. Journal of Rheumatology2001;28(1):173‐81. SawitzkeAD , ShiH , FincoMF , DunlopDD , Bingham IIICO , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis and Rheumatism2008;58:3183‐91. ">Mazieres 2001</a>; <a href="./references#CD005614-bbs2-0024" title="MichelBA , StuckiG , FreyD , DeVathaireF , VignonE , BruehlmannP , et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis and Rheumatism2005;52(3):779‐86. ">Michel 2005</a>; <a href="./references#CD005614-bbs2-0026" title="MorrealeP , ManopuloR , GalatiM , BoccaneraL , SaponatiG , BocchiL . Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. Journal of Rheumatology1996;23(8):1385‐91. ">Morreale 1996</a>; <a href="./references#CD005614-bbs2-0039" title="UebelhartD , ThonarEJ , DelmasPD , ChantraineA , VignonE . Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage1998;6(Suppl A):39‐46. ">Uebelhart 1998</a>; <a href="./references#CD005614-bbs2-0040" title="UebelhartD , MalaiseM , MarcolongoR , deVathaireF , PipernoM , MailleuxE , et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one‐year, randomized, double‐blind, multicenter study versus placebo. Osteoarthritis Cartilage2004;12(4):269‐76. ">Uebelhart 2004</a>; <a href="./references#CD005614-bbs2-0041" title="VerbruggenG , GoemaereS , VeysEM . Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clinical Rheumatology2002;21:231‐43. ">Verbruggen 2002</a>; <a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). The number of participants who withdrew from the study because of inefficacy did not differ significantly between chondroitin and placebo groups (RR 1.22, 95% CI 0.88 to 1.70; P = 0.23). </p> <p><b>44. Number of adverse events:</b> Eight studies provided data (<a href="./references#CD005614-bbs2-0006" title="BourgeoisP , ChalesG , DehaisJ , DelcambreB , KuntzJL , RozenbergS . Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage1998;6(Suppl A):25‐30. ">Bourgeois 1998</a>; <a href="./references#CD005614-bbs2-0015" title="GabayC , Medinger‐SadowskiC , GasconD , KoloF , FinckhA . Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis. Arthritis and Rheumatism2011;63(11):3383‐91. ">Gabay 2011</a>; <a href="./references#CD005614-bbs2-0016" title="KahanA , UebelhartD , DeVathaireF , DelmasPD , ReginsterJY . Long‐term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2009;60(2):524‐33. ">Kahan 2009</a>; <a href="./references#CD005614-bbs2-0022" title="MazieresB , CombeB , Phan VanA , TondutJ , GrynfelttM . Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. Journal of Rheumatology2001;28(1):173‐81. SawitzkeAD , ShiH , FincoMF , DunlopDD , Bingham IIICO , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis and Rheumatism2008;58:3183‐91. ">Mazieres 2001</a>; <a href="./references#CD005614-bbs2-0025" title="MöllerI , PérezM , MonfortJ , BenitoP , CuevasJ , PernaC , et al. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double‐blind, placebo‐controlled study. Osteoarthritis and Cartilage2010;18:S32‐40. ">Moller 2010</a>; <a href="./references#CD005614-bbs2-0026" title="MorrealeP , ManopuloR , GalatiM , BoccaneraL , SaponatiG , BocchiL . Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. Journal of Rheumatology1996;23(8):1385‐91. ">Morreale 1996</a>; <a href="./references#CD005614-bbs2-0030" title="PavelkaK , ManopuloR , BusciL . Double‐blind, dose‐effect study of oral chondroitin 4 &amp; 6 sulfate 1200 mg, 800 mg, 200 mg, and placebo in the treatment of knee osteoarthritis. Litera Rhumatologica1999;24:21‐30. ">Pavelka 1999</a>; <a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). The number of adverse events did not differ significantly between chondroitin and placebo groups (RR 0.96, 95% CI 0.78 to 1.18; P = 0.69). </p> <p><b>45. Number of serious adverse events:</b> Six studies provided data (<a href="./references#CD005614-bbs2-0006" title="BourgeoisP , ChalesG , DehaisJ , DelcambreB , KuntzJL , RozenbergS . Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage1998;6(Suppl A):25‐30. ">Bourgeois 1998</a>; <a href="./references#CD005614-bbs2-0015" title="GabayC , Medinger‐SadowskiC , GasconD , KoloF , FinckhA . Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis. Arthritis and Rheumatism2011;63(11):3383‐91. ">Gabay 2011</a>; <a href="./references#CD005614-bbs2-0026" title="MorrealeP , ManopuloR , GalatiM , BoccaneraL , SaponatiG , BocchiL . Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. Journal of Rheumatology1996;23(8):1385‐91. ">Morreale 1996</a>; <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a>; <a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>; <a href="./references#CD005614-bbs2-0043" title="ZegelsB , CrozesP , UebelhartD , BruyereO , ReginsterJY . Equivalence of a single dose (1200 mg) compared to a three‐time a day dose (400 mg) of chondroitin 4&amp;6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthritis &amp; Cartilage2013;21(1):22‐7. ">Zegels 2012</a>). The risk of serious adverse events was lower with chondroitin compared to placebo in the long‐term with an RR of 0.38 (95% CI 0.17 to 0.84; P = 0.01] , but not in the short‐term studies, RR of 0.50 [95% CI, 0.09 to 2.78]. The overall risk, combining both short‐ and long‐term studies, was 0.40 (95% CI 0.19 to 0.82]. </p> <p><b>46. Gastrointestinal adverse events:</b> Nine studies provided data (<a href="./references#CD005614-bbs2-0006" title="BourgeoisP , ChalesG , DehaisJ , DelcambreB , KuntzJL , RozenbergS . Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage1998;6(Suppl A):25‐30. ">Bourgeois 1998</a>; <a href="./references#CD005614-bbs2-0015" title="GabayC , Medinger‐SadowskiC , GasconD , KoloF , FinckhA . Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis. Arthritis and Rheumatism2011;63(11):3383‐91. ">Gabay 2011</a>; <a href="./references#CD005614-bbs2-0016" title="KahanA , UebelhartD , DeVathaireF , DelmasPD , ReginsterJY . Long‐term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2009;60(2):524‐33. ">Kahan 2009</a>; <a href="./references#CD005614-bbs2-0021" title="MazieresB , LoyauG , MenkesCJ , ValatJP , DreiserRL , CharlotJ , et al. Chondroitin sulfate in the treatment of gonarthrosis and coxarthrosis. 5‐months result of a multicenter double‐blind controlled prospective study using placebo. Rev Rhum Mal Osteoartic1992;59(7‐8):466‐72. ">Mazieres 1992</a>; <a href="./references#CD005614-bbs2-0024" title="MichelBA , StuckiG , FreyD , DeVathaireF , VignonE , BruehlmannP , et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis and Rheumatism2005;52(3):779‐86. ">Michel 2005</a>; <a href="./references#CD005614-bbs2-0025" title="MöllerI , PérezM , MonfortJ , BenitoP , CuevasJ , PernaC , et al. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double‐blind, placebo‐controlled study. Osteoarthritis and Cartilage2010;18:S32‐40. ">Moller 2010</a>; <a href="./references#CD005614-bbs2-0040" title="UebelhartD , MalaiseM , MarcolongoR , deVathaireF , PipernoM , MailleuxE , et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one‐year, randomized, double‐blind, multicenter study versus placebo. Osteoarthritis Cartilage2004;12(4):269‐76. ">Uebelhart 2004</a>; <a href="./references#CD005614-bbs2-0041" title="VerbruggenG , GoemaereS , VeysEM . Systems to assess the progression of finger joint osteoarthritis and the effects of disease modifying osteoarthritis drugs. Clinical Rheumatology2002;21:231‐43. ">Verbruggen 2002</a>; <a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). The number of gastrointestinal adverse events did not differ significantly between chondroitin and placebo groups (RR 0.68, 95% CI 0.45 to 1.04; P = 0.07). </p> <p><b>47. Other adverse events:</b> These were defined as adverse events other than gastrointestinal, cardiac, or hematologic. Six studies provided data (<a href="./references#CD005614-bbs2-0006" title="BourgeoisP , ChalesG , DehaisJ , DelcambreB , KuntzJL , RozenbergS . Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage1998;6(Suppl A):25‐30. ">Bourgeois 1998</a>; <a href="./references#CD005614-bbs2-0015" title="GabayC , Medinger‐SadowskiC , GasconD , KoloF , FinckhA . Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis. Arthritis and Rheumatism2011;63(11):3383‐91. ">Gabay 2011</a>; <a href="./references#CD005614-bbs2-0024" title="MichelBA , StuckiG , FreyD , DeVathaireF , VignonE , BruehlmannP , et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis and Rheumatism2005;52(3):779‐86. ">Michel 2005</a>; <a href="./references#CD005614-bbs2-0025" title="MöllerI , PérezM , MonfortJ , BenitoP , CuevasJ , PernaC , et al. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double‐blind, placebo‐controlled study. Osteoarthritis and Cartilage2010;18:S32‐40. ">Moller 2010</a>; <a href="./references#CD005614-bbs2-0040" title="UebelhartD , MalaiseM , MarcolongoR , deVathaireF , PipernoM , MailleuxE , et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one‐year, randomized, double‐blind, multicenter study versus placebo. Osteoarthritis Cartilage2004;12(4):269‐76. ">Uebelhart 2004</a>; <a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). The number of other adverse events was not significantly different between chondroitin and placebo groups (RR 0.95, 95% CI 0.79 to 1.15; P = 0.66). </p> <p><b>48. Death:</b> Seven studies provided data (<a href="./references#CD005614-bbs2-0006" title="BourgeoisP , ChalesG , DehaisJ , DelcambreB , KuntzJL , RozenbergS . Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage1998;6(Suppl A):25‐30. ">Bourgeois 1998</a>; <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0015" title="GabayC , Medinger‐SadowskiC , GasconD , KoloF , FinckhA . Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis. Arthritis and Rheumatism2011;63(11):3383‐91. ">Gabay 2011</a>; <a href="./references#CD005614-bbs2-0025" title="MöllerI , PérezM , MonfortJ , BenitoP , CuevasJ , PernaC , et al. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double‐blind, placebo‐controlled study. Osteoarthritis and Cartilage2010;18:S32‐40. ">Moller 2010</a>; <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a>; <a href="./references#CD005614-bbs2-0039" title="UebelhartD , ThonarEJ , DelmasPD , ChantraineA , VignonE . Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage1998;6(Suppl A):39‐46. ">Uebelhart 1998</a>; <a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). Two deaths were reported in the placebo group and none in the chondroitin group. No significant difference was noted between the two groups (RR 0.34, 95% CI 0.04 to 3.20; P = 0.35). </p> </section> <section id="CD005614-sec-0086"> <h4 class="title">CHONDROITIN SULFATE VERSUS CONTROL</h4> <p>(<i>See Table 2 under Data and Analyses.</i>) </p> <p>Control treatment was avocado soybean unsaponifiable (ASU) in <a href="./references#CD005614-bbs2-0031" title="PavelkaK , CosteP , GéherP . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659–70. ">Pavelka 2010</a>, “regular treatment” of osteoarthritis according to physician’s preferences in <a href="./references#CD005614-bbs2-0028" title="NasonovaVA , AlekseevaLI , Arkhangel'skaiaGS , DavydovaAF , Karmil'tsevaEA , KoganKM , et al. Results of the multicenter clinical trial of structum preparation in Russia. Ter Arkh2001;73(11):84‐7. ">Nasonova 2001</a>, and ibuprofen 1200 mg daily in <a href="./references#CD005614-bbs2-0001" title="AlekseevaLI , BenevolenskaiaLI , NasonovEL , ChichasovaNV , KariakinAN . Structum (chondroitin sulfate)—a new agent for the treatment of osteoarthrosis. Ter Arkh1999;71(5):51‐3. ">Alekseeva 1999</a>. </p> <p><b>1. Pain (0‐100 scale):</b> One study (<a href="./references#CD005614-bbs2-0031" title="PavelkaK , CosteP , GéherP . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659–70. ">Pavelka 2010</a>) provided both short‐ and long‐term data. No significant difference was noted between chondroitin and control; SMD was ‐0.06 [95% CI, ‐0.26 to 0.15] for short‐term and ‐0.10 [95% CI, ‐0.31 to 0.11] for long‐term studies. This translates to a mean differences of ‐1.14 [95% CI, ‐5.32 to 3.04] and ‐2.02 [95% CI, ‐6.12 to 2.08], respectively. </p> <p><b>2. WOMAC stiffness:</b> One study (<a href="./references#CD005614-bbs2-0031" title="PavelkaK , CosteP , GéherP . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659–70. ">Pavelka 2010</a>) provided both short‐ and long‐term data. No significant difference was reported between chondroitin and control; mean differences in short‐ and long‐terms studies were ‐1.00 [95% CI, ‐5.77 to 3.77] and ‐0.60 [95% CI, ‐5.25 to 4.05], respectively. </p> <p><b>3. WOMAC physical function:</b> One study (<a href="./references#CD005614-bbs2-0031" title="PavelkaK , CosteP , GéherP . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659–70. ">Pavelka 2010</a>) provided both short‐ and long‐term data. No significant difference was noted between chondroitin and control; mean differences in short‐ and long‐terms studies were ‐2.10 [95% CI, ‐6.44 to 2.24] and ‐1.56 [95% CI, ‐5.70 to 2.58], respectively. </p> <p><b>4. WOMAC Total:</b> One study (<a href="./references#CD005614-bbs2-0031" title="PavelkaK , CosteP , GéherP . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659–70. ">Pavelka 2010</a>) provided both short‐ and long‐term data. No significant difference was reported between chondroitin and control; mean differences in short‐ and long‐terms studies were ‐1.80 [95% CI, ‐6.06 to 2.46] and ‐1.60 [95% CI, ‐5.69 to 2.49], respectively. </p> <p><b>5. Lequesne's index:</b> Two studies provided data (<a href="./references#CD005614-bbs2-0028" title="NasonovaVA , AlekseevaLI , Arkhangel'skaiaGS , DavydovaAF , Karmil'tsevaEA , KoganKM , et al. Results of the multicenter clinical trial of structum preparation in Russia. Ter Arkh2001;73(11):84‐7. ">Nasonova 2001</a>; <a href="./references#CD005614-bbs2-0031" title="PavelkaK , CosteP , GéherP . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659–70. ">Pavelka 2010</a>). Both were long‐term studies. No statistically significant difference was noted between chondroitin and control; mean difference was ‐1.36 [95% CI, ‐3.60 to 0.89]. </p> <p><b>6. Patient global assessment (% with improvement)</b>: Two studies provided data (<a href="./references#CD005614-bbs2-0028" title="NasonovaVA , AlekseevaLI , Arkhangel'skaiaGS , DavydovaAF , Karmil'tsevaEA , KoganKM , et al. Results of the multicenter clinical trial of structum preparation in Russia. Ter Arkh2001;73(11):84‐7. ">Nasonova 2001</a>; <a href="./references#CD005614-bbs2-0031" title="PavelkaK , CosteP , GéherP . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659–70. ">Pavelka 2010</a>). Both were long‐term studies. Investigators found that participants treated with chondroitin sulfate scored better than participants in the control group, with an odds ratio (OR) of 5.04 (95% CI 1.95 to 13.05; P = 0.0008). </p> <p><b>7. Physician global assessment (% with improvement):</b> Two studies provided data (<a href="./references#CD005614-bbs2-0028" title="NasonovaVA , AlekseevaLI , Arkhangel'skaiaGS , DavydovaAF , Karmil'tsevaEA , KoganKM , et al. Results of the multicenter clinical trial of structum preparation in Russia. Ter Arkh2001;73(11):84‐7. ">Nasonova 2001</a>; <a href="./references#CD005614-bbs2-0031" title="PavelkaK , CosteP , GéherP . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659–70. ">Pavelka 2010</a>). Both were long‐term studies. Investigators found that participants treated with chondroitin sulfate scored better than participants in the control group (OR 7.68, 95% CI 4.48 to 13.15; P &lt; 0.00001). </p> <p><b>8. NSAID consumption:</b> One study (<a href="./references#CD005614-bbs2-0031" title="PavelkaK , CosteP , GéherP . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659–70. ">Pavelka 2010</a>) provided both short‐ and long‐term data. No significant difference was reported between chondroitin and control; mean differences in short‐ and long‐terms studies were ‐0.02 [95% CI, ‐0.23 to 0.19] and 0.00 [95% CI, ‐0.20 to 0.20], respectively. </p> <p><b>9. All withdrawals:</b> Three studies provided data (<a href="./references#CD005614-bbs2-0001" title="AlekseevaLI , BenevolenskaiaLI , NasonovEL , ChichasovaNV , KariakinAN . Structum (chondroitin sulfate)—a new agent for the treatment of osteoarthrosis. Ter Arkh1999;71(5):51‐3. ">Alekseeva 1999</a>; <a href="./references#CD005614-bbs2-0028" title="NasonovaVA , AlekseevaLI , Arkhangel'skaiaGS , DavydovaAF , Karmil'tsevaEA , KoganKM , et al. Results of the multicenter clinical trial of structum preparation in Russia. Ter Arkh2001;73(11):84‐7. ">Nasonova 2001;</a><a href="./references#CD005614-bbs2-0031" title="PavelkaK , CosteP , GéherP . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659–70. ">Pavelka 2010</a> ). No significant difference was noted between chondroitin and control (OR 0.39, 95% CI 0.09 to 1.74; P = 0.22). </p> <p><b>10. Withdrawals due to adverse events:</b> Two studies provided data (<a href="./references#CD005614-bbs2-0001" title="AlekseevaLI , BenevolenskaiaLI , NasonovEL , ChichasovaNV , KariakinAN . Structum (chondroitin sulfate)—a new agent for the treatment of osteoarthrosis. Ter Arkh1999;71(5):51‐3. ">Alekseeva 1999</a>; <a href="./references#CD005614-bbs2-0031" title="PavelkaK , CosteP , GéherP . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659–70. ">Pavelka 2010</a>). No significant difference was reported between chondroitin and control (RR 0.27, 95% CI 0.03 to 2.65; P = 0.26). </p> <p><b>11. Number of adverse events:</b> Two studies provided data (<a href="./references#CD005614-bbs2-0001" title="AlekseevaLI , BenevolenskaiaLI , NasonovEL , ChichasovaNV , KariakinAN . Structum (chondroitin sulfate)—a new agent for the treatment of osteoarthrosis. Ter Arkh1999;71(5):51‐3. ">Alekseeva 1999</a>; <a href="./references#CD005614-bbs2-0031" title="PavelkaK , CosteP , GéherP . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659–70. ">Pavelka 2010</a>). No significant difference was noted between chondroitin and control (RR 0.08, 95% CI 0.00 to 4.82; P = 0.22). </p> <p><b>12. Number of GI adverse events:</b> Two studies provided data (<a href="./references#CD005614-bbs2-0001" title="AlekseevaLI , BenevolenskaiaLI , NasonovEL , ChichasovaNV , KariakinAN . Structum (chondroitin sulfate)—a new agent for the treatment of osteoarthrosis. Ter Arkh1999;71(5):51‐3. ">Alekseeva 1999</a>; <a href="./references#CD005614-bbs2-0031" title="PavelkaK , CosteP , GéherP . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659–70. ">Pavelka 2010</a>). No significant difference was reported between chondroitin and control RR 0.51, 95% CI 0.24 to 1.07; P = 0.08). </p> </section> <section id="CD005614-sec-0087"> <h4 class="title">CHONDROITIN SULFATE PLUS GLUCOSAMINE VERSUS PLACEBO</h4> <p>(<i>See Table 3 under Data and Analyses.</i>) </p> <p><b>1. Pain:</b> Five studies provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0017" title="KanzakiN , SaitoK , MaedaA , KitagawaY , KisoY , WatanabeK , et al. Effect of a dietary supplement containing glucosamine hydrochloride, chondroitin sulfate and quercetin glycosides on symptomatic knee osteoarthritis: a randomized, double‐blind, placebo‐controlled study. Journal of Science and Food Agriculture2012;92:862‐9. ">Kanzaki 2011</a>; <a href="./references#CD005614-bbs2-0023" title="MessierSP , MihalkoS , LoeserRF , LegaultC , JollaJ , PfruenderJ , et al. Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study. Osteoarthritis Cartilage2007;15(11):1256‐66. ">Messier 2007</a>; <a href="./references#CD005614-bbs2-0027" title="NakasoneY , WatabeK , WatanabeK , TomonagaA , NagaokaI , YamamotoT , et al. Effect of a glucosamine‐based combination supplement containing chondroitin sulfate and antioxidant micronutrients in subjects with symptomatic knee osteoarthritis: a pilot study. Experimental and Therapeutic Medicine2011;2(5):893. ">Nakasone 2011</a>; <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a>). Three were short‐term studies (<a href="./references#CD005614-bbs2-0017" title="KanzakiN , SaitoK , MaedaA , KitagawaY , KisoY , WatanabeK , et al. Effect of a dietary supplement containing glucosamine hydrochloride, chondroitin sulfate and quercetin glycosides on symptomatic knee osteoarthritis: a randomized, double‐blind, placebo‐controlled study. Journal of Science and Food Agriculture2012;92:862‐9. ">Kanzaki 2011</a>; <a href="./references#CD005614-bbs2-0027" title="NakasoneY , WatabeK , WatanabeK , TomonagaA , NagaokaI , YamamotoT , et al. Effect of a glucosamine‐based combination supplement containing chondroitin sulfate and antioxidant micronutrients in subjects with symptomatic knee osteoarthritis: a pilot study. Experimental and Therapeutic Medicine2011;2(5):893. ">Nakasone 2011</a>; <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a>), and three were long‐term studies (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0023" title="MessierSP , MihalkoS , LoeserRF , LegaultC , JollaJ , PfruenderJ , et al. Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study. Osteoarthritis Cartilage2007;15(11):1256‐66. ">Messier 2007</a>; <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a>). No statistically significant difference was noted between the chondroitin plus glucosamine group and the placebo group for either the short‐term studies (SMD ‐0.06, 95% CI ‐0.33 to 0.20; P = 0.63) or the long‐term studies (SMD ‐0.09, 95% CI ‐0.21 to 0.04; P = 0.17). </p> <p>Sensitvity analyses were robust to allocation concealment, blinding, study size, study sponsorship, publication year, and impact of true ITT analyses. </p> <p><b>2. MCII WOMAC pain:</b> One study provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>). No significant difference between active treatment and placebo was reported (P = 0.09). </p> <p><b>3. Physical function:</b> Four studies provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0017" title="KanzakiN , SaitoK , MaedaA , KitagawaY , KisoY , WatanabeK , et al. Effect of a dietary supplement containing glucosamine hydrochloride, chondroitin sulfate and quercetin glycosides on symptomatic knee osteoarthritis: a randomized, double‐blind, placebo‐controlled study. Journal of Science and Food Agriculture2012;92:862‐9. ">Kanzaki 2011</a>; <a href="./references#CD005614-bbs2-0023" title="MessierSP , MihalkoS , LoeserRF , LegaultC , JollaJ , PfruenderJ , et al. Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study. Osteoarthritis Cartilage2007;15(11):1256‐66. ">Messier 2007</a>; <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a>). <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a> and <a href="./references#CD005614-bbs2-0017" title="KanzakiN , SaitoK , MaedaA , KitagawaY , KisoY , WatanabeK , et al. Effect of a dietary supplement containing glucosamine hydrochloride, chondroitin sulfate and quercetin glycosides on symptomatic knee osteoarthritis: a randomized, double‐blind, placebo‐controlled study. Journal of Science and Food Agriculture2012;92:862‐9. ">Kanzaki 2011</a> were in the short‐term category. The rest of the studies, including <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a> at 24 months, were in the long‐term subgroup. No significant difference was noted between active treatment and placebo in the short‐ (SMD 0.11, 95% CI ‐0.31 to 0.54; P = 0.60) or long‐term subgroups (SMD ‐0.11, 95% CI ‐0.24 to 0.01; P = 0.08). </p> <p>Sensitivity analyses were robust to allocation concealment, blinding, study size, study sponsorship, publication year, and impact of true ITT analyses. </p> <p><b>4. Six‐minute walk, distance in meters:</b> One study provided data (<a href="./references#CD005614-bbs2-0023" title="MessierSP , MihalkoS , LoeserRF , LegaultC , JollaJ , PfruenderJ , et al. Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study. Osteoarthritis Cartilage2007;15(11):1256‐66. ">Messier 2007</a>). No significant difference was reported between active treatment and placebo (P = 0.8); mean difference was ‐2.90 [95% CI, ‐24.94 to 19.14]. </p> <p><b>5. WOMAC stiffness:</b> One study provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>). No significant difference was reported between active treatment and placebo (P = 0.25); mean difference was ‐2.20 [95% CI, ‐5.97 to 1.57]. </p> <p><b>6. WOMAC Total:</b> One study provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>). Participants treated with chondroitin sulfate in combination with glucosamine had significantly better scores on WOMAC Total (MD ‐2.60, 95% CI ‐5.29 to 0.72; P = 0.13). The results for WOMAC Total as reported by <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a> were presented as normalized WOMAC scores on a 0 to 300 scale, which we then normalized to a 0 to 100 scale. </p> <p><b>7. Patient global assessment on VAS:</b> Two studies provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0012" title="DasA , Jr , HammadTA . Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage2000;8(5):343‐50. ">Das 2000</a>). No significant difference was noted between active treatment and placebo (P = 0.39); mean difference was ‐1.60 [95% CI, ‐5.29 to 2.09]. </p> <p><b>8 Physician global assessment on VAS:</b> One study provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>). No significant difference between active treatment and placebo was reported (P = 0.43); mean difference was ‐1.40 [95% CI, ‐4.87 to 2.07]. </p> <p><b>9. OMERACT‐OARSI responder:</b> One study provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>). The proportion of participants achieving responder status in the chondroitin sulfate in combination with glucosamine group was significantly greater in the active treatment group than in the placebo group (P = 0.03); odds ratio was 1.15 [95% CI, 1.02 to 1.31]. </p> <p><b>10. HAQ Disability score:</b> One study provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>). No significant difference between active treatment and placebo was noted (P = 0.24); mean difference was ‐0.04 [95% CI, ‐0.11 to 0.03]. </p> <p><b>11. Objective joint function (flexion):</b> Only one study provided data on this outcome (<a href="./references#CD005614-bbs2-0023" title="MessierSP , MihalkoS , LoeserRF , LegaultC , JollaJ , PfruenderJ , et al. Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study. Osteoarthritis Cartilage2007;15(11):1256‐66. ">Messier 2007</a>). No significant difference between active treatment and placebo groups was reported (P = 0.96); mean difference was ‐0.60 [95% CI, ‐21.54 to 20.34]. </p> <p><b>12. Objective joint function (extension):</b> Only one study provided data on this outcome (<a href="./references#CD005614-bbs2-0023" title="MessierSP , MihalkoS , LoeserRF , LegaultC , JollaJ , PfruenderJ , et al. Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study. Osteoarthritis Cartilage2007;15(11):1256‐66. ">Messier 2007</a>). No significant difference between active treatment and placebo groups was reported (P = 0.29); mean difference was ‐25.80 [95% CI, ‐72.67 to 21.07]. </p> <p><b>13. Objective joint function (balance):</b> Only one study provided data on this outcome (<a href="./references#CD005614-bbs2-0023" title="MessierSP , MihalkoS , LoeserRF , LegaultC , JollaJ , PfruenderJ , et al. Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study. Osteoarthritis Cartilage2007;15(11):1256‐66. ">Messier 2007</a>). Participants in the active treatment group had significantly lower (better) scores on balance in objective joint function (P = 0.008); mean difference was ‐0.06 [95% CI, ‐0.10 to ‐0.02]. </p> <p><b>14. All withdrawals:</b> Three studies provided data on this outcome (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0012" title="DasA , Jr , HammadTA . Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage2000;8(5):343‐50. ">Das 2000</a>; <a href="./references#CD005614-bbs2-0029" title="NguyenP , MohamedSE , GardinerD , SalinasT . A randomized double‐blind clinical trial of the effect of chondroitin sulfate and glucosamine hydrochloride on temporomandibular joint disorders: a pilot study. Cranio2001;19(2):130‐9. ">Nguyen 2001</a>). No significant difference between active treatment and placebo groups was noted (Risk Ratio [RR] 1.24, 95% CI 0.40 to 3.85; P = 0.70). </p> <p><b>15. Withdrawals due to adverse events:</b> Four studies provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0012" title="DasA , Jr , HammadTA . Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage2000;8(5):343‐50. ">Das 2000</a>; <a href="./references#CD005614-bbs2-0027" title="NakasoneY , WatabeK , WatanabeK , TomonagaA , NagaokaI , YamamotoT , et al. Effect of a glucosamine‐based combination supplement containing chondroitin sulfate and antioxidant micronutrients in subjects with symptomatic knee osteoarthritis: a pilot study. Experimental and Therapeutic Medicine2011;2(5):893. ">Nakasone 2011;</a><a href="./references#CD005614-bbs2-0029" title="NguyenP , MohamedSE , GardinerD , SalinasT . A randomized double‐blind clinical trial of the effect of chondroitin sulfate and glucosamine hydrochloride on temporomandibular joint disorders: a pilot study. Cranio2001;19(2):130‐9. ">Nguyen 2001</a>). The numbers of participants who withdrew from the study because of adverse events did not differ significantly between active and placebo groups (RR 1.21, 95% CI 0.57 to 2.55; P = 0.62). </p> <p><b>16. Withdrawals due to inefficacy:</b> Three studies provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0012" title="DasA , Jr , HammadTA . Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage2000;8(5):343‐50. ">Das 2000</a>; <a href="./references#CD005614-bbs2-0029" title="NguyenP , MohamedSE , GardinerD , SalinasT . A randomized double‐blind clinical trial of the effect of chondroitin sulfate and glucosamine hydrochloride on temporomandibular joint disorders: a pilot study. Cranio2001;19(2):130‐9. ">Nguyen 2001</a>). No significant difference was noted between chondroitin and placebo in the number of withdrawals due to inefficacy (RR 0.76, 95% CI 0.41 to 1.41; P = 0.39). </p> <p><b>17. Number of adverse events:</b> Three studies provided data (<a href="./references#CD005614-bbs2-0012" title="DasA , Jr , HammadTA . Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage2000;8(5):343‐50. ">Das 2000</a>; <a href="./references#CD005614-bbs2-0027" title="NakasoneY , WatabeK , WatanabeK , TomonagaA , NagaokaI , YamamotoT , et al. Effect of a glucosamine‐based combination supplement containing chondroitin sulfate and antioxidant micronutrients in subjects with symptomatic knee osteoarthritis: a pilot study. Experimental and Therapeutic Medicine2011;2(5):893. ">Nakasone 2011;</a><a href="./references#CD005614-bbs2-0029" title="NguyenP , MohamedSE , GardinerD , SalinasT . A randomized double‐blind clinical trial of the effect of chondroitin sulfate and glucosamine hydrochloride on temporomandibular joint disorders: a pilot study. Cranio2001;19(2):130‐9. ">Nguyen 2001</a>). No significant difference was noted in the number of adverse events between chondroitin and placebo groups (RR 1.11, 95% CI 0.67 to 1.84; P = 0.68). </p> <p><b>18. Number of serious adverse events:</b> Three studies provided data (<a href="./references#CD005614-bbs2-0012" title="DasA , Jr , HammadTA . Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage2000;8(5):343‐50. ">Das 2000</a>; <a href="./references#CD005614-bbs2-0029" title="NguyenP , MohamedSE , GardinerD , SalinasT . A randomized double‐blind clinical trial of the effect of chondroitin sulfate and glucosamine hydrochloride on temporomandibular joint disorders: a pilot study. Cranio2001;19(2):130‐9. ">Nguyen 2001</a>; <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a>). No significant difference between placebo and chondroitin groups was reported (RR 1.45, 95% CI 0.77 to 2.75; P = 0.25). </p> <p><b>19. Gastrointestinal adverse events:</b> Two studies provided data (<a href="./references#CD005614-bbs2-0012" title="DasA , Jr , HammadTA . Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage2000;8(5):343‐50. ">Das 2000</a>; <a href="./references#CD005614-bbs2-0029" title="NguyenP , MohamedSE , GardinerD , SalinasT . A randomized double‐blind clinical trial of the effect of chondroitin sulfate and glucosamine hydrochloride on temporomandibular joint disorders: a pilot study. Cranio2001;19(2):130‐9. ">Nguyen 2001</a>). No difference between chondroitin and placebo groups was reported (RR 0.68, 95% CI 0.34 to 1.37; P = 0.28). </p> <p><b>20. Hematologic adverse events:</b> Two studies provided data (<a href="./references#CD005614-bbs2-0012" title="DasA , Jr , HammadTA . Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage2000;8(5):343‐50. ">Das 2000</a>; <a href="./references#CD005614-bbs2-0029" title="NguyenP , MohamedSE , GardinerD , SalinasT . A randomized double‐blind clinical trial of the effect of chondroitin sulfate and glucosamine hydrochloride on temporomandibular joint disorders: a pilot study. Cranio2001;19(2):130‐9. ">Nguyen 2001</a>). No difference between chondroitin and placebo groups was noted (RR 0.34, 95% CI 0.01 to 8.15; P = 0.51). </p> <p><b>21. Other adverse events:</b> These were defined as adverse events other than gastrointestinal, cardiac, or hematologic. Two studies provided data (<a href="./references#CD005614-bbs2-0012" title="DasA , Jr , HammadTA . Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage2000;8(5):343‐50. ">Das 2000</a>; <a href="./references#CD005614-bbs2-0029" title="NguyenP , MohamedSE , GardinerD , SalinasT . A randomized double‐blind clinical trial of the effect of chondroitin sulfate and glucosamine hydrochloride on temporomandibular joint disorders: a pilot study. Cranio2001;19(2):130‐9. ">Nguyen 2001</a>). The number of other adverse events was not significantly different between chondroitin and placebo groups (RR 1.35, 95% CI 0.43 to 4.19; P = 0.61). </p> <p><b>22. Death:</b> Four studies provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0012" title="DasA , Jr , HammadTA . Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage2000;8(5):343‐50. ">Das 2000</a>; <a href="./references#CD005614-bbs2-0029" title="NguyenP , MohamedSE , GardinerD , SalinasT . A randomized double‐blind clinical trial of the effect of chondroitin sulfate and glucosamine hydrochloride on temporomandibular joint disorders: a pilot study. Cranio2001;19(2):130‐9. ">Nguyen 2001</a>; <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a>). No significant difference between the two groups was reported (RR 0.34, 95% CI 0.01 to 8.23; P = 0.51). </p> </section> <section id="CD005614-sec-0088"> <h4 class="title">CHONDROITIN SULFATE PLUS GLUCOSAMINE VERSUS NSAIDs CONTROL</h4> <p><i>(See Table 4 under Data and Anayses.)</i> </p> <p><b>1. Pain:</b> Four studies provided data (<a href="./references#CD005614-bbs2-0005" title="ArtemenkoNA , ChvamaniyaNA . Characteristics of progression and treatment of osteoarthritis. Russkiy Meditsinksiy Journal2005;13(7):403. ">Artemenko 2005</a>; <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0019" title="LilaAM , MazurovVI , ShidlovskayaOV , ShostakMS . THERAFLEX in comprehensive therapy of knee osteoarthrosis and spinal osteochondrosis (results of a clinical trial). Russkiy Meditsinskiy Journal2005;13(24):1618. ">Lila 2005</a>; <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a>). Participants in the chondroitin sulfate and glucosamine group had significantly lower pain scores than those in the NSAIDs control group (SMD ‐1.41, 95% CI ‐2.18 to ‐0.63; P = 0.0004). Two studies provided short‐term data (<a href="./references#CD005614-bbs2-0019" title="LilaAM , MazurovVI , ShidlovskayaOV , ShostakMS . THERAFLEX in comprehensive therapy of knee osteoarthrosis and spinal osteochondrosis (results of a clinical trial). Russkiy Meditsinskiy Journal2005;13(24):1618. ">Lila 2005</a>; <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a>), and four studies provided long‐term data (<a href="./references#CD005614-bbs2-0005" title="ArtemenkoNA , ChvamaniyaNA . Characteristics of progression and treatment of osteoarthritis. Russkiy Meditsinksiy Journal2005;13(7):403. ">Artemenko 2005</a>; <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0019" title="LilaAM , MazurovVI , ShidlovskayaOV , ShostakMS . THERAFLEX in comprehensive therapy of knee osteoarthrosis and spinal osteochondrosis (results of a clinical trial). Russkiy Meditsinskiy Journal2005;13(24):1618. ">Lila 2005;</a><a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a>). Short‐term studies showed no significant difference between NSAIDs control and chondroitin sulfate in combination with glucosamine (SMD ‐1.41, 95% CI ‐4.41 to 1.58; P = 0.35). Heterogeneity was high among these studies (T<sup>2</sup> = 4.60). Long‐term studies showed that participants in the chondroitin and glucosamine combination group experienced significantly better pain scores than those in the NSAIDs control group (SMD ‐1.48, 95% CI ‐2.51 to ‐0.44; P = 0.005). Heterogeneity was high (T<sup>2</sup> = 1.02). </p> <p>Sensitivity analyses were robust to study sponsorship and publication year. Results were not robust to allocation concealment, blinding, study size, and impact of true ITT analyses. </p> <p>In groups with both adequate and unclear methods of allocation concealment the estimate was similar to the original estimate. However, among studies with inadequate methods of allocation concealment and blinding, small studies (N&lt;100), unclear pharmaceutical sponsorship, and high risk of bias due to unclear or non‐use of ITT analyses, participants treated with chondroitin sulfate had statistically better pain scores than those in the NSAID group. </p> <p><b>2. MCII WOMAC:</b> One study provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>). No significant difference was reported between chondroitin sulfate in combination with glucosamine and the NSAIDs control (P = 0.33); 0.85 [0.61, 1.19]. </p> <p><b>3. Physical function:</b> Two studies provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a>). No significant difference was noted between chondroitin sulfate in combination with glucosamine and the NSAIDs control with SMD in short‐ and long‐terms studies of 0.04 [95% CI, ‐0.20 to 0.28; p=0.35] and 0.02 [95% CI, ‐0.11 to 0.15; p=0.005], respectively. This translates to mean differences of 0.80 [95% CI, ‐4.09 to 5.69] and 0.34 [95% CI, ‐2.46 to 3.14], respectively. </p> <p><b>4. WOMAC stiffness:</b> Three studies provided data (<a href="./references#CD005614-bbs2-0005" title="ArtemenkoNA , ChvamaniyaNA . Characteristics of progression and treatment of osteoarthritis. Russkiy Meditsinksiy Journal2005;13(7):403. ">Artemenko 2005</a>; <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0019" title="LilaAM , MazurovVI , ShidlovskayaOV , ShostakMS . THERAFLEX in comprehensive therapy of knee osteoarthrosis and spinal osteochondrosis (results of a clinical trial). Russkiy Meditsinskiy Journal2005;13(24):1618. ">Lila 2005</a>). Participants in the chondroitin sulfate in combination with glucosamine group achieved significantly better scores in WOMAC Stiffness than those in the NSAID group with mean differences in short‐ and long‐terms studies of ‐2.50 [95% CI, ‐4.27 to ‐.073; p=0.006] and ‐7.72 [95% CI, ‐15.36 to ‐0.08; p=0.05], respectively. </p> <p><b>5. WOMAC Total:</b> Three studies provided data (<a href="./references#CD005614-bbs2-0005" title="ArtemenkoNA , ChvamaniyaNA . Characteristics of progression and treatment of osteoarthritis. Russkiy Meditsinksiy Journal2005;13(7):403. ">Artemenko 2005</a>; <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0019" title="LilaAM , MazurovVI , ShidlovskayaOV , ShostakMS . THERAFLEX in comprehensive therapy of knee osteoarthrosis and spinal osteochondrosis (results of a clinical trial). Russkiy Meditsinskiy Journal2005;13(24):1618. ">Lila 2005</a>). No significant difference between chondroitin sulfate in combination with glucosamine and NSAIDs control  was noted (MD ‐4.77, 95% CI ‐9.75 to 0.20, P = 0.06). WOMAC Total for <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a> was presented as a normalized WOMAC score on a 0 to 300 scale, which we normalized further to a 0 to 100 scale. </p> <p><b>6. Patient global assessment of good to very good:</b> Three studies provided data (<a href="./references#CD005614-bbs2-0002" title="AlekseevaLI , CichasovaNV , BenevolenskaiaLI , NasonovEL , MendelOI . Combined medication ARTRA in the treatment of osteoarthrosis. Ter Arkh2005;77(11):69‐75. ">Alekseeva 2005a</a>; <a href="./references#CD005614-bbs2-0003" title="AlekseevaLI , ArtemenkoNA , ZotkinEG , KudryavtcevaNV , LesnyakOM , MendelOI , et al. Rational selection of basal therapy in osteoarthritis. Results of the open randomized multicenter clinical trial of ARTRA preparation in Russia. Russkiy Meditsinskiy Journal2005;13(24):1637. ">Alekseeva 2005b</a>; <a href="./references#CD005614-bbs2-0019" title="LilaAM , MazurovVI , ShidlovskayaOV , ShostakMS . THERAFLEX in comprehensive therapy of knee osteoarthrosis and spinal osteochondrosis (results of a clinical trial). Russkiy Meditsinskiy Journal2005;13(24):1618. ">Lila 2005</a>). Significantly more participants in the chondroitin sulfate in combination with glucosamine group were able to achieve a good to very good global assessment as compared with the NSAIDs control (SMD 1.43, 95% CI 1.29 to 1.58; P &lt; 0.00001). </p> <p><b>7. Physician global assessment of good to very good:</b> Three studies provided data (<a href="./references#CD005614-bbs2-0002" title="AlekseevaLI , CichasovaNV , BenevolenskaiaLI , NasonovEL , MendelOI . Combined medication ARTRA in the treatment of osteoarthrosis. Ter Arkh2005;77(11):69‐75. ">Alekseeva 2005a</a>; <a href="./references#CD005614-bbs2-0003" title="AlekseevaLI , ArtemenkoNA , ZotkinEG , KudryavtcevaNV , LesnyakOM , MendelOI , et al. Rational selection of basal therapy in osteoarthritis. Results of the open randomized multicenter clinical trial of ARTRA preparation in Russia. Russkiy Meditsinskiy Journal2005;13(24):1637. ">Alekseeva 2005b</a>; <a href="./references#CD005614-bbs2-0019" title="LilaAM , MazurovVI , ShidlovskayaOV , ShostakMS . THERAFLEX in comprehensive therapy of knee osteoarthrosis and spinal osteochondrosis (results of a clinical trial). Russkiy Meditsinskiy Journal2005;13(24):1618. ">Lila 2005</a>). Significantly more participants in the chondroitin sulfate in combination with glucosamine group said they were able to achieve a good to very good global assessment as compared with those in the NSAIDs control group (SMD 1.51, 95% CI 1.35 to 1.68; P &lt; 0.00001). </p> <p><b>8. OMERACT‐OARSI responder:</b> One study provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>). The proportion of participants achieving responder status in the chondroitin sulfate group was not significantly different from the proportion in the active treatment group (P = 0.65); RR was 0.93 [95% CI 0.67 to 1.29]. </p> <p><b>9. HAQ Disability score:</b> One study provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>). No significant difference was reported between chondroitin sulfate in combination with glucosamine and NSAIDs control (P = 0.77); mean difference was 0.01 [95% CI ‐0.06 to 0.08]. </p> <p><b>10. Radiographic outcome: change in mean JSW:</b> One study provided data (<a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a>). No difference was noted between chondroitin sulfate in combination with glucosamine and NSAIDs control (P = 0.63); mean difference was 0.08 [95% CI, ‐0.26 to 0.42]. </p> <p><b>11. All withdrawals:</b> Five studies provided data on this outcome (<a href="./references#CD005614-bbs2-0002" title="AlekseevaLI , CichasovaNV , BenevolenskaiaLI , NasonovEL , MendelOI . Combined medication ARTRA in the treatment of osteoarthrosis. Ter Arkh2005;77(11):69‐75. ">Alekseeva 2005a</a>; <a href="./references#CD005614-bbs2-0003" title="AlekseevaLI , ArtemenkoNA , ZotkinEG , KudryavtcevaNV , LesnyakOM , MendelOI , et al. Rational selection of basal therapy in osteoarthritis. Results of the open randomized multicenter clinical trial of ARTRA preparation in Russia. Russkiy Meditsinskiy Journal2005;13(24):1637. ">Alekseeva 2005b</a>; <a href="./references#CD005614-bbs2-0005" title="ArtemenkoNA , ChvamaniyaNA . Characteristics of progression and treatment of osteoarthritis. Russkiy Meditsinksiy Journal2005;13(7):403. ">Artemenko 2005</a>; <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006;</a><a href="./references#CD005614-bbs2-0019" title="LilaAM , MazurovVI , ShidlovskayaOV , ShostakMS . THERAFLEX in comprehensive therapy of knee osteoarthrosis and spinal osteochondrosis (results of a clinical trial). Russkiy Meditsinskiy Journal2005;13(24):1618. ">Lila 2005</a>). No significant difference between chondroitin sulfate in combination with glucosamine and active treatment was reported (RR 0.31, 95% CI 0.08 to 1.18; P = 0.09). </p> <p><b>12. Withdrawals due to adverse events:</b> One study provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>). The number of participants who withdrew from the study because of adverse events did not differ significantly between chondroitin sulfate in combination with glucosamine and NSAIDs control groups (RR 1.72, 95% CI 0.69 to 4.31; P = 0.25). </p> <p><b>13. Withdrawals due to inefficacy:</b> One study provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>). The number of participants who withdrew from the study because of inefficacy did not differ significantly between chondroitin sulfate in combination with glucosamine and NSAIDs control groups (RR 1.55, 95% CI 0.74 to 3.26; P = 0.25). </p> <p><b>14. Adverse events:</b> Four studies provided data (<a href="./references#CD005614-bbs2-0002" title="AlekseevaLI , CichasovaNV , BenevolenskaiaLI , NasonovEL , MendelOI . Combined medication ARTRA in the treatment of osteoarthrosis. Ter Arkh2005;77(11):69‐75. ">Alekseeva 2005a</a>; <a href="./references#CD005614-bbs2-0003" title="AlekseevaLI , ArtemenkoNA , ZotkinEG , KudryavtcevaNV , LesnyakOM , MendelOI , et al. Rational selection of basal therapy in osteoarthritis. Results of the open randomized multicenter clinical trial of ARTRA preparation in Russia. Russkiy Meditsinskiy Journal2005;13(24):1637. ">Alekseeva 2005b</a>; <a href="./references#CD005614-bbs2-0019" title="LilaAM , MazurovVI , ShidlovskayaOV , ShostakMS . THERAFLEX in comprehensive therapy of knee osteoarthrosis and spinal osteochondrosis (results of a clinical trial). Russkiy Meditsinskiy Journal2005;13(24):1618. ">Lila 2005</a>; <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a>). No significant difference was reported in adverse events between chondroitin sulfate in combination with glucosamine and NSAIDs control groups (SMD 0.45, 95% CI 0.17 to 1.21; P = 0.11). </p> <p><b>15. Serious adverse events:</b> Two studies provided data (<a href="./references#CD005614-bbs2-0002" title="AlekseevaLI , CichasovaNV , BenevolenskaiaLI , NasonovEL , MendelOI . Combined medication ARTRA in the treatment of osteoarthrosis. Ter Arkh2005;77(11):69‐75. ">Alekseeva 2005a</a>; <a href="./references#CD005614-bbs2-0019" title="LilaAM , MazurovVI , ShidlovskayaOV , ShostakMS . THERAFLEX in comprehensive therapy of knee osteoarthrosis and spinal osteochondrosis (results of a clinical trial). Russkiy Meditsinskiy Journal2005;13(24):1618. ">Lila 2005</a>). No significant difference was noted between the chondroitin sulfate in combination with glucosamine and NSAIDs control groups (RR 3.00, 95% CI 0.13 to 70.83; P = 0.50). </p> <p><b>16. Gastrointestinal adverse events:</b> Three studies provided data (<a href="./references#CD005614-bbs2-0002" title="AlekseevaLI , CichasovaNV , BenevolenskaiaLI , NasonovEL , MendelOI . Combined medication ARTRA in the treatment of osteoarthrosis. Ter Arkh2005;77(11):69‐75. ">Alekseeva 2005a</a>; <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0019" title="LilaAM , MazurovVI , ShidlovskayaOV , ShostakMS . THERAFLEX in comprehensive therapy of knee osteoarthrosis and spinal osteochondrosis (results of a clinical trial). Russkiy Meditsinskiy Journal2005;13(24):1618. ">Lila 2005</a>). No difference was reported between the chondroitin sulfate in combination with glucosamine and NSAIDs control groups (RR 0.54, 95% CI 0.29 to 1.01; P = 0.06). </p> <p><b>17. Other adverse events:</b> These were defined as adverse events other than gastrointestinal, cardiac, or hematologic. Two studies provided data (<a href="./references#CD005614-bbs2-0002" title="AlekseevaLI , CichasovaNV , BenevolenskaiaLI , NasonovEL , MendelOI . Combined medication ARTRA in the treatment of osteoarthrosis. Ter Arkh2005;77(11):69‐75. ">Alekseeva 2005a</a>; <a href="./references#CD005614-bbs2-0019" title="LilaAM , MazurovVI , ShidlovskayaOV , ShostakMS . THERAFLEX in comprehensive therapy of knee osteoarthrosis and spinal osteochondrosis (results of a clinical trial). Russkiy Meditsinskiy Journal2005;13(24):1618. ">Lila 2005</a>). The number of other adverse events was not significantly different between chondroitin sulfate in combination with glucosamine and NSAIDs control groups (RR 0.42, 95% CI 0.16 to 1.13; P = 0.08). </p> <p><b>18. Death:</b> One study provided data (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>). No deaths were reported in either the chondroitin sulfate in combination with glucosamine group or the NSAIDs control group (not estimable). </p> </section> <section id="CD005614-sec-0089"> <h4 class="title">CHONDROITIN SULFATE ALONE OR WITH GLUCOSAMINE OR WITH OTHER SUPPLEMENT VERSUS PLACEBO OR CONTROL </h4> <p><i>(See Table 5 under Data and Anayses.)</i> </p> <p>In this group, we combined all studies in all comparison arms to assess the overall effect of chondroitin (with or without glucosamine) compared with placebo or control resulting in a greater number of studies for the outcomes of pain and physical function. This decision was clinically relevant because many patients take glucosamine and chondroitin together. </p> <p><b>1. Pain (All studies):</b> Before sensitivity analysis was performed, when all studies were combined into one large overall group, 17 studies were identified (<a href="./references#CD005614-bbs2-0005" title="ArtemenkoNA , ChvamaniyaNA . Characteristics of progression and treatment of osteoarthritis. Russkiy Meditsinksiy Journal2005;13(7):403. ">Artemenko 2005</a>; <a href="./references#CD005614-bbs2-0006" title="BourgeoisP , ChalesG , DehaisJ , DelcambreB , KuntzJL , RozenbergS . Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage1998;6(Suppl A):25‐30. ">Bourgeois 1998</a>; <a href="./references#CD005614-bbs2-0007" title="BucsiL , PoorG . Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow‐acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage1998;6(Suppl A):31‐6. ">Bucsi 1998</a>; <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0017" title="KanzakiN , SaitoK , MaedaA , KitagawaY , KisoY , WatanabeK , et al. Effect of a dietary supplement containing glucosamine hydrochloride, chondroitin sulfate and quercetin glycosides on symptomatic knee osteoarthritis: a randomized, double‐blind, placebo‐controlled study. Journal of Science and Food Agriculture2012;92:862‐9. ">Kanzaki 2011</a>; <a href="./references#CD005614-bbs2-0019" title="LilaAM , MazurovVI , ShidlovskayaOV , ShostakMS . THERAFLEX in comprehensive therapy of knee osteoarthrosis and spinal osteochondrosis (results of a clinical trial). Russkiy Meditsinskiy Journal2005;13(24):1618. ">Lila 2005</a>; <a href="./references#CD005614-bbs2-0022" title="MazieresB , CombeB , Phan VanA , TondutJ , GrynfelttM . Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. Journal of Rheumatology2001;28(1):173‐81. SawitzkeAD , ShiH , FincoMF , DunlopDD , Bingham IIICO , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis and Rheumatism2008;58:3183‐91. ">Mazieres 2001</a>; <a href="./references#CD005614-bbs2-0023" title="MessierSP , MihalkoS , LoeserRF , LegaultC , JollaJ , PfruenderJ , et al. Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study. Osteoarthritis Cartilage2007;15(11):1256‐66. ">Messier 2007</a>: <a href="./references#CD005614-bbs2-0026" title="MorrealeP , ManopuloR , GalatiM , BoccaneraL , SaponatiG , BocchiL . Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. Journal of Rheumatology1996;23(8):1385‐91. ">Morreale 1996</a>; <a href="./references#CD005614-bbs2-0027" title="NakasoneY , WatabeK , WatanabeK , TomonagaA , NagaokaI , YamamotoT , et al. Effect of a glucosamine‐based combination supplement containing chondroitin sulfate and antioxidant micronutrients in subjects with symptomatic knee osteoarthritis: a pilot study. Experimental and Therapeutic Medicine2011;2(5):893. ">Nakasone 2011</a>; <a href="./references#CD005614-bbs2-0030" title="PavelkaK , ManopuloR , BusciL . Double‐blind, dose‐effect study of oral chondroitin 4 &amp; 6 sulfate 1200 mg, 800 mg, 200 mg, and placebo in the treatment of knee osteoarthritis. Litera Rhumatologica1999;24:21‐30. ">Pavelka 1999</a>; <a href="./references#CD005614-bbs2-0031" title="PavelkaK , CosteP , GéherP . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659–70. ">Pavelka 2010</a>; <a href="./references#CD005614-bbs2-0039" title="UebelhartD , ThonarEJ , DelmasPD , ChantraineA , VignonE . Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage1998;6(Suppl A):39‐46. ">Uebelhart 1998</a>; <a href="./references#CD005614-bbs2-0040" title="UebelhartD , MalaiseM , MarcolongoR , deVathaireF , PipernoM , MailleuxE , et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one‐year, randomized, double‐blind, multicenter study versus placebo. Osteoarthritis Cartilage2004;12(4):269‐76. ">Uebelhart 2004</a>; <a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>; <a href="./references#CD005614-bbs2-0033" title="RailhacJJ , ZaimM , SaurelAS , VialJ , FournieB . Effect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: A randomized, double‐blind, placebo‐controlled pilot study using MRI. Clinical Rheumatology2012;31(9):1347‐57. ">Railhac 2012</a>; <a href="./references#CD005614-bbs2-0043" title="ZegelsB , CrozesP , UebelhartD , BruyereO , ReginsterJY . Equivalence of a single dose (1200 mg) compared to a three‐time a day dose (400 mg) of chondroitin 4&amp;6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthritis &amp; Cartilage2013;21(1):22‐7. ">Zegels 2012</a>). Participants treated with chondroitin alone and in combination with other supplements such as glucosamine showed significantly better pain scores than those treated with a control or placebo in short‐ and long‐terms studies with an SMD ‐0.65, 95% CI ‐0.95 to ‐0.35; P &lt; 0.0001). This translates into an absolute risk difference of which translated into an absolute risk difference of ‐9.6 (95% CI ‐14 to ‐5.2) on a 0 to 100 scale (absolute percent change 10% lower (14% lower to 5% lower ;T<sup>2</sup> = 0.33; n = 17 trials; level of evidence, low). Because were more than 10 studies were included, we created a funnel plot to detect bias. As <a href="#CD005614-fig-0006">Figure 6</a> shows, the possibility of publication bias is high. Removing one study with a small standard deviation (<a href="./references#CD005614-bbs2-0019" title="LilaAM , MazurovVI , ShidlovskayaOV , ShostakMS . THERAFLEX in comprehensive therapy of knee osteoarthrosis and spinal osteochondrosis (results of a clinical trial). Russkiy Meditsinskiy Journal2005;13(24):1618. ">Lila 2005</a>), reduced the SMD for pain to ‐0.47 (95% CI ‐0.70 to ‐0.23) and I<sup>2</sup> to 84%.  </p> <div class="figure" id="CD005614-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Funnel plot of comparison: 5 chondroitin sulfate/CSGH versus Placebo/Control, outcome: 5.1 Pain on a 0 to 100 scale (short‐ and long‐term results)." data-id="CD005614-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Funnel plot of comparison: 5 chondroitin sulfate/CSGH versus Placebo/Control, outcome: 5.1 Pain on a 0 to 100 scale (short‐ and long‐term results). </p> </div> </div> </div> <p>Sensitivity analyses showed that the results were robust to blinding but not robust to allocation concealment, study size, study sponsorship, publication year, and impact of true ITT analyses (<a href="./references#CD005614-fig-0120" title="">Analysis 9.1</a>; <a href="./references#CD005614-fig-0129" title="">Analysis 13.1</a>; <a href="./references#CD005614-fig-0138" title="">Analysis 17.1</a>; <a href="./references#CD005614-fig-0147" title="">Analysis 21.1</a>; <a href="./references#CD005614-fig-0156" title="">Analysis 25.1</a>; <a href="./references#CD005614-fig-0182" title="">Analysis 34.1</a>). Among studies with adequate allocation concealment, sample size greater than 100, no pharmaceutical sponsorship, publication year &gt;2010, and high risk of bias due to the use of non‐ITT analyses, there was no statistically significant difference between treatment and control groups. </p> <p><b>1.1 Pain ‐ restricted to chondroitin dose ≧800 mg/day (therapeutic dose):</b> 14 studies were included in this analysis (<a href="./references#CD005614-bbs2-0005" title="ArtemenkoNA , ChvamaniyaNA . Characteristics of progression and treatment of osteoarthritis. Russkiy Meditsinksiy Journal2005;13(7):403. ">Artemenko 2005</a>; <a href="./references#CD005614-bbs2-0006" title="BourgeoisP , ChalesG , DehaisJ , DelcambreB , KuntzJL , RozenbergS . Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage1998;6(Suppl A):25‐30. ">Bourgeois 1998</a>; <a href="./references#CD005614-bbs2-0007" title="BucsiL , PoorG . Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow‐acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage1998;6(Suppl A):31‐6. ">Bucsi 1998</a>; <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0019" title="LilaAM , MazurovVI , ShidlovskayaOV , ShostakMS . THERAFLEX in comprehensive therapy of knee osteoarthrosis and spinal osteochondrosis (results of a clinical trial). Russkiy Meditsinskiy Journal2005;13(24):1618. ">Lila 2005</a>; <a href="./references#CD005614-bbs2-0022" title="MazieresB , CombeB , Phan VanA , TondutJ , GrynfelttM . Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. Journal of Rheumatology2001;28(1):173‐81. SawitzkeAD , ShiH , FincoMF , DunlopDD , Bingham IIICO , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis and Rheumatism2008;58:3183‐91. ">Mazieres 2001</a>; <a href="./references#CD005614-bbs2-0023" title="MessierSP , MihalkoS , LoeserRF , LegaultC , JollaJ , PfruenderJ , et al. Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study. Osteoarthritis Cartilage2007;15(11):1256‐66. ">Messier 2007</a>: <a href="./references#CD005614-bbs2-0026" title="MorrealeP , ManopuloR , GalatiM , BoccaneraL , SaponatiG , BocchiL . Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. Journal of Rheumatology1996;23(8):1385‐91. ">Morreale 1996</a>; <a href="./references#CD005614-bbs2-0031" title="PavelkaK , CosteP , GéherP . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659–70. ">Pavelka 2010</a>; <a href="./references#CD005614-bbs2-0039" title="UebelhartD , ThonarEJ , DelmasPD , ChantraineA , VignonE . Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage1998;6(Suppl A):39‐46. ">Uebelhart 1998</a>; <a href="./references#CD005614-bbs2-0040" title="UebelhartD , MalaiseM , MarcolongoR , deVathaireF , PipernoM , MailleuxE , et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one‐year, randomized, double‐blind, multicenter study versus placebo. Osteoarthritis Cartilage2004;12(4):269‐76. ">Uebelhart 2004</a>; <a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>; <a href="./references#CD005614-bbs2-0033" title="RailhacJJ , ZaimM , SaurelAS , VialJ , FournieB . Effect of 12 months treatment with chondroitin sulfate on cartilage volume in knee osteoarthritis patients: A randomized, double‐blind, placebo‐controlled pilot study using MRI. Clinical Rheumatology2012;31(9):1347‐57. ">Railhac 2012</a>; <a href="./references#CD005614-bbs2-0043" title="ZegelsB , CrozesP , UebelhartD , BruyereO , ReginsterJY . Equivalence of a single dose (1200 mg) compared to a three‐time a day dose (400 mg) of chondroitin 4&amp;6 sulfate in patients with knee osteoarthritis. Results of a randomized double blind placebo controlled study. Osteoarthritis &amp; Cartilage2013;21(1):22‐7. ">Zegels 2012</a>) .Participants treated with chondroitin alone at a therapeutic dose of <b>≧</b>800 mg/day and in combination with other supplements such as glucosamine showed significantly better pain scores than those treated with a control or placebo in short‐ and long‐terms studies with an SMD ‐0.67, 95% CI ‐0.99 to ‐0.34; P &lt; 0.0001); absolute percent change 10% lower (14.6% lower to 5% lower) (<a href="#CD005614-fig-0007">Figure 7</a>). </p> <div class="figure" id="CD005614-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of comparison: 5 Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo or Control, outcome: 5.5 Pain on 0 to 100 scale (short‐ or long‐term) for CS dose &gt;= 800 mg/day." data-id="CD005614-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of comparison: 5 Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo or Control, outcome: 5.5 Pain on 0 to 100 scale (short‐ or long‐term) for CS dose &gt;= 800 mg/day. </p> </div> </div> </div> <p><b>2. Physical function (All studies</b> —<b>physical function):</b> Overall, before sensitivity analysis was performed, five studies provided data on physical function (<a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0017" title="KanzakiN , SaitoK , MaedaA , KitagawaY , KisoY , WatanabeK , et al. Effect of a dietary supplement containing glucosamine hydrochloride, chondroitin sulfate and quercetin glycosides on symptomatic knee osteoarthritis: a randomized, double‐blind, placebo‐controlled study. Journal of Science and Food Agriculture2012;92:862‐9. ">Kanzaki 2011</a>; <a href="./references#CD005614-bbs2-0023" title="MessierSP , MihalkoS , LoeserRF , LegaultC , JollaJ , PfruenderJ , et al. Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study. Osteoarthritis Cartilage2007;15(11):1256‐66. ">Messier 2007</a>; <a href="./references#CD005614-bbs2-0031" title="PavelkaK , CosteP , GéherP . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659–70. ">Pavelka 2010</a>; <a href="./references#CD005614-bbs2-0039" title="UebelhartD , ThonarEJ , DelmasPD , ChantraineA , VignonE . Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage1998;6(Suppl A):39‐46. ">Uebelhart 1998</a>). No significant difference was reported between chondroitin or a combination of chondroitin with other supplements and placebo or control (SMD ‐0.07, 95% CI ‐0.31 to 0.17) which equates to an absolute risk difference of ‐1% lower (‐6% lower to 3% higher; level of evidence, moderate). </p> <p>Sensitivity analyses demonstrated that results were robust with respect to allocation concealment, blinding, study size, study sponsor, and impact of use of non‐ITT analyses (<a href="./references#CD005614-fig-0121" title="">Analysis 9.2</a>; <a href="./references#CD005614-fig-0130" title="">Analysis 13.2</a>; <a href="./references#CD005614-fig-0139" title="">Analysis 17.2</a>; <a href="./references#CD005614-fig-0148" title="">Analysis 21.2</a>; <a href="./references#CD005614-fig-0157" title="">Analysis 25.2</a>; <a href="./references#CD005614-fig-0183" title="">Analysis 34.2</a>). Results were not robust to publication year, with one study published 1999 showing a statistically significant result for improvement in function in favour of the treatment group. </p> <p><b>3. Lequesne's index</b>: 10 studies provided data. Chondroitin with or without glucosamine was associated with statistically significantly better score on Lequesne's index compared to control or placebo, with a mean difference of 2.14 lower (95% CI 1.39 lower to 2.88 lower; p&lt;0.00001) and SMD of ‐0.48 (95% CI ‐0.72 to ‐0.24). </p> </section> <section id="CD005614-sec-0090"> <h4 class="title">SUMMARY OF SENSITIVITY ANALYSIS BY RISK OF BIAS AND OTHER CRITERIA</h4> <p><i>(See Tables 5‐25 and Tables 31‐34 under Data and Anayses.)</i> </p> <p>In summary, the beneficial effects of chondroitin on pain severity persisted when evidence was limited to studies with adequate blinding or studies using ITT analyses. On the other hand, pain reduction effects were smaller or were nonexistent when we limited data to studies with appropriate allocation concealment or a large study sample (&gt; 200) or to studies without pharmaceutical funding. </p> </section> <section id="CD005614-sec-0091"> <h4 class="title">SENSITIVITY ANALYSIS INCLUDING STUDIES WITH AN ESTIMATED STANDARD DEVIATION</h4> <p><i>(See Tables 26‐30 under Data and Anayses.)</i> </p> <p>In this analysis, along with studies that provided standard deviations in their results section, we included studies for which the standard deviation was not provided and was, therefore, estimated using the estimation method described in the Methods section. This analysis revealed significant differences in the results on the efficacy of chondroitin in several outcomes under each comparison group. </p> <p>In the chondroitin sulfate versus placebo group, five studies were added when we included estimated standard deviation studies (<a href="./references#CD005614-bbs2-0010" title="ConrozierT , VignonE . The efficacy of chondroitin sulfate in the treatment of the arthrosis of the hip joint. A double‐blind study versus placebo [Die Wirkung von Chondroitinsulfat bei der Behandlungder Hu¨ftgelenksarthrose: eine Doppelblindstudie gegen Placebo]. Litera Rheumatoiogica1992;14:69‐75. ">Conrozier 1992</a>; <a href="./references#CD005614-bbs2-0011" title="ConrozierT . Anti‐arthrosis treatments: efficacy and tolerance of chondroitin sulfates (CS 4&amp;6). Presse Med1998;27:1862‐5. ">Conrozier 1998</a>; <a href="./references#CD005614-bbs2-0018" title="L’HirondelJL . Clinical double‐blinded study with orally administered chondroitin sulfate versus placebo in patients with tibiofemoral gonarthrosis (125 patients) [Klinische Doppelblind‐Studie mit oral verabreichtem Chondroitinsulfatgegen Placebo bei der tibiofemoralen Gonarthrose (125 patients)]. Litera Rheumatologica1992;14:77‐84. ">L'Hirondel 1992</a>; <a href="./references#CD005614-bbs2-0001" title="AlekseevaLI , BenevolenskaiaLI , NasonovEL , ChichasovaNV , KariakinAN . Structum (chondroitin sulfate)—a new agent for the treatment of osteoarthrosis. Ter Arkh1999;71(5):51‐3. ">Alekseeva 1999</a>; <a href="./references#CD005614-bbs2-0003" title="AlekseevaLI , ArtemenkoNA , ZotkinEG , KudryavtcevaNV , LesnyakOM , MendelOI , et al. Rational selection of basal therapy in osteoarthritis. Results of the open randomized multicenter clinical trial of ARTRA preparation in Russia. Russkiy Meditsinskiy Journal2005;13(24):1637. ">Alekseeva 2005b</a>) for pain outcome and six studies for Lequesne's index (<a href="./references#CD005614-bbs2-0010" title="ConrozierT , VignonE . The efficacy of chondroitin sulfate in the treatment of the arthrosis of the hip joint. A double‐blind study versus placebo [Die Wirkung von Chondroitinsulfat bei der Behandlungder Hu¨ftgelenksarthrose: eine Doppelblindstudie gegen Placebo]. Litera Rheumatoiogica1992;14:69‐75. ">Conrozier 1992</a>; <a href="./references#CD005614-bbs2-0011" title="ConrozierT . Anti‐arthrosis treatments: efficacy and tolerance of chondroitin sulfates (CS 4&amp;6). Presse Med1998;27:1862‐5. ">Conrozier 1998</a>; <a href="./references#CD005614-bbs2-0018" title="L’HirondelJL . Clinical double‐blinded study with orally administered chondroitin sulfate versus placebo in patients with tibiofemoral gonarthrosis (125 patients) [Klinische Doppelblind‐Studie mit oral verabreichtem Chondroitinsulfatgegen Placebo bei der tibiofemoralen Gonarthrose (125 patients)]. Litera Rheumatologica1992;14:77‐84. ">L'Hirondel 1992</a>; <a href="./references#CD005614-bbs2-0001" title="AlekseevaLI , BenevolenskaiaLI , NasonovEL , ChichasovaNV , KariakinAN . Structum (chondroitin sulfate)—a new agent for the treatment of osteoarthrosis. Ter Arkh1999;71(5):51‐3. ">Alekseeva 1999</a>; <a href="./references#CD005614-bbs2-0012" title="DasA , Jr , HammadTA . Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage2000;8(5):343‐50. ">Das 2000</a>; <a href="./references#CD005614-bbs2-0032" title="RaiJ , PalSK , GulA , SenthilR , SinghH . Efficacy of chondroitin sulfate and glucosamine sulfate in the progression of symptomatic knee osteoarthritis: a randomized, placebo‐controlled, double‐blind study. Bulletin PGI2004;38:18‐22. ">Rai 2004</a>) . The addition of these studies did not affect the results for pain and Lequesne's index. </p> <p>In the comparison group of chondroitin sulfate versus control, one study was added (<a href="./references#CD005614-bbs2-0001" title="AlekseevaLI , BenevolenskaiaLI , NasonovEL , ChichasovaNV , KariakinAN . Structum (chondroitin sulfate)—a new agent for the treatment of osteoarthrosis. Ter Arkh1999;71(5):51‐3. ">Alekseeva 1999</a>). The addition of this study resulted in notable differences in the outcomes of pain and Lequesne's index. For pain, the main analysis revealed no significant difference between chondroitin sulfate and control (SMD ‐0.08, 95% CI ‐0.23 to 0.07; P = 0.29); this held true after <a href="./references#CD005614-bbs2-0001" title="AlekseevaLI , BenevolenskaiaLI , NasonovEL , ChichasovaNV , KariakinAN . Structum (chondroitin sulfate)—a new agent for the treatment of osteoarthrosis. Ter Arkh1999;71(5):51‐3. ">Alekseeva 1999</a> was added with an estimated standard deviation (SMD 0.34, 95% CI ‐0.85 to 0.18; P = 0.20). In the main analysis, Lequesne's index showed no significant difference between control and active treatment with a mean difference of ‐1.36 (95% CI ‐3.60 to 0.89; P = 0.24). After <a href="./references#CD005614-bbs2-0001" title="AlekseevaLI , BenevolenskaiaLI , NasonovEL , ChichasovaNV , KariakinAN . Structum (chondroitin sulfate)—a new agent for the treatment of osteoarthrosis. Ter Arkh1999;71(5):51‐3. ">Alekseeva 1999</a> was added to the meta‐analysis, however, these results switched with a mean difference of ‐1.99 (95% CI ‐3.27 to ‐0.70; P = 0.002). </p> <p>The sensitivity analysis revealed no noteworthy difference between active treatment and control in the glucosamine and chondroitin sulfate versus placebo comparison group after studies with estimated standard deviations were added (<a href="./references#CD005614-bbs2-0012" title="DasA , Jr , HammadTA . Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage2000;8(5):343‐50. ">Das 2000</a>). </p> <p>In the comparison group of chondroitin sulfate and glucosamine versus NSAIDs, the sensitivity analysis revealed notable changes in physical function, WOMAC stiffness, and WOMAC Total. For physical function, a moderate difference between the results of the main analysis and the results of the sensitivity analysis was observed, with the SMD increasing to ‐0.17 (95% CI ‐0.57 to 0.23; P = 0.41). In the outcome of stiffness on WOMAC, a slight difference was noted between the main analysis and the sensitivity analysis, with the mean difference decreasing to ‐8.49 (95% CI ‐14.52 to ‐2.46; P = 0.006). In WOMAC Total, a significant difference was observed, with the results switching from non significant to significant in favor of chondroitin (MD ‐6.94, 95% CI ‐12.86 to ‐1.01; P = 0.02). </p> <p>In the comparison arm of chondroitin with/without glucosamine versus placebo/control, a moderate difference in the results was noted after the addition of studies with estimated SDs (SMD ‐0.73, 95% CI ‐1.00 to ‐0.46; P &lt; 0.00001 for pain). Removing one study with a small standard deviation (<a href="./references#CD005614-bbs2-0019" title="LilaAM , MazurovVI , ShidlovskayaOV , ShostakMS . THERAFLEX in comprehensive therapy of knee osteoarthrosis and spinal osteochondrosis (results of a clinical trial). Russkiy Meditsinskiy Journal2005;13(24):1618. ">Lila 2005</a>), the SMD was ‐0.52 (95% CI, ‐0.71 to 0.33; I<sup>2</sup> = 82%) for pain.  </p> <p><b>Studies Not Included in Data Analyses</b> </p> <p><a href="./references#CD005614-bbs2-0029" title="NguyenP , MohamedSE , GardinerD , SalinasT . A randomized double‐blind clinical trial of the effect of chondroitin sulfate and glucosamine hydrochloride on temporomandibular joint disorders: a pilot study. Cranio2001;19(2):130‐9. ">Nguyen 2001</a> studies the efficacy of chondroitin sulfate and glucosamine hydrochloride in participants diagnosed with capsulitis, disk displacement, disk dislocation, or painful osteoarthritis of the temporomandibular joint (TMJ). This study found no statistically significant decrease in the VAS pain ratings of participants treated with chondroitin sulfate‐glucosamine hydrochloride, although it did find that participants in the placebo group experienced a statistically significant decrease in their pain ratings. In the outcome of the McGill Pain Questionnaire (MPQ), again no statistically significant change was observed in the sensory, affective, miscellaneous, total, and number of words pain rating indices in the chondroitin sulfate‐glucosamine hydrochloride group. Only in the evaluative Pain Rating index was a significant decrease seen in the pain rating, which changed from 3.4 to 2.4. It is interesting to note that participants in the placebo group again underwent statistically significant changes in sensory, evaluative, miscellaneous, and number of words Pain Rating indices. In the placebo group, the evaluative pain rating also decreased from 3.1 to 2. In summary, this study showed that participants treated with chondroitin sulfate‐glucosamine hydrochloride showed improvement in one scale of the MPQ, and participants treated with placebo experienced statistically significant improvement on four scales of the MPQ. In measures of mood and functioning, the results were again interesting, as participants in the chondroitin sulfate‐glucosamine hydrochloride group showed slight worsening of their mood and functioning score, although this decrease was not statistically significant. Participants in the placebo group, on the other hand, showed improvement in their mood and functioning, although this was not significant either. In the outcome of TMJ palpation score, participants in the chondroitin sulfate‐glucosamine hydrochloride group showed a statistically significant decrease, and those in the placebo group did not. In the outcome of myofascial pain, no statistically significant improvement was observed in the placebo group or the active group. In the outcome of jaw range of motion, no statistically significant improvement was observed. However, this study did show that chondroitin sulfate‐glucosamine hydrochloride participants took statistically significantly less medication per day than those in the placebo group (1.42 in the placebo group vs 0.72 in the active group).<br/> <br/> <a href="./references#CD005614-bbs2-0036" title="RovettaG , MontefortP , MolfettaG , BalestraV . A two‐year study of chondroitin sulfate in erosive osteoarthritis of the hands: behavior of erosions, osteophytes, pain and hand dysfunction. Drugs Under Experimental and Clinical Research2004;XXX(1):11‐6. ">Rovetta 2004</a> studies the efficacy of chondroitin at 800 mg daily plus naproxen versus naproxen alone in participants with erosive osteoarthritis of the hands. This study found that participants in the active and placebo groups showed worsening in their scores on nearly all outcomes as compared with baseline. In the outcomes of degree of erosion, Heberden and Bouchard nodes, and Dreiser index scores, the treated group showed significant worsening, and the Patient and Physician global assessment showed no significant change. The untreated group also showed significant worsening in degree of erosion, Heberden and Bourchard nodes, Dreiser index, and Physician and Patient global assessment scores. Using the Mann‐Whitney test, the authors concluded at the end of the study that the results show less worsening in study outcomes in the treated group than in the placebo group. </p> <p><a href="./references#CD005614-bbs2-0035" title="RovettaG , MonteforteP , MolfettaG , BalestraV . Chondroitin sulfate in erosive osteoarthritis of the hands. International Journal of Tissue Reactions2002;24(1):29‐32. ">Rovetta 2002</a> is a study conducted to evaluate the effect of 800 mg of chondroitin sulfate in combination with naproxen per day on the joint count for erosions in participants with erosive osteoarthritis of the hands as compared with naproxen alone. In both the active group and the placebo group, the general tendency for the joint count was for erosion to increase over time. Progression of erosion over 24 months, however, was significantly less for participants in the chondroitin sulfate–treated group than for those treated with naproxen alone. After the first year, although 11 of the 12 participants in the chondroitin sulfate group had remained at the same joint erosion count, only six in the placebo group had done so. Although only one participant in the chondroitin sulfate group increased by one erosive joint count, five participants in the naproxen alone group experienced a one‐count increase in the number of their erosive joints. The authors concluded that the difference between participants with erosive joint count increases and those without in group B versus group A is statistically significant.<br/> <br/> <a href="./references#CD005614-bbs2-0004" title="AlekseevaLI . Results of an open comparative randomized clinical trial to assess efficacy and safety of two regimens of treatment with Theraflex preparation in knee osteoarthritis patients. Russkiy Meditsinskiy Journal2008;16(5):316. ">Alekseeva 2008</a> studied the efficacy of chondroitin sulfate plus glucosamine administered daily for nine months ("constant therapy") versus the efficacy of the two supplements administered for three‐month cycles with a treatment‐free cycle between the two treated three‐month cycles. The study revealed no significant difference between constant and intermittent treatment groups in WOMAC Total, physical function, pain and stiffness scales, or in the time it took to complete a 10‐feet week at the end of the 12‐month trial. </p> <p><a href="./references#CD005614-bbs2-0020" title="Magrans‐CourtneyT , WilbornC , RasmussenC , FerreiraM , GreenwoodL , CampbellB , et al. Effects of diet type and supplementation of glucosamine, chondroitin, and MSM on body composition, functional status, and markers of health in women with knee osteoarthritis initiating a resistance‐based exercise and weight loss program. Journal of International Society of Sports Medicine2011;8:8. ">Magrans‐Courtney 2011</a> is a study undertaken to evaluate the efficacy of glucosamine and chondroitin sulfate in combination with a 14‐week exercise program and one of two different diet programs. All participants participated in a 14‐week exercise plan. Simultaneously, participants were randomly assigned to receive a high‐protein or a high‐carbohydrate diet program. Then, they were randomly assigned to receive a placebo or 1500 mg of glucosamine, 1200 mg of chondroitin, and 900 mg of methylsulfonylmethane (MSM) daily. The study found that participants in all groups experienced improvement in their physical functioning test, as well as on WOMAC, VAS, and quality of life measures. However, the authors do not note any significant correlation between the use of chondroitin sulfate, glucosamine, and MSM and improvement on these scales, stating, "no significant differences [were] observed among diet and supplement groups," which would indicate such a correlation.<br/> <br/> <a href="./references#CD005614-bbs2-0013" title="DebiR . Glucosamine sulfate and chondroitin sulfate for degenerative joint disease. Harefuah2000;138:451. ">Debi 2000</a> studied the efficacy of glucosamine sulfate and chondroitin sulfate in participants suffering from osteoarthritis. The authors reported on the outcome of Patient global assessment, finding that participants treated with glucosamine and chondroitin sulfate had significantly better global assessments than those treated with placebo. </p> <p><a href="./references#CD005614-bbs2-0009" title="CohenM , WolfeR , MaiT , LewisD . A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. Journal of Rheumatology2003;30(3):523‐8. ">Cohen 2003</a> studied the efficacy of a chondroitin cream versus a cream containing placebo. Participants in the chondroitin sulfate in combination with glucosamine group had significantly lower (better) pain scores on VAS (0 to 100 mm) after eight weeks. Those treated with chondroitin sulfate also had improved scores on pain on the WOMAC and SF‐36 scales. </p> <p><a href="./references#CD005614-bbs2-0014" title="FardelloneP , ZaimM , SaurelAS , MaheuE . Comparative efficacy and safety study of two chondroitin sulfate preparations from different origin (avian and bovine) in symptomatic osteoarthritis of the knee. The open rheumatology journal2013;7(1):1‐12. ">Fardellone 2013</a> compared two chondroitin preparations, Structum® 500 mg twice daily or Chondrosulf® 400 mg three times daily over a 24‐week duration. There was no control group or placebo group. </p> <p><a href="./references#CD005614-bbs2-0034" title="RaynauldJP , Martel‐PelletierJ , DoraisM , HaraouiB , ChoquetteD , AbramF , et al. Total Knee Replacement as a Knee Osteoarthritis Outcome: Predictors Derived from a 4‐Year Long‐Term Observation following a Randomized Clinical Trial Using Chondroitin Sulfate. Cartilage2013;4(3):219‐26. ">Raynauld 2013</a> was a long‐term follow‐up study of <a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>, that assessed 4‐year outcome of total knee replacement. Two groups of patients were treated with chondroitin or placebo once daily for the first 6 months (double‐blind phase) followed by 6 months of treatment with 800 mg chondroitin sulfate once daily for both groups (open‐label phase). Thirteen patients underwent total knee replacement at 4‐years, 9/34 in the placebo and 4/35 in the chondroitin group.  However since both patient groups were exposed to chondroitin, data from this study could not be used. However, the rates of arthroplasty seemed to be trending towards a difference between groups. </p> <p><b>FDA and EMEA on Chondroitin</b> </p> <p>The U.S. FDA focused its recent review on the efficacy of chondroitin in reducing the risk of osteoarthritis and “....tentatively concluded that a relationship between glucosamine and chondroitin sulfate and a reduced risk of osteoarthritis is not established" (<a href="./references#CD005614-bbs2-0119" title="Food , DrugAdministration . Glucosamine and chondroitin sulfate: scientific evaluation. http://www.fda.gov/ohrms/dockets/ac/04/briefing/4045b1_05‐conclusions.htm (accessed on 06 September 2012). ">FDA 2004b</a>). </p> <p>In 2004, the FDA reviewed health claims from Weider Nutrition International, Inc., regarding glucosamine and chondroitin sulfate, and osteoarthritis, joint degeneration, cartilage deterioration, and osteoarthritis‐related joint pain, tenderness, and swelling (<a href="./references#CD005614-bbs2-0118" title="FDA . Letter regarding the relationship between the consumption of glucosamine and/or chondroitin sulfate and a reduced risk of osteoarthritis; osteoarthritis‐related joint pain, joint tenderness, and joint swelling; joint degeneration; and cartilage deterioration (Docket No. 2004P‐0059). http://www.fda.gov/food/labelingnutrition/labelclaims/qualifiedhealthclaims/ucm073400.htm (accessed on 06 September 2012). ">FDA 2004a</a>). The FDA rejected these claims.  </p> <p>The FDA did not evaluate the safety of chondroitin, citing “...the Agency did not perform a full safety review and make its own determination on this issue. It was not necessary for FDA to do so because the Agency is denying the proposed claims for lack of credible evidence, as discussed in section II below.”  We could not find any other safety data on the FDA website. A similar search on EMEA website revealed a waiver to Bioiberica S.A., Spain, but no information related to adverse events was provided.  </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD005614-sec-0092" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD005614-sec-0092"></div> <section id="CD005614-sec-0093"> <h3 class="title" id="CD005614-sec-0093">Summary of main results</h3> <p>Overall, 43 trials were included in this meta‐analysis, of which 30 contributed data to meta‐analyses for clinical outcomes analyzed. Of these 30 studies, 18 assessed the efficacy of chondroitin sulfate in comparison with placebo, three assessed chondroitin sulfate in comparison with control, seven assessed chondroitin sulfate and glucosamine in comparison with placebo, and eight assessed chondroitin sulfate in combination with glucosamine in comparison with control (some studies had more than one active intervention arm). Three studies presented data on more than one of the comparison groups in this meta‐analysis. <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a> and <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a> (a follow‐up of Clegg 2006) compared the efficacy of chondroitin versus placebo, chondroitin and glucosamine versus placebo, and chondroitin and glucosamine versus active control. <a href="./references#CD005614-bbs2-0037" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , BinghamCOIII , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis Rheum2008;58:3183‐91. ">Sawitzke 2008</a> compared the efficacy of chondroitin versus placebo and of chondroitin and glucosamine versus active control. Chondroitin (alone or in combination with glucosamine) seemed to be more effective for pain than the comparator among these studies and seemed to be well tolerated. Even though adverse events reporting by most trials was not very detailed, very few participants in either treatment groups reported adverse events. </p> <p>Eleven studies (with 12 reports; <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a> was a follow‐up of <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a> provided data on pain for chondroitin versus placebo, the first major outcome. These data showed that those treated with chondroitin sulfate alone had statistically significantly better scores on pain than those treated with placebo with a mean difference of ‐10.1 mm (95% CI ‐14.1 to ‐4.9) between chondroitin and placebo for pain on 0‐100 scale in studies less than 6 months. The corresponding standardized mean difference was ‐0.51 (95% CI, ‐0.74 to ‐0.23) and absolute risk difference ‐9% (95% CI, ‐14% to ‐5%) between chondroitin sulfate alone vs. placebo. Standardized mean difference was ‐0.63 (95% CI, ‐0.93 to ‐0.33) for pain for chondroitin with/without glucosamine vs. placebo; this equals mean difference of ‐9.96 mm (95% CI ‐15.86 to ‐0.34). The risk of bias was high and the level of evidence was low. A common statistic used in non‐Cochrane literature is effect size, such as Cohen's effect size, which is conceptually similar to standardized mean difference in its depiction of the influence of the effects of the experimental treatment. Cohen's effect size categorizes an effect size of 0.20 as small, 0.50 as medium, and 0.80 as large (<a href="./references#CD005614-bbs2-0108" title="CohenJ . A power primer. Psychological Bulletin1992;112:115‐59. ">Cohen 1992</a>). Based on this categorization, the observed standardized mean difference of ‐0.51 for pain corresponded to a medium/moderate effect size with chondroitin alone and ‐0.63 corresponding with medium/moderate effect size with chondroitin with/without glucosamine. </p> <p>Analyses of pain studies has shown a reduction of pain between 0.9‐1.3 cm on a 0‐10 cm pain scale is clinically meaningful (<a href="./references#CD005614-bbs2-0132" title="KellyAM . Does the clinically significant diVerence in VAS pain score diVer with age, gender or cause of pain?. Acad Emerg Med1998;5:1086‐90. ">Kelly 1998</a>; <a href="./references#CD005614-bbs2-0133" title="KellyAM . The minimum clinically significant difference in visual analogue scale pain score does not differ with severity of pain. Emerg Med J2001;18(3):205‐7. ">Kelly 2001</a>; <a href="./references#CD005614-bbs2-0150" title="ToddKH . Clinical versus statistical significance in the assessment of pain relief. Ann Emerg Med1996;27(4):439‐41. ">Todd 1996</a>), and as expected lower than the thresholds for "much improved" pain thresholds (<a href="./references#CD005614-bbs2-0117" title="FarrarJT , YoungJP , Jr , LaMoreauxL , WerthJL , PooleRM . Clinical importance of changes in chronic pain intensity measured on an 11‐point numerical pain rating scale. Pain2001;94(2):149‐58. ">Farrar 2001</a>; <a href="./references#CD005614-bbs2-0116" title="FarrarJT . What is clinically meaningful: outcome measures in pain clinical trials. Clin J Pain.2000;16(2 Suppl):S106‐12. ">Farrar 2000</a>). The clinically meaningful threshold of 1 cm reduction in pain intensity was also endorsed by the The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) (<a href="./references#CD005614-bbs2-0113" title="DworkinRH , TurkDC , WyrwichKW , BeatonD , CleelandCS , FarrarJT , et al. Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations. J Pain2008;9:105–21. ">Dworkin 2008</a>). Using the threshold of 0.9 cm on 0‐10 cm scale for a clinical meaningful improvement, chondroitin alone or in combination with glucosamine led to clinically meaningful and statistically significantly improvement in pain, compared to placebo. The absolute improvements shown in the Summary of Findings tables of 9‐10% also meet the clinically meaningful change threshold. One should note that the actual improvement with chondroitin alone or in combination with glucosamine was higher, given that 0.9 represents the difference between chondroitin (with/without glucosamine) and placebo/control groups. However, assessments of quality of evidence using GRADE method (see summary of findings table) indicated that several studies reporting on pain suffered from low quality of evidence; thus, we performed further sensitivity analyses to detect the influence of study quality on this observed effect from pain. </p> <p>When stratified by study size, for example, studies with large sample sizes (100 or more) found no statistically significant difference in the pain scores of participants treated with chondroitin and those treated with placebo, but studies with smaller sample sizes showed a statistically significant difference in favor of chondroitin. With the exception of three studies, most studies had a sample size of fewer than 100. Stratification by study sponsorship further revealed that studies that were not funded by a manufacturer of chondroitin showed no significant difference between chondroitin and placebo, but among studies sponsored by a manufacturer of chondroitin, participants treated with chondroitin showed significantly better pain scores than those treated with placebo. However, sensitivity analysis by the blinding method or the ITT confirmed our initial results in favor of chondroitin, with studies that had adequate blinding methods and those using ITT analyses finding that participants treated with chondroitin sulfate had statistically significantly better pain ratings than those treated with placebo. </p> <p>These sensitivity analyses indicate that the effects of chondroitin are variable in sensitivity analyses that adjust for study quality and/or funding source. The standardized mean differences varied from small‐medium and statistically significant overall in some sensitivity analyses to minimal to nonexistent and statistically insignificant in others. Statistically insignificant results were seen particularly in studies with large sample sizes, independent sources of funding, and adequate methods of allocation concealment that did not show any statistically significant difference between the pain scores of participants treated with chondroitin and those treated with placebo. </p> <p>The studies also showed better Lequesne's index scores (range 0‐24) in patients receiving chondroitin compared to control/placebo with effect sizes of ‐0.52 with chondroitin and ‐0.48 with chondroitin with/without glucosamine (2.1 or 1.9 unit difference), compared to placebo. This corresponded to small to medium effect size benefit with chondroitin, and seemed clinically meaningful (though no published MCID threshold, a 2‐point difference on this scale corresponds to ˜10% or more improvement in one group compared to the other). </p> <p>Of the 28 studies assessing chondroitin versus placebo, only two provided data for WOMAC MCII (<a href="./references#CD005614-bbs2-0016" title="KahanA , UebelhartD , DeVathaireF , DelmasPD , ReginsterJY . Long‐term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2009;60(2):524‐33. ">Kahan 2009</a> and <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>). This is not surprising because this outcome has been defined recently, and many studies precede the description of this outcome; many others published since then have reported pain on various scales as the primary outcome. When chondroitin was compared with placebo, a significantly greater number of participants treated with chondroitin attained clinically meaningful and statistically significant improvement on WOMAC in pain than those treated with placebo (RR 1.12, 95% CI 1.01 to 1.24; P = 0.04). </p> <p>Other outcomes that were significantly better in the chondroitin group compared with the placebo group were the patient and physician global assessments. Significantly higher proportions of participants reported very good or excellent on the global assessment in the chondroitin group compared with the placebo group. </p> <p>For a few outcomes, the data reveal that participants treated with chondroitin had statistically significant improvement as compared with those treated with placebo. For instance, participants in the chondroitin sulfate group experienced statistically significantly less loss of cartilage volume in global, lateral compartment, tibial plateaus and medial tibial plateaus, and less reduction in minimal joint space narrowing. However, among studies that found a statistically significantly positive effect with chondroitin for these various outcomes, heterogeneity was moderate, and factors that affect the study's quality, such as size and independence of funding, were generally low quality. </p> <p>In nearly all other outcomes, including physical function, stiffness, grip strength, morning stiffness, global assessment on VAS (mm), change in bone marrow lesion scores of several different compartments, OMERACT‐OARSI, HAQ Disability, HAQ continuous, HAQ MCID scores, and both mental and physical components of SF‐36, no statistically significant difference between chondroitin and placebo was noted. </p> <p>Of the 43 studies contributing data to this systematic review and meta‐analysis, seven studies assessed the efficacy of chondroitin sulfate in combination with glucosamine versus placebo. Among these studies, five provided data on some measure of pain. When data were not stratified by any of our considered factors, the studies showed no statistically significant difference between pain scores for participants in the placebo group compared with those in the chondroitin in combination with glucosamine group. Stratification by blinding, study size, study sponsors, and publication year confirmed these results, showing again no significant difference between chondroitin sulfate in combination with glucosamine and placebo in any of the subgroups. For other outcomes, no significant difference between chondroitin and placebo was reported, except in the number of participants achieving OMERACT‐OARSI responder status; significantly more participants achieved OMERACT‐OARSI responder status in the chondroitin in combination with glucosamine group than in the placebo group and had significantly better scores on balance than those in the placebo group. Few studies provided data on efficacy outcomes in this comparison arm, and only one study reported under many of the outcomes, making the authors' conclusions less reliable than desired. </p> <p>Of the 43 studies contributing data, eight studies provided data that compared the efficacy of chondroitin in combination with glucosamine (along with NSAIDs) with the efficacy of NSAIDs or another active control alone. These studies allowed for the concomitant use of NSAIDs along with chondroitin and glucosamine and assessed whether the use of chondroitin in combination with glucosamine and NSAIDs was more effective than the use of NSAIDs alone. Four studies provided data on pain in this comparison arm. Participants in the chondroitin sulfate in combination with glucosamine and NSAIDs group had statistically significantly lower pain scores than those in the NSAIDs control group before sensitivity analysis. Heterogeneity was statistically significant among the studies. Sensitivity analysis by blinding method showed that studies that reported adequate blinding did not find a statistically significant difference between the use of NSAIDs in combination with chondroitin and glucosamine and alone. Studies that were not blinded, however, reported that those treated with chondroitin in combination with glucosamine and NSAIDs scored statistically significantly better on pain scales than those taking NSAIDs alone. Moreover, sensitivity analysis by study size revealed that those studies with large sample sizes (more than 100) showed no statistically significant difference between therapy with NSAIDs in combination with chondroitin and glucosamine and NSAIDs alone, and studies with small sample sizes did reveal such a statistically significant difference. This shows again that studies of higher quality (large sample sizes and adequate methods of allocation concealment) detected no statistically significant difference between chondroitin and placebo. No statistically significant difference was noted between the active and control groups in any other outcomes, except WOMAC stiffness and Patient and Physical global assessments of good to very good, where the studies revealed that participants treated with chondroitin and glucosamine in combination with NSAIDs did have statistically significantly better scores than those treated with NSAIDs alone. However, heterogeneity was high among these studies. Moreover, most outcomes that did not show a significant difference between active treatment and placebo were populated by studies of higher methodological quality, and those that did show a statistically significant difference were populated by studies with significant between‐study heterogeneity and typically lower methodological quality. </p> <p>We also performed data analysis combining all studies that reported on pain and physical function without differentiating between the various compositions of their treatment arms, as long as chondroitin was included in the intervention arm. For pain, this sensitivity analysis revealed that participants treated with chondroitin alone or in combination with another supplement including glucosamine in most instances scored statistically significantly better on pain scales than those treated with placebo or control (SMD ‐0.65, 95% CI ‐0.95 to ‐0.35; P &lt; 0.00001), which translated into an absolute risk difference of ‐9.6 (95% CI ‐14 to ‐5.2) on a 0 to 100 scale (<a href="./references#CD005614-fig-0108" title="">Analysis 5.1</a>). A similar result was found when we restricted the analysis to studies with a dose of chondroitin ≧800 mg/day, the therapeutic dose, with an SMD ‐0.67, 95% CI ‐0.99 to ‐0.34; P &lt; 0.0001); absolute percent change 10% lower (14.6% lower to 5% lower). Our previous conclusion was again confirmed in this analysis, when all studies were combined and stratified by study size. Studies that had large sample sizes showed no significant difference between chondroitin and placebo, and studies with small sample sizes showed that participants treated with chondroitin alone or in combination with other supplements scored better on pain scales than those treated with a placebo or control. These results were replicated in our sensitivity analysis by source of funding and allocation concealment, showing that higher‐quality studies found no statistically significant difference between participants treated with chondroitin alone or in combination with other supplements such as glucosamine and placebo or control. In the outcome of physical function, no statistically significant difference was noted between participants treated with chondroitin alone or in combination with other supplements such as glucosamine (P = 0.52 before the sensitivity analysis), and these results were confirmed in our sensitivity analysis. </p> </section> <section id="CD005614-sec-0094"> <h3 class="title" id="CD005614-sec-0094">Overall completeness and applicability of evidence</h3> <p>The evidence presented herein is up to date. Furthermore, the data presented here are taken from a large number of studies that span a long range of time for their publication. The review authors compared their list of included studies with those of other published reviews and meta‐analyses to ensure the inclusion of all relevant studies. In this process, we discovered several studies, which, although they assessed the efficacy of chondroitin, did not offer data that could be used in our meta‐analysis. <a href="./references#CD005614-bbs2-0009" title="CohenM , WolfeR , MaiT , LewisD . A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. Journal of Rheumatology2003;30(3):523‐8. ">Cohen 2003</a> assessed the efficacy of a chondroitin sulfate cream and since chondroitin was not orally administered chondroitin sulfate, the study could not be used. <a href="./references#CD005614-bbs2-0096" title="VertkinAL , NaumovAV . Deforming osteoarthrosis: strategy of treatment in patients with co‐morbidities. Russkiy Meditsinskiy Journal2007;15(4):319. ">Vertkin 2007</a> had an obvious mismatch in study data and therefore could not be used. <a href="./references#CD005614-bbs2-0012" title="DasA , Jr , HammadTA . Efficacy of a combination of FCHG49 glucosamine hydrochloride, TRH122 low molecular weight sodium chondroitin sulfate and manganese ascorbate in the management of knee osteoarthritis. Osteoarthritis Cartilage2000;8(5):343‐50. ">Das 2000</a> divided its participants by the severity of their osteoarthritis and presented separate data for severe and moderate/mild cases of osteoarthritis; therefore, we estimated overall scores using these numbers. <a href="./references#CD005614-bbs2-0029" title="NguyenP , MohamedSE , GardinerD , SalinasT . A randomized double‐blind clinical trial of the effect of chondroitin sulfate and glucosamine hydrochloride on temporomandibular joint disorders: a pilot study. Cranio2001;19(2):130‐9. ">Nguyen 2001</a> had a before and after trial design; therefore, only its safety data were used, and the rest of the study results are summarized above, at the end of the <a href="./full#CD005614-sec-0073">Results</a> section. <a href="./references#CD005614-bbs2-0001" title="AlekseevaLI , BenevolenskaiaLI , NasonovEL , ChichasovaNV , KariakinAN . Structum (chondroitin sulfate)—a new agent for the treatment of osteoarthrosis. Ter Arkh1999;71(5):51‐3. ">Alekseeva 1999</a>; <a href="./references#CD005614-bbs2-0010" title="ConrozierT , VignonE . The efficacy of chondroitin sulfate in the treatment of the arthrosis of the hip joint. A double‐blind study versus placebo [Die Wirkung von Chondroitinsulfat bei der Behandlungder Hu¨ftgelenksarthrose: eine Doppelblindstudie gegen Placebo]. Litera Rheumatoiogica1992;14:69‐75. ">Conrozier 1992;</a><a href="./references#CD005614-bbs2-0011" title="ConrozierT . Anti‐arthrosis treatments: efficacy and tolerance of chondroitin sulfates (CS 4&amp;6). Presse Med1998;27:1862‐5. ">Conrozier 1998</a>; <a href="./references#CD005614-bbs2-0018" title="L’HirondelJL . Clinical double‐blinded study with orally administered chondroitin sulfate versus placebo in patients with tibiofemoral gonarthrosis (125 patients) [Klinische Doppelblind‐Studie mit oral verabreichtem Chondroitinsulfatgegen Placebo bei der tibiofemoralen Gonarthrose (125 patients)]. Litera Rheumatologica1992;14:77‐84. ">L'Hirondel 1992</a>; and <a href="./references#CD005614-bbs2-0032" title="RaiJ , PalSK , GulA , SenthilR , SinghH . Efficacy of chondroitin sulfate and glucosamine sulfate in the progression of symptomatic knee osteoarthritis: a randomized, placebo‐controlled, double‐blind study. Bulletin PGI2004;38:18‐22. ">Rai 2004</a> did not provide standard deviations in their data reports and could not be used in the main meta‐analysis, except with categorical outcomes. As has been done previously in the systematic review and meta‐analysis published by <a href="./references#CD005614-bbs2-0146" title="ReichenbachS , SterchiR , SchererM , TrelleS , BurglE , BurglU , et al. Meta‐analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine2007;146:580‐90. ">Reichenbach 2007</a>, we estimated standard deviations using the formula presented in <a href="#CD005614-fig-0001">Figure 1</a> and performed a sensitivity analysis, in which we included all studies with estimated standard deviations as well. </p> <p>In studies that were included in the data analysis of this review, we made sure to confirm the accuracy of studies with suspect data, such as data presented that appeared more like standard errors than standard deviations, despite the article's claims that they were standard deviations. In these instances, we contacted the authors of the study to double‐check the accuracy of the data and indeed found and corrected several such errors. </p> <p>Furthermore, because the current review assesses the efficacy of not only chondroitin sulfate in comparison with an inert placebo but also chondroitin sulfate in combination with glucosamine and in comparison with NSAIDs, the evidence applies to a broader range of clinical practice. Additionally, we performed numerous sensitivity analyses to try to more completely understand our results. In fact, as our conclusion suggests, the sensitivity analyses performed offer indispensable insight into the efficacy of chondroitin, as the sensitivity analyses show that studies with higher methodological quality show no significant difference between chondroitin and placebo or control. </p> <p><b>Search for unpublished studies </b> </p> <p>Because (1) the funnel plot suggested publication bias and (2) we noted two radiographic studies, both with positive data, we contacted IBSA, the manufacturer of chondroitin sulfate and a supporter of several of these studies, on July 30, 2013 to request all unpublished radiographic data. In its response, dated July 30, 2013, IBSA provided us with five published studies, all of which had been considered in the screening process. They also responded that no radiographic data related to chondroitin from their studies were unpublished. </p> </section> <section id="CD005614-sec-0095"> <h3 class="title" id="CD005614-sec-0095">Quality of the evidence</h3> <p>The quality of the evidence presented in the various studies here may be limited by the fact that heterogeneity between the studies was rather large, and various subscales of an outcome were normalized and used in one overall outcome. For instance, pain on WOMAC, pain on VAS, and pain on the Japanese Orthopedic Association (JOA) scale were normalized and presented as one overall pain outcome. The decision to combine various subscales of an outcome was made a priori because a high degree of heterogeneity among the studies was suspected for the scales used to present data, thus hindering the execution of a fruitful meta‐analysis. Several studies in the past have looked at multiple pain scales including numeric rating scales and visual analogue scales and have determined that they provide similar information and are comparable (<a href="./references#CD005614-bbs2-0106" title="BreivikH , BorchgrevinkPC , AllenSM , RosselandLA , RomundstadL , HalsEK , et al. Assessment of pain. Br J Anaesth2008;101(1):17‐24. ">Breivik 2008</a>; <a href="./references#CD005614-bbs2-0122" title="Ferreira‐ValenteMA , Pais‐RibeiroJL , JensenMP . Validity of four pain intensity rating scales. Pain2011;152(10):2399‐404. ">Ferreira‐Valente 2011</a>). </p> <p>Furthermore, the methodological quality of several studies included in the meta‐analysis was low. Although most of the studies reported adequate blinding methods and performed appropriate ITT analyses, these authors did not report adequate methods of allocation concealment or randomization. Moreover, most of the studies were funded by manufacturers of chondroitin sulfate, such as IBSA, Rexall Sundown Inc., etc. The degree to which the involvement of chondroitin manufacturers played a role in these studies was not definitively clear. The quality of the evidence from many of these studies was further compromised because study authors did not clearly describe blinding and allocation concealment. </p> <p>Several other studies with no sponsorship from chondroitin sulfate manufacturers had large sample sizes and minimal amounts of bias, such as <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0016" title="KahanA , UebelhartD , DeVathaireF , DelmasPD , ReginsterJY . Long‐term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2009;60(2):524‐33. ">Kahan 2009</a>; <a href="./references#CD005614-bbs2-0023" title="MessierSP , MihalkoS , LoeserRF , LegaultC , JollaJ , PfruenderJ , et al. Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study. Osteoarthritis Cartilage2007;15(11):1256‐66. ">Messier 2007</a>; and <a href="./references#CD005614-bbs2-0040" title="UebelhartD , MalaiseM , MarcolongoR , deVathaireF , PipernoM , MailleuxE , et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one‐year, randomized, double‐blind, multicenter study versus placebo. Osteoarthritis Cartilage2004;12(4):269‐76. ">Uebelhart 2004</a>. These four studies clearly described adequate methods of randomization, allocation concealment, blinding, and handling of missing outcome data, although the remaining studies are unclear in addressing at least one key source of bias, and in most of the studies, more than half of these factors of bias were not described. Additionally, we did not have access to enough information such as complete study protocols to make definitive judgments regarding the risk of selective reporting. Thus, we performed sensitivity analysis by blinding, study size, publication year, source of funding and ITT to detect the impact of such biases on our main results. </p> </section> <section id="CD005614-sec-0096"> <h3 class="title" id="CD005614-sec-0096">Potential biases in the review process</h3> <p>The quality of the information arrived at in this meta‐analysis herein is by and large sound. All data and risk of bias assessments were performed by two independent review authors. The accuracy of the data was cross‐checked by two research associates (KM, PF). Furthermore, as noted, possible inaccuracies in any part of the article's presentation of data were inquired about from the authors of the study and, when instructed by these authors, corrected. </p> </section> <section id="CD005614-sec-0097"> <h3 class="title" id="CD005614-sec-0097">Agreements and disagreements with other studies or reviews</h3> <p>In this meta‐analysis, most of the published studies detected a statistically significant positive effect on pain. However, sensitivity analyses showed that the effect of chondroitin was persisted in some sensitivity analyses (those with adequate blinding and ITT analyses), but not in other sensitivity analyses. Current guidelines of the ACR, using the GRADE approach, discourage the use of supplements because of lack of evidence from high‐quality trials (<a href="./references#CD005614-bbs2-0130" title="HochbergMC , AltmanRD , AprilKT , BenkhaltiM , GuyattG , McGowanJ , et al. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Research (Hoboken)2012;64(4):465‐74. ">Hochberg 2012</a>). </p> <p>Other recently published meta‐analyses have reported similar findings, with fewer trials, some with a different interpretation. For instance, in a meta‐analysis of 21 studies (<a href="./references#CD005614-bbs2-0001" title="AlekseevaLI , BenevolenskaiaLI , NasonovEL , ChichasovaNV , KariakinAN . Structum (chondroitin sulfate)—a new agent for the treatment of osteoarthrosis. Ter Arkh1999;71(5):51‐3. ">Alekseeva 1999</a>; <a href="./references#CD005614-bbs2-0006" title="BourgeoisP , ChalesG , DehaisJ , DelcambreB , KuntzJL , RozenbergS . Efficacy and tolerability of chondroitin sulfate 1200 mg/day vs chondroitin sulfate 3 × 400 mg/day vs placebo. Osteoarthritis Cartilage1998;6(Suppl A):25‐30. ">Bourgeois 1998</a>; <a href="./references#CD005614-bbs2-0007" title="BucsiL , PoorG . Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow‐acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis. Osteoarthritis Cartilage1998;6(Suppl A):31‐6. ">Bucsi 1998</a>; <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a>; <a href="./references#CD005614-bbs2-0010" title="ConrozierT , VignonE . The efficacy of chondroitin sulfate in the treatment of the arthrosis of the hip joint. A double‐blind study versus placebo [Die Wirkung von Chondroitinsulfat bei der Behandlungder Hu¨ftgelenksarthrose: eine Doppelblindstudie gegen Placebo]. Litera Rheumatoiogica1992;14:69‐75. ">Conrozier 1992</a>; <a href="./references#CD005614-bbs2-0011" title="ConrozierT . Anti‐arthrosis treatments: efficacy and tolerance of chondroitin sulfates (CS 4&amp;6). Presse Med1998;27:1862‐5. ">Conrozier 1998</a>; <a href="./references#CD005614-bbs2-0061" title="FleischAM , MerlinC , ImhoffA , HodlerJ , KisslingR . A one‐year randomized, double‐blind, placebo‐controlled study with oral chondroitin sulfate in patients with knee osteoarthritis. Osteoarthritis Cartilage1997;5(Suppl A):S70. ">Fleisch 1997</a>; <a href="./references#CD005614-bbs2-0065" title="KerzbergEM , RoldanEJ , CastelliG , HubermanED . Combination of glycosaminoglycans and acetylsalicylic acid in knee osteoarthrosis. Scandinavian Journal of Rheumatology1987;16:377‐80. ">Kerzberg 1987</a>; <a href="./references#CD005614-bbs2-0018" title="L’HirondelJL . Clinical double‐blinded study with orally administered chondroitin sulfate versus placebo in patients with tibiofemoral gonarthrosis (125 patients) [Klinische Doppelblind‐Studie mit oral verabreichtem Chondroitinsulfatgegen Placebo bei der tibiofemoralen Gonarthrose (125 patients)]. Litera Rheumatologica1992;14:77‐84. ">L'Hirondel 1992</a>; <a href="./references#CD005614-bbs2-0071" title="MalaiseM , MarcolongoR , UebelhartD , VignonE . Efficacy and tolerability of 800 mg oral chondroitin 4&amp;6 sulfate in the treatment of knee osteoarthritis: a randomised, double‐blind, multicentre study versus placebo. Litera Rheumatologica1999;24:31‐42. ">Malaise 1999</a>; <a href="./references#CD005614-bbs2-0021" title="MazieresB , LoyauG , MenkesCJ , ValatJP , DreiserRL , CharlotJ , et al. Chondroitin sulfate in the treatment of gonarthrosis and coxarthrosis. 5‐months result of a multicenter double‐blind controlled prospective study using placebo. Rev Rhum Mal Osteoartic1992;59(7‐8):466‐72. ">Mazieres 1992</a>; <a href="./references#CD005614-bbs2-0022" title="MazieresB , CombeB , Phan VanA , TondutJ , GrynfelttM . Chondroitin sulfate in osteoarthritis of the knee: a prospective, double blind, placebo controlled multicenter clinical study. Journal of Rheumatology2001;28(1):173‐81. SawitzkeAD , ShiH , FincoMF , DunlopDD , Bingham IIICO , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis and Rheumatism2008;58:3183‐91. ">Mazieres 2001</a>; <a href="./references#CD005614-bbs2-0073" title="MazieresB , HucherMMH , ZamMMZ . Chondroitin sulfate in the treatment for knee osteoarthritis: a randomized, double blind, multicenter, placebo controlled trial. Annals of Rheumatic Disease2006;65(Suppl II):398. ">Mazieres 2006</a>; <a href="./references#CD005614-bbs2-0024" title="MichelBA , StuckiG , FreyD , DeVathaireF , VignonE , BruehlmannP , et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis and Rheumatism2005;52(3):779‐86. ">Michel 2005</a>; <a href="./references#CD005614-bbs2-0026" title="MorrealeP , ManopuloR , GalatiM , BoccaneraL , SaponatiG , BocchiL . Comparison of the antiinflammatory efficacy of chondroitin sulfate and diclofenac sodium in patients with knee osteoarthritis. Journal of Rheumatology1996;23(8):1385‐91. ">Morreale 1996</a>; <a href="./references#CD005614-bbs2-0028" title="NasonovaVA , AlekseevaLI , Arkhangel'skaiaGS , DavydovaAF , Karmil'tsevaEA , KoganKM , et al. Results of the multicenter clinical trial of structum preparation in Russia. Ter Arkh2001;73(11):84‐7. ">Nasonova 2001</a>; <a href="./references#CD005614-bbs2-0030" title="PavelkaK , ManopuloR , BusciL . Double‐blind, dose‐effect study of oral chondroitin 4 &amp; 6 sulfate 1200 mg, 800 mg, 200 mg, and placebo in the treatment of knee osteoarthritis. Litera Rhumatologica1999;24:21‐30. ">Pavelka 1999</a>; <a href="./references#CD005614-bbs2-0085" title="RovettaG . Galactosaminoglycuronoglycan sulfate (matrix) in therapy of tibiofibular osteoarthritis of the knee. Drugs Under Experimental and Clinical Research1991;17:53‐7. ">Rovetta 1991</a>; <a href="./references#CD005614-bbs2-0089" title="SorokaNF , ChyzhKA . Clinical efficiency and pharmacoeconomical evaluation of treatment by chondroitin sulphate (Structumc) in patients with primary osteoarthritis (POA). Annals of Rheumatic Disease2002;61(Suppl 1):AB0289. ">Soroka &amp; Chyzh 2002</a>; <a href="./references#CD005614-bbs2-0039" title="UebelhartD , ThonarEJ , DelmasPD , ChantraineA , VignonE . Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage1998;6(Suppl A):39‐46. ">Uebelhart 1998</a>; <a href="./references#CD005614-bbs2-0093" title="UebelhartD , KrusselO , TheilerR . Efficacy and tolerability of oral avian chondroitin sulfate in painful knee OA. Schweizerische Medizinische Wochenschrift1999;129(33):1174. ">Uebelhart 1999</a>) that assessed the efficacy of chondroitin in the treatment of osteoarthritis, published in 2007, <a href="./references#CD005614-bbs2-0146" title="ReichenbachS , SterchiR , SchererM , TrelleS , BurglE , BurglU , et al. Meta‐analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine2007;146:580‐90. ">Reichenbach 2007</a> found that “...large‐scale, methodologically sound trials indicate that the symptomatic benefit of chondroitin is minimal or nonexistent. Use of chondroitin in routine clinical practice should therefore be discouraged.” </p> <p>In this meta‐analysis, <a href="./references#CD005614-bbs2-0146" title="ReichenbachS , SterchiR , SchererM , TrelleS , BurglE , BurglU , et al. Meta‐analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine2007;146:580‐90. ">Reichenbach 2007</a> included all "randomized or quasi‐randomized trials which compared chondroitin with either no treatment or placebo." The review authors performed sensitivity analyses on the data by concealment of allocation, use of placebo in control, participant blinding, use of ITT, trial size, funding, use of co‐intervention, route of administration, and length of follow‐up. In so doing, they found that higher‐quality studies with adequate concealment of allocation and proper ITT analysis showed small to nonexistent effects from chondroitin. The review authors also found a high degree of heterogeneity between the studies included. </p> <p>We observed several points of agreement and disagreement between <a href="./references#CD005614-bbs2-0146" title="ReichenbachS , SterchiR , SchererM , TrelleS , BurglE , BurglU , et al. Meta‐analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine2007;146:580‐90. ">Reichenbach 2007</a> and our review, as noted in the Methods and Results sections. For instance, <a href="./references#CD005614-bbs2-0146" title="ReichenbachS , SterchiR , SchererM , TrelleS , BurglE , BurglU , et al. Meta‐analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine2007;146:580‐90. ">Reichenbach 2007</a> had broader inclusion criteria than we did. They included studies published in abstract form (<a href="./references#CD005614-bbs2-0061" title="FleischAM , MerlinC , ImhoffA , HodlerJ , KisslingR . A one‐year randomized, double‐blind, placebo‐controlled study with oral chondroitin sulfate in patients with knee osteoarthritis. Osteoarthritis Cartilage1997;5(Suppl A):S70. ">Fleisch 1997</a>; <a href="./references#CD005614-bbs2-0064" title="KahanA . STOPP (STudy on Osteoarthritis Progression Prevention): a new two‐year trial with chondroitin 4&amp;6 sulfate (CS). www.ibsa‐ch.com/eular_2006_amsterdam_vignon‐2.pdf (accessed on 18 September 2006). ">Kahan 2006</a>; <a href="./references#CD005614-bbs2-0073" title="MazieresB , HucherMMH , ZamMMZ . Chondroitin sulfate in the treatment for knee osteoarthritis: a randomized, double blind, multicenter, placebo controlled trial. Annals of Rheumatic Disease2006;65(Suppl II):398. ">Mazieres 2006</a>; <a href="./references#CD005614-bbs2-0089" title="SorokaNF , ChyzhKA . Clinical efficiency and pharmacoeconomical evaluation of treatment by chondroitin sulphate (Structumc) in patients with primary osteoarthritis (POA). Annals of Rheumatic Disease2002;61(Suppl 1):AB0289. ">Soroka &amp; Chyzh 2002</a>; <a href="./references#CD005614-bbs2-0093" title="UebelhartD , KrusselO , TheilerR . Efficacy and tolerability of oral avian chondroitin sulfate in painful knee OA. Schweizerische Medizinische Wochenschrift1999;129(33):1174. ">Uebelhart 1999</a>), but we decided a priori to include only full publications. In addition, they included studies that assessed the efficacy of chondroitin administered intramuscularly and topically (<a href="./references#CD005614-bbs2-0009" title="CohenM , WolfeR , MaiT , LewisD . A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. Journal of Rheumatology2003;30(3):523‐8. ">Cohen 2003</a>; <a href="./references#CD005614-bbs2-0065" title="KerzbergEM , RoldanEJ , CastelliG , HubermanED . Combination of glycosaminoglycans and acetylsalicylic acid in knee osteoarthrosis. Scandinavian Journal of Rheumatology1987;16:377‐80. ">Kerzberg 1987</a>; <a href="./references#CD005614-bbs2-0085" title="RovettaG . Galactosaminoglycuronoglycan sulfate (matrix) in therapy of tibiofibular osteoarthritis of the knee. Drugs Under Experimental and Clinical Research1991;17:53‐7. ">Rovetta 1991</a>). However, we decided a priori to include only studies that assessed the efficacy of oral chondroitin to limit heterogeneity of effect; therefore, we did not include the results of <a href="./references#CD005614-bbs2-0009" title="CohenM , WolfeR , MaiT , LewisD . A randomized, double blind, placebo controlled trial of a topical cream containing glucosamine sulfate, chondroitin sulfate, and camphor for osteoarthritis of the knee. Journal of Rheumatology2003;30(3):523‐8. ">Cohen 2003</a> in our meta‐analyses but have only summarized them. </p> <p>Furthermore, we discovered that over the several years that passed between the publishing of <a href="./references#CD005614-bbs2-0146" title="ReichenbachS , SterchiR , SchererM , TrelleS , BurglE , BurglU , et al. Meta‐analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine2007;146:580‐90. ">Reichenbach 2007</a> and the preparation of this review, several new published studies had assessed the efficacy of chondroitin sulfate (<a href="./references#CD005614-bbs2-0004" title="AlekseevaLI . Results of an open comparative randomized clinical trial to assess efficacy and safety of two regimens of treatment with Theraflex preparation in knee osteoarthritis patients. Russkiy Meditsinskiy Journal2008;16(5):316. ">Alekseeva 2008</a>; <a href="./references#CD005614-bbs2-0015" title="GabayC , Medinger‐SadowskiC , GasconD , KoloF , FinckhA . Symptomatic effects of chondroitin 4 and chondroitin 6 sulfate on hand osteoarthritis. Arthritis and Rheumatism2011;63(11):3383‐91. ">Gabay 2011</a>; <a href="./references#CD005614-bbs2-0016" title="KahanA , UebelhartD , DeVathaireF , DelmasPD , ReginsterJY . Long‐term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2009;60(2):524‐33. ">Kahan 2009</a>; <a href="./references#CD005614-bbs2-0017" title="KanzakiN , SaitoK , MaedaA , KitagawaY , KisoY , WatanabeK , et al. Effect of a dietary supplement containing glucosamine hydrochloride, chondroitin sulfate and quercetin glycosides on symptomatic knee osteoarthritis: a randomized, double‐blind, placebo‐controlled study. Journal of Science and Food Agriculture2012;92:862‐9. ">Kanzaki 2011</a>; <a href="./references#CD005614-bbs2-0020" title="Magrans‐CourtneyT , WilbornC , RasmussenC , FerreiraM , GreenwoodL , CampbellB , et al. Effects of diet type and supplementation of glucosamine, chondroitin, and MSM on body composition, functional status, and markers of health in women with knee osteoarthritis initiating a resistance‐based exercise and weight loss program. Journal of International Society of Sports Medicine2011;8:8. ">Magrans‐Courtney 2011</a>; <a href="./references#CD005614-bbs2-0023" title="MessierSP , MihalkoS , LoeserRF , LegaultC , JollaJ , PfruenderJ , et al. Glucosamine/chondroitin combined with exercise for the treatment of knee osteoarthritis: a preliminary study. Osteoarthritis Cartilage2007;15(11):1256‐66. ">Messier 2007</a>; <a href="./references#CD005614-bbs2-0025" title="MöllerI , PérezM , MonfortJ , BenitoP , CuevasJ , PernaC , et al. Effectiveness of chondroitin sulphate in patients with concomitant knee osteoarthritis and psoriasis: a randomized, double‐blind, placebo‐controlled study. Osteoarthritis and Cartilage2010;18:S32‐40. ">Moller 2010</a>; <a href="./references#CD005614-bbs2-0027" title="NakasoneY , WatabeK , WatanabeK , TomonagaA , NagaokaI , YamamotoT , et al. Effect of a glucosamine‐based combination supplement containing chondroitin sulfate and antioxidant micronutrients in subjects with symptomatic knee osteoarthritis: a pilot study. Experimental and Therapeutic Medicine2011;2(5):893. ">Nakasone 2011</a>; <a href="./references#CD005614-bbs2-0031" title="PavelkaK , CosteP , GéherP . Efficacy and safety of piascledine 300 versus chondroitin sulfate in a 6 months treatment plus 2 months observation in patients with osteoarthritis of the knee. Clinical Rheumatology2010;29:659–70. ">Pavelka 2010</a>; <a href="./references#CD005614-bbs2-0037" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , BinghamCOIII , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis Rheum2008;58:3183‐91. ">Sawitzke 2008</a>; <a href="./references#CD005614-bbs2-0038" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , HarrisCL , SingerNG , et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2‐year results from GAIT. Annals of the Rheumatic Diseases2010;69:1459–64. ">Sawitzke 2010</a>; <a href="./references#CD005614-bbs2-0042" title="WildiLM , RaynauldJ‐P , Martel‐PelletierJ , BeaulieuA , BessetteL , MorinF , et al. Chondroitin sulfate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomized, double‐blind, placebo‐controlled pilot study using MRI. Annals of the Rheumatic Diseases2011;70:982–9. ">Wildi 2011</a>). We included these studies in our review so we could assess whether the publication of more recent studies had any influence on the previously arrived at conclusions regarding the use of chondroitin. </p> <p>Moreover, we found that <a href="./references#CD005614-bbs2-0146" title="ReichenbachS , SterchiR , SchererM , TrelleS , BurglE , BurglU , et al. Meta‐analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine2007;146:580‐90. ">Reichenbach 2007</a> did not account for the possible clinical effect of heterogeneity arising from combining studies assessing the efficacy of chondroitin alone with those assessing the efficacy of chondroitin in combination with other treatments such as glucosamine or NSAIDs. The inclusion of studies that assess the effects of using a combination of chondroitin with other supplements poses the risk of confounding the observed results. It is difficult to see in such studies whether the observed effect in the active group is due to the presence of chondroitin or to another of the matrix components that was administered along with chondroitin. In our review, therefore, to control for any confounding effects arising from the use of other treatments in combination with chondroitin sulfate, we decided to stratify our data based on the make‐up of the active treatment groups; therefore, we have separate comparison arms for studies that used chondroitin alone, studies that used chondroitin in combination with supplements, and studies that used chondroitin in combination with NSAIDs. To facilitate the comparison of our results with those of other reviews, however, we performed a sensitivity on all studies, regardless of whether they included confounding treatments, as long as they had chondroitin in the active arm compared with placebo/control (<a href="./references#CD005614-fig-0108" title="">Analysis 5.1</a>; <a href="./references#CD005614-fig-0109" title="">Analysis 5.2</a>; <a href="./references#CD005614-fig-0110" title="">Analysis 5.3</a> and associated sensitivity analyses). </p> <p>Moreover, we discovered that many of the studies included in <a href="./references#CD005614-bbs2-0146" title="ReichenbachS , SterchiR , SchererM , TrelleS , BurglE , BurglU , et al. Meta‐analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine2007;146:580‐90. ">Reichenbach 2007</a> had data for which standard deviations were provided in published studies. In such instances, <a href="./references#CD005614-bbs2-0146" title="ReichenbachS , SterchiR , SchererM , TrelleS , BurglE , BurglU , et al. Meta‐analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine2007;146:580‐90. ">Reichenbach 2007</a> et al. had estimated the standard deviations. We also therefore performed a sensitivity analysis wherein we included studies for which we estimated standard deviations to allow comparisons. </p> <p>Comparing the results of <a href="./references#CD005614-bbs2-0146" title="ReichenbachS , SterchiR , SchererM , TrelleS , BurglE , BurglU , et al. Meta‐analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine2007;146:580‐90. ">Reichenbach 2007</a> with ours, we discovered that both reviews agreed to a large extent regarding what the data showed. Both discovered that chondroitin was more efficacious as compared with placebo for pain‐related outcomes; however, with the performance of sensitivity analysis, it became obvious that in some sensitivity analyses, beneficial effects from chondroitin were uncertain, while in others these beneficial effects persisted. This is where our findings differ from <a href="./references#CD005614-bbs2-0146" title="ReichenbachS , SterchiR , SchererM , TrelleS , BurglE , BurglU , et al. Meta‐analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine2007;146:580‐90. ">Reichenbach 2007</a>. </p> <p>In our study, findings of clinically meaningful benefit with chondroitin compared to placebo for pain and Lequensne's index was robust for sensitivity analyses limited to studies with adequate blinding or studies that used appropriate intention to treat (ITT) analyses, but were uncertain when we limited data to studies with appropriate allocation concealment or a large study sample (&gt; 200) or to studies without pharmaceutical funding. </p> <p>For pain‐related outcomes, 20 of the 22 studies included in <a href="./references#CD005614-bbs2-0146" title="ReichenbachS , SterchiR , SchererM , TrelleS , BurglE , BurglU , et al. Meta‐analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine2007;146:580‐90. ">Reichenbach 2007</a> provided data. These included studies for which no standard deviations were available and had to be estimated. Among these studies, the review authors witnessed a large "effect size" of ‐0.75 (95% CI ‐0.99 to ‐0.50). This effect size corresponded to a difference in pain scores of 1.6 cm (on a 10‐cm VAS) between chondroitin and placebo groups. However, among studies reporting on this outcome, investigators witnessed an I<sup>2</sup> of 92%, indicating a high degree of between‐trial heterogeneity. </p> <p>For pain‐related outcomes, we identified a total of 22 studies that provided data; for some of these, we were forced to estimate standard deviations (included only in the sensitivity analysis). To facilitate the most accurate comparison possible between our review and <a href="./references#CD005614-bbs2-0146" title="ReichenbachS , SterchiR , SchererM , TrelleS , BurglE , BurglU , et al. Meta‐analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine2007;146:580‐90. ">Reichenbach 2007</a>, we used data from <a href="./references#CD005614-fig-0172" title="">Analysis 30.1</a><a href="./references#CD005614-fig-0168" title="">Analysis 29.1</a>, which analyzed the results of all studies, including those with estimated standard deviations and those that assessed the efficacy of chondroitin sulfate alone or in combination with other supplements in the active group and in the placebo group, with no treatment or control in the control arm. For the outcome of pain, our analysis revealed an SMD of ‐0.64 and a 95% CI of ‐0.88 to ‐0.41, corresponding to a P‐value &lt; 0.0001 and a moderate‐large effect size. This SMD corresponded to a 11.2 mm difference in pain scores on a 0 to 100‐mm VAS scale. Among these studies, we observed a large degree of between‐trial heterogeneity, with an I<sup>2</sup> of 91%. It is clear from these results that before sensitivity analysis was performed, the findings of our study were largely in agreement with the findings of <a href="./references#CD005614-bbs2-0146" title="ReichenbachS , SterchiR , SchererM , TrelleS , BurglE , BurglU , et al. Meta‐analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine2007;146:580‐90. ">Reichenbach 2007</a>. </p> <p>Our results also found agreement after the sensitivity analysis was performed. <a href="./references#CD005614-bbs2-0146" title="ReichenbachS , SterchiR , SchererM , TrelleS , BurglE , BurglU , et al. Meta‐analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine2007;146:580‐90. ">Reichenbach 2007</a> performed sensitivity analysis by allocation concealment, source of sponsorship, and sample size, among others. The mentioned sensitivity analyses revealed a significant interaction between the presence of adequate allocation concealment and sample size and the effect size of chondroitin. </p> <p>In studies with adequate allocation concealment, chondroitin sulfate showed smaller effects, with a P for interaction of 0.05. Two studies in <a href="./references#CD005614-bbs2-0146" title="ReichenbachS , SterchiR , SchererM , TrelleS , BurglE , BurglU , et al. Meta‐analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine2007;146:580‐90. ">Reichenbach 2007</a> had adequate allocation concealment. Among these two studies, the "effect size" decreased to ‐0.01 with a 95% CI level of ‐0.12 to 0.10. Our sensitivity analysis by allocation concealment revealed the same conclusion. We identified a total of four studies that had adequate allocation concealment. These studies showed no significant effect from chondroitin with an SMD of 0.03, a 95% CI of ‐0.08 to 0.14, and a P value of 0.62. Heterogeneity was also non significant, with an I<sup>2</sup> of 36%. </p> <p>Sensitivity analysis by sample size showed the same conclusion. In <a href="./references#CD005614-bbs2-0146" title="ReichenbachS , SterchiR , SchererM , TrelleS , BurglE , BurglU , et al. Meta‐analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine2007;146:580‐90. ">Reichenbach 2007</a>, when data were stratified according to sample size, studies with large sample sizes (more than 200) showed a non‐significant "effect size" of ‐0.26 with a 95% CI of ‐0.56 to 0.04. When our data were stratified by sample size, studies with large sample sizes (greater than 100) had a decreased SMD of 0.03, with 95% CI of ‐0.08 to 0.14. Neither <a href="./references#CD005614-bbs2-0146" title="ReichenbachS , SterchiR , SchererM , TrelleS , BurglE , BurglU , et al. Meta‐analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine2007;146:580‐90. ">Reichenbach 2007</a> nor our review discovered any significant difference between chondroitin and control. </p> <p>Moreover, sensitivity analysis by source of funding again revealed the same conclusion. <a href="./references#CD005614-bbs2-0146" title="ReichenbachS , SterchiR , SchererM , TrelleS , BurglE , BurglU , et al. Meta‐analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine2007;146:580‐90. ">Reichenbach 2007</a> stratified results between those funded by nonprofit organizations and those not funded by nonprofit organizations or those with unclear sources of funding. Studies that had nonprofit sponsorship showed no significant effect from chondroitin, with an "effect size" of 0.01 and a 95% CI of ‐0.15 to 0.16. In our review, we stratified our data according to whether the study was sponsored by a manufacturer of chondroitin sulfate or whether the study did not specify its source of funding or was not supported by a manufacturer of chondroitin sulfate. This analysis revealed an SMD of 0.00 with a 95% CI of ‐0.15 to 0.16 in one study that was not funded by a chondroitin sulfate manufacturer. Studies funded by manufacturers had a smaller effect size of ‐0.52 compared to ‐0.75 for studies with unclear funding. Therefore, the results of our meta‐analysis and the results of <a href="./references#CD005614-bbs2-0146" title="ReichenbachS , SterchiR , SchererM , TrelleS , BurglE , BurglU , et al. Meta‐analysis: chondroitin for osteoarthritis of the knee or hip. Annals of Internal Medicine2007;146:580‐90. ">Reichenbach 2007</a> are in some disagreement in these regards. </p> <p><a href="./references#CD005614-bbs2-0084" title="RichyF , BruyereO , EthgenO , CucheratM , HenrotinY , ReginsterJY . Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta‐analysis. Archives of Internal Medicine2003;163(13):1514‐22. ">Richy 2003</a> is another meta‐analysis on the efficacy of chondroitin sulfate. Upon performing a meta‐analysis on nine studies, <a href="./references#CD005614-bbs2-0084" title="RichyF , BruyereO , EthgenO , CucheratM , HenrotinY , ReginsterJY . Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta‐analysis. Archives of Internal Medicine2003;163(13):1514‐22. ">Richy 2003</a> found that chondroitin was more effective on Lequesne’s index, visual analogue scale for pain, mobility, and responder status. Although the review authors note that the quality of the chondroitin studies included in their review was lower than that of studies reporting on the efficacy of glucosamine, they do not perform sensitivity analyses to discover the effect of low methodological quality on their outcomes. This accounts for the high level of variation between results of our meta‐analysis and the results presented in <a href="./references#CD005614-bbs2-0084" title="RichyF , BruyereO , EthgenO , CucheratM , HenrotinY , ReginsterJY . Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta‐analysis. Archives of Internal Medicine2003;163(13):1514‐22. ">Richy 2003</a>. Our overall conclusion revealed a positive effect from chondroitin in comparison with placebo, as does <a href="./references#CD005614-bbs2-0084" title="RichyF , BruyereO , EthgenO , CucheratM , HenrotinY , ReginsterJY . Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta‐analysis. Archives of Internal Medicine2003;163(13):1514‐22. ">Richy 2003</a>. However, upon further stratification of the data by factors such as sample size, and source of sponsorship, it became clear that studies with high methodological quality, we found that effects persisted in some, but not all sensitivity analyses. </p> <p>Other reviews, such as <a href="./references#CD005614-bbs2-0129" title="HochbergMC . Structure‐modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta‐analysis of randomized placebo‐controlled trials of 2‐year duration. Osteoarthritis and Cartilage2010;18:S28‐31. ">Hochberg 2010</a> and <a href="./references#CD005614-bbs2-0135" title="LeeYH , WooJ , ChoiSJ , JiDJ , SongGG . Effects of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta‐analysis. Rheumatology International2010;30:357‐63. ">Lee 2010</a>, studied the efficacy of chondroitin in slowing the progression of joint space width loss. Although the number of studies included in this meta‐analysis was small—three in <a href="./references#CD005614-bbs2-0129" title="HochbergMC . Structure‐modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta‐analysis of randomized placebo‐controlled trials of 2‐year duration. Osteoarthritis and Cartilage2010;18:S28‐31. ">Hochberg 2010</a> (<a href="./references#CD005614-bbs2-0016" title="KahanA , UebelhartD , DeVathaireF , DelmasPD , ReginsterJY . Long‐term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2009;60(2):524‐33. ">Kahan 2009</a>; <a href="./references#CD005614-bbs2-0024" title="MichelBA , StuckiG , FreyD , DeVathaireF , VignonE , BruehlmannP , et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis and Rheumatism2005;52(3):779‐86. ">Michel 2005</a>; <a href="./references#CD005614-bbs2-0037" title="SawitzkeAD , ShiH , FincoMF , DunlopDD , BinghamCOIII , HarrisCL , et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the Glucosamine/Chondroitin Arthritis Intervention Trial. Arthritis Rheum2008;58:3183‐91. ">Sawitzke 2008</a>) and four in <a href="./references#CD005614-bbs2-0135" title="LeeYH , WooJ , ChoiSJ , JiDJ , SongGG . Effects of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta‐analysis. Rheumatology International2010;30:357‐63. ">Lee 2010</a> (<a href="./references#CD005614-bbs2-0064" title="KahanA . STOPP (STudy on Osteoarthritis Progression Prevention): a new two‐year trial with chondroitin 4&amp;6 sulfate (CS). www.ibsa‐ch.com/eular_2006_amsterdam_vignon‐2.pdf (accessed on 18 September 2006). ">Kahan 2006</a>; <a href="./references#CD005614-bbs2-0024" title="MichelBA , StuckiG , FreyD , DeVathaireF , VignonE , BruehlmannP , et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis and Rheumatism2005;52(3):779‐86. ">Michel 2005</a>; <a href="./references#CD005614-bbs2-0039" title="UebelhartD , ThonarEJ , DelmasPD , ChantraineA , VignonE . Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study. Osteoarthritis Cartilage1998;6(Suppl A):39‐46. ">Uebelhart 1998</a>; <a href="./references#CD005614-bbs2-0040" title="UebelhartD , MalaiseM , MarcolongoR , deVathaireF , PipernoM , MailleuxE , et al. Intermittent treatment of knee osteoarthritis with oral chondroitin sulfate: a one‐year, randomized, double‐blind, multicenter study versus placebo. Osteoarthritis Cartilage2004;12(4):269‐76. ">Uebelhart 2004</a>)—investigators did detect a small but significant positive effect in the rate of joint space width narrowing in participants treated with chondroitin. </p> <p><a href="./references#CD005614-bbs2-0135" title="LeeYH , WooJ , ChoiSJ , JiDJ , SongGG . Effects of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta‐analysis. Rheumatology International2010;30:357‐63. ">Lee 2010</a> concludes that chondroitin sulfate "had a small but significant protective effect on minimum JSN [joint space narrowing] after two years (SMD 0.261, 95% CI 0.131‐0.392, <i>P</i> &lt; 0.001). This meta‐analysis of available data shows that glucosamine and chondroitin sulfate may delay radiologic progression of osteoarthritis of the knee after daily administration for over 2 or 3 years." <a href="./references#CD005614-bbs2-0129" title="HochbergMC . Structure‐modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta‐analysis of randomized placebo‐controlled trials of 2‐year duration. Osteoarthritis and Cartilage2010;18:S28‐31. ">Hochberg 2010</a> echoes these results, stating that the analysis results showed "a small significant effect of chondroitin sulfate on the reduction in rate of decline in minimum joint space width of 0.13 mm [95% confidence interval (CI) 0.06, 0.19] (P &lt; 0.0002) that corresponded to an effect size of 0.23 (95% CI 0.11, 0.35) (P &lt; 0.0001). These results demonstrate that chondroitin sulfate is effective for reducing the rate of decline in minimum joint space width in patients with knee OA.” Our estimates of minimum joint space width changes agree with those of <a href="./references#CD005614-bbs2-0129" title="HochbergMC . Structure‐modifying effects of chondroitin sulfate in knee osteoarthritis: an updated meta‐analysis of randomized placebo‐controlled trials of 2‐year duration. Osteoarthritis and Cartilage2010;18:S28‐31. ">Hochberg 2010</a> and <a href="./references#CD005614-bbs2-0135" title="LeeYH , WooJ , ChoiSJ , JiDJ , SongGG . Effects of glucosamine or chondroitin sulfate on the osteoarthritis progression: a meta‐analysis. Rheumatology International2010;30:357‐63. ">Lee 2010</a>. What is not known is whether these radiographic differences are clinically meaningful. Moreover, the small number of studies used in the meta‐analysis makes it difficult to draw firm conclusions, indicating that more data are needed. </p> <p>Another review, <a href="./references#CD005614-bbs2-0155" title="WandelS , JüniP , TendalB , NüeschE , VilligerPM , WeltonNJ , et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta‐analysis. BMJ Sept 16 2010;341:c4675. ">Wandel 2010</a>, studied the efficacy of glucosamine, chondroitin, and glucosamine and chondroitin in combination as compared with placebo in reducing pain and joint space width loss and in ensuring safety. This review includes ten studies (<a href="./references#CD005614-bbs2-0127" title="Herrero‐BeaumontG , IvorraJA , DelCarmen TrabadoM , BlancoFJ , BenitoP , Martin‐MolaE , et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double‐blind, placebo‐controlled study using acetaminophen as a side comparator. Arthritis and Rheumatism2007;56:555‐67. ">Herrero‐Beaumont 2007</a>; <a href="./references#CD005614-bbs2-0016" title="KahanA , UebelhartD , DeVathaireF , DelmasPD , ReginsterJY . Long‐term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2009;60(2):524‐33. ">Kahan 2009</a>; <a href="./references#CD005614-bbs2-0140" title="McAlindonT , FormicaM , LaValleyM , LehmerM , KabbaraK . Effectiveness of glucosamine for symptoms of knee osteoarthritis: results from an Internet‐based randomized double‐blind controlled trial. American Journal of Medicine2004;117:643‐9. ">McAlindon 2004</a>; <a href="./references#CD005614-bbs2-0141" title="NoackW , FischerM , ForsterKK , RovatiLC , SetnikarI . Glucosaminesulfate in osteoarthritis of the knee. Osteoarthr Cartil1994;2:51‐9. ">Novack 1994</a>; <a href="./references#CD005614-bbs2-0142" title="PavelkaK , GatterovaJ , OlejarovaM , MachacekS , GiacovelliG , RovatiLC . Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3‐year, randomized, placebo‐controlled, double‐blind study. Archives of Internal Medicine2002;162:2113‐23. ">Pavelka 2002</a>; <a href="./references#CD005614-bbs2-0083" title="ReginsterJ , TajanaE . Single oral dose of (1200 MG) sachet of chondroitin 4&amp;6 sulfate (CS4&amp;6‐chondrosulf) relieves pain and improves function. Results of a double blind study versus placebo and an active treatment in knee OA patients. Osteoarthritis and CartilageSeptember 2011;19:S226‐7. ">Reginster 2011</a>; <a href="./references#CD005614-bbs2-0147" title="RozendaalRM , KoesBW , vanOschGJ , UitterlindenEJ , GarlingEH , WillemsenSP , et al. Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial. Annals of Internal Medicine2008;148:268‐77. ">Rozendaal 2008</a> in glucosamine vs placebo comparison arm; <a href="./references#CD005614-bbs2-0016" title="KahanA , UebelhartD , DeVathaireF , DelmasPD , ReginsterJY . Long‐term effects of chondroitins 4 and 6 sulfate on knee osteoarthritis: the study on osteoarthritis progression prevention, a two‐year, randomized, double‐blind, placebo‐controlled trial. Arthritis and Rheumatism2009;60(2):524‐33. ">Kahan 2009</a>; <a href="./references#CD005614-bbs2-0138" title="MazièresB , HucherM , ZaimM , GarneroP . Effect of chondroitinsulphate in symptomatic knee osteoarthritis: a multicentre,randomised, double‐blind, placebo‐controlled study. Ann Rheum Dis2007;66:639‐45. ">Mazieres 2007</a>; and <a href="./references#CD005614-bbs2-0024" title="MichelBA , StuckiG , FreyD , DeVathaireF , VignonE , BruehlmannP , et al. Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial. Arthritis and Rheumatism2005;52(3):779‐86. ">Michel 2005</a> in the chondroitin vs placebo comparison arm; and <a href="./references#CD005614-bbs2-0008" title="CleggDO , RedaDJ , HarrisCL , KleinMA , O'DellJR , HooperMM , et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. New England Journal of Medicine2006;354(8):795‐808. ">Clegg 2006</a> for glucosamine and chondroitin combination vs the placebo comparison arm). In their analysis of the three studies comparing chondroitin alone with placebo, the authors found that participants treated with chondroitin did not experience a statistically significant reduction in pain intensity with a 95% confidence interval level of ‐0.3 cm (‐0.7 to 0.0 cm) on a 10‐cm visual analogue scale. Treatment with chondroitin alone was shown to have "minute" effects on radiographic joint space width, with a 95% confidence interval level of ‐0.1 mm (‐0.3 to 0.1 mm) in favor of chondroitin. In the safety outcomes, chondroitin was shown to have an odds ratio of 0.99 with a 95% confidence interval level of 0.49 to 2.00 in the number of adverse events and 0.92 with a 95% confidence interval of 0.56 to 1.51 for withdrawals or dropouts due to adverse events. This meta‐analysis differed from ours in that it included a much smaller number of studies in both the chondroitin versus placebo comparison arm and the chondroitin and glucosamine combination versus placebo comparison arm, thus limiting the scope of the presented findings. Despite the small number of studies included in each of the comparison arms, <a href="./references#CD005614-bbs2-0155" title="WandelS , JüniP , TendalB , NüeschE , VilligerPM , WeltonNJ , et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta‐analysis. BMJ Sept 16 2010;341:c4675. ">Wandel 2010</a> still found, as did our meta‐analysis, that studies with industry sponsorship showed that chondroitin had a greater effect on pain than studies that did not have industry sponsorship. "On average, the estimated differences between supplements and placebo were 0.5 cm less pronounced in industry independent trials compared with industry sponsored trials, and estimated treatment effects in industry independent trials were minute to zero and by no means clinically relevant," the authors write. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD005614-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Formula used to estimate standard deviations for studies that did not provide them." data-id="CD005614-fig-0001" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Formula used to estimate standard deviations for studies that did not provide them.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/full#CD005614-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Figure 2. Study Flow chart" data-id="CD005614-fig-0002" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Figure 2. Study Flow chart</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/full#CD005614-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality summary: review authors' judgements about each methodological quality item for each included study." data-id="CD005614-fig-0003" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Methodological quality summary: review authors' judgements about each methodological quality item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/full#CD005614-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies." data-id="CD005614-fig-0004" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/full#CD005614-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 1 Chondroitin versus placebo, outcome: 1.1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0005" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Funnel plot of comparison: 1 Chondroitin versus placebo, outcome: 1.1 Pain on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/full#CD005614-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Funnel plot of comparison: 5 chondroitin sulfate/CSGH versus Placebo/Control, outcome: 5.1 Pain on a 0 to 100 scale (short‐ and long‐term results)." data-id="CD005614-fig-0006" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Funnel plot of comparison: 5 chondroitin sulfate/CSGH versus Placebo/Control, outcome: 5.1 Pain on a 0 to 100 scale (short‐ and long‐term results). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/full#CD005614-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Forest plot of comparison: 5 Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo or Control, outcome: 5.5 Pain on 0 to 100 scale (short‐ or long‐term) for CS dose &gt;= 800 mg/day." data-id="CD005614-fig-0007" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of comparison: 5 Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo or Control, outcome: 5.5 Pain on 0 to 100 scale (short‐ or long‐term) for CS dose &gt;= 800 mg/day. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/full#CD005614-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0008" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 1 Pain on a 0 to 100 scale.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 2 WOMAC MCII." data-id="CD005614-fig-0009" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 2 WOMAC MCII.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 3 Physical Function on a 0 to 100 scale." data-id="CD005614-fig-0010" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 3 Physical Function on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 4 WOMAC Stiffness on a 0 to 100 scale." data-id="CD005614-fig-0011" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 4 WOMAC Stiffness on a 0 to 100 scale.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 5 Patient Global Assessment—rating it good to very good." data-id="CD005614-fig-0012" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 5 Patient Global Assessment—rating it good to very good. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 6 Patient Global Assessment on a VAS 0 to 100‐mm scale." data-id="CD005614-fig-0013" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 6 Patient Global Assessment on a VAS 0 to 100‐mm scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 7 MD Global Assessment of good to very good." data-id="CD005614-fig-0014" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 7 MD Global Assessment of good to very good. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 8 MD Global Assessment on a VAS 0 to 100‐mm scale." data-id="CD005614-fig-0015" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 8 MD Global Assessment on a VAS 0 to 100‐mm scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 9 Total Knee Arthroplasty during follow‐up." data-id="CD005614-fig-0016" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 9 Total Knee Arthroplasty during follow‐up. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 10 Grip Strength (kg/cm2)." data-id="CD005614-fig-0017" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 10 Grip Strength (kg/cm<sup>2</sup>). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 11 Morning Stiffness, minutes." data-id="CD005614-fig-0018" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 11 Morning Stiffness, minutes.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 12 Cartilage Volume Loss (global)." data-id="CD005614-fig-0019" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 12 Cartilage Volume Loss (global).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 13 Cartilage Volume Loss (lateral compartment)." data-id="CD005614-fig-0020" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 13 Cartilage Volume Loss (lateral compartment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 14 Cartilage Volume Loss (medial compartment)." data-id="CD005614-fig-0021" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 14 Cartilage Volume Loss (medial compartment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 15 Cartilage Volume Loss (condyles)." data-id="CD005614-fig-0022" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 15 Cartilage Volume Loss (condyles).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 16 Cartilage Volume Loss (lateral condyles)." data-id="CD005614-fig-0023" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 16 Cartilage Volume Loss (lateral condyles). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 17 Cartilage Volume Loss (medial condyles)." data-id="CD005614-fig-0024" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 17 Cartilage Volume Loss (medial condyles). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 18 Cartilage Volume Loss (tibial plateaus)." data-id="CD005614-fig-0025" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 18 Cartilage Volume Loss (tibial plateaus). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 19 Cartilage Volume Loss (lateral tibial plateaus)." data-id="CD005614-fig-0026" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.19</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 19 Cartilage Volume Loss (lateral tibial plateaus). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 20 Cartilage Volume Loss (medial tibial plateau)." data-id="CD005614-fig-0027" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.20</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 20 Cartilage Volume Loss (medial tibial plateau). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 21 Cartilage Volume Loss (trochlea)." data-id="CD005614-fig-0028" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.21</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 21 Cartilage Volume Loss (trochlea).</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 22 Change in Bone Marrow Lesion Score (global)." data-id="CD005614-fig-0029" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.22</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 22 Change in Bone Marrow Lesion Score (global). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-23" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-23.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 23 Change in Bone Marrow Lesion Score (lateral compartment)." data-id="CD005614-fig-0030" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-23.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.23</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 23 Change in Bone Marrow Lesion Score (lateral compartment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-23.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-24" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-24.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 24 Change in Bone Marrow Lesion score (medial compartment)." data-id="CD005614-fig-0031" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-24.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.24</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 24 Change in Bone Marrow Lesion score (medial compartment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-24.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-25" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-25.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 25 Change in Bone Marrow Lesion score (condyles)." data-id="CD005614-fig-0032" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-25.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.25</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 25 Change in Bone Marrow Lesion score (condyles). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-25.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-26" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-26.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 26 Change in Bone Marrow Lesion score (lateral condyles)." data-id="CD005614-fig-0033" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-26.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.26</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 26 Change in Bone Marrow Lesion score (lateral condyles). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-26.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-27" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-27.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 27 Change in Bone Marrow Lesion score (medial condyles)." data-id="CD005614-fig-0034" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-27.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.27</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 27 Change in Bone Marrow Lesion score (medial condyles). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-27.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-28" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-28.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 28 Change in Bone Marrow Lesion score (tibial plateaus)." data-id="CD005614-fig-0035" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-28.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.28</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 28 Change in Bone Marrow Lesion score (tibial plateaus). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-28.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-29" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-29.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 29 Change in Bone Marrow Lesion score (lateral tibial plateaus)." data-id="CD005614-fig-0036" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-29.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.29</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 29 Change in Bone Marrow Lesion score (lateral tibial plateaus). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-29.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-30" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-30.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 30 Change in Bone Marrow Lesion score (medial tibial plateau)." data-id="CD005614-fig-0037" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-30.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.30</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 30 Change in Bone Marrow Lesion score (medial tibial plateau). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-30.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-31" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-31.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 31 Change in Bone Marrow Lesion score (trochlea)." data-id="CD005614-fig-0038" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-31.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.31</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 31 Change in Bone Marrow Lesion score (trochlea). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-31.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-32" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-32.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 32 OMERACT‐OARSI Responder." data-id="CD005614-fig-0039" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-32.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.32</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 32 OMERACT‐OARSI Responder.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-32.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-33" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-33.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 33 Lequesne's Index on 0 to 24 scale (higher is worse)." data-id="CD005614-fig-0040" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-33.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.33</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 33 Lequesne's Index on 0 to 24 scale (higher is worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-33.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-34" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-34.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 34 HAQ Disability Score on 0 to 3 scale (higher is worse)." data-id="CD005614-fig-0041" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-34.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.34</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 34 HAQ Disability Score on 0 to 3 scale (higher is worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-34.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-35" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-35.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 35 Radiographic Outcome: Minimum JSW in mm." data-id="CD005614-fig-0042" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-35.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.35</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 35 Radiographic Outcome: Minimum JSW in mm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-35.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-36" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-36.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 36 Radiographic Outcome: Reduction in Minimum JSW in mm." data-id="CD005614-fig-0043" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-36.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.36</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 36 Radiographic Outcome: Reduction in Minimum JSW in mm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-36.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-37" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-37.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 37 Radiographic Outcome: Mean JSW in mm." data-id="CD005614-fig-0044" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-37.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.37</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 37 Radiographic Outcome: Mean JSW in mm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-37.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-38" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-38.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 38 Radiographic Outcome: Change in Mean JSW in mm." data-id="CD005614-fig-0045" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-38.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.38</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 38 Radiographic Outcome: Change in Mean JSW in mm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-38.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-39" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-39.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 39 SF‐36—Physical Component Score." data-id="CD005614-fig-0046" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-39.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.39</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 39 SF‐36—Physical Component Score.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-39.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-40" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-40.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 40 SF‐36—Mental Component Summary Score." data-id="CD005614-fig-0047" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-40.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.40</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 40 SF‐36—Mental Component Summary Score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-40.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-41" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-41.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 41 All withdrawals." data-id="CD005614-fig-0048" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-41.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.41</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 41 All withdrawals.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-41.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-42" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-42.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 42 Withdrawals due to adverse events." data-id="CD005614-fig-0049" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-42.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.42</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 42 Withdrawals due to adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-42.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-43" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-43.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 43 Withdrawals due to inefficacy." data-id="CD005614-fig-0050" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-43.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.43</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 43 Withdrawals due to inefficacy.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-43.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-44" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-44.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 44 Number of adverse events." data-id="CD005614-fig-0051" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-44.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.44</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 44 Number of adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-44.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-45" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-45.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 45 Number of serious adverse events." data-id="CD005614-fig-0052" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-45.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.45</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 45 Number of serious adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-45.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-46" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-46.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 46 GI adverse events." data-id="CD005614-fig-0053" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-46.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.46</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 46 GI adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-46.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-47" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-47.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 47 Other adverse events." data-id="CD005614-fig-0054" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-47.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.47</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 47 Other adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-47.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-001-48" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-001-48.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Chondroitin versus Placebo, Outcome 48 Deaths." data-id="CD005614-fig-0055" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-48.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.48</div> <div class="figure-caption"> <p>Comparison 1 Chondroitin versus Placebo, Outcome 48 Deaths.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-001-48.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Chondroitin sulfate versus Control, Outcome 1 Pain on various scales standardized to a 0 to 100 scale." data-id="CD005614-fig-0056" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 Chondroitin sulfate versus Control, Outcome 1 Pain on various scales standardized to a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Chondroitin sulfate versus Control, Outcome 2 WOMAC Stiffness on a 0 to 100 scale." data-id="CD005614-fig-0057" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 Chondroitin sulfate versus Control, Outcome 2 WOMAC Stiffness on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Chondroitin sulfate versus Control, Outcome 3 WOMAC Physical Function on a 0 to 100 scale." data-id="CD005614-fig-0058" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 Chondroitin sulfate versus Control, Outcome 3 WOMAC Physical Function on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Chondroitin sulfate versus Control, Outcome 4 WOMAC Total." data-id="CD005614-fig-0059" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 Chondroitin sulfate versus Control, Outcome 4 WOMAC Total.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-002-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-002-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Chondroitin sulfate versus Control, Outcome 5 Lequesne's Index (higher is worse)." data-id="CD005614-fig-0060" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-002-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.5</div> <div class="figure-caption"> <p>Comparison 2 Chondroitin sulfate versus Control, Outcome 5 Lequesne's Index (higher is worse). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-002-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0061"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-002-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-002-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Chondroitin sulfate versus Control, Outcome 6 Patient Global Assessment (% with improvement)." data-id="CD005614-fig-0061" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-002-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.6</div> <div class="figure-caption"> <p>Comparison 2 Chondroitin sulfate versus Control, Outcome 6 Patient Global Assessment (% with improvement). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0061">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-002-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0062"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-002-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-002-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Chondroitin sulfate versus Control, Outcome 7 MD Global Assessment (% with improvement)." data-id="CD005614-fig-0062" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-002-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.7</div> <div class="figure-caption"> <p>Comparison 2 Chondroitin sulfate versus Control, Outcome 7 MD Global Assessment (% with improvement). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0062">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-002-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0063"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-002-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-002-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Chondroitin sulfate versus Control, Outcome 8 NSAID consumption." data-id="CD005614-fig-0063" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-002-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.8</div> <div class="figure-caption"> <p>Comparison 2 Chondroitin sulfate versus Control, Outcome 8 NSAID consumption.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0063">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-002-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0064"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-002-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-002-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Chondroitin sulfate versus Control, Outcome 9 All withdrawals." data-id="CD005614-fig-0064" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-002-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.9</div> <div class="figure-caption"> <p>Comparison 2 Chondroitin sulfate versus Control, Outcome 9 All withdrawals.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0064">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-002-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0065"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-002-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-002-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Chondroitin sulfate versus Control, Outcome 10 Withdrawals due to adverse events." data-id="CD005614-fig-0065" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-002-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.10</div> <div class="figure-caption"> <p>Comparison 2 Chondroitin sulfate versus Control, Outcome 10 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0065">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-002-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0066"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-002-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-002-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Chondroitin sulfate versus Control, Outcome 11 Number of adverse events." data-id="CD005614-fig-0066" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-002-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.11</div> <div class="figure-caption"> <p>Comparison 2 Chondroitin sulfate versus Control, Outcome 11 Number of adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0066">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-002-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0067"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-002-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-002-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 Chondroitin sulfate versus Control, Outcome 12 GI adverse events." data-id="CD005614-fig-0067" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-002-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.12</div> <div class="figure-caption"> <p>Comparison 2 Chondroitin sulfate versus Control, Outcome 12 GI adverse events.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0067">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-002-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0068"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-003-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-003-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 1 Pain on 0 to 100 scale." data-id="CD005614-fig-0068" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.1</div> <div class="figure-caption"> <p>Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 1 Pain on 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0068">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0069"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-003-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-003-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 2 WOMAC MCII." data-id="CD005614-fig-0069" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.2</div> <div class="figure-caption"> <p>Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 2 WOMAC MCII.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0069">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0070"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-003-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-003-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 3 Physical Function on a 0 to 100 scale." data-id="CD005614-fig-0070" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.3</div> <div class="figure-caption"> <p>Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 3 Physical Function on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0070">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0071"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-003-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-003-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 4 Six‐minute walk distance in meters walked." data-id="CD005614-fig-0071" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.4</div> <div class="figure-caption"> <p>Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 4 Six‐minute walk distance in meters walked. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0071">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0072"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-003-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-003-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 5 WOMAC Stiffness." data-id="CD005614-fig-0072" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.5</div> <div class="figure-caption"> <p>Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 5 WOMAC Stiffness.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0072">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0073"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-003-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-003-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 6 WOMAC Total." data-id="CD005614-fig-0073" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.6</div> <div class="figure-caption"> <p>Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 6 WOMAC Total.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0073">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0074"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-003-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-003-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 7 Patient Global Assessment VAS (0 to 100 mm)." data-id="CD005614-fig-0074" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.7</div> <div class="figure-caption"> <p>Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 7 Patient Global Assessment VAS (0 to 100 mm). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0074">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0075"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-003-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-003-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 8 MD Global Assessment VAS (0 to 100 mm)." data-id="CD005614-fig-0075" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.8</div> <div class="figure-caption"> <p>Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 8 MD Global Assessment VAS (0 to 100 mm). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0075">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0076"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-003-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-003-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 9 OMERACT‐OARSI Responders." data-id="CD005614-fig-0076" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.9</div> <div class="figure-caption"> <p>Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 9 OMERACT‐OARSI Responders. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0076">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0077"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-003-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-003-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 10 HAQ Disability Score." data-id="CD005614-fig-0077" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.10</div> <div class="figure-caption"> <p>Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 10 HAQ Disability Score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0077">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0078"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-003-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-003-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 11 Objective Joint Function (Flexion)." data-id="CD005614-fig-0078" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.11</div> <div class="figure-caption"> <p>Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 11 Objective Joint Function (Flexion). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0078">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0079"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-003-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-003-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 12 Objective Joint Function (extension)." data-id="CD005614-fig-0079" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.12</div> <div class="figure-caption"> <p>Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 12 Objective Joint Function (extension). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0079">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0080"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-003-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-003-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 13 Objective Joint Function (balance)." data-id="CD005614-fig-0080" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.13</div> <div class="figure-caption"> <p>Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 13 Objective Joint Function (balance). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0080">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0081"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-003-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-003-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 14 All withdrawals." data-id="CD005614-fig-0081" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.14</div> <div class="figure-caption"> <p>Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 14 All withdrawals.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0081">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0082"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-003-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-003-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 15 Withdrawals due to adverse events." data-id="CD005614-fig-0082" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.15</div> <div class="figure-caption"> <p>Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 15 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0082">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0083"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-003-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-003-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 16 Withdrawals due to inefficacy." data-id="CD005614-fig-0083" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.16</div> <div class="figure-caption"> <p>Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 16 Withdrawals due to inefficacy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0083">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0084"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-003-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-003-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 17 Number of adverse events." data-id="CD005614-fig-0084" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.17</div> <div class="figure-caption"> <p>Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 17 Number of adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0084">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0085"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-003-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-003-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 18 Serious adverse events." data-id="CD005614-fig-0085" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.18</div> <div class="figure-caption"> <p>Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 18 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0085">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0086"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-003-19" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-003-19.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 19 GI adverse events." data-id="CD005614-fig-0086" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-19.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.19</div> <div class="figure-caption"> <p>Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 19 GI adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0086">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-19.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0087"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-003-20" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-003-20.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 20 Hematologic adverse events." data-id="CD005614-fig-0087" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-20.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.20</div> <div class="figure-caption"> <p>Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 20 Hematologic adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0087">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-20.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0088"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-003-21" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-003-21.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 21 Other adverse events." data-id="CD005614-fig-0088" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-21.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.21</div> <div class="figure-caption"> <p>Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 21 Other adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0088">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-21.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0089"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-003-22" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-003-22.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 22 Death." data-id="CD005614-fig-0089" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-22.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 3.22</div> <div class="figure-caption"> <p>Comparison 3 Chondroitin sulfate + Glucosamine versus Placebo, Outcome 22 Death.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0089">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-003-22.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0090"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-004-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-004-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0090" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.1</div> <div class="figure-caption"> <p>Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 1 Pain on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0090">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0091"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-004-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-004-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 2 WOMAC MCII." data-id="CD005614-fig-0091" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.2</div> <div class="figure-caption"> <p>Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 2 WOMAC MCII. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0091">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0092"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-004-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-004-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 3 Physical Function on a 0 to 100 scale." data-id="CD005614-fig-0092" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.3</div> <div class="figure-caption"> <p>Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 3 Physical Function on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0092">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0093"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-004-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-004-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 4 WOMAC Stiffness." data-id="CD005614-fig-0093" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.4</div> <div class="figure-caption"> <p>Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 4 WOMAC Stiffness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0093">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0094"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-004-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-004-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 5 WOMAC Total." data-id="CD005614-fig-0094" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.5</div> <div class="figure-caption"> <p>Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 5 WOMAC Total. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0094">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0095"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-004-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-004-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 6 Percentage with improved Patient Global Assessment." data-id="CD005614-fig-0095" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.6</div> <div class="figure-caption"> <p>Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 6 Percentage with improved Patient Global Assessment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0095">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0096"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-004-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-004-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 7 Percentage with improved MD Global Assessment." data-id="CD005614-fig-0096" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.7</div> <div class="figure-caption"> <p>Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 7 Percentage with improved MD Global Assessment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0096">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0097"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-004-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-004-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 8 OMERACT‐OARSI." data-id="CD005614-fig-0097" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.8</div> <div class="figure-caption"> <p>Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 8 OMERACT‐OARSI. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0097">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0098"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-004-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-004-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 9 HAQ Disability Score." data-id="CD005614-fig-0098" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.9</div> <div class="figure-caption"> <p>Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 9 HAQ Disability Score. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0098">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0099"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-004-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-004-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 10 Radiographic Outcome: Change in Mean JSW in mm." data-id="CD005614-fig-0099" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.10</div> <div class="figure-caption"> <p>Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 10 Radiographic Outcome: Change in Mean JSW in mm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0099">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0100"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-004-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-004-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 11 All withdrawals." data-id="CD005614-fig-0100" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.11</div> <div class="figure-caption"> <p>Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 11 All withdrawals. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0100">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0101"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-004-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-004-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 12 Withdrawals due to adverse events." data-id="CD005614-fig-0101" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.12</div> <div class="figure-caption"> <p>Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 12 Withdrawals due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0101">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0102"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-004-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-004-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 13 Withdrawals due to inefficacy." data-id="CD005614-fig-0102" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.13</div> <div class="figure-caption"> <p>Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 13 Withdrawals due to inefficacy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0102">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0103"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-004-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-004-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 14 Number of adverse events." data-id="CD005614-fig-0103" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.14</div> <div class="figure-caption"> <p>Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 14 Number of adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0103">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0104"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-004-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-004-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 15 Serious adverse events." data-id="CD005614-fig-0104" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.15</div> <div class="figure-caption"> <p>Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 15 Serious adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0104">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0105"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-004-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-004-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 16 GI adverse events." data-id="CD005614-fig-0105" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.16</div> <div class="figure-caption"> <p>Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 16 GI adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0105">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0106"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-004-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-004-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 17 Other adverse events." data-id="CD005614-fig-0106" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.17</div> <div class="figure-caption"> <p>Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 17 Other adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0106">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0107"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-004-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-004-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 18 Death." data-id="CD005614-fig-0107" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 4.18</div> <div class="figure-caption"> <p>Comparison 4 Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs), Outcome 18 Death. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0107">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-004-18.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0108"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-005-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-005-01.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo or Control, Outcome 1 Pain on 0 to 100 scale (short‐ and long‐term results)." data-id="CD005614-fig-0108" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-005-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.1</div> <div class="figure-caption"> <p>Comparison 5 Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo or Control, Outcome 1 Pain on 0 to 100 scale (short‐ and long‐term results). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0108">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-005-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0109"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-005-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-005-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo or Control, Outcome 2 Physical Function on 0 to 100 scale (short‐ and long‐term results)." data-id="CD005614-fig-0109" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-005-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.2</div> <div class="figure-caption"> <p>Comparison 5 Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo or Control, Outcome 2 Physical Function on 0 to 100 scale (short‐ and long‐term results). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0109">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-005-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0110"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-005-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-005-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo or Control, Outcome 3 Lequesne's Index." data-id="CD005614-fig-0110" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-005-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.3</div> <div class="figure-caption"> <p>Comparison 5 Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo or Control, Outcome 3 Lequesne's Index. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0110">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-005-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0111"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-005-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-005-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo or Control, Outcome 4 WOMAC MCII." data-id="CD005614-fig-0111" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-005-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.4</div> <div class="figure-caption"> <p>Comparison 5 Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo or Control, Outcome 4 WOMAC MCII. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0111">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-005-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0112"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-005-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-005-05.png" target="_blank"><b></b></a></p> </div><img alt="Comparison 5 Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo or Control, Outcome 5 Pain on 0 to 100 scale (short‐ or long‐term) for CS dose &gt;= 800 mg/day." data-id="CD005614-fig-0112" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-005-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 5.5</div> <div class="figure-caption"> <p>Comparison 5 Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo or Control, Outcome 5 Pain on 0 to 100 scale (short‐ or long‐term) for CS dose &gt;= 800 mg/day. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0112">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-005-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0113"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-006-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-006-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity analysis (blinding): Chondroitin sulfate versus Placebo, Outcome 1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0113" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-006-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.1</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity analysis (blinding): Chondroitin sulfate versus Placebo, Outcome 1 Pain on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0113">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-006-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0114"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-006-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-006-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity analysis (blinding): Chondroitin sulfate versus Placebo, Outcome 2 WOMAC MCII." data-id="CD005614-fig-0114" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-006-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.2</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity analysis (blinding): Chondroitin sulfate versus Placebo, Outcome 2 WOMAC MCII. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0114">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-006-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0115"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-006-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-006-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity analysis (blinding): Chondroitin sulfate versus Placebo, Outcome 3 Physical Function on a 0 to 100 scale." data-id="CD005614-fig-0115" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-006-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.3</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity analysis (blinding): Chondroitin sulfate versus Placebo, Outcome 3 Physical Function on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0115">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-006-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0116"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-006-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-006-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 6 Sensitivity analysis (blinding): Chondroitin sulfate versus Placebo, Outcome 4 Radiographic outcome: Change in Mean JSW in mm." data-id="CD005614-fig-0116" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-006-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 6.4</div> <div class="figure-caption"> <p>Comparison 6 Sensitivity analysis (blinding): Chondroitin sulfate versus Placebo, Outcome 4 Radiographic outcome: Change in Mean JSW in mm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0116">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-006-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0117"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-007-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-007-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Sensitivity analysis (blinding): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0117" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-007-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.1</div> <div class="figure-caption"> <p>Comparison 7 Sensitivity analysis (blinding): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 1 Pain on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0117">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-007-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0118"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-007-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-007-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 7 Sensitivity analysis (blinding): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 2 Physical Function on a 0 to 100 scale." data-id="CD005614-fig-0118" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-007-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 7.2</div> <div class="figure-caption"> <p>Comparison 7 Sensitivity analysis (blinding): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 2 Physical Function on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0118">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-007-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0119"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-008-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-008-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 8 Sensitivity analysis (blinding): Glucosamine + Chondroitin sulfate versus NSAIDs, Outcome 1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0119" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-008-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 8.1</div> <div class="figure-caption"> <p>Comparison 8 Sensitivity analysis (blinding): Glucosamine + Chondroitin sulfate versus NSAIDs, Outcome 1 Pain on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0119">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-008-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0120"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-009-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-009-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sensitivity analysis (blinding): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 1 Pain—Blinding." data-id="CD005614-fig-0120" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-009-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.1</div> <div class="figure-caption"> <p>Comparison 9 Sensitivity analysis (blinding): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 1 Pain—Blinding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0120">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-009-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0121"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-009-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-009-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 9 Sensitivity analysis (blinding): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 2 Physical Function—Blinding." data-id="CD005614-fig-0121" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-009-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 9.2</div> <div class="figure-caption"> <p>Comparison 9 Sensitivity analysis (blinding): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 2 Physical Function—Blinding. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0121">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-009-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0122"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-010-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-010-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Sensitivity analysis (study size): Chondroitin sulfate versus Placebo, Outcome 1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0122" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-010-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.1</div> <div class="figure-caption"> <p>Comparison 10 Sensitivity analysis (study size): Chondroitin sulfate versus Placebo, Outcome 1 Pain on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0122">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-010-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0123"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-010-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-010-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Sensitivity analysis (study size): Chondroitin sulfate versus Placebo, Outcome 2 WOMAC MCII." data-id="CD005614-fig-0123" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-010-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.2</div> <div class="figure-caption"> <p>Comparison 10 Sensitivity analysis (study size): Chondroitin sulfate versus Placebo, Outcome 2 WOMAC MCII. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0123">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-010-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0124"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-010-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-010-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Sensitivity analysis (study size): Chondroitin sulfate versus Placebo, Outcome 3 Physical Function on a 0 to 100 scale." data-id="CD005614-fig-0124" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-010-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.3</div> <div class="figure-caption"> <p>Comparison 10 Sensitivity analysis (study size): Chondroitin sulfate versus Placebo, Outcome 3 Physical Function on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0124">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-010-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0125"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-010-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-010-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 10 Sensitivity analysis (study size): Chondroitin sulfate versus Placebo, Outcome 4 Radiographic outcome: Change in Mean JSW in mm." data-id="CD005614-fig-0125" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-010-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 10.4</div> <div class="figure-caption"> <p>Comparison 10 Sensitivity analysis (study size): Chondroitin sulfate versus Placebo, Outcome 4 Radiographic outcome: Change in Mean JSW in mm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0125">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-010-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0126"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-011-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-011-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Sensitivity analysis (study size): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0126" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-011-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.1</div> <div class="figure-caption"> <p>Comparison 11 Sensitivity analysis (study size): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 1 Pain on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0126">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-011-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0127"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-011-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-011-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 11 Sensitivity analysis (study size): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 2 Physical Function on a 0 to 100 scale." data-id="CD005614-fig-0127" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-011-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 11.2</div> <div class="figure-caption"> <p>Comparison 11 Sensitivity analysis (study size): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 2 Physical Function on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0127">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-011-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0128"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-012-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-012-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 12 Sensitivity analysis (study size): Glucosamine + Chondroitin sulfate versus NSAIDs, Outcome 1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0128" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-012-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 12.1</div> <div class="figure-caption"> <p>Comparison 12 Sensitivity analysis (study size): Glucosamine + Chondroitin sulfate versus NSAIDs, Outcome 1 Pain on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0128">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-012-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0129"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-013-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-013-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Sensitivity analysis (study size): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 1 Pain—study size." data-id="CD005614-fig-0129" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-013-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.1</div> <div class="figure-caption"> <p>Comparison 13 Sensitivity analysis (study size): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 1 Pain—study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0129">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-013-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0130"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-013-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-013-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 13 Sensitivity analysis (study size): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 2 Physical Function—study size." data-id="CD005614-fig-0130" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-013-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 13.2</div> <div class="figure-caption"> <p>Comparison 13 Sensitivity analysis (study size): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 2 Physical Function—study size. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0130">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-013-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0131"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-014-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-014-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Sensitivity analysis (study sponsors): Chondroitin versus Placebo, Outcome 1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0131" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-014-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.1</div> <div class="figure-caption"> <p>Comparison 14 Sensitivity analysis (study sponsors): Chondroitin versus Placebo, Outcome 1 Pain on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0131">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-014-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0132"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-014-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-014-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Sensitivity analysis (study sponsors): Chondroitin versus Placebo, Outcome 2 WOMAC MCII." data-id="CD005614-fig-0132" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-014-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.2</div> <div class="figure-caption"> <p>Comparison 14 Sensitivity analysis (study sponsors): Chondroitin versus Placebo, Outcome 2 WOMAC MCII. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0132">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-014-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0133"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-014-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-014-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Sensitivity analysis (study sponsors): Chondroitin versus Placebo, Outcome 3 Physical Function on a 0 to 100 scale." data-id="CD005614-fig-0133" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-014-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.3</div> <div class="figure-caption"> <p>Comparison 14 Sensitivity analysis (study sponsors): Chondroitin versus Placebo, Outcome 3 Physical Function on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0133">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-014-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0134"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-014-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-014-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 14 Sensitivity analysis (study sponsors): Chondroitin versus Placebo, Outcome 4 Radiographic outcome: Change in Mean JSW in mm." data-id="CD005614-fig-0134" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-014-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 14.4</div> <div class="figure-caption"> <p>Comparison 14 Sensitivity analysis (study sponsors): Chondroitin versus Placebo, Outcome 4 Radiographic outcome: Change in Mean JSW in mm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0134">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-014-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0135"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-015-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-015-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Sensitivity analysis (study sponsors): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0135" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-015-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.1</div> <div class="figure-caption"> <p>Comparison 15 Sensitivity analysis (study sponsors): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 1 Pain on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0135">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-015-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0136"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-015-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-015-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 15 Sensitivity analysis (study sponsors): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 2 Physical Function on a 0 to 100 scale." data-id="CD005614-fig-0136" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-015-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 15.2</div> <div class="figure-caption"> <p>Comparison 15 Sensitivity analysis (study sponsors): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 2 Physical Function on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0136">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-015-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0137"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-016-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-016-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 16 Sensitivity analysis (study sponsors): Chondroitin sulfate + Glucosamine versus NSAIDs, Outcome 1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0137" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-016-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 16.1</div> <div class="figure-caption"> <p>Comparison 16 Sensitivity analysis (study sponsors): Chondroitin sulfate + Glucosamine versus NSAIDs, Outcome 1 Pain on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0137">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-016-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0138"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-017-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-017-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Sensitivity analysis (study sponsors): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Control/Placebo, Outcome 1 Pain—study sponsors." data-id="CD005614-fig-0138" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-017-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.1</div> <div class="figure-caption"> <p>Comparison 17 Sensitivity analysis (study sponsors): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Control/Placebo, Outcome 1 Pain—study sponsors. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0138">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-017-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0139"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-017-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-017-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 17 Sensitivity analysis (study sponsors): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Control/Placebo, Outcome 2 Physical Function—study sponsors." data-id="CD005614-fig-0139" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-017-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 17.2</div> <div class="figure-caption"> <p>Comparison 17 Sensitivity analysis (study sponsors): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Control/Placebo, Outcome 2 Physical Function—study sponsors. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0139">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-017-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0140"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-018-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-018-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Sensitivity analysis (publication year): Chondroitin versus Placebo, Outcome 1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0140" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-018-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.1</div> <div class="figure-caption"> <p>Comparison 18 Sensitivity analysis (publication year): Chondroitin versus Placebo, Outcome 1 Pain on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0140">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-018-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0141"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-018-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-018-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Sensitivity analysis (publication year): Chondroitin versus Placebo, Outcome 2 WOMAC MCII." data-id="CD005614-fig-0141" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-018-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.2</div> <div class="figure-caption"> <p>Comparison 18 Sensitivity analysis (publication year): Chondroitin versus Placebo, Outcome 2 WOMAC MCII. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0141">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-018-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0142"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-018-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-018-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Sensitivity analysis (publication year): Chondroitin versus Placebo, Outcome 3 Physical Function on a 0 to 100 scale." data-id="CD005614-fig-0142" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-018-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.3</div> <div class="figure-caption"> <p>Comparison 18 Sensitivity analysis (publication year): Chondroitin versus Placebo, Outcome 3 Physical Function on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0142">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-018-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0143"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-018-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-018-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 18 Sensitivity analysis (publication year): Chondroitin versus Placebo, Outcome 4 Radiographic outcome: Change in Mean JSW in mm." data-id="CD005614-fig-0143" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-018-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 18.4</div> <div class="figure-caption"> <p>Comparison 18 Sensitivity analysis (publication year): Chondroitin versus Placebo, Outcome 4 Radiographic outcome: Change in Mean JSW in mm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0143">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-018-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0144"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-019-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-019-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Sensitivity analysis (publication year): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0144" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-019-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.1</div> <div class="figure-caption"> <p>Comparison 19 Sensitivity analysis (publication year): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 1 Pain on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0144">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-019-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0145"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-019-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-019-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 19 Sensitivity analysis (publication year): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 2 Physical Function on a 0 to 100 scale." data-id="CD005614-fig-0145" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-019-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 19.2</div> <div class="figure-caption"> <p>Comparison 19 Sensitivity analysis (publication year): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 2 Physical Function on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0145">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-019-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0146"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-020-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-020-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 20 Sensitivity analysis (publication year): Glucosamine + Chondroitin sulfate versus NSAIDs, Outcome 1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0146" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-020-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 20.1</div> <div class="figure-caption"> <p>Comparison 20 Sensitivity analysis (publication year): Glucosamine + Chondroitin sulfate versus NSAIDs, Outcome 1 Pain on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0146">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-020-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0147"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-021-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-021-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Sensitivity analysis (publication year): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 1 Pain—publication year." data-id="CD005614-fig-0147" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-021-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.1</div> <div class="figure-caption"> <p>Comparison 21 Sensitivity analysis (publication year): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 1 Pain—publication year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0147">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-021-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0148"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-021-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-021-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 21 Sensitivity analysis (publication year): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 2 Physical Function—publication year." data-id="CD005614-fig-0148" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-021-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 21.2</div> <div class="figure-caption"> <p>Comparison 21 Sensitivity analysis (publication year): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 2 Physical Function—publication year. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0148">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-021-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0149"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-022-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-022-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 Sensitivity analysis (allocation concealment): Chondroitin sulfate versus Placebo, Outcome 1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0149" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-022-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.1</div> <div class="figure-caption"> <p>Comparison 22 Sensitivity analysis (allocation concealment): Chondroitin sulfate versus Placebo, Outcome 1 Pain on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0149">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-022-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0150"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-022-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-022-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 Sensitivity analysis (allocation concealment): Chondroitin sulfate versus Placebo, Outcome 2 WOMAC MCII." data-id="CD005614-fig-0150" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-022-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.2</div> <div class="figure-caption"> <p>Comparison 22 Sensitivity analysis (allocation concealment): Chondroitin sulfate versus Placebo, Outcome 2 WOMAC MCII. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0150">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-022-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0151"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-022-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-022-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 Sensitivity analysis (allocation concealment): Chondroitin sulfate versus Placebo, Outcome 3 Physical Function on a 0 to 100 scale." data-id="CD005614-fig-0151" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-022-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.3</div> <div class="figure-caption"> <p>Comparison 22 Sensitivity analysis (allocation concealment): Chondroitin sulfate versus Placebo, Outcome 3 Physical Function on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0151">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-022-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0152"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-022-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-022-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 22 Sensitivity analysis (allocation concealment): Chondroitin sulfate versus Placebo, Outcome 4 Radiographic outcome: Change in Mean JSW in mm." data-id="CD005614-fig-0152" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-022-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 22.4</div> <div class="figure-caption"> <p>Comparison 22 Sensitivity analysis (allocation concealment): Chondroitin sulfate versus Placebo, Outcome 4 Radiographic outcome: Change in Mean JSW in mm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0152">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-022-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0153"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-023-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-023-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 23 Sensitivity analysis (allocation concealment): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0153" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-023-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.1</div> <div class="figure-caption"> <p>Comparison 23 Sensitivity analysis (allocation concealment): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 1 Pain on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0153">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-023-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0154"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-023-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-023-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 23 Sensitivity analysis (allocation concealment): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 2 Physical Function on a 0 to 100 scale." data-id="CD005614-fig-0154" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-023-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 23.2</div> <div class="figure-caption"> <p>Comparison 23 Sensitivity analysis (allocation concealment): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 2 Physical Function on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0154">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-023-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0155"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-024-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-024-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 24 Sensitivity analysis (allocation concealment): Chondroitin sulfate + Glucosamine versus NSAIDs, Outcome 1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0155" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-024-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 24.1</div> <div class="figure-caption"> <p>Comparison 24 Sensitivity analysis (allocation concealment): Chondroitin sulfate + Glucosamine versus NSAIDs, Outcome 1 Pain on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0155">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-024-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0156"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-025-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-025-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 25 Sensitivity analysis (allocation concealment): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 1 Pain—allocation concealment." data-id="CD005614-fig-0156" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-025-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.1</div> <div class="figure-caption"> <p>Comparison 25 Sensitivity analysis (allocation concealment): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 1 Pain—allocation concealment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0156">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-025-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0157"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-025-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-025-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 25 Sensitivity analysis (allocation concealment): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 2 Physical Function—allocation concealment." data-id="CD005614-fig-0157" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-025-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 25.2</div> <div class="figure-caption"> <p>Comparison 25 Sensitivity analysis (allocation concealment): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 2 Physical Function—allocation concealment. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0157">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-025-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0158"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-026-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-026-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 26 Sensitivity analysis (estimated SD): Chondroitin versus Placebo, Outcome 1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0158" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-026-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.1</div> <div class="figure-caption"> <p>Comparison 26 Sensitivity analysis (estimated SD): Chondroitin versus Placebo, Outcome 1 Pain on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0158">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-026-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0159"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-026-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-026-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 26 Sensitivity analysis (estimated SD): Chondroitin versus Placebo, Outcome 2 Physical Function on a 0 to 100 scale." data-id="CD005614-fig-0159" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-026-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.2</div> <div class="figure-caption"> <p>Comparison 26 Sensitivity analysis (estimated SD): Chondroitin versus Placebo, Outcome 2 Physical Function on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0159">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-026-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0160"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-026-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-026-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 26 Sensitivity analysis (estimated SD): Chondroitin versus Placebo, Outcome 3 Lequesne's Index." data-id="CD005614-fig-0160" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-026-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 26.3</div> <div class="figure-caption"> <p>Comparison 26 Sensitivity analysis (estimated SD): Chondroitin versus Placebo, Outcome 3 Lequesne's Index. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0160">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-026-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0161"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-027-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-027-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 27 Sensitivity analysis (estimated SD): Chondroitin sulfate versus Control, Outcome 1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0161" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-027-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 27.1</div> <div class="figure-caption"> <p>Comparison 27 Sensitivity analysis (estimated SD): Chondroitin sulfate versus Control, Outcome 1 Pain on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0161">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-027-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0162"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-027-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-027-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 27 Sensitivity analysis (estimated SD): Chondroitin sulfate versus Control, Outcome 2 Lequesne's Index." data-id="CD005614-fig-0162" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-027-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 27.2</div> <div class="figure-caption"> <p>Comparison 27 Sensitivity analysis (estimated SD): Chondroitin sulfate versus Control, Outcome 2 Lequesne's Index. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0162">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-027-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0163"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-027-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-027-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 27 Sensitivity analysis (estimated SD): Chondroitin sulfate versus Control, Outcome 3 Patient Global Assessment (VAS)." data-id="CD005614-fig-0163" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-027-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 27.3</div> <div class="figure-caption"> <p>Comparison 27 Sensitivity analysis (estimated SD): Chondroitin sulfate versus Control, Outcome 3 Patient Global Assessment (VAS). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0163">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-027-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0164"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-028-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-028-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 28 Sensitivity analysis (estimated SD): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0164" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-028-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.1</div> <div class="figure-caption"> <p>Comparison 28 Sensitivity analysis (estimated SD): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 1 Pain on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0164">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-028-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0165"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-028-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-028-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 28 Sensitivity analysis (estimated SD): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 2 WOMAC Total." data-id="CD005614-fig-0165" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-028-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.2</div> <div class="figure-caption"> <p>Comparison 28 Sensitivity analysis (estimated SD): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 2 WOMAC Total. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0165">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-028-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0166"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-028-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-028-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 28 Sensitivity analysis (estimated SD): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 3 Patient Global Assessment VAS (0 to 100 mm)." data-id="CD005614-fig-0166" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-028-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.3</div> <div class="figure-caption"> <p>Comparison 28 Sensitivity analysis (estimated SD): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 3 Patient Global Assessment VAS (0 to 100 mm). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0166">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-028-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0167"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-028-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-028-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 28 Sensitivity analysis (estimated SD): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 4 Lequesne's Index." data-id="CD005614-fig-0167" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-028-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 28.4</div> <div class="figure-caption"> <p>Comparison 28 Sensitivity analysis (estimated SD): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 4 Lequesne's Index. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0167">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-028-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0168"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-029-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-029-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 29 Sensitivity analysis (estimated SD): Chondroitin sulfate + Glucosamine versus NSAIDs, Outcome 1 Pain (0 to 100)." data-id="CD005614-fig-0168" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-029-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 29.1</div> <div class="figure-caption"> <p>Comparison 29 Sensitivity analysis (estimated SD): Chondroitin sulfate + Glucosamine versus NSAIDs, Outcome 1 Pain (0 to 100). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0168">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-029-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0169"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-029-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-029-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 29 Sensitivity analysis (estimated SD): Chondroitin sulfate + Glucosamine versus NSAIDs, Outcome 2 Physical Function." data-id="CD005614-fig-0169" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-029-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 29.2</div> <div class="figure-caption"> <p>Comparison 29 Sensitivity analysis (estimated SD): Chondroitin sulfate + Glucosamine versus NSAIDs, Outcome 2 Physical Function. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0169">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-029-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0170"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-029-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-029-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 29 Sensitivity analysis (estimated SD): Chondroitin sulfate + Glucosamine versus NSAIDs, Outcome 3 WOMAC Stiffness." data-id="CD005614-fig-0170" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-029-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 29.3</div> <div class="figure-caption"> <p>Comparison 29 Sensitivity analysis (estimated SD): Chondroitin sulfate + Glucosamine versus NSAIDs, Outcome 3 WOMAC Stiffness. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0170">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-029-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0171"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-029-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-029-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 29 Sensitivity analysis (estimated SD): Chondroitin sulfate + Glucosamine versus NSAIDs, Outcome 4 WOMAC Total." data-id="CD005614-fig-0171" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-029-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 29.4</div> <div class="figure-caption"> <p>Comparison 29 Sensitivity analysis (estimated SD): Chondroitin sulfate + Glucosamine versus NSAIDs, Outcome 4 WOMAC Total. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0171">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-029-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0172"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-030-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-030-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 30 Sensitivity analysis (estimated SD): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 1 Pain (0 to 100)." data-id="CD005614-fig-0172" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-030-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.1</div> <div class="figure-caption"> <p>Comparison 30 Sensitivity analysis (estimated SD): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 1 Pain (0 to 100). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0172">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-030-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0173"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-030-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-030-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 30 Sensitivity analysis (estimated SD): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 2 Physical Function on a 0 to 100 scale (short‐ and long‐term results)." data-id="CD005614-fig-0173" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-030-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.2</div> <div class="figure-caption"> <p>Comparison 30 Sensitivity analysis (estimated SD): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 2 Physical Function on a 0 to 100 scale (short‐ and long‐term results). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0173">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-030-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0174"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-030-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-030-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 30 Sensitivity analysis (estimated SD): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 3 Lequesne's Index." data-id="CD005614-fig-0174" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-030-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 30.3</div> <div class="figure-caption"> <p>Comparison 30 Sensitivity analysis (estimated SD): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 3 Lequesne's Index. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0174">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-030-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0175"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-031-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-031-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 31 Sensitivity analysis (ITT): Chondroitin sulfate versus Placebo, Outcome 1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0175" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-031-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.1</div> <div class="figure-caption"> <p>Comparison 31 Sensitivity analysis (ITT): Chondroitin sulfate versus Placebo, Outcome 1 Pain on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0175">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-031-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0176"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-031-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-031-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 31 Sensitivity analysis (ITT): Chondroitin sulfate versus Placebo, Outcome 2 WOMAC MCII." data-id="CD005614-fig-0176" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-031-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.2</div> <div class="figure-caption"> <p>Comparison 31 Sensitivity analysis (ITT): Chondroitin sulfate versus Placebo, Outcome 2 WOMAC MCII. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0176">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-031-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0177"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-031-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-031-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 31 Sensitivity analysis (ITT): Chondroitin sulfate versus Placebo, Outcome 3 Physical Function on a 0 to 100 scale." data-id="CD005614-fig-0177" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-031-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.3</div> <div class="figure-caption"> <p>Comparison 31 Sensitivity analysis (ITT): Chondroitin sulfate versus Placebo, Outcome 3 Physical Function on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0177">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-031-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0178"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-031-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-031-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 31 Sensitivity analysis (ITT): Chondroitin sulfate versus Placebo, Outcome 4 Radiographic outcome: Change in Mean JSW in mm." data-id="CD005614-fig-0178" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-031-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 31.4</div> <div class="figure-caption"> <p>Comparison 31 Sensitivity analysis (ITT): Chondroitin sulfate versus Placebo, Outcome 4 Radiographic outcome: Change in Mean JSW in mm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0178">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-031-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0179"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-032-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-032-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 32 Sensitivity analysis (ITT): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0179" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-032-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 32.1</div> <div class="figure-caption"> <p>Comparison 32 Sensitivity analysis (ITT): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 1 Pain on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0179">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-032-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0180"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-032-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-032-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 32 Sensitivity analysis (ITT): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 2 Physical Function on a 0 to 100 scale." data-id="CD005614-fig-0180" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-032-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 32.2</div> <div class="figure-caption"> <p>Comparison 32 Sensitivity analysis (ITT): Chondroitin sulfate + Glucosamine versus Placebo, Outcome 2 Physical Function on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0180">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-032-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0181"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-033-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-033-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 33 Sensitivity analysis (ITT): Glucosamine + Chondroitin sulfate versus NSAID, Outcome 1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0181" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-033-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 33.1</div> <div class="figure-caption"> <p>Comparison 33 Sensitivity analysis (ITT): Glucosamine + Chondroitin sulfate versus NSAID, Outcome 1 Pain on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0181">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-033-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0182"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-034-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-034-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 34 Sensitivity analysis (ITT): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 1 Pain on a 0 to 100 scale." data-id="CD005614-fig-0182" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-034-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 34.1</div> <div class="figure-caption"> <p>Comparison 34 Sensitivity analysis (ITT): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 1 Pain on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0182">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-034-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD005614-fig-0183"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/urn:x-wiley:14651858:media:CD005614:CD005614-CMP-034-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_t/tCD005614-CMP-034-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 34 Sensitivity analysis (ITT): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 2 Physical Function on a 0 to 100 scale." data-id="CD005614-fig-0183" src="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-034-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 34.2</div> <div class="figure-caption"> <p>Comparison 34 Sensitivity analysis (ITT): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control, Outcome 2 Physical Function on a 0 to 100 scale. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-fig-0183">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/media/CDSR/CD005614/image_n/nCD005614-CMP-034-02.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD005614-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Chondroitin versus placebo for osteoarthritis</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chondroitin versus placebo for osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> patients with osteoarthritis<br/> <b>Settings:</b> international inpatient and outpatient clinics, hospitals, and research centers<br/> <b>Intervention:</b> Chondroitin versus placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of Participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Chondroitin versus Placebo</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain on a 0 to 100 mm scale ‐ Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain on a 0 to 100 scale in the control groups was</p> <p><b>28 points</b><sup>3</sup> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain on a 0 to 100 scale in the intervention groups was</p> <p><b>10.1 mm lower</b> </p> <p>(14.6 to 5.7 lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1077<br/> (8 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean Difference ‐10.14 (95% CI ‐14.58 to ‐5.71)</p> <p>Absolute risk difference</p> <p>‐10% (95% CI ‐15% to ‐6%)</p> <p>Relative risk difference</p> <p>‐36% (95% CI ‐52% to ‐20%)</p> <p>NNTB = 5 (95% CI 3 to 8)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain on a 0 to 100 scale ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain on a 0 to 100 scale in the control groups was</p> <p><b>30 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain on a 0 to 100 scale in the intervention groups was</p> <p><b>9 points lower</b> </p> <p>(18 to 0 lower)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>989<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean Difference ‐9.01 (95% CI ‐17.68 to ‐0.34)</p> <p>Absolute risk difference</p> <p>‐9% (95% CI ‐18% to 0%)</p> <p>Relative risk difference</p> <p>‐30% (95% CI ‐60% to 0%)</p> <p>NNTB = n/a</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>WOMAC MCII Pain subscale (reduction in knee pain by 20%) ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>471 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>528 per 1000</b> <br/> (476 to 584) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> <br/> (1.01 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1253<br/> (2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference 6% (1% to 11%)</p> <p>Relative risk difference 12% (1% to 24%)</p> <p>NNTB = 16 (9 to 136)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Composite Measure of Pain, Function and Disability as assessed with Lequesne's Index on 0 to 24 scale (lower indicates less pain and disability) ‐ Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean Lequesne's index on 0 to 24 scale in the control groups was <b>7.4 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean Lequesne's index on 0 to 24 scale in the intervention groups was<br/> <b>1.98 lower</b> <br/> (2.79 to 1.17 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>903<br/> (7 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.57 (95% CI ‐0.84 to ‐0.30)<br/> Absolute risk difference ‐8% (95% CI ‐12% to ‐5%) </p> <p>Relative risk difference ‐18% (95% CI ‐25% to ‐10%)</p> <p>NNTB=2 (95% CI 2, 3)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Radiographic Outcome: Reduction in Minimum Joint Space Width (JSW) in mm ‐ Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</b> </p> <p>Scale: millimeters (smaller decrease in reduction in minimum joint space width is better)<br/> Follow‐up: 3 to 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction in JSW in the control group was <b>0.3 mm</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean reduction in JSW in the intervention groups was<br/> <b>0.18 mm lower</b> <br/> (0.06 to 0.30 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>922<br/> (2 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference not calculable because no range is provided for this measure</p> <p>Relative risk difference: 4.7% (95% CI, 1.6% to 7.8%)</p> <p>NNTB = 7 (95% CI 5 to 13)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Withdrawals due to adverse events</b> Follow up: 3 to 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>44 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>47 per 1000</b> <br/> (32 to 69) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.08</b> <br/> (0.74 to 1.57) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2406</p> <p>(10 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: 0% change (‐1% to 2%)</p> <p>Relative percentage change: 8% (‐26% to 57%)</p> <p>NNTH = not applicable</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of serious adverse events</b> Follow‐up: 3 to 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>63 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>27 per 1000</b> <br/> (13 to 53) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>OR 0.40</b> <br/> (0.19 to 0.82) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>954<br/> (6 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝</p> <p><b>moderate</b><sup>6</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference: ‐3% (95% CI ‐6% to ‐1%)</p> <p>Relative percentage change: ‐58% (95% CI ‐17% to ‐79%)</p> <p>NNTH was significantly in favor of chondroitin and was 29 (95% CI 22 to 93)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; <b>RR:</b> Risk ratio; <b>OR:</b> Odds ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup> Concerns of risk of bias due to lack of reporting of methods of randomization or allocation concealment or methods were unclear and the majority were sponsored by a manufacturer of chondroitin sulfate.<br/> <sup>2</sup>Significant heterogeneity between study results is evident, with I<sup>2</sup> over 70%, and the studies are split between significant and non significant results from chondroitin. Two studies reporting significant benefit from chondroitin have confidence intervals that do not overlap with those of two studies that report no significant benefit from chondroitin.<br/> <sup>3</sup> This baseline came from Clegg as Sawitzke referenced Clegg and provided both shorter and longer term outcomes </p> <p><sup>4</sup> Four of the seven studies reporting on this outcome did not report their methods of randomization, five did not report allocation concealment and seven are sponsored by a manufacturer of chondroitin sulfate or do not report their source of sponsorship. I<sup>2</sup>=67%<br/> <sup>5</sup> Downgraded for imprecision; total number of events less than 300 and relative risk increase is larger than 25%<br/> <sup>6</sup> Two of six studies did not report their methods of randomization, five of the six studies did not report their methods of allocation concealment, and all six studies were sponsored by a manufacturer of chondroitin sulfate or did not report their source of funding. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Chondroitin versus placebo for osteoarthritis</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/full#CD005614-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005614-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Chondroitin with or without glucosamine versus placebo/control for osteoarthritis (studies with estimated SDs not analyzed)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chondroitin sulfate/CSGH versus placebo/control for osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with osteoarthritis<br/> <b>Settings:</b> international inpatient and outpatient clinics, hospitals, and research centers<br/> <b>Intervention:</b> chondroitin sulfate or chondroitin sulfate with glucosamine versus placebo/control </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Chondroitin sulfate/chondroitin sulfate with glucosamineversus placebo/control</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain (short‐ and long‐term)</b> <br/> Scale from 0 to 100 mm </p> <p>(lower is better)<br/> Follow‐up: 3 to 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain (short‐ and long‐term) in the control groups was<br/> <b>30.2 mm</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain on 0 to 100 scale (short‐ and long‐term studies) in the intervention groups was </p> <p><b>9.6 mm lower</b> <br/> (14 mm to 5.2 mm lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2262<br/> (17 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.65 (95% CI ‐0.95 to ‐0.35)</p> <p>Absolute risk difference</p> <p>‐10% lower (95% CI ‐14% to ‐5%)</p> <p>Relative risk difference</p> <p>‐20% lower (95% CI ‐30% to ‐11%)</p> <p>NNTB = 4 (95% CI 3 to 6)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>WOMAC MCII Pain subscale (reduction in knee pain by 20%) Long‐term studies (≥ 6 months) dose ≥ 800 mg/d</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>471 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>528 per 1000</b> <br/> (476 to 584) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.12</b> <br/> (1.01 to 1.24) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1253<br/> (2) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>high</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Absolute risk difference 6% (1% to 11%)</p> <p>Relative risk difference 12% (1% to 24%)</p> <p>NNTB = 16 (9 to 136)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Composite Measure of Pain, Function and Disability as assessed through Lequesne's index</b> <br/> Scale from 0 to 24 </p> <p>(lower indicates less pain and disability)<br/> Follow‐up: 3 to 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean Lequesne's index in the control groups was <b>9.7 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean Lequesne's index on 0 to 24 scale in the intervention groups was<br/> <b>2 points lower</b> <br/> (3 lower to 1 lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1756<br/> (10 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>3,4</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.48 (95% CI ‐0.72 to ‐0.24)</p> <p>Absolute risk difference</p> <p>‐8% (95% CI ‐12% to ‐4%)</p> <p>Relative risk difference</p> <p>‐18% lower (95% CI ‐26% to ‐9%)</p> <p>NNTB = 5 (95% CI 3 to 9)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; NNTB: Number needed to treat for an additional beneficial outcome. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>11 of the 17 studies reporting on this outcome did not report their methods of randomization, 13 of the 17 did not report the method of allocation concealment. 16 of the 17 studies were sponsored by a manufacturer of chondroitin sulfate or did not report their source of funding.<br/> <sup>2</sup>Significant heterogeneity among the results is evident, with I<sup>2</sup> of 90%. The confidence intervals did not overlap one another, indicating a high degree of inconsistency in the effects observed in each study.<br/> <sup>3</sup> Significant inconsistency was noted in the results of these studies, with five studies reporting significant benefit from chondroitin and three reporting no significant difference between chondroitin. This inconsistency is made serious by the lack of overlap in the confidence intervals of studies with contradictory results. </p> <p><sup>4</sup>Six of the 10 studies did not report their methods of randomization or allocation concealment. All ten studies did not report their source of funding or were sponsored by a manufacturer of chondroitin sulfate. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Chondroitin with or without glucosamine versus placebo/control for osteoarthritis (studies with estimated SDs not analyzed)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/full#CD005614-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD005614-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Chondroitin with or without glucosamine versus placebo/control for osteoarthritis (sensitivity analysis including studies with estimated SDs)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Chondroitin sulfate/CSGH versus placebo/control for osteoarthritis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> participants with osteoarthritis<br/> <b>Settings:</b> international inpatient and outpatient clinics, hospitals, and research centers <br/> <b>Intervention:</b> Chondroitin sulfate or Chondroitin sulfate with glucosamine versus placebo/control </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b> Control</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Chondroitin sulfate/Chondroitin sulfate with glucosamineversus placebo/control</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Pain (short‐ and long‐term)</b> <br/> Scale from 0 to 100 </p> <p>(lower is better)<br/> Follow‐up: 3 to 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain (short‐ and long‐term) in the control groups was<br/> <b>30.2 mm</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean pain on 0 to 100 scale (short‐ and long‐term studies) in the intervention groups was<br/> <b>9.5 mm lower</b> <br/> (13mm lower to 6.1 mm lower) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3038<br/> (22 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.64 (95% CI ‐0.88 to ‐0.41)</p> <p>Absolute risk difference</p> <p>‐10% (95% CI ‐13% to ‐6%)</p> <p>Relative risk difference</p> <p>‐20% (95% CI ‐27% to ‐13%)</p> <p>NNTB = 4 (95% CI 3 to 6)</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Physical function (short‐ and long‐term)</b> <br/> Scale from 0 to 100 </p> <p>(lower is better)<br/> Follow‐up: 3‐24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physical function (short‐ and long‐term) in the control groups was<br/> <b>31.8 mm</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean physical function (short‐ and long‐term) on a 0 to 100 scale (higher is worse) in the intervention groups was </p> <p><b>1.3 mm lower</b> <br/> (5.7 mm lower to 3.1 mm higher) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1163<br/> (5 studies) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>SMD ‐0.07 (95% CI ‐0.31 to 0.17)</p> <p>Absolute risk difference</p> <p>‐1% (95% CI ‐6% to 3%)</p> <p>Relative risk difference</p> <p>‐3% (95% CI ‐13% to 7%)</p> <p>NNTB = not applicable</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Composite Measure of Pain, Function and Disability as assessed through Lequesne's index (short‐ and long‐term)</b> <br/> Scale from 0 to 24 (lower indicates less pain and disability)<br/> Follow‐up: 3 to 24 months </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean Lequesne's index (short‐ and long‐term) in the control groups was<br/> <b>9.7 points</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>The mean Lequesne's index on 0 to 24 scale (higher is worse; short‐ and long‐term results combined) in the intervention groups was<br/> <b>2.5 points lower</b> <br/> (3.5 to 1.5 lower) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2334<br/> (16 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>⊕⊕⊕⊝<br/> <b>moderate</b><sup>4</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>SMD ‐0.57 (95% CI ‐0.79 to ‐0.35)</p> <p>Absolute risk difference</p> <p>‐10% (95% CI ‐14% to ‐6%)</p> <p>Relative risk difference</p> <p>‐22% (95% CI ‐30% to ‐13%)</p> <p>NNTB = 4 (95% CI 3 to 6)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g., the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> Confidence interval; NNTB: Number needed to treat for an additional beneficial outcome. NNTB is not applicable when the result is not statistically significant. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence.<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>17 of the 23 studies reporting on this outcome did not report their methods of randomization, 19 of the 23 did not report the method of allocation concealment. 22 of the 23 studies were sponsored by a manufacturer of chondroitin sulfate or did not report their source of funding.<br/> <sup>2</sup>Significant heterogeneity among the results is evident, with I<sup>2</sup> of 88%. The confidence intervals did not overlap one another, indicating a high degree of inconsistency in the effects observed in each study.<br/> <sup>3</sup>Two of the five studies reporting on this outcome did not report their methods of randomization. Three of the five studies did not report their methods of allocation concealment. All five studies were funded by a manufacturer of chondroitin sulfate or did not report their source of funding.<br/> <sup>4</sup>13 of the 16 studies did not report their methods of randomization, 14 of the 16 did not describe the method of allocation concealment. All 16 studies did not report their source of funding or were sponsored by a manufacturer of chondroitin sulfate. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Chondroitin with or without glucosamine versus placebo/control for osteoarthritis (sensitivity analysis including studies with estimated SDs)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/full#CD005614-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Chondroitin versus Placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.51 [‐0.74, ‐0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>989</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐0.78, 0.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC MCII <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.01, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.01, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Physical Function on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>303</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.47, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐1.33, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 WOMAC Stiffness on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.5 [‐1.43, 6.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.5 [‐1.43, 6.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Patient Global Assessment—rating it good to very good <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.11 [1.49, 2.99]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.04 [1.28, 3.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Patient Global Assessment on a VAS 0 to 100‐mm scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>130</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.48, 0.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1415</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.21, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 MD Global Assessment of good to very good <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.95 [1.42, 2.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.12 [1.33, 3.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 MD Global Assessment on a VAS 0 to 100‐mm scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.05, 0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1259</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.09 [‐0.05, 0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Total Knee Arthroplasty during follow‐up <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.15, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Grip Strength (kg/cm<sup>2</sup>) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [‐2.29, 4.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [‐2.29, 4.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Morning Stiffness, minutes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐5.16, 3.96]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>162</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐5.16, 3.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Cartilage Volume Loss (global) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.23, 3.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.80 [0.23, 3.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Cartilage Volume Loss (lateral compartment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.19 [0.31, 4.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.19 [0.31, 4.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Cartilage Volume Loss (medial compartment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [‐0.88, 3.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.47 [‐0.88, 3.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Cartilage Volume Loss (condyles) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [‐1.59, 2.87]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.64 [‐1.59, 2.87]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Cartilage Volume Loss (lateral condyles) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [‐0.44, 4.12]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.84 [‐0.44, 4.12]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Cartilage Volume Loss (medial condyles) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.65 [‐4.14, 2.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.65 [‐4.14, 2.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Cartilage Volume Loss (tibial plateaus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.98 [1.15, 4.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.98 [1.15, 4.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 Cartilage Volume Loss (lateral tibial plateaus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.31 [‐0.09, 4.71]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.31 [‐0.09, 4.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Cartilage Volume Loss (medial tibial plateau) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.47 [1.57, 7.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.47 [1.57, 7.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Cartilage Volume Loss (trochlea) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [‐1.79, 3.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [‐1.79, 3.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Change in Bone Marrow Lesion Score (global) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.65, 0.51]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.65, 0.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">23 Change in Bone Marrow Lesion Score (lateral compartment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.30, 0.10]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>23.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.30, 0.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">24 Change in Bone Marrow Lesion score (medial compartment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.52, 0.56]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>24.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.52, 0.56]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">25 Change in Bone Marrow Lesion score (condyles) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.35, 0.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>25.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.35, 0.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">26 Change in Bone Marrow Lesion score (lateral condyles) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.14, 0.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>26.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.14, 0.06]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">27 Change in Bone Marrow Lesion score (medial condyles) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.22, 0.48]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>27.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [‐0.22, 0.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">28 Change in Bone Marrow Lesion score (tibial plateaus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.1 [‐0.46, 0.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>28.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.1 [‐0.46, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">29 Change in Bone Marrow Lesion score (lateral tibial plateaus) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.18, 0.16]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>29.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.18, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">30 Change in Bone Marrow Lesion score (medial tibial plateau) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.1 [‐0.40, 0.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>30.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.1 [‐0.40, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">31 Change in Bone Marrow Lesion score (trochlea) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [‐0.10, 0.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>31.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.16 [‐0.10, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">32 OMERACT‐OARSI Responder <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.98, 1.27]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>32.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [0.98, 1.27]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">33 Lequesne's Index on 0 to 24 scale (higher is worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>903</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.98 [‐2.79, ‐1.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>33.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>243</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐3.49, 0.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">34 HAQ Disability Score on 0 to 3 scale (higher is worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.11, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>34.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.11, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">35 Radiographic Outcome: Minimum JSW in mm <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐0.27, 0.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>35.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐0.27, 0.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">36 Radiographic Outcome: Reduction in Minimum JSW in mm <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.06, 0.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>36.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.18 [0.06, 0.30]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">37 Radiographic Outcome: Mean JSW in mm <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [‐0.47, 0.81]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>37.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>156</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [‐0.47, 0.81]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">38 Radiographic Outcome: Change in Mean JSW in mm <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.07, 0.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>38.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.07, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">39 SF‐36—Physical Component Score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.76 [‐19.84, 25.36]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>39.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>2.76 [‐19.84, 25.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">40 SF‐36—Mental Component Summary Score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.59 [‐24.84, 23.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>40.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.59 [‐24.84, 23.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">41 All withdrawals <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2763</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.80 [0.63, 1.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>675</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.67 [0.41, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>41.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2088</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.62, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">42 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2406</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.08 [0.74, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>489</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.31, 2.89]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>42.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1917</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.73, 1.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">43 Withdrawals due to inefficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2314</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [0.88, 1.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>360</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.62 [0.15, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>43.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1954</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.27 [0.91, 1.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">44 Number of adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1579</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.97 [0.83, 1.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>795</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.04 [0.81, 1.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>44.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>784</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.50, 1.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">45 Number of serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>954</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.40 [0.19, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>45.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.5 [0.09, 2.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>45.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>488</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.38 [0.17, 0.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">46 GI adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1684</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.45, 1.04]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.15, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>46.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1355</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.75 [0.47, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">47 Other adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>787</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.79, 1.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.02 [0.72, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>47.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>574</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.82 [0.35, 1.96]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">48 Deaths <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.04, 3.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>213</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>48.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.04, 3.20]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Chondroitin versus Placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Chondroitin sulfate versus Control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on various scales standardized to a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.26, 0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.31, 0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC Stiffness on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.0 [‐5.77, 3.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐5.25, 4.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 WOMAC Physical Function on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.10 [‐6.44, 2.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.56 [‐5.70, 2.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 WOMAC Total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.80 [‐6.06, 2.46]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐5.69, 2.49]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Lequesne's Index (higher is worse) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1187</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.36 [‐3.60, 0.89]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐2.51, 2.51]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>830</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.02 [‐5.06, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Patient Global Assessment (% with improvement) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.04 [1.95, 13.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>573</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>5.04 [1.95, 13.05]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 MD Global Assessment (% with improvement) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.68 [4.48, 13.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>473</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>7.68 [4.48, 13.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 NSAID consumption <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.23, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>357</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.20, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 All withdrawals <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.09, 1.74]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1012</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.09, 1.74]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.03, 2.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.27 [0.03, 2.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Number of adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 4.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [0.00, 4.82]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 GI adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.03, 6.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.41 [0.03, 6.60]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Chondroitin sulfate versus Control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Chondroitin sulfate + Glucosamine versus Placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.33, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.25, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC MCII <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.96, 1.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.32 [0.96, 1.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Physical Function on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.31, 0.54]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.28, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Six‐minute walk distance in meters walked <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.90 [‐24.94, 19.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.90 [‐24.94, 19.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 WOMAC Stiffness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.20 [‐5.97, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.20 [‐5.97, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 WOMAC Total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.60 [‐5.92, 0.72]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.60 [‐5.92, 0.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Patient Global Assessment VAS (0 to 100 mm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐5.29, 2.09]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.60 [‐5.29, 2.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 MD Global Assessment VAS (0 to 100 mm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.40 [‐4.87, 2.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.40 [‐4.87, 2.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 OMERACT‐OARSI Responders <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [1.02, 1.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.15 [1.02, 1.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 HAQ Disability Score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.11, 0.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.04 [‐0.11, 0.03]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Objective Joint Function (Flexion) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐21.54, 20.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐21.54, 20.34]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Objective Joint Function (extension) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐25.80 [‐72.67, 21.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐25.80 [‐72.67, 21.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Objective Joint Function (balance) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.10, ‐0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.10, ‐0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 All withdrawals <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.40, 3.85]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [0.40, 3.85]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>800</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.57, 2.55]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.21 [0.57, 2.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Withdrawals due to inefficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.41, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>768</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.41, 1.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Number of adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>170</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [0.67, 1.84]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.6 [0.67, 3.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.51, 1.72]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.77, 2.75]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>398</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.45 [0.77, 2.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">19 GI adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.34, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>19.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.68 [0.34, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">20 Hematologic adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.15]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>20.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">21 Other adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.43, 4.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>21.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>138</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.35 [0.43, 4.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">22 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>22.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1028</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.34 [0.01, 8.23]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 3.</span> <span class="table-title">Chondroitin sulfate + Glucosamine versus Placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0007"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>331</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.41 [‐4.41, 1.58]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.22 [‐4.87, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC MCII <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.61, 1.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.85 [0.61, 1.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Physical Function on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.20, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.18, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 WOMAC Stiffness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Short‐term studies (&lt; 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>60</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.5 [‐4.27, ‐0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐7.72 [‐15.36, ‐0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 WOMAC Total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>772</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.77 [‐9.75, 0.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>772</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.77 [‐9.75, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Percentage with improved Patient Global Assessment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [1.28, 1.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>6.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.42 [1.28, 1.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Percentage with improved MD Global Assessment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [1.35, 1.68]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>525</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.51 [1.35, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 OMERACT‐OARSI <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.67, 1.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>8.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.93 [0.67, 1.29]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 HAQ Disability Score <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.06, 0.08]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.06, 0.08]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Radiographic Outcome: Change in Mean JSW in mm <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.26, 0.42]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>10.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>139</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.08 [‐0.26, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 All withdrawals <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.08, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>11.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1207</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.31 [0.08, 1.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Withdrawals due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [0.69, 4.31]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>12.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.72 [0.69, 4.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Withdrawals due to inefficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.74, 3.26]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.55 [0.74, 3.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Number of adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>796</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.17, 1.21]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>14.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>796</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.45 [0.17, 1.21]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Serious adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 70.83]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>15.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>3.0 [0.13, 70.83]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 GI adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.29, 1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>785</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.29, 1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Other adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.16, 1.13]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>17.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>150</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.42 [0.16, 1.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 4.</span> <span class="table-title">Chondroitin sulfate + Glucosamine versus Nonsteroidal anti‐inflammatory drugs (NSAIDs)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo or Control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on 0 to 100 scale (short‐ and long‐term results) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.65 [‐0.95, ‐0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Physical Function on 0 to 100 scale (short‐ and long‐term results) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.31, 0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Lequesne's Index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1756</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.48 [‐0.72, ‐0.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 WOMAC MCII <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.01, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Long‐term studies (≥ 6 months)—dose ≥ 800 mg/d</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.01, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Pain on 0 to 100 scale (short‐ or long‐term) for CS dose &gt;= 800 mg/day <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2136</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.67 [‐0.99, ‐0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 5.</span> <span class="table-title">Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo or Control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Sensitivity analysis (blinding): Chondroitin sulfate versus Placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1653</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐0.76, ‐0.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Blinding: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1499</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐0.80, ‐0.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Blinding: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐1.48, 0.79]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Blinding: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC MCII <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.01, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Blinding: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.01, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Blinding: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Blinding: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Physical Function on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐1.33, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Blinding: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐1.33, 0.50]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Blinding: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Blinding: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Radiographic outcome: Change in Mean JSW in mm <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.03, 0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Blinding: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.03, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Blinding: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Blinding: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 6.</span> <span class="table-title">Sensitivity analysis (blinding): Chondroitin sulfate versus Placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0010"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Sensitivity analysis (blinding): Chondroitin sulfate + Glucosamine versus Placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>791</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.26, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Blinding: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.13 [‐0.27, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Blinding: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.59, 0.80]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Blinding: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Physical Function on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.31, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Blinding: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.31, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Blinding: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Blinding: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 7.</span> <span class="table-title">Sensitivity analysis (blinding): Chondroitin sulfate + Glucosamine versus Placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0011"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Sensitivity analysis (blinding): Glucosamine + Chondroitin sulfate versus NSAIDs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.22 [‐4.87, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Blinding: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.13, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Blinding: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Blinding: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.37 [‐5.74, ‐1.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 8.</span> <span class="table-title">Sensitivity analysis (blinding): Glucosamine + Chondroitin sulfate versus NSAIDs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Sensitivity analysis (blinding): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain—Blinding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2278</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.65 [‐0.95, ‐0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Blinding: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1985</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐0.64, ‐0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Blinding: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>186</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐1.01, 0.59]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Blinding: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.37 [‐5.74, ‐1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Physical Function—Blinding <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.30, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Blinding: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.30, 0.19]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Blinding: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Blinding: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 9.</span> <span class="table-title">Sensitivity analysis (blinding): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0012">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0013"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Sensitivity analysis (study size): Chondroitin sulfate versus Placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1653</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐0.76, ‐0.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Studies with n ≥ 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>865</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.45, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Studies with n &lt; 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>788</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.59 [‐0.88, ‐0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC MCII <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.01, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Studies with n ≥ 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.01, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Studies with n &lt; 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Physical Function on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐1.33, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Studies with n ≥ 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.15, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Studies with n &lt; 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.93 [‐1.54, ‐0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Radiographic outcome: Change in Mean JSW in mm <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐0.02, 0.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Studies with n ≥ 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐0.02, 0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Studies with n &lt; 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 10.</span> <span class="table-title">Sensitivity analysis (study size): Chondroitin sulfate versus Placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0014"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Sensitivity analysis (study size): Chondroitin sulfate + Glucosamine versus Placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>791</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.26, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Studies with n ≥ 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.28, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Studies with n &lt; 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>161</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.42, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Physical Function on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.31, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Studies with n ≥ 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.29, 0.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Studies with n &lt; 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>129</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.10 [‐0.46, 0.66]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 11.</span> <span class="table-title">Sensitivity analysis (study size): Chondroitin sulfate + Glucosamine versus Placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0015"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Sensitivity analysis (study size): Glucosamine + Chondroitin sulfate versus NSAIDs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.22 [‐4.87, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Studies with n ≥ 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.13, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Studies with n &lt; 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.37 [‐5.74, ‐1.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 12.</span> <span class="table-title">Sensitivity analysis (study size): Glucosamine + Chondroitin sulfate versus NSAIDs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0016"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Sensitivity analysis (study size): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain—study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.65 [‐0.96, ‐0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Studies with n ≥ 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.04 [‐0.09, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Studies with n &lt; 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1166</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.78 [‐1.15, ‐0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Physical Function—study size <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.30, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Studies with n ≥ 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.03 [‐0.09, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Studies with n &lt; 100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>175</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.90, 0.48]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 13.</span> <span class="table-title">Sensitivity analysis (study size): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0017"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Sensitivity analysis (study sponsors): Chondroitin versus Placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐0.77, ‐0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Pharmaceutical sponsorship: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>698</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐0.80, ‐0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Pharmaceutical sponsorship: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>200</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.73 [‐1.66, 0.20]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Pharmaceutical sponsorship: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.15, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC MCII <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.01, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Pharmaceutical sponsorship: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.20 [0.98, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Pharmaceutical sponsorship: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Pharmaceutical sponsorship: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.09 [0.97, 1.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Physical Function on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐1.33, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Pharmaceutical sponsorship: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.93 [‐1.54, ‐0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Pharmaceutical sponsorship: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Pharmaceutical sponsorship: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.15, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Radiographic outcome: Change in Mean JSW in mm <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐0.02, 0.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Pharmaceutical sponsorship: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.26 [0.11, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Pharmaceutical sponsorship: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [0.10, 0.55]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Pharmaceutical sponsorship: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.31, 0.18]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 14.</span> <span class="table-title">Sensitivity analysis (study sponsors): Chondroitin versus Placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0018"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Sensitivity analysis (study sponsors): Chondroitin sulfate + Glucosamine versus Placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>791</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.26, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Pharmaceutical sponsorship: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [‐0.42, 0.42]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Pharmaceutical sponsorship: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.80, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Pharmaceutical sponsorship: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.28, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Physical Function on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.31, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Pharmaceutical sponsorship: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>89</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.55, 0.28]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Pharmaceutical sponsorship: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [‐0.19, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Pharmaceutical sponsorship: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>630</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.29, 0.02]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 15.</span> <span class="table-title">Sensitivity analysis (study sponsors): Chondroitin sulfate + Glucosamine versus Placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0019"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Sensitivity analysis (study sponsors): Chondroitin sulfate + Glucosamine versus NSAIDs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.22 [‐4.87, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Pharmaceutical sponsorship: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Pharmaceutical sponsorship: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.37 [‐5.74, ‐1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Pharmaceutical sponsorship: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.13, 0.18]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 16.</span> <span class="table-title">Sensitivity analysis (study sponsors): Chondroitin sulfate + Glucosamine versus NSAIDs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0020"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Sensitivity analysis (study sponsors): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Control/Placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain—study sponsors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.65 [‐0.96, ‐0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Pharmaceutical sponsorship: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1144</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.39 [‐0.67, ‐0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Pharmaceutical sponsorship: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>379</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.39 [‐2.41, ‐0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Pharmaceutical sponsorship: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.00 [‐0.15, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Physical Function—study sponsors <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.30, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Pharmaceutical sponsorship: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>492</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.26 [‐0.75, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Pharmaceutical sponsorship: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [‐0.19, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Pharmaceutical sponsorship: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.15, 0.16]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 17.</span> <span class="table-title">Sensitivity analysis (study sponsors): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Control/Placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0021"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Sensitivity analysis (publication year): Chondroitin versus Placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1786</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.45 [‐0.69, ‐0.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 1990 &lt; Publication year ≤ 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.89 [‐1.13, ‐0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 2000 ≤ Publication year ≤ 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>871</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.18 [‐0.45, 0.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Publication year ≥ 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>484</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.25, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC MCII <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.01, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 1990 &lt; Publication year ≤ 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 2000 ≤ Publication year ≤ 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.01, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Publication year ≥ 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Physical Function on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>934</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.20 [‐0.53, 0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 1990 &lt; Publication year ≤ 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.93 [‐1.54, ‐0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 2000 ≤ Publication year ≤ 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.15, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Publication year ≥ 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.32, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Radiographic outcome: Change in Mean JSW in mm <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [‐0.02, 0.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 1990 &lt; Publication year ≤ 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 2000 &lt; Publication year ≤ 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>922</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.15, 0.41]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Publication year ≥ 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>257</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.31, 0.18]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 18.</span> <span class="table-title">Sensitivity analysis (publication year): Chondroitin versus Placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0022"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Sensitivity analysis (publication year): Chondroitin sulfate + Glucosamine versus Placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1051</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.10 [‐0.22, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 1990 &lt; Publication year ≤ 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 2000 &lt; Publication year ≤ 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.25, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Publication year ≥ 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.31, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Physical Function on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1019</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.08 [‐0.22, 0.05]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 1990 &lt; Publication year ≤ 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 2000 &lt; Publication year ≤ 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.28, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Publication year ≥ 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.33, 0.55]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 19.</span> <span class="table-title">Sensitivity analysis (publication year): Chondroitin sulfate + Glucosamine versus Placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0023"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Sensitivity analysis (publication year): Glucosamine + Chondroitin sulfate versus NSAIDs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1013</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.48 [‐2.51, ‐0.44]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 1990 &lt; Publication year ≤ 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 2000 &lt; Publication year ≤ 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.22 [‐4.87, 0.43]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Publication year ≥ 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>271</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.17 [‐0.07, 0.41]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 20.</span> <span class="table-title">Sensitivity analysis (publication year): Glucosamine + Chondroitin sulfate versus NSAIDs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0023">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0024"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Sensitivity analysis (publication year): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain—publication year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>18</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2411</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.60 [‐0.89, ‐0.32]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 1990 &lt; Publication year ≤ 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>431</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.89 [‐1.13, ‐0.66]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 2000 ≤ Publication year ≤ 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1067</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.09 [‐1.82, ‐0.36]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Publication year ≥ 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>913</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.02 [‐0.18, 0.13]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Physical Function—publication year <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1420</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.24, 0.14]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 1990 &lt; Publication year ≤ 1999</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.93 [‐1.54, ‐0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 2000 ≤ Publication year ≤ 2009</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.16, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Publication year ≥ 2010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>654</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.05 [‐0.14, 0.23]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 21.</span> <span class="table-title">Sensitivity analysis (publication year): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0024">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0025"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Sensitivity analysis (allocation concealment): Chondroitin sulfate versus Placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐0.77, ‐0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Allocation concealment: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>810</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.37, 0.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Allocation concealment: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.67 [‐0.93, ‐0.40]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Allocation concealment: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC MCII <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.01, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Allocation concealment: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.01, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Allocation concealment: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Allocation concealment: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Physical Function on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐1.33, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Allocation concealment: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.15, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Allocation concealment: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.93 [‐1.54, ‐0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 Allocation concealment: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Radiographic outcome: Change in Mean JSW in mm <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.03, 0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Allocation concealment: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>879</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.07 [‐0.11, 0.26]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Allocation concealment: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>300</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.19 [0.06, 0.31]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 Allocation concealment: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 22.</span> <span class="table-title">Sensitivity analysis (allocation concealment): Chondroitin sulfate versus Placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0025">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0026"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Sensitivity analysis (allocation concealment): Chondroitin sulfate + Glucosamine versus Placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>791</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.26, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Allocation concealment: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.25, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Allocation concealment: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.80, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Allocation concealment: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Physical Function on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.31, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Allocation concealment: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.28, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Allocation concealment: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [‐0.19, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Allocation concealment: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 23.</span> <span class="table-title">Sensitivity analysis (allocation concealment): Chondroitin sulfate + Glucosamine versus Placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0026">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0027"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Sensitivity analysis (allocation concealment): Chondroitin sulfate + Glucosamine versus NSAIDs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.22 [‐4.87, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Allocation concealment: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.13, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Allocation concealment: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Allocation concealment: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.37 [‐5.74, ‐1.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 24.</span> <span class="table-title">Sensitivity analysis (allocation concealment): Chondroitin sulfate + Glucosamine versus NSAIDs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0027">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0028"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">Sensitivity analysis (allocation concealment): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain—allocation concealment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.65 [‐0.96, ‐0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Allocation concealment: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>899</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.05 [‐0.27, 0.17]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Allocation concealment: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1148</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐0.81, ‐0.23]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 Allocation concealment: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.37 [‐5.74, ‐1.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Physical Function—allocation concealment <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.30, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Allocation concealment: yes</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>720</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.01 [‐0.16, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Allocation concealment: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>443</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.77, 0.53]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 Allocation concealment: no</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 25.</span> <span class="table-title">Sensitivity analysis (allocation concealment): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0028">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0029"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">Sensitivity analysis (estimated SD): Chondroitin versus Placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1814</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.52 [‐0.75, ‐0.29]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Physical Function on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐1.33, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Lequesne's Index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>929</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.61 [‐0.83, ‐0.39]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 26.</span> <span class="table-title">Sensitivity analysis (estimated SD): Chondroitin versus Placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0029">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0030"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">Sensitivity analysis (estimated SD): Chondroitin sulfate versus Control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>457</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.34 [‐0.85, 0.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Lequesne's Index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>930</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.99 [‐3.27, ‐0.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Patient Global Assessment (VAS) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>100</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.0 [‐7.80, ‐0.20]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 27.</span> <span class="table-title">Sensitivity analysis (estimated SD): Chondroitin sulfate versus Control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0030">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0031"> <div class="table-heading"><span class="table-label">Comparison 28.</span> <span class="table-title">Sensitivity analysis (estimated SD): Chondroitin sulfate + Glucosamine versus Placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>791</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.26, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC Total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.29 [‐5.38, 0.79]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Patient Global Assessment VAS (0 to 100 mm) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>723</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.22, 0.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Lequesne's Index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>193</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐4.46 [‐10.97, 2.06]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 28.</span> <span class="table-title">Sensitivity analysis (estimated SD): Chondroitin sulfate + Glucosamine versus Placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0031">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0032"> <div class="table-heading"><span class="table-label">Comparison 29.</span> <span class="table-title">Sensitivity analysis (estimated SD): Chondroitin sulfate + Glucosamine versus NSAIDs</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain (0 to 100) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.70 [‐2.70, ‐0.70]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Physical Function <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1010</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.30 [‐0.85, 0.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 WOMAC Stiffness <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1117</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐8.49 [‐14.52, ‐2.46]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 WOMAC Total <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1147</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐6.94 [‐12.86, ‐1.01]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 29.</span> <span class="table-title">Sensitivity analysis (estimated SD): Chondroitin sulfate + Glucosamine versus NSAIDs</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0032">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0033"> <div class="table-heading"><span class="table-label">Comparison 30.</span> <span class="table-title">Sensitivity analysis (estimated SD): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain (0 to 100) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3038</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.64 [‐0.88, ‐0.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Physical Function on a 0 to 100 scale (short‐ and long‐term results) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.07 [‐0.31, 0.17]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Lequesne's Index <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2334</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.57 [‐0.79, ‐0.35]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 30.</span> <span class="table-title">Sensitivity analysis (estimated SD): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0033">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0034"> <div class="table-heading"><span class="table-label">Comparison 31.</span> <span class="table-title">Sensitivity analysis (ITT): Chondroitin sulfate versus Placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1529</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.50 [‐0.77, ‐0.23]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 ITT: low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1329</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.46 [‐0.75, ‐0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 ITT: unclear risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>131</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐1.00 [‐1.37, ‐0.63]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 ITT: high risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>69</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.24 [‐0.24, 0.71]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 WOMAC MCII <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.01, 1.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 ITT: low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1253</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.12 [1.01, 1.24]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 ITT: unclear risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 ITT: high risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Physical Function on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>677</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.41 [‐1.33, 0.50]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 ITT: low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>631</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.01 [‐0.15, 0.16]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 ITT: unclear risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>46</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.93 [‐1.54, ‐0.32]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.3 ITT: high risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Radiographic outcome: Change in Mean JSW in mm <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.03, 0.22]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 ITT: low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1179</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.13 [0.03, 0.22]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 ITT: unclear risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.3 ITT: high risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 31.</span> <span class="table-title">Sensitivity analysis (ITT): Chondroitin sulfate versus Placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0034">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0035"> <div class="table-heading"><span class="table-label">Comparison 32.</span> <span class="table-title">Sensitivity analysis (ITT): Chondroitin sulfate + Glucosamine versus Placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>791</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.12 [‐0.26, 0.02]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.11 [‐0.25, 0.04]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Unclear risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>72</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.21 [‐0.80, 0.38]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Physical Function on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>759</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.31, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>719</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.14 [‐0.28, 0.01]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Unclear risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [‐0.19, 1.07]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 High risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 32.</span> <span class="table-title">Sensitivity analysis (ITT): Chondroitin sulfate + Glucosamine versus Placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0035">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0036"> <div class="table-heading"><span class="table-label">Comparison 33.</span> <span class="table-title">Sensitivity analysis (ITT): Glucosamine + Chondroitin sulfate versus NSAID</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>742</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.22 [‐4.87, 0.43]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 ITT: low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>635</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.13, 0.18]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 ITT: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 ITT: high risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>107</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐3.37 [‐5.74, ‐1.01]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 33.</span> <span class="table-title">Sensitivity analysis (ITT): Glucosamine + Chondroitin sulfate versus NSAID</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0036">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD005614-tbl-0037"> <div class="table-heading"><span class="table-label">Comparison 34.</span> <span class="table-title">Sensitivity analysis (ITT): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Pain on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2154</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.65 [‐0.96, ‐0.34]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 ITT: low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1775</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.35 [‐0.58, ‐0.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 ITT: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>203</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.65 [‐1.15, ‐0.15]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3 ITT: high risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>176</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐2.16 [‐4.88, 0.57]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Physical Function on a 0 to 100 scale <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1163</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.06 [‐0.30, 0.19]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 ITT: low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1077</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.02 [‐0.10, 0.14]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 ITT: unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>86</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>‐0.25 [‐1.59, 1.10]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.3 ITT: high risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.0 [0.0, 0.0]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 34.</span> <span class="table-title">Sensitivity analysis (ITT): Chondroitin sulfate or Chondroitin sulfate + Glucosamine versus Placebo/Control</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD005614.pub2/references#CD005614-tbl-0037">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD005614.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="de#CD005614-note-0001">Deutsch</a> </li> <li class="section-language"> <a class="" href="es#CD005614-note-0009">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD005614-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD005614-note-0007">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD005614-note-0006">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD005614-note-0005">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD005614-note-0003">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD005614-note-0004">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ta#CD005614-note-0008">தமிழ்</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD005614-note-0002">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005614\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005614\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005614\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005614\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005614\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005614\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005614\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005614\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005614\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005614\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005614\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005614\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005614\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005614\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005614\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD005614\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD005614\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD005614\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=eLIOL3Be&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005614.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD005614.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD005614.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD005614.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD005614.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740714837915"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005614.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740714837919"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD005614.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918d786dbab2937d',t:'MTc0MDcxNDgzOC4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 